PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
33694335-0	2021	Successful management of familial hemophagocytic lymphohistiocytosis by the JAK 1/2 inhibitor ruxolitinib.	ruxolitinib	94-105	Janus kinase 1	Homo sapiens	76-83
33534941-9	2021	Poly(I:C)-induced CCL5 production occurred via the TLR3-IRF3 and IFNAR/JAK1-phosphoinositide 3-kinase (PI3K) pathways, but not the IFNAR/JAK1-STATs pathway.	Poly I-C	0-9	Janus kinase 1	Homo sapiens	71-75
33534941-12	2021	The JAK1/2 inhibitor, ruxolitinib, was demonstrated to more effectively decrease CCL5 production in BEAS-2B cells than fluticasone propionate.	ruxolitinib	22-33	Janus kinase 1	Homo sapiens	4-10
33534941-12	2021	The JAK1/2 inhibitor, ruxolitinib, was demonstrated to more effectively decrease CCL5 production in BEAS-2B cells than fluticasone propionate.	Fluticasone	119-141	Janus kinase 1	Homo sapiens	4-10
33745126-4	2021	CIM activates complement cascade and increased monocyte infiltration in the soleus muscle, which was ameliorated by JAK1/2 inhibition, leading to reduced muscle degeneration and improved muscle force.	cim	0-3	Janus kinase 1	Homo sapiens	116-122
34042156-0	2021	Randomized Controlled Trial Substudy of Cell-specific Mechanisms of Janus Kinase 1 Inhibition With Upadacitinib in the Crohn"s Disease Intestinal Mucosa: Analysis From the CELEST Study.	upadacitinib	99-111	Janus kinase 1	Homo sapiens	68-82
34042156-2	2021	We aimed to provide mechanistic insights into the JAK1-selective inhibitor upadacitinib through a transcriptomics substudy on biopsies from patients with Crohn"s disease from CELEST.	upadacitinib	75-87	Janus kinase 1	Homo sapiens	50-54
34054304-3	2021	Methods: In this study, we characterized a JAK1-specific inhibitor, LW402, on biochemical and human whole-blood assays.	lw402	68-73	Janus kinase 1	Homo sapiens	43-47
34052462-0	2021	The JAK Inhibitor Tofacitinib Inhibits Structural Damage in Osteoarthritis by Modulating JAK1/TNF-alpha/IL-6 Signaling Through Mir-149-5p.	tofacitinib	18-29	Janus kinase 1	Homo sapiens	89-93
34052462-10	2021	CONCLUSION: We show for the first time that tofacitinib suppresses the expression level of JAK1/TNF-alpha/IL-6 by upregulating miR-149-5p level.	tofacitinib	44-55	Janus kinase 1	Homo sapiens	91-95
34052462-11	2021	Our findings revealed the functional association between proinflammatory JAK1/TNF-alpha/IL-6 signaling and ACs development and highlight the therapeutic potential of tofacitinib in OA.	tofacitinib	166-177	Janus kinase 1	Homo sapiens	73-77
34023851-1	2021	JAK1/2 inhibitor ruxolitinib (RUX) is approved in patients with myelofibrosis but the impact of pretreatment with RUX on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) remains to be determined.	ruxolitinib	17-28	Janus kinase 1	Homo sapiens	0-6
34023851-1	2021	JAK1/2 inhibitor ruxolitinib (RUX) is approved in patients with myelofibrosis but the impact of pretreatment with RUX on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) remains to be determined.	ruxolitinib	30-33	Janus kinase 1	Homo sapiens	0-6
34054304-6	2021	Results: LW402 exhibited potent nanomolar activity against JAK1 and showed a 45-fold selectivity for inhibition of JAK1- over JAK2-dependent signaling induced by either IL6 or GM-CSF in human whole-blood assays.	lw402	9-14	Janus kinase 1	Homo sapiens	59-63
34054304-6	2021	Results: LW402 exhibited potent nanomolar activity against JAK1 and showed a 45-fold selectivity for inhibition of JAK1- over JAK2-dependent signaling induced by either IL6 or GM-CSF in human whole-blood assays.	lw402	9-14	Janus kinase 1	Homo sapiens	115-119
33595362-14	2021	Pre-incubation with the JAK1 inhibitor filgotinib ameliorated the barrier dysfunction induced by IL-28A.	GLPG0634	39-49	Janus kinase 1	Homo sapiens	24-28
34023008-1	2021	BACKGROUND: Upadacitinib is an oral Janus kinase (JAK) inhibitor with greater inhibitory potency for JAK1 than JAK2, JAK3, and tyrosine kinase 2.	upadacitinib	12-24	Janus kinase 1	Homo sapiens	101-105
34023009-2	2021	Upadacitinib is an oral Janus kinase (JAK) inhibitor with greater inhibitory potency for JAK1 than JAK2, JAK3, or tyrosine kinase 2 that is being tested for atopic dermatitis.	upadacitinib	0-12	Janus kinase 1	Homo sapiens	89-93
34008179-1	2021	Tofacitinib is a JAK1/3 inhibitor used off-label to treat alopecia areata (AA).	tofacitinib	0-11	Janus kinase 1	Homo sapiens	17-23
33727040-6	2021	Meanwhile, polarized M2 macrophages enhance 5-FU resistance in tumor cells by secreting CCL8 and activating phosphorylation of JAK1/STAT3 signaling pathway.	Fluorouracil	44-48	Janus kinase 1	Homo sapiens	127-131
33982267-2	2021	A cream formulation of ruxolitinib, a potent selective JAK1/JAK2 inhibitor, was developed for topical delivery.	ruxolitinib	23-34	Janus kinase 1	Homo sapiens	55-59
34016786-8	2021	Then ruxolitinib was selected to perform molecular docking simulations with ANGPT2, FGF7, NT5E, CSF3R, JAK1, JAK2, JAK3, TYK2.	ruxolitinib	5-16	Janus kinase 1	Homo sapiens	103-107
34025783-2	2021	We evaluated real-life efficacy and safety of Baricitinib, an oral selective JAK1-2 inhibitor, in RA patients using clinical, clinimetric, and US assessments.	baricitinib	46-57	Janus kinase 1	Homo sapiens	77-83
33950225-1	2021	Upadacitinib and filgotinib, two JAK1 selective drugs have undergone extensive phase III clinical trials in RA and have demonstrated rapid improvements in disease activity, function and patient reported outcomes.	upadacitinib	0-12	Janus kinase 1	Homo sapiens	33-37
33950225-1	2021	Upadacitinib and filgotinib, two JAK1 selective drugs have undergone extensive phase III clinical trials in RA and have demonstrated rapid improvements in disease activity, function and patient reported outcomes.	GLPG0634	17-27	Janus kinase 1	Homo sapiens	33-37
33950226-5	2021	Tofacitinib, a JAK1 inhibitor, is now licensed for use in the induction and maintenance of ulcerative colitis and there are a large number of molecules currently under investigation.	tofacitinib	0-11	Janus kinase 1	Homo sapiens	15-19
33950228-4	2021	With this proposal, early phase trials of selective JAK1 inhibitors, namely upadacitinib, filgotinib and itacitinib, were initiated in recent years to identify the efficacy and adverse effects of these agents and to define their potential role in treatment of inflammatory and autoimmune diseases.	upadacitinib	76-88	Janus kinase 1	Homo sapiens	52-56
33950228-4	2021	With this proposal, early phase trials of selective JAK1 inhibitors, namely upadacitinib, filgotinib and itacitinib, were initiated in recent years to identify the efficacy and adverse effects of these agents and to define their potential role in treatment of inflammatory and autoimmune diseases.	GLPG0634	90-100	Janus kinase 1	Homo sapiens	52-56
33950228-4	2021	With this proposal, early phase trials of selective JAK1 inhibitors, namely upadacitinib, filgotinib and itacitinib, were initiated in recent years to identify the efficacy and adverse effects of these agents and to define their potential role in treatment of inflammatory and autoimmune diseases.	INCB039110	105-115	Janus kinase 1	Homo sapiens	52-56
33950228-5	2021	Early phase (Phase I-II) studies of upadacitinib and filgotinib provided evidence for efficacy and safety of the selective JAK1 inhibitors in refractory populations of RA patients and allowed informed selection of the appropriate dose by balancing the optimal benefit-risk profile for further evaluation in the later successfully performed Phase III trials.	upadacitinib	36-48	Janus kinase 1	Homo sapiens	123-127
33950228-5	2021	Early phase (Phase I-II) studies of upadacitinib and filgotinib provided evidence for efficacy and safety of the selective JAK1 inhibitors in refractory populations of RA patients and allowed informed selection of the appropriate dose by balancing the optimal benefit-risk profile for further evaluation in the later successfully performed Phase III trials.	GLPG0634	53-63	Janus kinase 1	Homo sapiens	123-127
33950230-2	2021	JAK1 selective drugs, upadacitinib and filgotinib, have broadly come with the same overarching safety recommendations as other immunosuppressive drugs for RA: caution is needed regarding infection risk; monitoring for laboratory abnormalities, including lipids and muscle enzymes, is indicated.	upadacitinib	22-34	Janus kinase 1	Homo sapiens	0-4
33950230-2	2021	JAK1 selective drugs, upadacitinib and filgotinib, have broadly come with the same overarching safety recommendations as other immunosuppressive drugs for RA: caution is needed regarding infection risk; monitoring for laboratory abnormalities, including lipids and muscle enzymes, is indicated.	GLPG0634	39-49	Janus kinase 1	Homo sapiens	0-4
33950231-2	2021	Newer generations of Jak inhibitors, like upadacitinib and filgotinib, target Jak 1 selectively with the aim of maximizing efficacy and to improve safety.	upadacitinib	42-54	Janus kinase 1	Homo sapiens	78-83
33950231-2	2021	Newer generations of Jak inhibitors, like upadacitinib and filgotinib, target Jak 1 selectively with the aim of maximizing efficacy and to improve safety.	GLPG0634	59-69	Janus kinase 1	Homo sapiens	78-83
33755884-1	2021	INTRODUCTION: In the phase 2 CELEST study, positive efficacy results were obtained with the Janus kinase 1 inhibitor upadacitinib for adult patients with moderate to severe Crohn"s disease.	upadacitinib	117-129	Janus kinase 1	Homo sapiens	92-106
33585999-0	2021	Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer.	ruxolitinib	34-45	Janus kinase 1	Homo sapiens	17-23
33337992-1	2021	OBJECTIVES: Baricitinib is a Janus-kinase (JAK) 1/2 inhibitor, approved for the treatment of moderate-to-severe rheumatoid arthritis (RA) patients with inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs).	baricitinib	12-23	Janus kinase 1	Homo sapiens	29-51
33585999-2	2021	Ruxolitinib is an orally bioavailable JAK1/2 inhibitor.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	38-44
33667986-12	2021	Our results suggest that improved stability and abnormal accumulation of Tregs in tumor microenvironment is IL-10/JAK1/STAT5 signal pathway-dependent and provide a novel approach for improving the efficiency of anti-tumor immunotherapy.	tregs	73-78	Janus kinase 1	Homo sapiens	114-118
33527177-3	2021	Upadacitinib is a once-daily, oral Janus kinase (JAK) inhibitor with increased selectivity for JAK1 over JAK2, JAK3, and tyrosine kinase 2.	upadacitinib	0-12	Janus kinase 1	Homo sapiens	95-99
33523540-3	2021	The JAK1/2 inhibitor ruxolitinib has recently gained attention as a treatment option for HLH due to its broad cytokine-modulating abilities and safety profile.	ruxolitinib	21-32	Janus kinase 1	Homo sapiens	4-10
33156550-1	2021	Upadacitinib is a selective Janus Kinase 1 inhibitor, which was recently approved for treatment of rheumatoid arthritis (RA) and is currently being evaluated for treatment of several other autoimmune diseases, including atopic dermatitis (AD).	upadacitinib	0-12	Janus kinase 1	Homo sapiens	28-42
33792103-5	2021	Therapies include hydroxyurea for cytoreduction, hypomethylating agents, and the JAK1/2 inhibitor ruxolitinib to address splenomegaly and constitutional symptoms.	ruxolitinib	98-109	Janus kinase 1	Homo sapiens	81-87
33747209-0	2021	Ruxolitinib induces apoptosis of human colorectal cancer cells by downregulating the JAK1/2-STAT1-Mcl-1 axis.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	85-91
32981124-2	2021	We report a case that demonstrated the efficacy and feasibility of ruxolitinib a JAK 1/2 inhibitor in the treatment of chronic steroid-refractory GVHD (SR-GVHD).	ruxolitinib	67-78	Janus kinase 1	Homo sapiens	81-88
33747209-6	2021	Firstly, JAK1/2-STAT1 was identified as the target of ruxolitinib.	ruxolitinib	54-65	Janus kinase 1	Homo sapiens	9-15
33747209-10	2021	Taken together, the results showed that ruxolitinib decreased JAK1/2-STAT1-Mcl-1 protein level and effectively suppressed CRC cell proliferation in vitro and in vivo.	ruxolitinib	40-51	Janus kinase 1	Homo sapiens	62-68
33850568-0	2021	miR-20a-5p inhibits endometrial cancer progression by targeting janus kinase 1.	mir-20a-5p	0-10	Janus kinase 1	Homo sapiens	64-78
33850568-4	2021	Whether miR-20a-5p could inhibit EC progression by targeting janus kinase 1 (Jak1) was subsequently investigated.	mir-20a-5p	8-18	Janus kinase 1	Homo sapiens	61-75
33850568-4	2021	Whether miR-20a-5p could inhibit EC progression by targeting janus kinase 1 (Jak1) was subsequently investigated.	mir-20a-5p	8-18	Janus kinase 1	Homo sapiens	77-81
32981124-2	2021	We report a case that demonstrated the efficacy and feasibility of ruxolitinib a JAK 1/2 inhibitor in the treatment of chronic steroid-refractory GVHD (SR-GVHD).	Steroids	127-134	Janus kinase 1	Homo sapiens	81-88
33965175-1	2021	Ruxolitinib is a JAK2/JAK1 inhibitor that blocks the inflammatory JAK-STAT signaling pathway.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	22-26
33965175-1	2021	Ruxolitinib is a JAK2/JAK1 inhibitor that blocks the inflammatory JAK-STAT signaling pathway.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	17-20
33740386-0	2021	Filgotinib, a Novel JAK1-Preferential Inhibitor for the Treatment of Rheumatoid Arthritis: An Overview from Clinical Trials.	GLPG0634	0-10	Janus kinase 1	Homo sapiens	20-24
33909185-3	2021	Upadacitinib, a JAK1 inhibitor, has also been evaluated in a phase III trial for its efficacy and safety in AS.	upadacitinib	0-12	Janus kinase 1	Homo sapiens	16-20
33870531-1	2021	Baricitinib is a JAK1/2 inhibitor first approved for treating moderate to severe rheumatoid arthritis but later showed considerable efficacy in the control of exaggerated inflammatory responses that occur in a wide range of diseases.	baricitinib	0-11	Janus kinase 1	Homo sapiens	17-23
33954282-1	2021	Even after development of the JAK1/JAK2 inhibitor ruxolitinib, myeloproliferative neoplasm (MPN) patients require novel therapeutic options.	ruxolitinib	50-61	Janus kinase 1	Homo sapiens	30-34
33517393-9	2021	Interestingly, the STAT3 phosphorylation could be inhibited with ruxolitinib as well as tofacitinib, which are clinically approved JAK1 and JAK3 (to lesser extent JAK2 and JAK1) inhibitors, respectively.	ruxolitinib	65-76	Janus kinase 1	Homo sapiens	172-176
33517393-9	2021	Interestingly, the STAT3 phosphorylation could be inhibited with ruxolitinib as well as tofacitinib, which are clinically approved JAK1 and JAK3 (to lesser extent JAK2 and JAK1) inhibitors, respectively.	tofacitinib	88-99	Janus kinase 1	Homo sapiens	131-135
33517393-9	2021	Interestingly, the STAT3 phosphorylation could be inhibited with ruxolitinib as well as tofacitinib, which are clinically approved JAK1 and JAK3 (to lesser extent JAK2 and JAK1) inhibitors, respectively.	tofacitinib	88-99	Janus kinase 1	Homo sapiens	172-176
33981229-0	2021	Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-21
33740386-3	2021	Filgotinib has demonstrated preferential inhibition of JAK1-dependent cytokine signaling in in vitro assays.	GLPG0634	0-10	Janus kinase 1	Homo sapiens	55-59
33936080-6	2021	To the best of our knowledge, this is the first case study depicting an SLE patient with refractory alopecia who experienced impressive hair regrowth with the JAK1/3 inhibitor tofacitinib therapy, which contributes to expanding the field of possible uses of tofacitinib in SLE patients with difficult-to-treat cutaneous involvement, including severe alopecia.	tofacitinib	176-187	Janus kinase 1	Homo sapiens	159-165
33992887-4	2021	Similarly, preliminary studies have shown that JAK1/2 inhibitor treatment with ruxolitinib or baricitinib may decrease mortality by dampening the deadly cytokine storm, which - in addition to the virus itself - also contributes to multi-organ thrombosis and multi-organ failure.	ruxolitinib	79-90	Janus kinase 1	Homo sapiens	47-53
33936080-6	2021	To the best of our knowledge, this is the first case study depicting an SLE patient with refractory alopecia who experienced impressive hair regrowth with the JAK1/3 inhibitor tofacitinib therapy, which contributes to expanding the field of possible uses of tofacitinib in SLE patients with difficult-to-treat cutaneous involvement, including severe alopecia.	tofacitinib	258-269	Janus kinase 1	Homo sapiens	159-165
33992887-4	2021	Similarly, preliminary studies have shown that JAK1/2 inhibitor treatment with ruxolitinib or baricitinib may decrease mortality by dampening the deadly cytokine storm, which - in addition to the virus itself - also contributes to multi-organ thrombosis and multi-organ failure.	baricitinib	94-105	Janus kinase 1	Homo sapiens	47-53
33847204-3	2021	Among these, Filgotinib (FIL) has been developed as Janus kinase1 (JAK1) selective inhibitor, specifically targeting key pro-inflammatory mediators in RA pathogenesis.	GLPG0634	13-23	Janus kinase 1	Homo sapiens	52-65
33847204-3	2021	Among these, Filgotinib (FIL) has been developed as Janus kinase1 (JAK1) selective inhibitor, specifically targeting key pro-inflammatory mediators in RA pathogenesis.	GLPG0634	13-23	Janus kinase 1	Homo sapiens	67-71
33830087-3	2021	We previously showed that therapeutic targeting of JAK/STAT pathways using the first-generation JAK1/2 inhibitor, ruxolitinib, and the pan-JAK inhibitor, tofacitinib, was highly effective in the treatment of human AA, as well as prevention and reversal of AA in the C3H/HeJ mouse model.	ruxolitinib	114-125	Janus kinase 1	Homo sapiens	96-102
33845867-10	2021	INTERVENTION AND COMPARATOR: RUXOLITINIB (RUX) (14 days): An oral selective and potent inhibitor of Janus Associated Kinases (JAK1 and JAK2) and cell proliferation (Verstovek, 2010).	ruxolitinib	29-40	Janus kinase 1	Homo sapiens	126-130
33845867-10	2021	INTERVENTION AND COMPARATOR: RUXOLITINIB (RUX) (14 days): An oral selective and potent inhibitor of Janus Associated Kinases (JAK1 and JAK2) and cell proliferation (Verstovek, 2010).	ruxolitinib	29-32	Janus kinase 1	Homo sapiens	126-130
33827897-8	2021	Ruxolitinib, a JAK1/2 inhibitor, normalized interferon signature genes and all complement gene transcripts induced by SARS-CoV-2 in lung epithelial cell lines, but did not affect NF-kappaB-regulated genes.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-21
33222197-1	2021	Ruxolitinib (RUX), the first JAK1/JAK2 inhibitor approved for myelofibrosis (MF) therapy, has recently been associated with the occurrence of second primary malignancies (SPMs), mainly lymphomas and non-melanoma skin cancers (NMSCs).	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	29-33
33222197-1	2021	Ruxolitinib (RUX), the first JAK1/JAK2 inhibitor approved for myelofibrosis (MF) therapy, has recently been associated with the occurrence of second primary malignancies (SPMs), mainly lymphomas and non-melanoma skin cancers (NMSCs).	ruxolitinib	13-16	Janus kinase 1	Homo sapiens	29-33
33744327-3	2021	OBJECTIVE: To determine whether GDC-0214 reduces fractional exhaled nitric oxide (FeNO), a JAK1-dependent biomarker of airway inflammation, in patients with mild asthma.	gdc-0214	32-40	Janus kinase 1	Homo sapiens	91-95
33795598-1	2022	BACKGROUND: Ruxolitinib, a JAK1/2 inhibitor, is used to treat chronic graft-versus-host-disease (cGVHD) in adult allogeneic hematopoietic stem cell transplant patients, but experience in children is limited, perhaps due to lack of pediatric dosing information.	ruxolitinib	12-23	Janus kinase 1	Homo sapiens	27-33
32989920-1	2021	Filgotinib (FIL) is a potent and selective JAK1 inhibitor in clinical development for treatment of severe inflammatory diseases.	GLPG0634	0-10	Janus kinase 1	Homo sapiens	43-47
32989920-1	2021	Filgotinib (FIL) is a potent and selective JAK1 inhibitor in clinical development for treatment of severe inflammatory diseases.	GLPG0634	12-15	Janus kinase 1	Homo sapiens	43-47
33423550-3	2021	Momelotinib (MMB) has been investigated in over 820 patients with MF and possesses a pharmacological and clinical profile differentiated from other JAKi by inhibition of JAK1, JAK2 and ACVR1.	N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	0-11	Janus kinase 1	Homo sapiens	170-174
33423550-3	2021	Momelotinib (MMB) has been investigated in over 820 patients with MF and possesses a pharmacological and clinical profile differentiated from other JAKi by inhibition of JAK1, JAK2 and ACVR1.	N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	13-16	Janus kinase 1	Homo sapiens	170-174
32814839-0	2021	Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study.	ruxolitinib	38-49	Janus kinase 1	Homo sapiens	21-27
32814839-2	2021	Ruxolitinib is a JAK1/JAK2 inhibitor with potent anti-inflammatory properties.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	17-21
33741556-0	2021	JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.	GLPG0634	103-113	Janus kinase 1	Homo sapiens	0-3
33741556-0	2021	JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.	upadacitinib	115-127	Janus kinase 1	Homo sapiens	0-3
33741556-0	2021	JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.	tofacitinib	129-140	Janus kinase 1	Homo sapiens	0-3
33741556-0	2021	JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.	baricitinib	145-156	Janus kinase 1	Homo sapiens	0-3
33741556-7	2021	JAK1-dependent pathways (interferon (IFN)alpha/pSTAT5, interleukin (IL)-6/pSTAT1) were among the most potently inhibited by all JAKinibs in healthy and RA blood, with filgotinib exhibiting the greatest selectivity for JAK1 pathways.	GLPG0634	167-177	Janus kinase 1	Homo sapiens	0-4
33741556-9	2021	Ex vivo pharmacodynamic data from phase 1 healthy volunteers clinically confirmed JAK1 selectivity of filgotinib.	GLPG0634	102-112	Janus kinase 1	Homo sapiens	82-86
33741556-10	2021	CONCLUSION: Filgotinib inhibited JAK1-mediated signalling similarly to other JAKinibs, but with less inhibition of JAK2-dependent and JAK3-dependent pathways, providing a mechanistic rationale for its apparently differentiated efficacy:safety profile.	GLPG0634	12-22	Janus kinase 1	Homo sapiens	33-37
33618802-5	2021	In this study, they show that inhibition of granzyme B with the Jak1/3 inhibitor, tofacitinib, is associated with decreased severity of cutaneous lesions without the attenuation of T helper type 1 signaling or parasite control.	tofacitinib	82-93	Janus kinase 1	Homo sapiens	64-70
33662027-0	2021	Differential responses to folic acid in an established keloid fibroblast cell line are mediated by JAK1/2 and STAT3.	Folic Acid	26-36	Janus kinase 1	Homo sapiens	99-105
33662027-5	2021	In healthy volunteer fibroblasts, folic acid exposure recapitulated the exaggerated closure and hyper-glycolytic state of keloid fibroblasts through JAK1/2- and STAT3-dependent pathways.	Folic Acid	34-44	Janus kinase 1	Homo sapiens	149-155
32648334-1	2021	This phase 1 study characterized the effect of multiple doses of upadacitinib, an oral Janus kinase 1 selective inhibitor, on the pharmacokinetics of the cytochrome P450 (CYP) 2B6 substrate bupropion.	upadacitinib	65-77	Janus kinase 1	Homo sapiens	87-101
32648334-1	2021	This phase 1 study characterized the effect of multiple doses of upadacitinib, an oral Janus kinase 1 selective inhibitor, on the pharmacokinetics of the cytochrome P450 (CYP) 2B6 substrate bupropion.	Bupropion	190-199	Janus kinase 1	Homo sapiens	87-101
33693561-2	2022	Ruxolitinib, a Jak 1/2 inhibitor, reduces systemic inflammation for individuals without HIV and HIV reservoir markers ex vivo.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-22
33600915-1	2021	BACKGROUND: Baricitinib, an oral, selective Janus kinase (JAK)1/JAK2 inhibitor, is being studied for moderate-to-severe atopic dermatitis (AD) in adults.	baricitinib	12-23	Janus kinase 1	Homo sapiens	44-63
33495807-11	2021	The inhibition of SOCS3 significantly activated JAK1/STAT3 signaling, as well as enhancing the levels of TNF-alpha, IL-6 and IL-1beta, and promoting apoptosis, which was reversed by the JAK1 inhibitor Tofacitinib.	tofacitinib	201-212	Janus kinase 1	Homo sapiens	186-190
33598678-8	2021	Targeting JAK/STAT pathway with the JAK1/2 inhibitor ruxolitinib or HDAC with belinostat both independently increased dependence on BCL-2 but not MCL-1, thereby sensitizing T-PLL cells to venetoclax.	ruxolitinib	53-64	Janus kinase 1	Homo sapiens	10-13
33598678-8	2021	Targeting JAK/STAT pathway with the JAK1/2 inhibitor ruxolitinib or HDAC with belinostat both independently increased dependence on BCL-2 but not MCL-1, thereby sensitizing T-PLL cells to venetoclax.	ruxolitinib	53-64	Janus kinase 1	Homo sapiens	36-42
33598678-8	2021	Targeting JAK/STAT pathway with the JAK1/2 inhibitor ruxolitinib or HDAC with belinostat both independently increased dependence on BCL-2 but not MCL-1, thereby sensitizing T-PLL cells to venetoclax.	belinostat	78-88	Janus kinase 1	Homo sapiens	10-13
33495807-11	2021	The inhibition of SOCS3 significantly activated JAK1/STAT3 signaling, as well as enhancing the levels of TNF-alpha, IL-6 and IL-1beta, and promoting apoptosis, which was reversed by the JAK1 inhibitor Tofacitinib.	tofacitinib	201-212	Janus kinase 1	Homo sapiens	48-52
33658996-5	2020	Ruxolitinib cream is a potent and selective JAK1/2 inhibitor currently undergoing clinical evaluation in adults with mild-to-moderate AD (NCT03745638, NCT03920852 and NCT03745651).	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	44-50
33586434-4	2022	Especially, compounds 15d and 15h potently inhibited JAK1/2/3 and HDAC1/6 and displayed antiproliferative and proapoptotic activities in triple-negative breast cancer cell lines.	(1s)-1-(1-{3-[4-(1,3-Benzothiazol-2-Ylamino)phenoxy]pyrazin-2-Yl}piperidin-4-Yl)ethanol	30-33	Janus kinase 1	Homo sapiens	53-61
33587766-2	2021	(1) Tofacitinib is an effective oral JAK 1/3 inhibitor that can block IL-2, IL-7 and IL-6 and is reported as an option for alopecia areata treatment.	tofacitinib	4-15	Janus kinase 1	Homo sapiens	37-44
33475190-9	2021	In addition, activation of the Jak1/Stat3 signaling pathway leads to high calcitriol levels and low parathyroid hormone production.	Calcitriol	74-84	Janus kinase 1	Homo sapiens	31-35
33634982-0	2021	Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF-kB signaling pathways synergistically.	Arsenic Trioxide	0-16	Janus kinase 1	Homo sapiens	116-120
33634982-8	2021	Synergistic inhibition of the LIF/JAK1/STAT3 and NF-kB signaling pathways by ATO and 5-FU/cisplatin is a potential molecular mechanism underlying the differentiation effect.	Arsenic Trioxide	77-80	Janus kinase 1	Homo sapiens	34-38
33634982-8	2021	Synergistic inhibition of the LIF/JAK1/STAT3 and NF-kB signaling pathways by ATO and 5-FU/cisplatin is a potential molecular mechanism underlying the differentiation effect.	Fluorouracil	85-89	Janus kinase 1	Homo sapiens	34-38
33634982-8	2021	Synergistic inhibition of the LIF/JAK1/STAT3 and NF-kB signaling pathways by ATO and 5-FU/cisplatin is a potential molecular mechanism underlying the differentiation effect.	Cisplatin	90-99	Janus kinase 1	Homo sapiens	34-38
33634982-9	2021	CONCLUSIONS: ATO induced the differentiation of HCC CSCs and potentiated the cytotoxic effects of 5-FU/cisplatin through synergistic inhibition of the LIF/JAK1/STAT3 and NF-kB signaling pathways.	Arsenic Trioxide	13-16	Janus kinase 1	Homo sapiens	155-159
33634982-9	2021	CONCLUSIONS: ATO induced the differentiation of HCC CSCs and potentiated the cytotoxic effects of 5-FU/cisplatin through synergistic inhibition of the LIF/JAK1/STAT3 and NF-kB signaling pathways.	Fluorouracil	98-102	Janus kinase 1	Homo sapiens	155-159
33634982-9	2021	CONCLUSIONS: ATO induced the differentiation of HCC CSCs and potentiated the cytotoxic effects of 5-FU/cisplatin through synergistic inhibition of the LIF/JAK1/STAT3 and NF-kB signaling pathways.	Cisplatin	103-112	Janus kinase 1	Homo sapiens	155-159
31916502-0	2021	Molecular modeling studies of pyrrolo[2,3-d]pyrimidin-4-amine derivatives as JAK1 inhibitors based on 3D-QSAR, molecular docking, molecular dynamics (MD) and MM-PBSA calculations.	7-deazaadenine	30-61	Janus kinase 1	Homo sapiens	77-81
33597887-7	2020	In addition, curcumin significantly inhibited the activation of the JAK1/STAT5 signaling pathway, downregulation of JAK1, STAT5, and p-STAT5 proteins in colon tissue, and upregulation of PIAS1 proteins.	Curcumin	13-21	Janus kinase 1	Homo sapiens	68-72
33597887-7	2020	In addition, curcumin significantly inhibited the activation of the JAK1/STAT5 signaling pathway, downregulation of JAK1, STAT5, and p-STAT5 proteins in colon tissue, and upregulation of PIAS1 proteins.	Curcumin	13-21	Janus kinase 1	Homo sapiens	116-120
33597887-8	2020	These results suggested that curcumin effectively regulated the differentiation of naive, TCM, and TEM cells in the peripheral blood to alleviate DSS-induced experimental colitis, which might be related to the inhibition of JAK1/STAT5 signaling activity.	Curcumin	29-37	Janus kinase 1	Homo sapiens	224-228
33597887-8	2020	These results suggested that curcumin effectively regulated the differentiation of naive, TCM, and TEM cells in the peripheral blood to alleviate DSS-induced experimental colitis, which might be related to the inhibition of JAK1/STAT5 signaling activity.	Dextran Sulfate	146-149	Janus kinase 1	Homo sapiens	224-228
32926462-2	2021	Baricitinib, an oral, reversible, selective inhibitor of JAK1/JAK2, is in late-stage development for adult patients with moderate-to-severe AD.	baricitinib	0-11	Janus kinase 1	Homo sapiens	57-61
33465556-6	2021	Notably, STAT3 knockdown or upstream inhibition through the JAK1/2 kinase inhibitor ruxolitinib prevented opioid-induced breast cancer cell metastasis and migration in vitro and in vivo.	ruxolitinib	84-95	Janus kinase 1	Homo sapiens	60-66
31916502-0	2021	Molecular modeling studies of pyrrolo[2,3-d]pyrimidin-4-amine derivatives as JAK1 inhibitors based on 3D-QSAR, molecular docking, molecular dynamics (MD) and MM-PBSA calculations.	poly(tetramethylene succinate-co-tetramethylene adipate)	161-165	Janus kinase 1	Homo sapiens	77-81
31916502-5	2021	In this study, we have performed three-dimensional quantitative structure-activity relationship (3 D-QSAR), molecular docking, molecular dynamics (MD) and free energy calculations on a series of pyrrolo[2,3-d]pyrimidin-4-amine JAK1 inhibitors.	7-deazaadenine	195-226	Janus kinase 1	Homo sapiens	227-231
31916502-9	2021	Analysis of the MD results of the most active compound (compound 49) with JAK1 showed the formation of H-bond interactions with residues Glu957, Leu959 and Gly887 and water-mediated H-bond interaction with Gly887 and His885.	Water	167-172	Janus kinase 1	Homo sapiens	74-78
31916502-12	2021	MM-PBSA based free energy calculations indicated that the designed compounds were able to form stable binding with JAK1 primarily through electrostatic interactions and van der Waal interactions.	poly(tetramethylene succinate-co-tetramethylene adipate)	3-7	Janus kinase 1	Homo sapiens	115-119
33428419-0	2021	Discovery and Biological Evaluation of N-Methyl-pyrrolo[2,3-b]pyridine-5-carboxamide Derivatives as JAK1-Selective Inhibitors.	n-methyl-pyrrolo[2,3-b]pyridine-5-carboxamide	39-84	Janus kinase 1	Homo sapiens	100-104
33509955-5	2021	METHODS: Assessment of cell senescence in lungs and cultured lung cells from patients with COPD and controls subjected to PLA2R1 knock-down, PLA2R1 gene transduction and treatment with the JAK1/2 inhibitor ruxolitinib.	ruxolitinib	206-217	Janus kinase 1	Homo sapiens	189-195
33504485-1	2021	OBJECTIVE: To evaluate the efficacy and safety of the Janus kinase-1-preferential inhibitor filgotinib versus placebo or tumour necrosis factor-alpha inhibitor therapy in patients with active rheumatoid arthritis (RA) despite ongoing treatment with methotrexate (MTX).	GLPG0634	92-102	Janus kinase 1	Homo sapiens	54-68
33434286-1	2021	Itacitinib is a potent, selective JAK-1 inhibitor currently in development for the treatment of chronic graft-versus-host-disease (GVHD) in combination with corticosteroids.	INCB039110	0-10	Janus kinase 1	Homo sapiens	34-39
32986914-3	2021	Herein we show that such ring systems can be useful for medicinal chemistry at the example of the enantioselective synthesis of triquinazine, a novel chiral piperazine analog derived from angular triquinane, and it"s use to design a nanomolar and selective inhibitor of Janus Kinase 1 related to the marketed drug Tofacitinib useful to treat auto-immune diseases.	triquinazine	128-140	Janus kinase 1	Homo sapiens	270-284
32986914-3	2021	Herein we show that such ring systems can be useful for medicinal chemistry at the example of the enantioselective synthesis of triquinazine, a novel chiral piperazine analog derived from angular triquinane, and it"s use to design a nanomolar and selective inhibitor of Janus Kinase 1 related to the marketed drug Tofacitinib useful to treat auto-immune diseases.	Piperazine	157-167	Janus kinase 1	Homo sapiens	270-284
32986914-3	2021	Herein we show that such ring systems can be useful for medicinal chemistry at the example of the enantioselective synthesis of triquinazine, a novel chiral piperazine analog derived from angular triquinane, and it"s use to design a nanomolar and selective inhibitor of Janus Kinase 1 related to the marketed drug Tofacitinib useful to treat auto-immune diseases.	triquinane	196-206	Janus kinase 1	Homo sapiens	270-284
32986914-3	2021	Herein we show that such ring systems can be useful for medicinal chemistry at the example of the enantioselective synthesis of triquinazine, a novel chiral piperazine analog derived from angular triquinane, and it"s use to design a nanomolar and selective inhibitor of Janus Kinase 1 related to the marketed drug Tofacitinib useful to treat auto-immune diseases.	tofacitinib	314-325	Janus kinase 1	Homo sapiens	270-284
33278358-2	2021	Baricitinib, a clinically approved JAK1/JAK2 inhibitor, is currently being investigated in COVID-19 clinical trials.	baricitinib	0-11	Janus kinase 1	Homo sapiens	35-39
33452004-1	2021	OBJECTIVES: To investigate efficacy and safety of the Janus kinase-1 inhibitor filgotinib in patients with active rheumatoid arthritis (RA) with limited or no prior methotrexate (MTX) exposure.	GLPG0634	79-89	Janus kinase 1	Homo sapiens	54-68
33489899-8	2020	Accordingly, ruxolitinib is the only selective JAK1 and JAK2-inhibitor approved for the treatment of myelofibrosis and aGVHD.	ruxolitinib	13-24	Janus kinase 1	Homo sapiens	47-51
33129109-4	2021	We previously performed a high-throughput screen that demonstrated additive/synergistic activity of Ruxolitinib, a JAK1/2 inhibitor, with AZD8055, an mTORC1/C2 inhibitor.	ruxolitinib	100-111	Janus kinase 1	Homo sapiens	115-121
32783069-8	2021	RESULTS: Stimulation with IL-17A induced STAT3 phosphorylation, which was inhibited by the pretreatment with JAK2 inhibitor AZD1480 or JAK1/3 inhibitor tofacitinib.	tofacitinib	152-163	Janus kinase 1	Homo sapiens	135-141
32829958-2	2021	Tofacitinib is one of these inhibitors targeting JAK1 and JAK3, and its efficacy has been demonstrated in the treatment of moderate to severe ulcerative colitis (UC).	tofacitinib	0-11	Janus kinase 1	Homo sapiens	49-53
33397481-1	2021	Baricitinib is an oral selective inhibitor of Janus kinase (JAK)1 and JAK2 that has proved effective and well tolerated in the treatment of rheumatoid arthritis (RA) in an extensive programme of clinical studies of patients with moderate-to-severe disease.	baricitinib	0-11	Janus kinase 1	Homo sapiens	46-65
33502484-1	2021	Importance: Ruxolitinib, a selective inhibitor of the Janus kinases 1/2 signaling pathway, has shown a significant response in steroid-refractory chronic graft-vs-host disease (SR-cGVHD), a major cause of morbidity and mortality in individuals who have undergone allogeneic hematopoietic stem cell transplantation (HSCT).	ruxolitinib	12-23	Janus kinase 1	Homo sapiens	54-71
33502484-1	2021	Importance: Ruxolitinib, a selective inhibitor of the Janus kinases 1/2 signaling pathway, has shown a significant response in steroid-refractory chronic graft-vs-host disease (SR-cGVHD), a major cause of morbidity and mortality in individuals who have undergone allogeneic hematopoietic stem cell transplantation (HSCT).	Steroids	127-134	Janus kinase 1	Homo sapiens	54-71
33129109-4	2021	We previously performed a high-throughput screen that demonstrated additive/synergistic activity of Ruxolitinib, a JAK1/2 inhibitor, with AZD8055, an mTORC1/C2 inhibitor.	(5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol	138-145	Janus kinase 1	Homo sapiens	115-121
33129109-6	2021	Here, we demonstrated that Upadacitinib, a JAK-1 inhibitor, inhibited the proliferation of cytokine-dependent ATL cell lines and the expression of p-STAT5.	upadacitinib	27-39	Janus kinase 1	Homo sapiens	43-48
33374783-0	2020	Curcumin Analogue L48H37 Suppresses Human Osteosarcoma U2OS and MG-63 Cells" Migration and Invasion in Culture by Inhibition of uPA via the JAK/STAT Signaling Pathway.	1-ethyl-3,5-bis[(3,4,5-trimethoxyphenyl)methylidene]piperidin-4-one	18-24	Janus kinase 1	Homo sapiens	140-143
33374783-0	2020	Curcumin Analogue L48H37 Suppresses Human Osteosarcoma U2OS and MG-63 Cells" Migration and Invasion in Culture by Inhibition of uPA via the JAK/STAT Signaling Pathway.	Curcumin	0-8	Janus kinase 1	Homo sapiens	140-143
33357183-0	2021	Design and Synthesis of New JAK1 Inhibitors based on SulfonamideTriazine Conjugates.	sulfonamidetriazine	53-72	Janus kinase 1	Homo sapiens	28-32
33357183-1	2021	AIMS: Design of sulfonamide-triazine derivatives as JAK1 inhibitors.	sulfonamide-triazine	16-36	Janus kinase 1	Homo sapiens	52-56
33357183-4	2021	OBJECTIVES: To design new JAK1 inhibitors based on sulfonamides-triazine conjugates capable of binding interactions comparable to observed interactions anchoring potent crystallographic JAK1 inhibitors.	Sulfonamides	51-63	Janus kinase 1	Homo sapiens	26-30
33357183-4	2021	OBJECTIVES: To design new JAK1 inhibitors based on sulfonamides-triazine conjugates capable of binding interactions comparable to observed interactions anchoring potent crystallographic JAK1 inhibitors.	Sulfonamides	51-63	Janus kinase 1	Homo sapiens	186-190
33357183-4	2021	OBJECTIVES: To design new JAK1 inhibitors based on sulfonamides-triazine conjugates capable of binding interactions comparable to observed interactions anchoring potent crystallographic JAK1 inhibitors.	Triazines	64-72	Janus kinase 1	Homo sapiens	26-30
33357183-4	2021	OBJECTIVES: To design new JAK1 inhibitors based on sulfonamides-triazine conjugates capable of binding interactions comparable to observed interactions anchoring potent crystallographic JAK1 inhibitors.	Triazines	64-72	Janus kinase 1	Homo sapiens	186-190
33357183-5	2021	METHODS: The crystallographic structures of 4 diverse nanomolar inhibitors complexed within JAK1 were used to guide the synthesis of new diaminotriazine-sulfonamide-based JAK1 inhibitors.	diaminotriazine	137-152	Janus kinase 1	Homo sapiens	92-96
33357183-5	2021	METHODS: The crystallographic structures of 4 diverse nanomolar inhibitors complexed within JAK1 were used to guide the synthesis of new diaminotriazine-sulfonamide-based JAK1 inhibitors.	diaminotriazine	137-152	Janus kinase 1	Homo sapiens	171-175
33357183-5	2021	METHODS: The crystallographic structures of 4 diverse nanomolar inhibitors complexed within JAK1 were used to guide the synthesis of new diaminotriazine-sulfonamide-based JAK1 inhibitors.	Sulfonamides	153-164	Janus kinase 1	Homo sapiens	92-96
33357183-5	2021	METHODS: The crystallographic structures of 4 diverse nanomolar inhibitors complexed within JAK1 were used to guide the synthesis of new diaminotriazine-sulfonamide-based JAK1 inhibitors.	Sulfonamides	153-164	Janus kinase 1	Homo sapiens	171-175
33357183-7	2021	CONCLUSIONS: Crystallographic complexes of diverse JAK1 inhibitors were successfully used to guide the synthesis of novel sulfonamide-triazine-based low micromolar JAK1 inhibitors.	sulfonamide-triazine	122-142	Janus kinase 1	Homo sapiens	51-55
33357183-7	2021	CONCLUSIONS: Crystallographic complexes of diverse JAK1 inhibitors were successfully used to guide the synthesis of novel sulfonamide-triazine-based low micromolar JAK1 inhibitors.	sulfonamide-triazine	122-142	Janus kinase 1	Homo sapiens	164-168
33374783-5	2020	L48H37 decreased the phosphorylation of STAT3, JAK1, JAK2, and JAK3 in U2OS cells, but did not affect the phosphorylation of ERK, JNK, p38, and Akt.	1-ethyl-3,5-bis[(3,4,5-trimethoxyphenyl)methylidene]piperidin-4-one	0-6	Janus kinase 1	Homo sapiens	47-51
33374783-7	2020	Collectively, L48H37 represses the invasion and migration capabilities of U2OS and MG-63 cells by the suppression of uPA expression and the inhibition of JAK/STAT signaling.	1-ethyl-3,5-bis[(3,4,5-trimethoxyphenyl)methylidene]piperidin-4-one	14-20	Janus kinase 1	Homo sapiens	154-157
33323549-6	2020	The signaling pathways associated with JAK1 expression were identified by performing a GSEA.	gsea	87-91	Janus kinase 1	Homo sapiens	39-43
33338537-9	2021	Conversely, JAK2 inhibition by Ruxolitinib (JAK1/2 inhibitor) or BMS-911543 (JAK2 inhibitor) abrogated the differentiation from monocytes into IDEC.	ruxolitinib	31-42	Janus kinase 1	Homo sapiens	44-50
32998963-0	2020	Itacitinib (INCB039110), a JAK1 inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-Cell Therapy.	INCB039110	0-10	Janus kinase 1	Homo sapiens	27-31
33338001-1	2021	OBJECTIVES: Baricitinib, an oral Janus kinase (JAK) 1-2 inhibitor, is currently used along biologic DMARDs (bDMARDs) after the failure of methotrexate (MTX) in rheumatoid arthritis (RA).	baricitinib	12-23	Janus kinase 1	Homo sapiens	33-55
33044324-9	2020	NEAT1 accelerated proliferation and weakened apoptosis of neuroblastoma cells treated by cisplatin by targeting miR-326 through activating JAK1/STAT3 signaling pathway, suggesting that NEAT1 was a potential biomarker against neuroblastoma.	Cisplatin	89-98	Janus kinase 1	Homo sapiens	139-143
32776305-0	2020	Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib.	upadacitinib	75-87	Janus kinase 1	Homo sapiens	10-14
32776305-7	2020	Upadacitinib and abrocitinib are oral small molecules that inhibit the JAK/STAT pathway by selectively blocking JAK1.	upadacitinib	0-12	Janus kinase 1	Homo sapiens	112-116
32818555-1	2020	Ruxolitinib is an oral JAK1/2 inhibitor that is approved for use in patients with intermediate and high-risk myelofibrosis (MF) based on its proven spleen and symptom burden reduction.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	23-29
32998963-0	2020	Itacitinib (INCB039110), a JAK1 inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-Cell Therapy.	INCB039110	12-22	Janus kinase 1	Homo sapiens	27-31
32998963-7	2020	RESULTS: We report that itacitinib, a potent, selective JAK1 inhibitor, was able to significantly and dose-dependently reduce levels of multiple cytokines implicated in CRS in several in vitro and in vivo models.	INCB039110	24-34	Janus kinase 1	Homo sapiens	56-60
32876903-1	2020	INTRODUCTION: Baricitinib is an oral selective inhibitor of Janus kinase (JAK) 1 and JAK 2, which has demonstrated significant efficacy in patients with moderately to severely active rheumatoid arthritis (RA).	baricitinib	14-25	Janus kinase 1	Homo sapiens	60-80
32801162-5	2020	As a result, increased P-Tyr was detected in previously reported TSLP-activated tyrosine kinases and substrates, including JAK1, JAK2, STAT5, and ERK1/2.	Phosphotyrosine	23-28	Janus kinase 1	Homo sapiens	123-127
32789663-7	2020	Ruxolitinib, a tyrosine kinase inhibitor selective for JAK1, 2, blocks many pro- and anti-inflammatory cytokines including IL6.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	55-59
33354610-0	2021	Bridging to a selective Janus kinase 1 inhibitor in severe atopic dermatitis: An instructive case with upadacitinib.	upadacitinib	103-115	Janus kinase 1	Homo sapiens	24-38
32738501-1	2020	Ruxolitinib, a selective Janus kinase (JAK)1/2 inhibitor, has recently been proposed for steroid refractory chronic graft-versus host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation (HSCT), particularly in severe skin cGVHD.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	39-46
32738501-1	2020	Ruxolitinib, a selective Janus kinase (JAK)1/2 inhibitor, has recently been proposed for steroid refractory chronic graft-versus host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation (HSCT), particularly in severe skin cGVHD.	Steroids	89-96	Janus kinase 1	Homo sapiens	39-46
33162993-8	2020	Also, Janus Associated Kinases (JAK1 and JAK2) inhibitors, such as itacitinib (JAK1) and ruxolitinib (JAK1 and 2), are promising in the treatment of cGvHD.	INCB039110	67-77	Janus kinase 1	Homo sapiens	32-36
32593209-4	2020	Here, we report a compelling case of a 55-yo patient with proven COVID-19 pneumonia, who was taking the JAK1/2 inhibitor ruxolitinib in-label for co-existing primary myelofibrosis for 15 months prior to coronavirus infection.	ruxolitinib	121-132	Janus kinase 1	Homo sapiens	104-110
33102814-0	2020	Cucurbitacin E and I target the JAK/STAT pathway and induce apoptosis in Sezary cells.	cucurbitacin E	0-14	Janus kinase 1	Homo sapiens	32-35
33102814-9	2020	Furthermore, while JAK2 inhibition leads to decreased viability in SeAx cells (IC50 of 9.98 and 29.15 muM for AZD1480 and ruxolitinib respectively), both JAK1 and JAK3 do not.	ruxolitinib	122-133	Janus kinase 1	Homo sapiens	154-158
32861662-0	2020	Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases.	INCB039110	32-42	Janus kinase 1	Homo sapiens	88-92
32861662-0	2020	Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases.	INCB039110	44-54	Janus kinase 1	Homo sapiens	88-92
32861662-3	2020	We used recombinant enzymes and primary human lymphocytes to assess the JAK1 specificity of itacitinib (INCB039110) and study inhibition of signal transducers and activators of transcription (STAT) signaling.	INCB039110	92-102	Janus kinase 1	Homo sapiens	72-76
32861662-5	2020	Itacitinib is a potent and selective JAK1 inhibitor when profiled against the other JAK family members.	INCB039110	0-10	Janus kinase 1	Homo sapiens	37-41
33055240-6	2020	Through independent mechanisms, overexpression of NLRC5 (nucleotide-binding oligomerization domain-like receptor family caspase recruitment domain containing 5) and intratumoral delivery of BO-112, a potent nanoplexed version of polyinosinic:polycytidylic acid (poly I:C), each restored the efficacy of ACT against B16-Jak1 KO tumors.	bo-112	190-196	Janus kinase 1	Homo sapiens	319-323
33332480-3	2020	Upadacitinib tartrate (Rinvoq), a selective and reversible JAK1 inhibitor, inhibited interleukin (IL)-6 and IL-7 and ameliorated adjuvant-induced arthritis in preclinical studies.	Upadacitinib tartrate	0-21	Janus kinase 1	Homo sapiens	59-63
33332480-3	2020	Upadacitinib tartrate (Rinvoq), a selective and reversible JAK1 inhibitor, inhibited interleukin (IL)-6 and IL-7 and ameliorated adjuvant-induced arthritis in preclinical studies.	upadacitinib	23-29	Janus kinase 1	Homo sapiens	59-63
32777582-2	2020	This case report on a critically ill patient with secondary hemophagocytic lymphohistiocytosis due to falciparum malaria treated successfully with ruxolitinib, demonstrates that JAK1/2 inhibition might be a promising treatment option for severe cases.	ruxolitinib	147-158	Janus kinase 1	Homo sapiens	178-184
33114733-1	2020	Ruxolitinib (RUX), a JAK1/JAK2 inhibitor, is approved for second-line therapy in patients with polycythemia vera (PV) who are resistant or intolerant to hydroxyurea.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	21-25
33114733-1	2020	Ruxolitinib (RUX), a JAK1/JAK2 inhibitor, is approved for second-line therapy in patients with polycythemia vera (PV) who are resistant or intolerant to hydroxyurea.	ruxolitinib	13-16	Janus kinase 1	Homo sapiens	21-25
33194706-3	2020	MS is treated with ruxolitinib, a selective JAK1 and JAK2 inhibitor.	ruxolitinib	19-30	Janus kinase 1	Homo sapiens	44-48
33193430-8	2020	Currently many trials with JAKinibs are ongoing for PsA and axSpA, with one phase III trial of upadacitinib (selective JAK1 inhibitor) showing good therapeutic response in active radiographic axSpA.	upadacitinib	95-107	Janus kinase 1	Homo sapiens	119-123
33087723-5	2020	Accordingly, patient-derived lymphocytes exhibit increased STAT activation in vitro in response to interferon-gamma, IL-2 and IL-4 that is reverted by the JAK1/JAK2 inhibitor ruxolitinib.	ruxolitinib	175-186	Janus kinase 1	Homo sapiens	155-159
32870648-4	2020	mVP40 also inhibits interferon (IFN) signaling by inhibiting the function of Janus kinase 1 (JAK1).	mvp40	0-5	Janus kinase 1	Homo sapiens	77-91
32870648-4	2020	mVP40 also inhibits interferon (IFN) signaling by inhibiting the function of Janus kinase 1 (JAK1).	mvp40	0-5	Janus kinase 1	Homo sapiens	93-97
33162993-8	2020	Also, Janus Associated Kinases (JAK1 and JAK2) inhibitors, such as itacitinib (JAK1) and ruxolitinib (JAK1 and 2), are promising in the treatment of cGvHD.	INCB039110	67-77	Janus kinase 1	Homo sapiens	79-83
33162993-8	2020	Also, Janus Associated Kinases (JAK1 and JAK2) inhibitors, such as itacitinib (JAK1) and ruxolitinib (JAK1 and 2), are promising in the treatment of cGvHD.	ruxolitinib	89-100	Janus kinase 1	Homo sapiens	32-36
33162993-8	2020	Also, Janus Associated Kinases (JAK1 and JAK2) inhibitors, such as itacitinib (JAK1) and ruxolitinib (JAK1 and 2), are promising in the treatment of cGvHD.	ruxolitinib	89-100	Janus kinase 1	Homo sapiens	102-112
33028646-8	2020	To our knowledge, this report provides the most detailed look yet at defective JAK1 signaling in the context of dMMR and immunotherapy resistance.	dmmr	112-116	Janus kinase 1	Homo sapiens	79-83
32697338-3	2020	Similarly, the role of the JAK1/JAK2 inhibitor ruxolitinib (RUX) is not well defined in patients who have increased blasts.	ruxolitinib	47-58	Janus kinase 1	Homo sapiens	27-31
32788396-1	2020	OBJECTIVES: To evaluate the incidence of infection in patients with active rheumatoid arthritis (RA) treated with baricitinib, an oral selective Janus kinase (JAK)1 and JAK2 inhibitor.	baricitinib	114-125	Janus kinase 1	Homo sapiens	145-164
32592721-0	2020	Natural cardenolides suppress coronaviral replication by downregulating JAK1 via a Na+/K+-ATPase independent proteolysis.	Cardenolides	8-20	Janus kinase 1	Homo sapiens	72-76
32697338-3	2020	Similarly, the role of the JAK1/JAK2 inhibitor ruxolitinib (RUX) is not well defined in patients who have increased blasts.	ruxolitinib	60-63	Janus kinase 1	Homo sapiens	27-31
32329368-7	2020	Quercetin treatment led to significantly higher levels of p-PI3K, p-AKT, p-JAK1, and p-STAT3.	Quercetin	0-9	Janus kinase 1	Homo sapiens	75-79
32703039-5	2020	Baricitinib, a novel JAK1/JAK2 inhibitor is currently under investigation in AD clinical trials.	baricitinib	0-11	Janus kinase 1	Homo sapiens	21-25
32329368-9	2020	CONCLUSION: Quercetin can mitigate LPS-induced injury in HOKs by downregulating miR-22, thereby activating PI3K/AKT and JAK1/STAT3 cascades.	Quercetin	12-21	Janus kinase 1	Homo sapiens	120-124
33037080-8	2020	CONCLUSION: Baricitinib treatment induced significant reduction in the RNA expression of a network of genes associated with the JAK/STAT pathway, cytokine signalling and SLE pathogenesis.	baricitinib	12-23	Janus kinase 1	Homo sapiens	128-131
32768575-10	2020	Inhibition of the IL-6/JAK/STAT3 pathway with the JAK1/2 specific inhibitor, AZD1480, reversed the associated increase of IL-6.	AZD 1480	77-84	Janus kinase 1	Homo sapiens	50-56
33092696-13	2020	In addition, we pretreated the JAK1 or STAT3 inhibitor with testosterone to block the signaling transduction before CFT073 and J96 UPEC infection, and found the significant restoring in both the sizes of IBCs and bacterial numbers in RWPE-1 cells.	Testosterone	60-72	Janus kinase 1	Homo sapiens	31-35
32943176-0	2020	Development and validation of an HPLC-MS/MS method for the determination of filgotinib, a selective Janus kinase 1 inhibitor: Application to a metabolic stability study.	GLPG0634	76-86	Janus kinase 1	Homo sapiens	100-114
32915978-0	2020	ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial.	N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	26-37	Janus kinase 1	Homo sapiens	6-10
33028675-0	2020	Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib.	baricitinib	143-154	Janus kinase 1	Homo sapiens	62-66
32822738-8	2020	Activation of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway by IFN-gamma was significantly suppressed by salinomycin, via inhibiting the Jak1, Jak2, and STAT1/3 phosphorylation.	salinomycin	144-155	Janus kinase 1	Homo sapiens	176-180
32822738-11	2020	These findings suggest that salinomycin suppresses kynurenine synthesis by inhibiting the catalytic activity of IDO1 and its expression by inhibiting the JAK/STAT and NF-kappaB pathways.	salinomycin	28-39	Janus kinase 1	Homo sapiens	154-157
32915978-1	2020	Momelotinib (MMB) is a JAK1/2 and ACVR1 inhibitor with demonstrated clinical activity in all 3 hallmarks of myelofibrosis (MF): anemia, constitutional symptoms, and splenomegaly.	N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	0-11	Janus kinase 1	Homo sapiens	23-29
32915978-1	2020	Momelotinib (MMB) is a JAK1/2 and ACVR1 inhibitor with demonstrated clinical activity in all 3 hallmarks of myelofibrosis (MF): anemia, constitutional symptoms, and splenomegaly.	N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	13-16	Janus kinase 1	Homo sapiens	23-29
32995780-3	2020	Baricitinib, a clinically approved JAK1/2 inhibitor with potent anti-inflammatory properties is currently being investigated in COVID-19 human clinical trials.	baricitinib	0-11	Janus kinase 1	Homo sapiens	35-41
33230423-3	2020	Specifically, cancer therapeutics have been hypothesized to treat cytokine release syndrome in patients with COVID-19, and the JAK1/2 inhibitor, ruxolitinib, is currently being used in a Phase III trial to assess its efficacy.	ruxolitinib	145-156	Janus kinase 1	Homo sapiens	127-133
32873116-7	2021	Tofacitinib is an oral pan-JAK inhibitor, primarily of JAK1 and JAK3, that was recently approved by the Food and Drug Administration (FDA) for the chronic treatment of UC in 2018.	tofacitinib	0-11	Janus kinase 1	Homo sapiens	55-59
32750333-7	2020	Given these results, the patient was treated with tofacitinib, a JAK inhibitor, leading to the rapid resolution of clinical disease.	tofacitinib	50-61	Janus kinase 1	Homo sapiens	65-68
32927842-2	2020	Baricitinib and Tofacitinib both act intracellularly, blocking the ATP-binding side of JAK proteins and thereby the downstream signalling pathway via STAT-3.	baricitinib	0-11	Janus kinase 1	Homo sapiens	87-90
32927842-2	2020	Baricitinib and Tofacitinib both act intracellularly, blocking the ATP-binding side of JAK proteins and thereby the downstream signalling pathway via STAT-3.	tofacitinib	16-27	Janus kinase 1	Homo sapiens	87-90
32927842-2	2020	Baricitinib and Tofacitinib both act intracellularly, blocking the ATP-binding side of JAK proteins and thereby the downstream signalling pathway via STAT-3.	Adenosine Triphosphate	67-70	Janus kinase 1	Homo sapiens	87-90
32895373-4	2020	AH057, the best JAK inhibitor identified, effectively blocked the JAK/STAT pathways by directly inhibiting JAK1/2 kinase activities, and led to compromised cell proliferation and invasion, increased apoptosis, arrested cell cycles, and impaired tumor progression in vitro and in vivo.	ah057	0-5	Janus kinase 1	Homo sapiens	107-113
33042272-9	2020	By contrast, pharmacological inhibition of JAK1/2 by ruxolitinib reversed paclitaxel resistance both in vitro and in vivo.	ruxolitinib	53-64	Janus kinase 1	Homo sapiens	43-49
32812339-2	2020	Herein, a noninteracting multiphase molecular assembly approach is developed to crystallize tofacitinib, a potent JAK1/3 inhibitor, within a shear-thinning self-assembled fibrillar peptide hydrogel network.	tofacitinib	92-103	Janus kinase 1	Homo sapiens	114-120
33042272-9	2020	By contrast, pharmacological inhibition of JAK1/2 by ruxolitinib reversed paclitaxel resistance both in vitro and in vivo.	Paclitaxel	74-84	Janus kinase 1	Homo sapiens	43-49
32515665-2	2020	New compounds under investigation, like upadacitinib, with greater selectivity for JAK1 inhibition have recently been approved for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to conventional synthetic disease-modifying antirheumatic drugs.	upadacitinib	40-52	Janus kinase 1	Homo sapiens	83-87
32515665-4	2020	EXPERT OPINION: Upadacitinib was able to accomplish all the primary and secondary end points in most of the trials, with a safety profile that is similar to the other JAK inhibitors.	upadacitinib	16-28	Janus kinase 1	Homo sapiens	167-170
31907296-5	2020	RESULTS: We identified 296 IHCA (45%), 81% of them were mutated in either IL6ST (61%), FRK (8%), STAT3 (5%), GNAS (3%) or JAK1 (2%).	2-(4-imidazoyl)hydrocinnamic acid	27-31	Janus kinase 1	Homo sapiens	122-126
32645632-6	2020	Baricitinib intracellularly inhibits the proinflammatory signal of several cytokines by suppressing Janus kinase (JAK) JAK1/JAK2.	baricitinib	0-11	Janus kinase 1	Homo sapiens	119-123
32585295-4	2020	As many of the elevated cytokines signal through Janus kinase (JAK)1/JAK2, inhibition of these pathways with ruxolitinib has the potential to mitigate the COVID-19-associated cytokine storm and reduce mortality.	ruxolitinib	109-120	Janus kinase 1	Homo sapiens	49-68
32530345-3	2020	Upadacitinib is a JAK inhibitor engineered to be selective for JAK1, and has recently been approved for use in patients with moderate-to-severe RA.	upadacitinib	0-12	Janus kinase 1	Homo sapiens	63-67
32629176-10	2020	Inhibition of JAK1 activity by ruxolitinib or knockdown of JAK1 expression by siRNA significantly inhibits TROY-induced STAT3 activation, GBM cell migration, and decreases resistance to temozolomide.	ruxolitinib	31-42	Janus kinase 1	Homo sapiens	14-18
32629176-10	2020	Inhibition of JAK1 activity by ruxolitinib or knockdown of JAK1 expression by siRNA significantly inhibits TROY-induced STAT3 activation, GBM cell migration, and decreases resistance to temozolomide.	Temozolomide	186-198	Janus kinase 1	Homo sapiens	14-18
32629176-10	2020	Inhibition of JAK1 activity by ruxolitinib or knockdown of JAK1 expression by siRNA significantly inhibits TROY-induced STAT3 activation, GBM cell migration, and decreases resistance to temozolomide.	Temozolomide	186-198	Janus kinase 1	Homo sapiens	59-63
32843425-5	2020	We describe a case of relapsed T-ALL in an adult patient, with two JAK3 activating mutations identified by whole-exome sequencing (WES), leading to hypothesis-based treatment with the JAK1 and JAK3 inhibitor, tofacitinib, following failure of salvage chemotherapy reinduction.	tofacitinib	209-220	Janus kinase 1	Homo sapiens	184-188
32904684-12	2020	Further investigations revealed that the constitutive activation of STAT3 may be induced by JAK1 and JAK2, and thus effect the 5-FU resistance by regulating NHE1.	Fluorouracil	127-131	Janus kinase 1	Homo sapiens	92-96
32536506-8	2020	Fresh EA NK cells generated high levels of gamma interferon (IFN-gamma), which was abrogated by JAK1/JAK2 inhibition with ruxolitinib, but C/T EA NK cells showed lower IFN-gamma unaffected by JAK1/JAK2 inhibition.	ruxolitinib	122-133	Janus kinase 1	Homo sapiens	96-100
32850921-6	2020	Methods: Ruxolitinib, a JAK1 and JAK2 inhibitor, has been successfully used to treat severe immune-mediated diseases, such as graft vs. host disease and Hemophagocytic lymphohistiocytosis.	ruxolitinib	9-20	Janus kinase 1	Homo sapiens	24-28
31821750-0	2020	Evaluation of Clinical Cardiac Safety of Itacitinib, a JAK1 Inhibitor, in Healthy Participants.	INCB039110	41-51	Janus kinase 1	Homo sapiens	55-59
31821750-1	2020	Itacitinib is a JAK1-selective inhibitor in phase 3 development in graft-versus-host disease.	INCB039110	0-10	Janus kinase 1	Homo sapiens	16-20
32808031-0	2020	The JAK1/3 inhibitor tofacitinib suppresses T cell homing and activation in chronic intestinal inflammation.	tofacitinib	21-32	Janus kinase 1	Homo sapiens	4-10
32473600-1	2020	Baricitinib is an oral Janus kinase (JAK)1/JAK2 inhibitor approved for the treatment of rheumatoid arthritis (RA) that was independently predicted, using artificial intelligence (AI) algorithms, to be useful for COVID-19 infection via proposed anti-cytokine effects and as an inhibitor of host cell viral propagation.	baricitinib	0-11	Janus kinase 1	Homo sapiens	23-42
32636055-1	2020	Ruxolitinib is the first approved JAK1 and JAK2 inhibitor, and is known to interfere with the JAK / STAT signaling pathway, one of the critical cellular signaling pathways involved in the inflammatory response.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	34-38
32598086-6	2020	Prior studies suggest that A77 1726, the active metabolite of leflunomide, inhibits the activity of JAK1 and JAK3.	Leflunomide	62-73	Janus kinase 1	Homo sapiens	100-104
33025946-1	2020	Peficitinib hydrobromide is a small Janus kinase inhibitor (JAK1, JAK2, JAK3 and TYK2) molecule for the treatment of rheumatoid arthritis (RA).	Peficitinib hydrobromide	0-24	Janus kinase 1	Homo sapiens	60-64
33025946-3	2020	This JAK inhibitor oral drug demonstrated clinical response as once-daily monotherapy in patients with moderate to severe RA, also in combination with methotrexate (MTX), who had an inadequate response to MTX.	Methotrexate	151-163	Janus kinase 1	Homo sapiens	5-8
33025946-3	2020	This JAK inhibitor oral drug demonstrated clinical response as once-daily monotherapy in patients with moderate to severe RA, also in combination with methotrexate (MTX), who had an inadequate response to MTX.	Methotrexate	165-168	Janus kinase 1	Homo sapiens	5-8
33025946-3	2020	This JAK inhibitor oral drug demonstrated clinical response as once-daily monotherapy in patients with moderate to severe RA, also in combination with methotrexate (MTX), who had an inadequate response to MTX.	Methotrexate	205-208	Janus kinase 1	Homo sapiens	5-8
31612426-0	2020	Discovery and evaluation of Atopaxar hydrobromide, a novel JAK1 and JAK2 inhibitor, selectively induces apoptosis of cancer cells with constitutively activated STAT3.	E 5555	28-49	Janus kinase 1	Homo sapiens	59-63
32180118-10	2020	We report the potential of JAK1/2 inhibition with ruxolitinib for both CMC and steroid-dependent autoimmunity.	ruxolitinib	50-61	Janus kinase 1	Homo sapiens	27-31
32180118-10	2020	We report the potential of JAK1/2 inhibition with ruxolitinib for both CMC and steroid-dependent autoimmunity.	Steroids	79-86	Janus kinase 1	Homo sapiens	27-31
31612426-7	2020	Our results suggest that AHB not only blocks constitutively activated and cytokine-induced STAT3 phosphorylation but also inhibits JAK1 and JAK2 phosphorylation.	E 5555	25-28	Janus kinase 1	Homo sapiens	131-135
32149388-1	2020	Itacitinib is a novel, selective, Janus kinase 1 inhibitor in development for treatment of graft-versus-host disease.	INCB039110	0-10	Janus kinase 1	Homo sapiens	34-48
32359221-0	2020	JAK1/STAT3 regulatory effect of beta-caryophyllene on MG-63 osteosarcoma cells via ROS-induced apoptotic mitochondrial pathway by DNA fragmentation.	caryophyllene	32-50	Janus kinase 1	Homo sapiens	0-4
32359221-0	2020	JAK1/STAT3 regulatory effect of beta-caryophyllene on MG-63 osteosarcoma cells via ROS-induced apoptotic mitochondrial pathway by DNA fragmentation.	Reactive Oxygen Species	83-86	Janus kinase 1	Homo sapiens	0-4
32359221-7	2020	Our results also showed stimulation of Janus kinase 1/signal transducer and activator of transcription 3 (JAK1/STAT3) signaling pathway in bone cancer MG-63 cells upon BCP treatment along with the induction of proinflammatory genes at the messenger RNA level.	caryophyllene	168-171	Janus kinase 1	Homo sapiens	39-53
32359221-7	2020	Our results also showed stimulation of Janus kinase 1/signal transducer and activator of transcription 3 (JAK1/STAT3) signaling pathway in bone cancer MG-63 cells upon BCP treatment along with the induction of proinflammatory genes at the messenger RNA level.	caryophyllene	168-171	Janus kinase 1	Homo sapiens	106-110
32359221-8	2020	Overall results suggest that the treatment of MG-63 cells with BCP promotes apoptosis and inflammation via ROS and JAK1/STAT3 signaling pathway.	caryophyllene	63-66	Janus kinase 1	Homo sapiens	115-119
31781755-5	2020	In contrast, efficacy of filgotinib, a selective JAK1 inhibitor, in CD patients was demonstrated in the randomized, double-blinded, placebo-controlled phase II FITZROY study.	GLPG0634	25-35	Janus kinase 1	Homo sapiens	49-53
31972249-0	2020	Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor, PF 06700841, Reveal Reduction of Skin Inflammation in Plaque Psoriasis: TYK2/JAK1 inhibitor in plaque psoriasis.	Platelet Factor 3	61-72	Janus kinase 1	Homo sapiens	45-49
32052886-1	2020	Although recent drugs including biological agents and small molecules targeting key inflammatory mediators have revolutionized the management of different chronic inflammatory diseases, these treatments lead to the development of psoriasis-like skin lesions in 2-5% of treated patients called paradoxical psoriasis.1 Here we report the first case of paradoxical psoriasis induced by baricitinib, a novel janus kinase (JAK) 1/2 inhibitor.	baricitinib	383-394	Janus kinase 1	Homo sapiens	404-426
31972249-0	2020	Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor, PF 06700841, Reveal Reduction of Skin Inflammation in Plaque Psoriasis: TYK2/JAK1 inhibitor in plaque psoriasis.	Platelet Factor 3	61-72	Janus kinase 1	Homo sapiens	138-142
31972249-2	2020	The tyrosine kinase 2 (TYK2)/Janus kinase 1 (JAK1) inhibitor, PF-06700841, will directly suppress TYK2-dependent IL-12 and IL-23 signaling and JAK1-dependent signaling in cells expressing these signaling molecules, including T cells and keratinocytes.	Platelet Factor 3	62-73	Janus kinase 1	Homo sapiens	29-43
31972249-2	2020	The tyrosine kinase 2 (TYK2)/Janus kinase 1 (JAK1) inhibitor, PF-06700841, will directly suppress TYK2-dependent IL-12 and IL-23 signaling and JAK1-dependent signaling in cells expressing these signaling molecules, including T cells and keratinocytes.	Platelet Factor 3	62-73	Janus kinase 1	Homo sapiens	45-49
31972249-2	2020	The tyrosine kinase 2 (TYK2)/Janus kinase 1 (JAK1) inhibitor, PF-06700841, will directly suppress TYK2-dependent IL-12 and IL-23 signaling and JAK1-dependent signaling in cells expressing these signaling molecules, including T cells and keratinocytes.	Platelet Factor 3	62-73	Janus kinase 1	Homo sapiens	143-147
31972249-9	2020	PF-06700841 improves clinical symptoms of chronic plaque psoriasis by inhibition of pro-inflammatory cytokines that require TYK2 and JAK1 for signal transduction.	Platelet Factor 3	0-11	Janus kinase 1	Homo sapiens	133-137
32428222-2	2020	In this study, we found that occupationally relevant level of Pb exposure impaired ILC development at the progenitor level by activating Janus Kinase1 (JAK1).	Lead	62-64	Janus kinase 1	Homo sapiens	137-150
32758351-6	2020	Chemical inhibition of JAK1 in COV434 cells with 100nM ruxolitinib for 72h resulted in significant increases in STAT3 mRNA (P=0.034) and p-Y701-STAT1 protein (P=0.0117), demonstrating a role for JAK1 in modulating STAT in granulosa cells.	ruxolitinib	55-66	Janus kinase 1	Homo sapiens	23-27
32758351-6	2020	Chemical inhibition of JAK1 in COV434 cells with 100nM ruxolitinib for 72h resulted in significant increases in STAT3 mRNA (P=0.034) and p-Y701-STAT1 protein (P=0.0117), demonstrating a role for JAK1 in modulating STAT in granulosa cells.	ruxolitinib	55-66	Janus kinase 1	Homo sapiens	195-199
32428222-8	2020	In vitro assays suggested that the obstruction of ILCP differentiation by Pb exposure was due to increased activation of JAK1.	Lead	74-76	Janus kinase 1	Homo sapiens	121-125
32297800-1	2020	Over the last decade, the Janus kinase1/2 (JAK1/2) inhibitor ruxolitinib has emerged as a cornerstone of myelofibrosis (MF) management.	ruxolitinib	61-72	Janus kinase 1	Homo sapiens	43-49
32724162-8	2020	Afterward, IL-6-JAK1-STAT3 signaling was demonstrated to promote SOX9 expression and invasion following ATP treatment.	Adenosine Triphosphate	104-107	Janus kinase 1	Homo sapiens	16-20
32428222-2	2020	In this study, we found that occupationally relevant level of Pb exposure impaired ILC development at the progenitor level by activating Janus Kinase1 (JAK1).	Lead	62-64	Janus kinase 1	Homo sapiens	152-156
32732872-9	2020	Administration of the JAK1 inhibitor, baricitinib, caused the activation of signal transducer and activator of transcription 3 (STAT3) and revealed an effect similar to that of circ9119 silencing on cell proliferation and apoptosis.	baricitinib	38-49	Janus kinase 1	Homo sapiens	22-26
32732872-10	2020	These results showed that circ9119 could modulate apoptosis, and broadly, cell proliferation by competitively binding miR-26a, which targeted JAK1-STAT3, in HCC cell lines.	circ9119	26-34	Janus kinase 1	Homo sapiens	142-146
32278762-8	2020	RESULTS: Curcumol reduced the expression of phosphorylated signal transducer and activator of transcription 3 (p-STAT3) via JAK1, JAK2, and Src pathways and inhibited hypoxia-inducible factor-1alpha (HIF-1alpha) protein synthesis via mTOR/p70S6K/eIF4E and MAPK pathways.	curcumol	9-17	Janus kinase 1	Homo sapiens	124-128
32732367-4	2021	This prospective study aimed to investigate the efficacy and safety of ruxolitinib, a Janus kinase (JAK) 1/2 inhibitor, as a front-line therapy in children with secondary HLH.	ruxolitinib	71-82	Janus kinase 1	Homo sapiens	86-108
32698510-13	2020	Ruxolitinib suppressed the phosphorylation of JAK1, JAK2 and JAK3, and STAT1 and 3 compared to IFN-gamma pretreated hDPCs.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	46-50
32614965-7	2020	Inhibition of JAK/STAT signaling using the selective JAK1/2 inhibitor ruxolitinib resulted in significant antileukemic activity in AML in vitro which is mediated through both cell-autonomous and microenvironment-mediated mechanisms.	ruxolitinib	70-81	Janus kinase 1	Homo sapiens	53-59
32462873-0	2020	Fragment-based discovery of pyrazolopyridones as JAK1 inhibitors with excellent subtype selectivity.	pyrazolopyridones	28-45	Janus kinase 1	Homo sapiens	49-53
32647892-12	2021	Notably, we demonstrate that CD28null T cell expansion was significantly inhibited by Tofacitinib, a selective JAK1/JAK3 inhibitor that blocks IL-7/IL-15 signalling.	tofacitinib	86-97	Janus kinase 1	Homo sapiens	111-115
32446385-10	2020	In addition, we confirmed the suppression of phosphorylated EGFR, JAK1, and Stat3 expression in erlotinib and CJ14939-treated human NSCLC cell lines.	cj14939	110-117	Janus kinase 1	Homo sapiens	66-70
32452344-1	2020	OBJECTIVES: This study evaluated the efficacy and safety of baricitinib, an oral Janus kinase (JAK)1/JAK2 inhibitor, in patients with moderately to severely active rheumatoid arthritis (RA) and inadequate response to methotrexate (MTX) therapy.	baricitinib	60-71	Janus kinase 1	Homo sapiens	81-100
32446385-6	2020	To overcome resistance to EGFR TKI, we discovered a JAK1 inhibitor, CJ14939.	cj14939	68-75	Janus kinase 1	Homo sapiens	52-56
32417942-3	2020	JAK 1/2 inhibitors, such as ruxolitinib and fedratinib, are the mainstay of therapy and produce significant and durable reductions in spleen volume.	ruxolitinib	28-39	Janus kinase 1	Homo sapiens	0-7
32417942-3	2020	JAK 1/2 inhibitors, such as ruxolitinib and fedratinib, are the mainstay of therapy and produce significant and durable reductions in spleen volume.	Fedratinib	44-54	Janus kinase 1	Homo sapiens	0-7
32923146-3	2020	Therapy with Ruxolitinib (RUX), a JAK1/2 inhibitor, may further increase the infectious risk.	ruxolitinib	13-24	Janus kinase 1	Homo sapiens	34-40
32923146-3	2020	Therapy with Ruxolitinib (RUX), a JAK1/2 inhibitor, may further increase the infectious risk.	ruxolitinib	26-29	Janus kinase 1	Homo sapiens	34-40
32446385-10	2020	In addition, we confirmed the suppression of phosphorylated EGFR, JAK1, and Stat3 expression in erlotinib and CJ14939-treated human NSCLC cell lines.	Erlotinib Hydrochloride	96-105	Janus kinase 1	Homo sapiens	66-70
32334196-3	2020	A cellular selectivity study further confirmed that 11i preferentially inhibits JAK3 over JAK1, in JAK/STAT signaling pathway.	11i	52-55	Janus kinase 1	Homo sapiens	90-94
32560455-8	2020	Next, we tested IL89"s sensitivity to the JAK inhibitor ruxolitinib and observed a potent anti-tumor effect, both in vitro and in vivo.	ruxolitinib	56-67	Janus kinase 1	Homo sapiens	42-45
32606953-12	2020	Tofacitinib (JAK1 inhibitor) reversed the tumor-promoting effect of LINC00346 overexpression on CRC cells.	tofacitinib	0-11	Janus kinase 1	Homo sapiens	13-17
32017044-1	2020	Ruxolitinib is a potent Janus kinase (JAK) 1/JAK2 inhibitor approved for the treatment of myelofibrosis (MF).	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	24-44
32295912-6	2020	It blocked STAT1 tyrosine phosphorylation induced either by type I IFN or over-expressed Jak1, paralleling MARV VP40.	Tyrosine	17-25	Janus kinase 1	Homo sapiens	89-93
33613945-1	2021	Tofacitinib is an oral, Janus kinase (JAK) molecule, which selectively inhibits Janus-associated tyrosine kinases JAK1 and JAK3.	tofacitinib	0-11	Janus kinase 1	Homo sapiens	114-118
32208940-3	2020	Baricitinib is an orally available selective JAK1/JAK2 inhibitor that is approved for use in the treatment of moderate-to-severe rheumatoid arthritis (RA).	baricitinib	0-11	Janus kinase 1	Homo sapiens	45-49
32092309-1	2020	BACKGROUND & AIMS: We evaluated the efficacy and safety of upadacitinib, an oral selective inhibitor of Janus kinase 1, as induction therapy for ulcerative colitis (UC).	upadacitinib	59-71	Janus kinase 1	Homo sapiens	104-118
32301699-1	2020	OBJECTIVES: We assessed the relative efficacy and safety of once-daily administration of 100 and 200 mg filgotinib (a JAK1-selective inhibitor) in patients with active rheumatoid arthritis (RA).	GLPG0634	104-114	Janus kinase 1	Homo sapiens	118-122
31867699-1	2020	Upadacitinib is a Janus kinase 1 inhibitor developed for treatment of moderate to severe rheumatoid arthritis (RA) and was recently approved by the US Food and Drug Administration for this indication in adults who have had an inadequate response or intolerance to methotrexate.	upadacitinib	0-12	Janus kinase 1	Homo sapiens	18-32
31286322-2	2020	We hypothesized that selective inhibition of JAK1/2 by ruxolitinib could induce autophagy and limit drug efficacy in myeloproliferative neoplasms (MPN).	ruxolitinib	55-66	Janus kinase 1	Homo sapiens	45-49
32125282-5	2020	By MSRE-qPCR, multiple genes of the IL-12-IFN-gamma signaling pathway (IL12B, IL12RB2, TYK2, IFNGR1, JAK1 and JAK2) were hyper-methylated in TB patients.	Terbium	141-143	Janus kinase 1	Homo sapiens	101-105
32320566-2	2020	In a phase 2 trial, ruxolitinib, a selective Janus kinase (JAK1 and JAK2) inhibitor, showed potential efficacy in patients with glucocorticoid-refractory acute GVHD.	ruxolitinib	20-31	Janus kinase 1	Homo sapiens	59-63
32022397-0	2020	Comparative QSAR model generation using Pyrazole derivatives for screening Janus Kinase-1 inhibitors.	Pyrazoles	40-48	Janus kinase 1	Homo sapiens	75-89
32022397-5	2020	In the present study,three dimensional QSAR analyses on a set of pyrazole derivatives against JAK1 and JAK2 enzymes inhibition had been executed.	Pyrazoles	65-73	Janus kinase 1	Homo sapiens	94-98
32022397-6	2020	Molecular docking studies were conducted with the target JAK1 using the pyrazole derivative compounds and found out potential intermolecular interactions operating among them.	Pyrazoles	72-80	Janus kinase 1	Homo sapiens	57-61
31575356-2	2020	Three publications reported success with ruxolitinib, a Janus-associated kinase (JAK1/2) inhibitor.	ruxolitinib	41-52	Janus kinase 1	Homo sapiens	81-87
31978425-8	2020	Finally, we show that the effects of nobiletin are mediated through the JAK1/STAT3 pathway, as nobiletin significantly reduced the phosphorylation of both JAK1 and STAT3.	nobiletin	37-46	Janus kinase 1	Homo sapiens	72-76
31978425-8	2020	Finally, we show that the effects of nobiletin are mediated through the JAK1/STAT3 pathway, as nobiletin significantly reduced the phosphorylation of both JAK1 and STAT3.	nobiletin	37-46	Janus kinase 1	Homo sapiens	155-159
31978425-8	2020	Finally, we show that the effects of nobiletin are mediated through the JAK1/STAT3 pathway, as nobiletin significantly reduced the phosphorylation of both JAK1 and STAT3.	nobiletin	95-104	Janus kinase 1	Homo sapiens	72-76
31978425-8	2020	Finally, we show that the effects of nobiletin are mediated through the JAK1/STAT3 pathway, as nobiletin significantly reduced the phosphorylation of both JAK1 and STAT3.	nobiletin	95-104	Janus kinase 1	Homo sapiens	155-159
32297743-6	2020	Herein, an account of the medicinal chemistry optimization from the promiscuous kinase screening hit 3 to the candidate drug 21 (AZD4205), a highly selective JAK1 kinase inhibitor, is reported.	golidocitinib	129-136	Janus kinase 1	Homo sapiens	158-162
32064884-0	2020	MiR-769-5p inhibits cancer progression in oral squamous cell carcinoma by directly targeting JAK1/STAT3 pathway.	ABT-769	0-10	Janus kinase 1	Homo sapiens	93-97
32293938-5	2020	Ruxolitinib phosphate is a Janus Kinase 1 and 2 (JAK1, JAK2) inhibitor which inhibits pro-inflammatory signaling, and modulates T-cell subsets to an anti-inflammatory phenotype.	Ruxolitinib phosphate	0-21	Janus kinase 1	Homo sapiens	49-53
32276266-0	2020	Inhibition of esophageal-carcinoma cell proliferation by genistein via suppression of JAK1/2-STAT3 and AKT/MDM2/p53 signaling pathways.	Genistein	57-66	Janus kinase 1	Homo sapiens	86-92
32113874-6	2020	Simultaneously, panaxadiol inhibited STAT3 activation through the JAK1, JAK2, and Src pathways.	panaxadiol	16-26	Janus kinase 1	Homo sapiens	66-70
32324888-0	2020	A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease.	INCB039110	19-29	Janus kinase 1	Homo sapiens	43-47
32324888-2	2020	Itacitinib is a Janus kinase (JAK)1-selective inhibitor that has demonstrated efficacy in preclinical models of aGVHD.	INCB039110	0-10	Janus kinase 1	Homo sapiens	30-35
32346301-1	2020	Background: Baricitinib is a janus kinase (JAK1/JAK2) inhibitor developed for the treatment of patients suffering from rheumatoid arthritis (RA).	baricitinib	12-23	Janus kinase 1	Homo sapiens	43-47
32122740-4	2020	The results of enzymatic activity assays supported compound 16m-(R) as a potential and selective JAK2 inhibitor, which exhibited high inhibitory activity with an IC50 of 3 nM against JAK2, and 85- and 76-fold selectivity over JAK1 and JAK3, respectively.	r)	65-67	Janus kinase 1	Homo sapiens	226-230
32276266-10	2020	Taken together, genistein suppressed the JAK1/2-STAT3 and AKT/MDM2/p53 signaling pathways by decreasing EGFR expression, leading to cell apoptosis, cell cycle arrest, and proliferation inhibition in EsC cells.	Genistein	16-25	Janus kinase 1	Homo sapiens	41-47
32276266-7	2020	Additionally, genistein dramatically decreased epidermal growth factor receptor (EGFR) expression and attenuated its down-stream signaling molecules STAT3, MDM2, Akt and JAK1/2 phosphorylation, resulting in inhibited nuclear translocation of STAT3 and MDM2, thereby inhibiting the JAK1/2-STAT3 and AKT/MDM2/p53 signaling pathways.	Genistein	14-23	Janus kinase 1	Homo sapiens	170-176
32276266-7	2020	Additionally, genistein dramatically decreased epidermal growth factor receptor (EGFR) expression and attenuated its down-stream signaling molecules STAT3, MDM2, Akt and JAK1/2 phosphorylation, resulting in inhibited nuclear translocation of STAT3 and MDM2, thereby inhibiting the JAK1/2-STAT3 and AKT/MDM2/p53 signaling pathways.	Genistein	14-23	Janus kinase 1	Homo sapiens	281-287
31880950-2	2020	We sought to evaluate safety and efficacy of the JAK1/2 inhibitor ruxolitinib in patients with CNL and aCML, irrespective of CSF3R mutation status.	ruxolitinib	66-77	Janus kinase 1	Homo sapiens	49-55
31605536-2	2020	Interferon-gamma signaling mediated by Janus kinase (JAK) has been implicated in the pathogenesis of vitiligo.1 Systemic administration of tofacitinib, a potent JAK1/3 inhibitor, has been effective in treating vitiligo in case reports,2 however, it is associated with infections, malignancies, cytopenias, gastrointestinal perforations, and hyperlipidemia in some patients with rheumatoid arthritis.	tofacitinib	139-150	Janus kinase 1	Homo sapiens	161-167
31992541-9	2020	Patient-derived organoids (PDOs) obtained from tumors with high AXL and JAK1 were sensitive to TP-0903 and ruxolitinib (JAK inhibitor) treatments supporting the CyTOF findings.	ceftaroline fosamil	95-102	Janus kinase 1	Homo sapiens	72-76
31992541-9	2020	Patient-derived organoids (PDOs) obtained from tumors with high AXL and JAK1 were sensitive to TP-0903 and ruxolitinib (JAK inhibitor) treatments supporting the CyTOF findings.	ruxolitinib	107-118	Janus kinase 1	Homo sapiens	72-76
32196928-0	2020	The JAK1/2 inhibitor ruxolitinib delays premature aging phenotypes.	ruxolitinib	21-32	Janus kinase 1	Homo sapiens	4-10
32196928-5	2020	Here, we show that JAK1/2 inhibition with ruxolitinib rescues progerin-induced cell cycle arrest, cellular senescence, and misshapen nuclei in human normal fibroblasts expressing progerin.	ruxolitinib	42-53	Janus kinase 1	Homo sapiens	19-23
32034662-3	2020	Other currently available therapies include pegylated interferon alfa-2a and the JAK1/2 inhibitor ruxolitinib.	ruxolitinib	98-109	Janus kinase 1	Homo sapiens	81-87
32166597-3	2020	Delgocitinib inhibits all members of the JAK family [JAK1, JAK2, JAK3 and tyrosine kinase 2].	delgocitinib	0-12	Janus kinase 1	Homo sapiens	53-57
32153201-1	2020	Introduction: Ruxolitinib is an oral selective JAK1/JAK2 inhibitor, initially approved by the FDA for the treatment of intermediate-2 or high-risk myelofibrosis and patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea.Areas Covered: Accumulating evidence supports the role of JAK1/JAK2 pathways in the pathogenesis of graft-versus-host disease (GVHD), and preclinical studies have demonstrated promising efficacy of ruxolitinib in treatment/prevention of GVHD.	ruxolitinib	14-25	Janus kinase 1	Homo sapiens	47-51
32153201-1	2020	Introduction: Ruxolitinib is an oral selective JAK1/JAK2 inhibitor, initially approved by the FDA for the treatment of intermediate-2 or high-risk myelofibrosis and patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea.Areas Covered: Accumulating evidence supports the role of JAK1/JAK2 pathways in the pathogenesis of graft-versus-host disease (GVHD), and preclinical studies have demonstrated promising efficacy of ruxolitinib in treatment/prevention of GVHD.	ruxolitinib	14-25	Janus kinase 1	Homo sapiens	324-328
32153201-3	2020	Based on the data from the REACH1 trial, ruxolitinib was approved by the FDA in May 2019 for SR acute GVHD in adult and pediatric patients 12 years and older.Expert Opinion: Ruxolitinib and other JAK1/JAK2 inhibitors hold promise in other treatment settings such as GVHD prevention and/or first line therapy.	ruxolitinib	41-52	Janus kinase 1	Homo sapiens	196-200
31701537-1	2020	Upadacitinib (ABT-494) is a selective Janus kinase (JAK)1 inhibitor being developed for treatment of several inflammatory disorders.	upadacitinib	0-12	Janus kinase 1	Homo sapiens	52-57
31701537-1	2020	Upadacitinib (ABT-494) is a selective Janus kinase (JAK)1 inhibitor being developed for treatment of several inflammatory disorders.	AG 494	14-21	Janus kinase 1	Homo sapiens	52-57
32201152-4	2021	The only and curative option for PMF is allogeneic hematopoietic stem cell transplant (allo-HSCT); however, the Janus kinase (JAK) 1/2 inhibitor ruxolitinib is highly effective in reducing constitutional symptoms and spleen volume, and has been found to improve survival.	ruxolitinib	145-156	Janus kinase 1	Homo sapiens	112-132
32609446-2	2020	Tofacitinib, an oral JAK 1/3 inhibitor approved for the treatment of rheumatoid arthritis, has previously been shown to induce significant re-pigmentation in vitiligo.	tofacitinib	0-11	Janus kinase 1	Homo sapiens	21-28
32019673-9	2020	Taken together, these findings identified a novel signaling axis, CYP1A1-15(S)-HETE-JAK1-STAT6, that may be a promising target for the proper maintenance of macrophage polarization and may also be a means by which to treat immune-related disease due to macrophage dysfunction.	15-hydroxy-5,8,11,13-eicosatetraenoic acid	73-83	Janus kinase 1	Homo sapiens	84-88
32011040-10	2020	Besides, ICA notably frustrated JAK1/STAT3 and PI3K/AKT activations in DAOY cells.	icariin	9-12	Janus kinase 1	Homo sapiens	32-36
31711337-1	2020	Ruxolitinib is a JAK1/2 inhibitor approved for the treatment of myelofibrosis (MF) and polycythemia vera (PV).	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	17-23
31970549-3	2020	As a selective inhibitor of JAK1 and JAK3, tofacitinib has the potential to play a role in the management of rheumatic diseases such as RA and PsA.	tofacitinib	43-54	Janus kinase 1	Homo sapiens	28-32
31970549-6	2020	In this review, the authors summarize current knowledge on the relationship between the immune system and the skeleton before examining the involvement of JAK-STAT signaling in bone homeostasis as well as the available preclinical and clinical evidence on the benefits of tofacitinib on prevention of bone involvement in RA and PsA.Key Points  Chronic inflammation in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) leads to disturbances in bone remodeling  Bone remodeling is mediated by several signaling pathways, including the JAK-STAT pathway  Tofacitinib, a selective inhibitor of JAK1 and JAK3, is active in RA and PsA and may help limit systemic bone loss through inhibiting disturbed osteoclastogenesis  Clinical trials show that tofacitinib reduces articular bone erosion.	tofacitinib	272-283	Janus kinase 1	Homo sapiens	595-599
32020553-8	2020	Brepocitinib, a potent TYK2/JAK1 inhibitor, is also being evaluated, as both oral and topical treatment.	Brepocitinib	0-12	Janus kinase 1	Homo sapiens	28-32
31786154-2	2020	OBJECTIVE: This study evaluated the safety and efficacy of multiple doses of the selective Janus kinase 1 inhibitor upadacitinib in patients with moderate-to-severe atopic dermatitis.	upadacitinib	116-128	Janus kinase 1	Homo sapiens	91-105
32022429-6	2020	Pre-treatment with ruxolitinib, a selective Janus kinase (JAK) 1/2 inhibitor, prevented the LPS-induced Stat3 phosphorylation and restored the sensitivity of hepatocytes to Fas-mediated apoptosis.	ruxolitinib	19-30	Janus kinase 1	Homo sapiens	44-66
31982039-2	2020	Ruxolitinib, a JAK 1 and JAK 2 inhibitor, showed superiority over best available therapy in a phase 2 study in patients with polycythaemia vera who were resistant to or intolerant of hydroxyurea.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-20
32011040-12	2020	The results concluded that ICA exhibited the antitumor activity in DAOY cells via decreasing SPARC and inactivating JAK1/STAT3 and PI3K/AKT pathways.	icariin	27-30	Janus kinase 1	Homo sapiens	116-120
32258058-7	2020	We report a positive clinical response in LPP to tofacitinib, a JAK1/3 inhibitor, and dapsone, an anti-neutrophilic agent.	tofacitinib	49-60	Janus kinase 1	Homo sapiens	64-70
31912462-0	2020	Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials.	GLPG0634	0-10	Janus kinase 1	Homo sapiens	14-18
31912462-2	2020	We sought to gain insight into the mode of action and immunological effects of filgotinib, a JAK1 selective inhibitor, in active RA by analyzing secreted and cell-based biomarkers key to RA pathophysiology in two phase 2b trials of filgotinib in active RA.	GLPG0634	79-89	Janus kinase 1	Homo sapiens	93-97
31697835-3	2020	Both receptors could be expressed in human T lymphocytes; Epo ligation induced STAT5 phosphorylation, which was abrogated by nontoxic concentrations of the JAK1/2 inhibitor ruxolitinib.	ruxolitinib	173-184	Janus kinase 1	Homo sapiens	156-162
31448433-8	2020	This study confirms that in humans, upadacitinib has greater selectivity for JAK1 vs JAK3 relative to the rheumatoid arthritis approved dose of tofacitinib, and results from these analyses informed the selection of upadacitinib IR doses evaluated in phase 2.	upadacitinib	36-48	Janus kinase 1	Homo sapiens	77-81
32054011-0	2020	Discovery of 9O-Substituted Palmatine Derivatives as a New Class of anti-COL1A1 Agents via Repressing TGF-beta1/Smads and JAK1/STAT3 Pathways.	palmatine	13-37	Janus kinase 1	Homo sapiens	122-126
31629805-0	2020	Treatment of Atopic Dermatitis With Ruxolitinib Cream (JAK1/JAK2 Inhibitor) or Triamcinolone Cream.	ruxolitinib	36-47	Janus kinase 1	Homo sapiens	55-59
31629805-2	2020	Ruxolitinib, a selective inhibitor of Janus kinase (JAK)-1 and JAK2, potently suppresses cytokine signaling involved in AD pathogenesis.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	38-58
31833760-1	2020	Tofacitinib is an orally administered medication with a mechanism of action that involves JAK1, JAK2, JAK3 and TYK2 pathway inhibition.	tofacitinib	0-11	Janus kinase 1	Homo sapiens	90-94
31782014-2	2020	Baricitinib is a synthetic small molecule which targets the JAK/STAT pathway which is implicated in the inflammatory response in RA.	baricitinib	0-11	Janus kinase 1	Homo sapiens	60-63
31782014-3	2020	Baricitinib selectively targets JAK1 and JAK2 and has been shown to have efficacy in treating patients with RA.	baricitinib	0-11	Janus kinase 1	Homo sapiens	32-36
32096183-0	2020	MiR-30c-5p inhibits high glucose-induced EMT and renal fibrogenesis by down-regulation of JAK1 in diabetic nephropathy.	mir-30c-5p	0-10	Janus kinase 1	Homo sapiens	90-94
32096183-0	2020	MiR-30c-5p inhibits high glucose-induced EMT and renal fibrogenesis by down-regulation of JAK1 in diabetic nephropathy.	Glucose	25-32	Janus kinase 1	Homo sapiens	90-94
32096183-12	2020	Furthermore, overexpression of JAK1 attenuated the inhibitory effect of miR-30c-5p on HG-induced EMT and renal fibrogenesis in HK2 cells.	mir-30c-5p	72-82	Janus kinase 1	Homo sapiens	31-35
31448433-1	2020	Upadacitinib is a selective Janus kinase (JAK) 1 inhibitor being developed for treatment of rheumatoid arthritis.	upadacitinib	0-12	Janus kinase 1	Homo sapiens	28-48
31448433-2	2020	This study characterizes the relationships between upadacitinib exposure and interleukin (IL)-6-induced signal transducer and activator of transcription proteins 3 (STAT3) phosphorylation (pSTAT3) and IL-7-induced STAT5 phosphorylation (pSTAT5) in the ex vivo setting as measures for JAK1 and JAK1/JAK3 inhibition, respectively, with comparison to tofacitinib.	upadacitinib	51-63	Janus kinase 1	Homo sapiens	284-288
31448433-2	2020	This study characterizes the relationships between upadacitinib exposure and interleukin (IL)-6-induced signal transducer and activator of transcription proteins 3 (STAT3) phosphorylation (pSTAT3) and IL-7-induced STAT5 phosphorylation (pSTAT5) in the ex vivo setting as measures for JAK1 and JAK1/JAK3 inhibition, respectively, with comparison to tofacitinib.	upadacitinib	51-63	Janus kinase 1	Homo sapiens	293-297
30725185-1	2020	OBJECTIVES: We assessed the relative efficacy and safety of once-daily administration of 15 and 30 mg upadacitinib (a JAK1-selective inhibitor) in patients with active rheumatoid arthritis (RA).	upadacitinib	102-114	Janus kinase 1	Homo sapiens	118-122
32099414-3	2020	Baricitinib is an oral JAK inhibitor highly selective for JAK1 and JAK2.	baricitinib	0-11	Janus kinase 1	Homo sapiens	58-62
31423579-0	2020	JAK1/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression.	Lenalidomide	92-104	Janus kinase 1	Homo sapiens	0-6
31831383-0	2020	Synthesis and biological evaluation of novel pyrazolo[1,5-a]pyrimidines: Discovery of a selective inhibitor of JAK1 JH2 pseudokinase and VPS34.	pyrazolo(1,5-a)pyrimidine	45-71	Janus kinase 1	Homo sapiens	111-115
31956784-3	2020	In the present study, the susceptibility of the oral JAK inhibitor tofacitinib against these three JAKs was elucidated using the 500-ns molecular dynamics (MD) simulations and free energy calculations based on MM-PB(GB)SA, QM/MM-GBSA (PM3 and SCC-DFTB), and SIE methods.	tofacitinib	67-78	Janus kinase 1	Homo sapiens	99-103
31956784-4	2020	The obtained results revealed that tofacitinib could interact with all JAKs at the ATP-binding site via electrostatic attraction, hydrogen bond formation, and in particular van der Waals interaction.	tofacitinib	35-46	Janus kinase 1	Homo sapiens	71-75
31956784-4	2020	The obtained results revealed that tofacitinib could interact with all JAKs at the ATP-binding site via electrostatic attraction, hydrogen bond formation, and in particular van der Waals interaction.	Adenosine Triphosphate	83-86	Janus kinase 1	Homo sapiens	71-75
31956784-5	2020	The conserved glutamate and leucine residues (E957 and L959 of JAK1, E930 and L932 of JAK2, and E903 and L905 of JAK3) located in the hinge region stabilized tofacitinib binding through strongly formed hydrogen bonds.	Glutamic Acid	14-23	Janus kinase 1	Homo sapiens	63-67
31956784-5	2020	The conserved glutamate and leucine residues (E957 and L959 of JAK1, E930 and L932 of JAK2, and E903 and L905 of JAK3) located in the hinge region stabilized tofacitinib binding through strongly formed hydrogen bonds.	Leucine	28-35	Janus kinase 1	Homo sapiens	63-67
31956784-5	2020	The conserved glutamate and leucine residues (E957 and L959 of JAK1, E930 and L932 of JAK2, and E903 and L905 of JAK3) located in the hinge region stabilized tofacitinib binding through strongly formed hydrogen bonds.	tofacitinib	158-169	Janus kinase 1	Homo sapiens	63-67
31956784-5	2020	The conserved glutamate and leucine residues (E957 and L959 of JAK1, E930 and L932 of JAK2, and E903 and L905 of JAK3) located in the hinge region stabilized tofacitinib binding through strongly formed hydrogen bonds.	Hydrogen	202-210	Janus kinase 1	Homo sapiens	63-67
31956784-7	2020	The binding affinities of tofacitinib/JAKs were ranked in the order of JAK3 > JAK2 ~ JAK1, which are in line with the reported experimental data.	tofacitinib	26-37	Janus kinase 1	Homo sapiens	38-42
31956784-7	2020	The binding affinities of tofacitinib/JAKs were ranked in the order of JAK3 > JAK2 ~ JAK1, which are in line with the reported experimental data.	tofacitinib	26-37	Janus kinase 1	Homo sapiens	85-89
31819176-0	2020	Serotonin activates glycolysis and mitochondria biogenesis in human breast cancer cells through activation of the Jak1/STAT3/ERK1/2 and adenylate cyclase/PKA, respectively.	Serotonin	0-9	Janus kinase 1	Homo sapiens	114-118
31534088-3	2020	We describe the case of a patient with MF-associated PH who developed left ventricular dysfunction after five years of treatment with the JAK 1/2 inhibitor, ruxolitinib.	ruxolitinib	157-168	Janus kinase 1	Homo sapiens	138-145
32067619-1	2020	BACKGROUND: Ruxolitinib is a selective JAK1/2 inhibitor approved by FDA for myelofibrosis in 2014 and nowadays, comprehensive investigations on the potential of the agent as a targeted therapy for haematological malignancies are on the rise.	ruxolitinib	12-23	Janus kinase 1	Homo sapiens	39-45
30962501-1	2020	Ruxolitinib (Rux), a Jak1/2 inhibitor, results in reduced spleen size and improvement in constitutional symptoms in the majority of patients with myelofibrosis (MF).	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	21-27
30962501-1	2020	Ruxolitinib (Rux), a Jak1/2 inhibitor, results in reduced spleen size and improvement in constitutional symptoms in the majority of patients with myelofibrosis (MF).	ruxolitinib	0-3	Janus kinase 1	Homo sapiens	21-27
31819176-5	2020	We also showed that increased glucose metabolism is provoked by the upregulation of pyruvate kinase M2 (PKM2) isoform through 5-HTR2A/C-triggered activation of Jak1/STAT3 and ERK1/2 subcellular pathways.	Glucose	30-37	Janus kinase 1	Homo sapiens	160-164
31423579-5	2020	Ruxolitinib (RUX) is an inhibitor of the Janus kinase family of protein tyrosine kinases (JAKs) and is effective for treating patients with myeloproliferative disorders.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	90-94
31819176-8	2020	CONCLUSIONS: We showed that serotonin, through 5-HTR2A/C, interferes with breast cancer cells proliferation and metabolism by triggering two distinct signalling pathways: Jak1/STAT3 that boosts glycolysis through upregulation of PKM2, and adenylyl cyclase/PKA that enhances mitochondrial biogenesis.	Serotonin	28-37	Janus kinase 1	Homo sapiens	171-175
31423579-5	2020	Ruxolitinib (RUX) is an inhibitor of the Janus kinase family of protein tyrosine kinases (JAKs) and is effective for treating patients with myeloproliferative disorders.	ruxolitinib	13-16	Janus kinase 1	Homo sapiens	90-94
31797578-1	2020	Filgotinib, a selective inhibitor of Janus kinase 1, is being developed for the treatment of chronic inflammatory diseases.	GLPG0634	0-10	Janus kinase 1	Homo sapiens	37-51
31378969-1	2020	The aim of this study was to characterize the effects of upadacitinib, a Janus kinase 1 inhibitor, on in vivo activity of different cytochrome P450 (CYP) enzymes using a cocktail approach.	upadacitinib	57-69	Janus kinase 1	Homo sapiens	73-87
31666386-4	2020	Based on these results she was treated with the JAK1/2 inhibitor ruxolitinib, which resulted in reduction in IFN signalling and appeared to be associated with partial though incomplete decrease in the severity of her pulmonary disease.	ruxolitinib	65-76	Janus kinase 1	Homo sapiens	48-54
31778911-1	2020	Ruxolitinib, a selective JAK1/JAK2 inhibitor, is the current first line therapy for myelofibrosis (MF), which reduces symptomatology and splenomegaly, but does not clearly modify disease course.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	25-29
30784354-1	2020	OBJECTIVES: Baricitinib is a selective oral inhibitor of JAK1/JAK2 for patients with moderately-to-severely active rheumatoid arthritis (RA).	baricitinib	12-23	Janus kinase 1	Homo sapiens	57-61
31654094-0	2020	Potent repression of C-reactive protein (CRP) expression by the JAK1/2 inhibitor ruxolitinib in inflammatory human hepatocytes.	ruxolitinib	81-92	Janus kinase 1	Homo sapiens	64-70
31821455-0	2019	Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinib.	ruxolitinib	101-112	Janus kinase 1	Homo sapiens	84-90
31892268-8	2019	In interleukin-2 (IL-2)-induced STAT5 activation JAK1 was dominant over JAK3 but in interferon-gamma (IFNgamma) and interferon-alpha (IFNalpha) signaling both JAK1 and heteromeric partner JAK2 or TYK2 were both indispensable for STAT1 activation.	Interferon-alpha	116-132	Janus kinase 1	Homo sapiens	159-163
31892268-10	2019	To investigate the regulatory function, we focused on two allosteric regions in JAK1 JH2, the ATP-binding pocket and the alphaC-helix.	Adenosine Triphosphate	94-97	Janus kinase 1	Homo sapiens	80-84
31920387-2	2019	In late 2019, the FDA approved the highly selective JAK2 inhibitor, fedratinib, for intermediate-2 or high-risk primary or secondary MF, making it the second drug approved for MF after ruxolitinib, a JAK1/2 inhibitor, which was approved for MF in 2011.	Fedratinib	68-78	Janus kinase 1	Homo sapiens	200-206
32015973-6	2020	LEARNING POINTS: Baricitinib is a small, orally active molecule that inhibits JAK-1 and JAK-2, which is used in the treatment of rheumatoid arthritis.Baricitinib has been also used in the treatment of psoriasis, alopecia areata and atopic dermatitis.Palmoplantar pustulosis is a rare cutaneous side effect of baricitinib.	baricitinib	17-28	Janus kinase 1	Homo sapiens	78-83
32015973-6	2020	LEARNING POINTS: Baricitinib is a small, orally active molecule that inhibits JAK-1 and JAK-2, which is used in the treatment of rheumatoid arthritis.Baricitinib has been also used in the treatment of psoriasis, alopecia areata and atopic dermatitis.Palmoplantar pustulosis is a rare cutaneous side effect of baricitinib.	baricitinib	150-161	Janus kinase 1	Homo sapiens	78-83
32015973-6	2020	LEARNING POINTS: Baricitinib is a small, orally active molecule that inhibits JAK-1 and JAK-2, which is used in the treatment of rheumatoid arthritis.Baricitinib has been also used in the treatment of psoriasis, alopecia areata and atopic dermatitis.Palmoplantar pustulosis is a rare cutaneous side effect of baricitinib.	baricitinib	309-320	Janus kinase 1	Homo sapiens	78-83
31878046-5	2019	Additionally, DDZ mitigated the phosphorylation of STAT3 upstream Janus-activated kinases (JAK1/2) and c-Src kinases.	daidzin	14-17	Janus kinase 1	Homo sapiens	91-97
31847229-6	2019	In addition, ACHP imparted inhibitory activity on the constitutive activation of upstream protein tyrosine kinases, including JAK1, JAK2, and Src.	2-amino-6-(2-(cyclopropylmethoxy)-6-hydroxyphenyl)-4-piperidin-4-yl nicotinonitrile	13-17	Janus kinase 1	Homo sapiens	126-130
31866997-8	2019	Treatment with Janus kinase 1 and 2 (JAK1/2) inhibitor baricitinib was beneficiary for a vasculitic ulcer, induced hair regrowth and improved overall well-being in one patient.	baricitinib	55-66	Janus kinase 1	Homo sapiens	37-43
31732180-2	2019	This study assessed the efficacy and safety of upadacitinib, a selective JAK1 inhibitor, in patients with ankylosing spondylitis.	upadacitinib	47-59	Janus kinase 1	Homo sapiens	73-77
30831034-0	2019	Notoginsenoside R1 promotes MC3T3-E1 differentiation by up-regulating miR-23a via MAPK and JAK1/STAT3 pathways.	notoginsenoside	0-15	Janus kinase 1	Homo sapiens	91-95
31791386-2	2019	We compared upadacitinib, an oral, selective JAK-1 inhibitor, with placebo to assess clinically meaningful improvements in PROs in patients with RA who have had inadequate responses to biologic disease-modifying antirheumatic drugs (bDMARD-IR).	upadacitinib	12-24	Janus kinase 1	Homo sapiens	45-50
31719581-1	2019	Ruxolitinib is an FDA approved janus kinase (JAK)1/2 inhibitor used to treat myeloproliferative neoplasms (MPNs), including myelofibrosis and polycythemia vera.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	31-50
31282592-1	2019	Itacitinib is a potent, selective JAK-1 inhibitor currently in phase 3 development for the treatment of acute and chronic graft-versus-host disease (GVHD) in combination with corticosteroids.	INCB039110	0-10	Janus kinase 1	Homo sapiens	34-39
31577341-3	2019	Abrocitinib (PF-04965842) is an oral Janus kinase 1 selective inhibitor under investigation for the treatment of atopic dermatitis.	Abrocitinib	0-11	Janus kinase 1	Homo sapiens	37-51
31577341-3	2019	Abrocitinib (PF-04965842) is an oral Janus kinase 1 selective inhibitor under investigation for the treatment of atopic dermatitis.	Abrocitinib	13-24	Janus kinase 1	Homo sapiens	37-51
31725895-7	2019	Here we report that the recently developed pan-PIM inhibitor INCB053914 augments the efficacy of the US Food and Drug Administration-approved JAK1/2 inhibitor ruxolitinib in both in vitro and in vivo MPN models.	INCB3619	61-71	Janus kinase 1	Homo sapiens	142-148
31725895-7	2019	Here we report that the recently developed pan-PIM inhibitor INCB053914 augments the efficacy of the US Food and Drug Administration-approved JAK1/2 inhibitor ruxolitinib in both in vitro and in vivo MPN models.	ruxolitinib	159-170	Janus kinase 1	Homo sapiens	142-148
31537486-4	2019	We therefore aimed to determine the activity and safety of ruxolitinib, a JAK inhibitor, in adults with secondary haemophagocytic lymphohistiocytosis.	ruxolitinib	59-70	Janus kinase 1	Homo sapiens	74-77
31287230-1	2019	OBJECTIVE: To evaluate the efficacy, including capacity for inhibition of radiographic progression, and safety of upadacitinib, a JAK1-selective inhibitor, as compared to placebo or adalimumab in patients with rheumatoid arthritis (RA) who have experienced an inadequate response to methotrexate (MTX).	upadacitinib	114-126	Janus kinase 1	Homo sapiens	130-134
31788449-4	2019	Ruxolitinib is a potent and selective oral inhibitor of both JAK2 and JAK1 protein kinases.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	70-74
31507089-5	2019	We showed that forced miR-206 expression restored gefitinib sensitivity in IL6-induced gefitinib-resistant EGFR-mutant lung cancer cells by inhibiting IL6/JAK1/STAT3 pathway.	Gefitinib	50-59	Janus kinase 1	Homo sapiens	155-159
31642025-1	2019	Upadacitinib (Rinvoq ), an orally-administered Janus kinase 1 (JAK-1) inhibitor, is being developed by AbbVie for the treatment of rheumatoid arthritis.	upadacitinib	0-12	Janus kinase 1	Homo sapiens	47-61
31642025-1	2019	Upadacitinib (Rinvoq ), an orally-administered Janus kinase 1 (JAK-1) inhibitor, is being developed by AbbVie for the treatment of rheumatoid arthritis.	upadacitinib	0-12	Janus kinase 1	Homo sapiens	63-68
31507089-5	2019	We showed that forced miR-206 expression restored gefitinib sensitivity in IL6-induced gefitinib-resistant EGFR-mutant lung cancer cells by inhibiting IL6/JAK1/STAT3 pathway.	Gefitinib	87-96	Janus kinase 1	Homo sapiens	155-159
31654328-1	2019	Upadacitinib is a selective Janus Kinase 1 inhibitor which is being developed for the treatment of several inflammatory diseases including rheumatoid arthritis.	upadacitinib	0-12	Janus kinase 1	Homo sapiens	28-42
31313387-4	2019	MTX has also been shown to exert JAK inhibition of JAK2 and JAK1 when tested in Drosophila melanogaster as a model of kinase activity and in human cell lines (nodular sclerosis Hodgkin"s lymphoma and acute myeloid leukemia cell lines).	Methotrexate	0-3	Janus kinase 1	Homo sapiens	60-64
31313387-5	2019	These effects may explain why MTX leads to clinical effects similar to anti-TNFalpha biologics in monotherapy, but is less effective when compared to anti-IL6R in monotherapy, which acting upstream exerts major effects downstream on the JAK1-STAT3 pathway.	Methotrexate	30-33	Janus kinase 1	Homo sapiens	237-241
31313387-6	2019	The MTX effects on JAK1/JAK2 inhibition also allows to understand why the combination of MTX with Leflunomide, or JAK1/JAK3 inhibitor leads to better clinical outcomes than monotherapy, while the combination with JAK1/JAK2 or JAK1 specific inhibitors does not seem to exert additive clinical benefit.	Methotrexate	4-7	Janus kinase 1	Homo sapiens	19-23
31313387-6	2019	The MTX effects on JAK1/JAK2 inhibition also allows to understand why the combination of MTX with Leflunomide, or JAK1/JAK3 inhibitor leads to better clinical outcomes than monotherapy, while the combination with JAK1/JAK2 or JAK1 specific inhibitors does not seem to exert additive clinical benefit.	Methotrexate	4-7	Janus kinase 1	Homo sapiens	114-118
31313387-6	2019	The MTX effects on JAK1/JAK2 inhibition also allows to understand why the combination of MTX with Leflunomide, or JAK1/JAK3 inhibitor leads to better clinical outcomes than monotherapy, while the combination with JAK1/JAK2 or JAK1 specific inhibitors does not seem to exert additive clinical benefit.	Methotrexate	4-7	Janus kinase 1	Homo sapiens	114-118
31313387-6	2019	The MTX effects on JAK1/JAK2 inhibition also allows to understand why the combination of MTX with Leflunomide, or JAK1/JAK3 inhibitor leads to better clinical outcomes than monotherapy, while the combination with JAK1/JAK2 or JAK1 specific inhibitors does not seem to exert additive clinical benefit.	Methotrexate	4-7	Janus kinase 1	Homo sapiens	114-118
31313387-6	2019	The MTX effects on JAK1/JAK2 inhibition also allows to understand why the combination of MTX with Leflunomide, or JAK1/JAK3 inhibitor leads to better clinical outcomes than monotherapy, while the combination with JAK1/JAK2 or JAK1 specific inhibitors does not seem to exert additive clinical benefit.	Methotrexate	89-92	Janus kinase 1	Homo sapiens	19-23
31313387-6	2019	The MTX effects on JAK1/JAK2 inhibition also allows to understand why the combination of MTX with Leflunomide, or JAK1/JAK3 inhibitor leads to better clinical outcomes than monotherapy, while the combination with JAK1/JAK2 or JAK1 specific inhibitors does not seem to exert additive clinical benefit.	Leflunomide	98-109	Janus kinase 1	Homo sapiens	19-23
31696160-1	2019	Background: Baricitinib, with a 2-(1-(ethylsulfonyl)azetidin-3-yl)acetonitrile moiety at N-2 position of the pyrazol skeleton, is an oral and selective reversible inhibitor of the JAK1 and JAK2 and displays potent anti-inflammatory activity.	baricitinib	12-23	Janus kinase 1	Homo sapiens	180-184
31635416-0	2019	Inhibition of JAK-STAT Signaling with Baricitinib Reduces Inflammation and Improves Cellular Homeostasis in Progeria Cells.	baricitinib	38-49	Janus kinase 1	Homo sapiens	14-17
31692920-6	2019	Both these new compounds are active on the majority of four JAK family members (JAK1, JAK2, JAK3, and TYK2), whereas the most recent emerging approach is directed toward the development of JAK1 selective inhibitors (upadacitinib and filgotinib) with the aim to improve the safety profile by minimizing the effects on JAK3 and, especially, JAK2.	upadacitinib and filgotinib	216-243	Janus kinase 1	Homo sapiens	189-193
31635416-7	2019	We report that the inhibition of the JAK-STAT pathway with baricitinib, a Food and Drug Administration-approved JAK1/2 inhibitor, restored cellular homeostasis, delayed senescence and decreased proinflammatory markers in HGPS cells.	baricitinib	59-70	Janus kinase 1	Homo sapiens	37-40
31635416-7	2019	We report that the inhibition of the JAK-STAT pathway with baricitinib, a Food and Drug Administration-approved JAK1/2 inhibitor, restored cellular homeostasis, delayed senescence and decreased proinflammatory markers in HGPS cells.	baricitinib	59-70	Janus kinase 1	Homo sapiens	112-118
31276975-5	2019	The results suggest that celastrol acts against rheumatoid arthritis by regulating the function of several signaling proteins, including MMP-9, COX-2, c-Myc, TGF-beta, c-JUN, JAK-1, JAK-3, IKK-beta, SYK, MMP-3, JNK and MEK1, which regulate the functions of Th1 and Th2 cells, macrophages, fibroblasts and endothelial cells in rheumatoid arthritis.	celastrol	25-34	Janus kinase 1	Homo sapiens	175-180
31575007-5	2019	The data from the cell-based experiments suggested that BT-induced cytotoxicity and abrogated the activation of STAT3 and that of upstream kinases such as JAK1, JAK2, and Src.	brusatol	56-58	Janus kinase 1	Homo sapiens	155-159
31348981-4	2019	The highest percentage of apoptosis was observed in the treatment of Jak1 siRNA/cisplatin group in cancerous HN5 cells (96.5%) where this treatment showed 12.84% apoptosis in normal HUVEC cell line.	Cisplatin	80-89	Janus kinase 1	Homo sapiens	69-73
31554739-6	2019	Last, using drug prediction algorithms, we identify JAK inhibitors as promising therapeutic agents in LP and demonstrate that the JAK1/2 inhibitor baricitinib fully protects keratinocytes against cell-mediated cytotoxic responses in vitro.	baricitinib	147-158	Janus kinase 1	Homo sapiens	130-136
31549971-6	2019	Recently, the Janus kinase (JAK) family of tyrosine kinases, including JAK1 and JAK2, has been shown to play a role in the pathogenesis of MM.	Tyrosine	43-51	Janus kinase 1	Homo sapiens	71-75
31549971-7	2019	Preclinical studies have demonstrated that the JAK1/2 inhibitor ruxolitinib, in combination with lenalidomide and dexamethasone, reduces proliferation of the MM cell lines and primary tumor cells derived from MM patients, and this inhibition is greater when these drugs are combined than with single agents.	ruxolitinib	64-75	Janus kinase 1	Homo sapiens	47-51
31549971-7	2019	Preclinical studies have demonstrated that the JAK1/2 inhibitor ruxolitinib, in combination with lenalidomide and dexamethasone, reduces proliferation of the MM cell lines and primary tumor cells derived from MM patients, and this inhibition is greater when these drugs are combined than with single agents.	lenalidomide	97-109	Janus kinase 1	Homo sapiens	47-51
31549971-7	2019	Preclinical studies have demonstrated that the JAK1/2 inhibitor ruxolitinib, in combination with lenalidomide and dexamethasone, reduces proliferation of the MM cell lines and primary tumor cells derived from MM patients, and this inhibition is greater when these drugs are combined than with single agents.	Dexamethasone	114-127	Janus kinase 1	Homo sapiens	47-51
30907116-4	2019	Data Synthesis: Baricitinib exerts its effects by inhibiting JAK1 and JAK2 enzymes, targeting cytokine and growth factor receptor stimulation, thus reducing downstream immune cell function.	baricitinib	16-27	Janus kinase 1	Homo sapiens	61-65
30671927-5	2019	TAM-derived IL-10 promoted CSC-like properties of NSCLC cells through JAK1/STAT1/NF-kappaB/Notch1 signaling.	tam	0-3	Janus kinase 1	Homo sapiens	70-74
30973649-1	2019	Upadacitinib is a selective Janus kinase 1 inhibitor being developed for the treatment of several inflammatory autoimmune diseases, including rheumatoid arthritis.	upadacitinib	0-12	Janus kinase 1	Homo sapiens	28-42
31401212-6	2019	Emerging data with selective JAK1 inhibitors upadacitinib and filgotinib looks very promising.	upadacitinib	45-57	Janus kinase 1	Homo sapiens	29-33
31401212-6	2019	Emerging data with selective JAK1 inhibitors upadacitinib and filgotinib looks very promising.	GLPG0634	62-72	Janus kinase 1	Homo sapiens	29-33
31449490-13	2019	In contrast to IL-1 (interleukin-1), IL-6, and TNF (tumor necrosis factor) inhibitors, baricitinib was very successful, probably because baricitinib acts as a JAK-1/2 (janus kinase-1/2) inhibitor in the IFNalpha/beta (inteferone alpha/beta) pathway.	baricitinib	87-98	Janus kinase 1	Homo sapiens	159-166
31449490-13	2019	In contrast to IL-1 (interleukin-1), IL-6, and TNF (tumor necrosis factor) inhibitors, baricitinib was very successful, probably because baricitinib acts as a JAK-1/2 (janus kinase-1/2) inhibitor in the IFNalpha/beta (inteferone alpha/beta) pathway.	baricitinib	137-148	Janus kinase 1	Homo sapiens	159-166
30671927-6	2019	Blockade of IL-10/JAK1 signaling inhibited TAM-mediated NSCLC tumor growth in vivo, and the TAM-mediated expression of CSC-related and mesenchymal-related genes in NSCLC.	tam	43-46	Janus kinase 1	Homo sapiens	18-22
30650179-6	2019	JAK1/2 inhibition via ruxolitinib decreased, while stimulation with LIF increased, phosphorylation of STAT3 and the number of cells with CSC properties indicating that JAK-STAT signalling controlled the number of cells with CSC features.	ruxolitinib	22-33	Janus kinase 1	Homo sapiens	0-6
31375130-6	2019	For example, tofacitinib and upadacitinib were the most potent inhibitors of the JAK1/3-dependent cytokines tested (interleukin [IL]-2, IL-4, IL-15, and IL-21) with lower IC50 values and increased time above IC50 translating to a greater overall inhibition of STAT signaling during the dosing interval.	tofacitinib	13-24	Janus kinase 1	Homo sapiens	81-85
31375130-6	2019	For example, tofacitinib and upadacitinib were the most potent inhibitors of the JAK1/3-dependent cytokines tested (interleukin [IL]-2, IL-4, IL-15, and IL-21) with lower IC50 values and increased time above IC50 translating to a greater overall inhibition of STAT signaling during the dosing interval.	upadacitinib	29-41	Janus kinase 1	Homo sapiens	81-85
31375130-9	2019	Notably, baricitinib inhibited JAK1/3 signaling to a lesser extent than upadacitinib and tofacitinib, while upadacitinib, baricitinib, and tofacitinib inhibited the signaling of JAK2/2-dependent cytokines, including GM-CSF and IL-3, as well as the signaling of the JAK2/TYK2-dependent cytokine G-CSF.	baricitinib	9-20	Janus kinase 1	Homo sapiens	31-35
30945116-1	2019	BACKGROUND AND OBJECTIVES: Upadacitinib is a selective Janus kinase (JAK) 1 inhibitor being developed as an orally administered treatment for patients with moderate to severe rheumatoid arthritis (RA) and other autoimmune disorders.	upadacitinib	27-39	Janus kinase 1	Homo sapiens	55-75
31201513-1	2019	Ruxolitinib is the only commercially available JAK1/2 inhibitor approved for the treatment of myelofibrosis-related splenomegaly and symptoms.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	47-53
31317509-10	2019	Several more selective JAK-1 inhibitors, including filgotinib and upadacitinib, have also shown positive results in phase II studies and are currently enrolling in phase III development programs.	GLPG0634	51-61	Janus kinase 1	Homo sapiens	23-28
31317509-10	2019	Several more selective JAK-1 inhibitors, including filgotinib and upadacitinib, have also shown positive results in phase II studies and are currently enrolling in phase III development programs.	upadacitinib	66-78	Janus kinase 1	Homo sapiens	23-28
31334773-0	2019	Filgotinib, a JAK1 Inhibitor, for Treatment-Resistant Rheumatoid Arthritis.	GLPG0634	0-10	Janus kinase 1	Homo sapiens	14-18
30768860-1	2019	Filgotinib is a potent, selective Janus kinase-1 inhibitor being developed to treat chronic inflammatory diseases.	GLPG0634	0-10	Janus kinase 1	Homo sapiens	34-48
31360575-1	2019	Baricitinib is a Janus kinase 1/2 (JAK1/2) inhibitor used in the treatment of rheumatoid arthritis.	baricitinib	0-11	Janus kinase 1	Homo sapiens	35-41
31289316-1	2019	JAK2/STAT signaling participates in the Ph-negative myeloproliferative neoplasms (MPN) pathophysiology and has been targeted by ruxolitinib, a JAK1/2 inhibitor.	ruxolitinib	128-139	Janus kinase 1	Homo sapiens	143-149
30663869-1	2019	OBJECTIVE: To assess the frequency of cardiovascular and venous thromboembolic events in clinical studies of baricitinib, an oral, selective JAK1 and JAK2 inhibitor approved in more than 50 countries for the treatment of moderately-to-severely active rheumatoid arthritis (RA).	baricitinib	109-120	Janus kinase 1	Homo sapiens	141-145
30940655-8	2019	By targeting the RET-Src axis, regorafenib potently inhibited JAK1/2-STAT1 and MAPK signaling and subsequently attenuated the IFNgamma-induced PD-L1 and IDO1 expression without affecting MHC-I expression much.	regorafenib	31-42	Janus kinase 1	Homo sapiens	62-66
31040122-1	2019	OBJECTIVE: To evaluate clinical outcomes in patients who changed treatment from adalimumab to baricitinib, an oral Janus kinase (JAK)1/JAK2 inhibitor, during a phase III programme.	baricitinib	94-105	Janus kinase 1	Homo sapiens	115-134
30767864-4	2019	Baricitinib, an oral selective inhibitor of JAK1 and JAK2, offers an effective treatment for RA in a wide range of patients.	baricitinib	0-11	Janus kinase 1	Homo sapiens	44-48
30767864-7	2019	This narrative review focuses on the clinical efficacy and safety of baricitinib, but also provides an overview of its mechanism of action in relation to JAK1/JAK2 signalling and discusses the possible clinical implications in patients with RA.	baricitinib	69-80	Janus kinase 1	Homo sapiens	154-158
31144250-5	2019	The JAK1/2 inhibitor ruxolitinib was administered on an off-label basis.	ruxolitinib	21-32	Janus kinase 1	Homo sapiens	4-10
30997845-0	2019	Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation.	ruxolitinib	52-63	Janus kinase 1	Homo sapiens	67-73
30997748-1	2019	Ruxolitinib, an orally bioavailable and selective inhibitor of Janus kinase 1 (JAK1) and JAK2, significantly reduces splenomegaly and disease-related symptoms in patients with myelofibrosis (MF).	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	63-77
31130260-1	2019	BACKGROUND: Upadacitinib, an oral Janus kinase (JAK)1-selective inhibitor, showed efficacy in combination with stable background conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in patients with rheumatoid arthritis who had an inadequate response to DMARDs.	upadacitinib	12-24	Janus kinase 1	Homo sapiens	34-53
30997748-1	2019	Ruxolitinib, an orally bioavailable and selective inhibitor of Janus kinase 1 (JAK1) and JAK2, significantly reduces splenomegaly and disease-related symptoms in patients with myelofibrosis (MF).	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	79-83
31059310-6	2019	Expert opinion: Peficitinib is a novel JAK3 inhibitor potently inhibiting JAK3 enzymatic activity and JAK1/3-mediated cell proliferation.	peficitinib	16-27	Janus kinase 1	Homo sapiens	102-106
31093950-1	2019	Peficitinib [Smyraf  (Astellas Pharma)] is a Janus kinase (JAK)1, JAK2, JAK3 and tyrosine kinase (Tyk)2 (pan-JAK) inhibitor recently approved in Japan for the treatment of rheumatoid arthritis.	peficitinib	0-11	Janus kinase 1	Homo sapiens	45-64
31096817-1	2019	BACKGROUND: Tofacitinib is an oral Janus kinase (JAK) inhibitor that targets JAK1 and JAK3, and thus regulates immune response.	tofacitinib	12-23	Janus kinase 1	Homo sapiens	77-81
30633369-1	2019	Upadacitinib is a novel selective Janus kinase 1 inhibitor developed for treatment of rheumatoid arthritis and other autoimmune diseases.	upadacitinib	0-12	Janus kinase 1	Homo sapiens	34-48
30814061-7	2019	We found that ibrutinib decreases the CLL PFs and, interestingly, also reduces AID expression, which correlates with dampened AKT and Janus Kinase 1 signaling.	ibrutinib	14-23	Janus kinase 1	Homo sapiens	134-148
31275057-11	2019	Focusing on IFN signaling, we showed that ligand, IFN receptor, the JAKs, and the STATs all undergo endocytosis and ATP-dependent nuclear translocation to promoters of genes specifically activated by IFNs.	Adenosine Triphosphate	116-119	Janus kinase 1	Homo sapiens	68-72
30981183-5	2019	CAG predominantly caused negative regulation of STAT3 phosphorylation at tyrosine 705 through the abrogation of Src and Janus-activated kinases (JAK1/2) activation.	cycloastragenol	0-3	Janus kinase 1	Homo sapiens	145-151
30990343-8	2019	The results of dual-luciferase reporter assay indicated that miR-1225 targeted the 3"-untranslated region of JAK1 for silencing.	mir-1225	61-69	Janus kinase 1	Homo sapiens	109-113
30990343-9	2019	Silencing of JAK1 expression counteracted the suppressive influence of miR-1225 depletion in PC cells.	mir-1225	71-79	Janus kinase 1	Homo sapiens	13-17
30999933-2	2019	Baricitinib is an oral, selective Janus kinase (JAK) 1/JAK 2 inhibitor and is approved for the treatment of moderately to severely active RA in adults in over 50 countries including European countries, the USA, and Japan.	baricitinib	0-11	Janus kinase 1	Homo sapiens	34-54
30688081-8	2019	A mixture of animal model studies and human case studies have reported the use of baricitinib (JAK 1/2), ruxolitinib (JAK 1/2), and tofacitinib (JAK 1/3) for the management of AA.	baricitinib	82-93	Janus kinase 1	Homo sapiens	95-102
30688081-8	2019	A mixture of animal model studies and human case studies have reported the use of baricitinib (JAK 1/2), ruxolitinib (JAK 1/2), and tofacitinib (JAK 1/3) for the management of AA.	tofacitinib	132-143	Janus kinase 1	Homo sapiens	145-152
31016396-5	2019	The JAK1/3 inhibitor, tofacitinib, was shown to both induce and maintain clinical remission and mucosal healing in ulcerative colitis (UC).	tofacitinib	22-33	Janus kinase 1	Homo sapiens	4-10
30833158-3	2019	Simulation of water networks in combination with docking enabled us to identify the key waters and to optimize our primary hit into a low nanomolar JAK2 lead with promising selectivity over JAK1.	Water	14-19	Janus kinase 1	Homo sapiens	190-194
29410014-1	2019	BACKGROUND: Baricitinib, an oral selective inhibitor of Janus kinase 1 and Janus kinase 2, modulates proinflammatory cytokine signaling.	baricitinib	12-23	Janus kinase 1	Homo sapiens	56-70
33911570-1	2019	Ruxolitinib is a Janus kinase (JAK)1 and JAK2 inhibitor approved for the treatment of myelofibrosis and for polycythemia patients who are resistant or intolerant to hydroxyurea.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	17-36
33911570-1	2019	Ruxolitinib is a Janus kinase (JAK)1 and JAK2 inhibitor approved for the treatment of myelofibrosis and for polycythemia patients who are resistant or intolerant to hydroxyurea.	Hydroxyurea	165-176	Janus kinase 1	Homo sapiens	17-36
30843659-3	2019	The JAK1/2 inhibitor ruxolitinib was prescribed to 12 CLL patients with abnormal serum beta-2 microglobulin levels after 6 months or persistent lymphadenopathy or splenomegaly after 12 months on ibrutinib using a 3 + 3 phase 1 trial design (NCT02912754).	ruxolitinib	21-32	Janus kinase 1	Homo sapiens	4-10
30961670-12	2019	Expressions of JAK1,2,  STAT3  PD-L1 and ATM were increased in A549CisR and H157CisR cells and could by induced by cisplatin in parental lung cancer cells.	Cisplatin	115-124	Janus kinase 1	Homo sapiens	15-21
30760472-13	2019	Blocking IL-21R or using the JAK1/2 inhibitor ruxolitinib reduced the Tfh cells" capacity to stimulate the plasmablasts and decreased the Ig production.	ruxolitinib	46-57	Janus kinase 1	Homo sapiens	29-35
30760472-15	2019	The IL-21 pathway or JAK1/2 blockade by ruxolitinib could be a promising strategy in the treatment of SSc.	ruxolitinib	40-51	Janus kinase 1	Homo sapiens	21-25
30931929-2	2019	Iron directly binds CDK1, which is upregulated in several cancers, thereby promoting JAK1 phosphorylation and activation of STAT3 signaling to promote colorectal carcinogenesis.	Iron	0-4	Janus kinase 1	Homo sapiens	85-89
30609183-0	2019	Expression of pro-inflammatory cytokines and mediators induced by Bisphenol A via ERK-NFkappaB and JAK1/2-STAT3 pathways in macrophages.	bisphenol A	66-77	Janus kinase 1	Homo sapiens	99-105
30609183-10	2019	Phosphorylation of JAK1 and JAK2 was also significantly induced by BPA in a concentration-dependent manner (P < 0.05).	bisphenol A	67-70	Janus kinase 1	Homo sapiens	19-23
30201397-4	2019	Ruxolitinib, a selective JAK1/2 inhibitor, has recently gained favor as a second-line approach in patients with steroid-refractory cGVHD.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	25-31
30930775-8	2019	Tofacitinib, a JAK inhibitor targeting predominantly JAK1 and JAK3, has been approved for the treatment of ulcerative colitis (UC), and there are other specific JAK inhibitors under development that may be effective in Crohn"s.	tofacitinib	0-11	Janus kinase 1	Homo sapiens	53-57
30639623-1	2019	Ruxolitinib is a JAK-1/JAK-2 inhibitor indicated for the treatment of polycythemia vera and primary or secondary myelofibrosis.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	17-22
30500075-1	2019	Upadacitinib is a novel selective oral Janus kinase 1 (JAK) inhibitor being developed for treatment of several inflammatory diseases.	upadacitinib	0-12	Janus kinase 1	Homo sapiens	39-53
30500075-1	2019	Upadacitinib is a novel selective oral Janus kinase 1 (JAK) inhibitor being developed for treatment of several inflammatory diseases.	upadacitinib	0-12	Janus kinase 1	Homo sapiens	55-58
30715158-0	2019	Reply: Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis.	baricitinib	40-51	Janus kinase 1	Homo sapiens	7-21
30571852-1	2019	Myeloproliferative neoplasms (MPNs) are developing resistance to therapy by JAK1/2 inhibitor ruxolitinib.	ruxolitinib	93-104	Janus kinase 1	Homo sapiens	76-82
30571852-2	2019	To explore the mechanism of ruxolitinib"s limited effect, we examined the JAK1/2 mediated induction of proliferation related ERK1/2 and AKT signaling by proinflammatory interleukin-6 (IL-6) in MPN granulocytes and JAK2V617F mutated human erythroleukemia (HEL) cells.	ruxolitinib	28-39	Janus kinase 1	Homo sapiens	74-80
30571852-5	2019	Only JAK1/2 inhibitor ruxolitinib largely activated ERK1/2 signaling in essential thrombocythemia and PMF (up to 4.6 fold), with a more prominent activation in JAK2V617F positive granulocytes.	ruxolitinib	22-33	Janus kinase 1	Homo sapiens	5-11
30357932-3	2019	OBJECTIVE: Our aim was to address the direct impact of kinase inhibition of the JAK1/3 pathways by tofacitinib on keratinocyte immune function and barrier formation in atopic dermatitis (AD) and psoriasis.	tofacitinib	99-110	Janus kinase 1	Homo sapiens	80-84
31327403-2	2019	To date, three JAK inhibitors have been tested in patients with moderate-to-severe CD: tofacitinib (pan-JAK inhibitor), filgotinib (JAK1 inhibitor) and upadacitinib (JAK1 inhibitor).	upadacitinib	152-164	Janus kinase 1	Homo sapiens	166-170
30675650-1	2019	OPINION STATEMENT: Seven years after the approval of the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib, it remains the only drug licensed for the treatment of myelofibrosis.	ruxolitinib	93-104	Janus kinase 1	Homo sapiens	75-81
30675650-4	2019	The JAK2-selective inhibitor fedratinib has recently been resurrected, and there has been a resurgence of interest in the failed JAK1/2 inhibitor momelotinib, which possibly improves anemia.	N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	146-157	Janus kinase 1	Homo sapiens	129-135
30670049-9	2019	Momelotinib, an inhibitor of JAK1/JAK2, consistently abrogated the STAT5/LY6G6D axis in vitro, sensitizing MSS cancer cells with an intact JAK-STAT signaling, to efficiently respond to trametinib, a MEK inhibitor used in clinical setting.	N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	0-11	Janus kinase 1	Homo sapiens	29-33
30670049-9	2019	Momelotinib, an inhibitor of JAK1/JAK2, consistently abrogated the STAT5/LY6G6D axis in vitro, sensitizing MSS cancer cells with an intact JAK-STAT signaling, to efficiently respond to trametinib, a MEK inhibitor used in clinical setting.	trametinib	185-195	Janus kinase 1	Homo sapiens	29-33
30621055-4	2019	We found that OMT can inhibit the constitutive activation of STAT5 by suppressing the activation of JAK1/2 and c-Src, nuclear localization, as well as STAT5 binding to DNA in A549 cells and abrogated IL-6-induced STAT5 phosphorylation in H1299 cells.	oxymatrine	14-17	Janus kinase 1	Homo sapiens	100-106
30806707-2	2019	Tofacitinib is a selective JAK1, 3 inhibitor with less activity against JAK2 and TYK2 and baricitinib is a selective, oral JAK1, 2 inhibitor with moderate activity against TYK2 and significantly less activity against JAK3.	tofacitinib	0-11	Janus kinase 1	Homo sapiens	27-31
30806707-2	2019	Tofacitinib is a selective JAK1, 3 inhibitor with less activity against JAK2 and TYK2 and baricitinib is a selective, oral JAK1, 2 inhibitor with moderate activity against TYK2 and significantly less activity against JAK3.	baricitinib	90-101	Janus kinase 1	Homo sapiens	123-127
30394138-8	2019	Expert commentary: Upadacitinib has displayed a rapid and favorable efficacy profile in RA but despite being a selective JAK1 inhibitor appears to have a similar safety profile to less-selective Jakinibs.	upadacitinib	19-31	Janus kinase 1	Homo sapiens	121-125
29714141-11	2019	Bazedoxifene also inhibited JAK1 binding to IL-6/IL-6R/GP130 complexes and STAT3 phosphorylation.	bazedoxifene	0-12	Janus kinase 1	Homo sapiens	28-32
33094033-1	2019	Introduction: The Janus kinase (JAK)1/2 inhibitor ruxolitinib provides rapid, sustained and often dramatic benefits to patients with myelofibrosis, inducing spleen shrinkage and ameliorating symptoms, and improves survival.	ruxolitinib	50-61	Janus kinase 1	Homo sapiens	18-39
30394138-2	2019	Upadacitinib selectively inhibits Janus Kinase 1 (JAK1) which could potentially reduce JAK2 and JAK3-related side effects.	upadacitinib	0-12	Janus kinase 1	Homo sapiens	34-48
30030153-5	2019	After intermittent UVB exposure, melanocytes treated with the JAK inhibitor ruxolitinib reduced expression of HMGB1 and MX1 as well as activation of JAK1 (pJAK1) and signal transducer and activator of transcription 1 (pSTAT1).	ruxolitinib	76-87	Janus kinase 1	Homo sapiens	149-153
30394138-2	2019	Upadacitinib selectively inhibits Janus Kinase 1 (JAK1) which could potentially reduce JAK2 and JAK3-related side effects.	upadacitinib	0-12	Janus kinase 1	Homo sapiens	50-54
30115734-5	2019	METHODS: This phase Ib/II dose-optimization study assessed itacitinib, a selective JAK1 inhibitor, combined with nab-paclitaxel plus gemcitabine in adults with treatment-naive advanced/metastatic disease (Part 1) or pancreatic adenocarcinoma (Parts 2/2A; NCT01858883).	INCB039110	59-69	Janus kinase 1	Homo sapiens	83-87
31288716-1	2019	The search for inhibitors of the Janus kinase family (JAK1, JAK2, JAK3 and TYK2) has been ongoing for several decades and has resulted in a number of JAK inhibitors being approved for use in patients, such as tofacitinib for the treatment of autoimmune diseases such as Rheumatoid Arthritis (RA).	tofacitinib	209-220	Janus kinase 1	Homo sapiens	54-58
31288716-2	2019	Although initially thought to be a JAK3 selective inhibitor, tofacitinib was subsequently found to possess significant activity to inhibit JAK1 and JAK2 which has contributed to some adverse side effects.	tofacitinib	61-72	Janus kinase 1	Homo sapiens	139-143
30219772-1	2019	OBJECTIVE: Baricitinib is an oral, once-daily selective Janus kinase (JAK1/JAK2) inhibitor for adults with moderately to severely active rheumatoid arthritis (RA).	baricitinib	11-22	Janus kinase 1	Homo sapiens	70-74
30558676-5	2018	Ruxolitinib is a tyrosine kinase inhibitor which inhibits JAK1 and JAK2.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	58-62
31484895-4	2019	The Jak1/2 inhibitor ruxolitinib can simultaneously inhibit the signaling pathway of multiple cytokines with relevance for GvHD, such as interferon (IFN-gamma), IL-2, and IL-6.	ruxolitinib	21-32	Janus kinase 1	Homo sapiens	4-10
30058112-1	2018	OBJECTIVE: Baricitinib is an orally administered inhibitor of JAK1 and JAK2 that has been shown to be effective in treating rheumatoid arthritis (RA).	baricitinib	11-22	Janus kinase 1	Homo sapiens	62-66
30526546-8	2018	Curcumin suppressed the phosphorylation levels of JAK1, STAT1, and STAT3, while curcumin did not inhibit the activation of JAK/STAT pathway when miR-99a was knocked down.	Curcumin	0-8	Janus kinase 1	Homo sapiens	50-54
30558329-7	2018	Based on QPCR data, the action of EGCG on p-STAT1 seems to be mediated via downregulation of the expression of JAK2 but not JAK1 leading to the inhibition of human leukocyte antigens (HLA-DR and HLA-B) expression probably via IRF-1.	epigallocatechin gallate	34-38	Janus kinase 1	Homo sapiens	124-128
30360969-0	2018	Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.	GLPG0634	23-33	Janus kinase 1	Homo sapiens	47-61
30088677-0	2018	Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor.	GLPG0634	78-88	Janus kinase 1	Homo sapiens	102-106
30088677-1	2018	AIMS: Filgotinib (GS-6034, formerly GLPG0634) is an oral, selective Janus kinase 1 (JAK1) inhibitor that showed early response and sustained efficacy in patients with rheumatoid arthritis and with Crohn"s disease.	GLPG0634	6-16	Janus kinase 1	Homo sapiens	68-82
30088677-1	2018	AIMS: Filgotinib (GS-6034, formerly GLPG0634) is an oral, selective Janus kinase 1 (JAK1) inhibitor that showed early response and sustained efficacy in patients with rheumatoid arthritis and with Crohn"s disease.	GLPG0634	6-16	Janus kinase 1	Homo sapiens	84-88
30088677-1	2018	AIMS: Filgotinib (GS-6034, formerly GLPG0634) is an oral, selective Janus kinase 1 (JAK1) inhibitor that showed early response and sustained efficacy in patients with rheumatoid arthritis and with Crohn"s disease.	Filgotinib maleate	18-25	Janus kinase 1	Homo sapiens	68-82
30088677-1	2018	AIMS: Filgotinib (GS-6034, formerly GLPG0634) is an oral, selective Janus kinase 1 (JAK1) inhibitor that showed early response and sustained efficacy in patients with rheumatoid arthritis and with Crohn"s disease.	Filgotinib maleate	18-25	Janus kinase 1	Homo sapiens	84-88
30088677-1	2018	AIMS: Filgotinib (GS-6034, formerly GLPG0634) is an oral, selective Janus kinase 1 (JAK1) inhibitor that showed early response and sustained efficacy in patients with rheumatoid arthritis and with Crohn"s disease.	GLPG0634	36-44	Janus kinase 1	Homo sapiens	68-82
30088677-1	2018	AIMS: Filgotinib (GS-6034, formerly GLPG0634) is an oral, selective Janus kinase 1 (JAK1) inhibitor that showed early response and sustained efficacy in patients with rheumatoid arthritis and with Crohn"s disease.	GLPG0634	36-44	Janus kinase 1	Homo sapiens	84-88
30360969-2	2018	We aimed to investigate the efficacy and safety of filgotinib, a selective JAK1 inhibitor, for the treatment of psoriatic arthritis.	GLPG0634	51-61	Janus kinase 1	Homo sapiens	75-79
30360970-0	2018	Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.	GLPG0634	23-33	Janus kinase 1	Homo sapiens	47-61
30360970-2	2018	The TORTUGA trial investigated the efficacy and safety of filgotinib, an oral selective Janus kinase 1 (JAK1) inhibitor, for the treatment of patients with active ankylosing spondylitis.	GLPG0634	58-68	Janus kinase 1	Homo sapiens	88-102
30360970-2	2018	The TORTUGA trial investigated the efficacy and safety of filgotinib, an oral selective Janus kinase 1 (JAK1) inhibitor, for the treatment of patients with active ankylosing spondylitis.	GLPG0634	58-68	Janus kinase 1	Homo sapiens	104-108
30519495-1	2018	Ruxolitinib is an oral selective Janus-associated kinase 1 (JAK1) and JAK2 inhibitor that was initially approved by the FDA in 2014 for treatment of myelofibrosis.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	60-64
30519664-0	2018	Fungal metabolite (+)-terrein suppresses IL-6/sIL-6R-induced CSF1 secretion by inhibiting JAK1 phosphorylation in human gingival fibroblasts.	terrein	18-29	Janus kinase 1	Homo sapiens	90-94
30519664-5	2018	In this study, we provided the possibility of novel action that (+)-terrein inhibits activation of Janus-activated kinase 1 (JAK1), which has a central function in IL-6 signaling cascade, and alters expression of mRNAs and proteins induced by IL-6/soluble IL-6 receptor (sIL-6R) stimulation in HGFs.	terrein	64-75	Janus kinase 1	Homo sapiens	99-123
30519664-5	2018	In this study, we provided the possibility of novel action that (+)-terrein inhibits activation of Janus-activated kinase 1 (JAK1), which has a central function in IL-6 signaling cascade, and alters expression of mRNAs and proteins induced by IL-6/soluble IL-6 receptor (sIL-6R) stimulation in HGFs.	terrein	64-75	Janus kinase 1	Homo sapiens	125-129
30519664-8	2018	Next, to test the effect of (+)-terrein on IL-6/sIL-6R signaling cascade, we demonstrated whether (+)-terrein affects phosphorylation of JAK1 and its downstream proteins, Akt and SHP-2.	terrein	98-109	Janus kinase 1	Homo sapiens	137-141
30519664-9	2018	Western blotting revealed that (+)-terrein inhibited IL-6/sIL-6R-induced phosphorylation of JAK1, Akt, and SHP-2.	terrein	31-42	Janus kinase 1	Homo sapiens	92-96
30519664-10	2018	Therefore, (+)-terrein suppresses IL-6/sIL-6R-induced expression of CSF1 and VEGF via inhibition of JAK1, Akt, and SHP-2.	terrein	11-22	Janus kinase 1	Homo sapiens	100-104
30453910-4	2018	Ruxolitinib is a small molecule inhibitor of JAK1 and JAK2.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	45-49
30519495-1	2018	Ruxolitinib is an oral selective Janus-associated kinase 1 (JAK1) and JAK2 inhibitor that was initially approved by the FDA in 2014 for treatment of myelofibrosis.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	33-58
29939445-14	2018	Ruxolitinib also significantly inhibited the production of IL-6, TNF-alpha and MCP-1 as induced by A23817 and substance P. Selective STAT5 inhibition with pimozide resulted in diminished degranulation and inhibition of cytokine production as induced by A23817 and substance P. CONCLUSIONS & CLINICAL RELEVANCE: This study demonstrates that the JAK1/JAK2 inhibitor ruxolitinib can inhibit MCactivity, possibly through prevention of STAT5 activation.	Pimozide	155-163	Janus kinase 1	Homo sapiens	344-348
30123970-2	2018	This study evaluated the addition of ruxolitinib, a potent JAK1/2 inhibitor, to regorafenib in patients with relapsed/refractory metastatic CRC.	ruxolitinib	37-48	Janus kinase 1	Homo sapiens	59-65
29939445-0	2018	The JAK1/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release.	ruxolitinib	25-36	Janus kinase 1	Homo sapiens	4-8
29939445-7	2018	Ruxolitinib, a JAK1/JAK2 inhibitor, indeed decreases symptoms like pruritus and fatigue in patients with myeloproliferative neoplasms.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-19
29939445-9	2018	OBJECTIVE: To investigate the effect of JAK1/2-inhibition with ruxolitinib in the human mast cell lines LAD2 and HMC1.	ruxolitinib	63-74	Janus kinase 1	Homo sapiens	40-46
29939445-14	2018	Ruxolitinib also significantly inhibited the production of IL-6, TNF-alpha and MCP-1 as induced by A23817 and substance P. Selective STAT5 inhibition with pimozide resulted in diminished degranulation and inhibition of cytokine production as induced by A23817 and substance P. CONCLUSIONS & CLINICAL RELEVANCE: This study demonstrates that the JAK1/JAK2 inhibitor ruxolitinib can inhibit MCactivity, possibly through prevention of STAT5 activation.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	344-348
30324817-1	2018	INTRODUCTION: Despite the dramatic progress made in the treatment of patients with myelofibrosis since the introduction of the JAK1/2 inhibitor ruxolitinib, a therapeutic option that can modify the natural history of the disease and prevent evolution to blast-phase is still lacking.	ruxolitinib	144-155	Janus kinase 1	Homo sapiens	127-133
30536347-14	2018	During this process, the activations of NF-kappaB and JAK1/STAT3 pathways were inhibited after interaction of ROR and miR-26.	mir-26	118-124	Janus kinase 1	Homo sapiens	54-58
29691471-6	2018	Furthermore, baricitinib (an inhibitor of Janus kinases 1 and 2 (JAK1/JAK2) downstream of IFNgammaR/IL6R) completely prevented GvHD; expanded regulatory T cells by preserving JAK3-STAT5 signaling; downregulated CXCR3 and helper T cells 1 and 2 while preserving allogeneic antigen-presenting cell-stimulated T-cell proliferation; and suppressed the expression of major histocompatibility complex II (I-Ad), CD80/86, and PD-L1 on host antigen-presenting cells.	baricitinib	13-24	Janus kinase 1	Homo sapiens	42-63
29691471-6	2018	Furthermore, baricitinib (an inhibitor of Janus kinases 1 and 2 (JAK1/JAK2) downstream of IFNgammaR/IL6R) completely prevented GvHD; expanded regulatory T cells by preserving JAK3-STAT5 signaling; downregulated CXCR3 and helper T cells 1 and 2 while preserving allogeneic antigen-presenting cell-stimulated T-cell proliferation; and suppressed the expression of major histocompatibility complex II (I-Ad), CD80/86, and PD-L1 on host antigen-presenting cells.	baricitinib	13-24	Janus kinase 1	Homo sapiens	65-69
30035369-9	2018	Moreover, STAT1 knockdown significantly reduced EGF-mediated PD-L1 expression, and ruxolitinib, a JAK1/JAK2 inhibitor, significantly inhibited STAT1 phosphorylation to reduce the IFNr-mediated PD-L1 axis.	ruxolitinib	83-94	Janus kinase 1	Homo sapiens	98-102
29481660-0	2018	JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial.	baricitinib	24-35	Janus kinase 1	Homo sapiens	0-4
29481660-2	2018	Baricitinib is an oral, reversible, selective inhibitor of JAK1 and JAK2.	baricitinib	0-11	Janus kinase 1	Homo sapiens	59-63
32004164-2	2018	Ruxolitinib is a selective inhibitor of JAK-1 and JAK-2 used to treat PMF.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	40-45
30257946-7	2018	Treating CD4+ T cells with Ruxolitinib, an inhibitor of JAK1 and JAK2, effectively blocked IL-15-induced SAMHD1 phosphorylation and protected CD4+ T cells from HIV infection.	ruxolitinib	27-38	Janus kinase 1	Homo sapiens	56-60
30257946-11	2018	Time-limited interventions with JAK1 inhibitors, such as Ruxolitinib, should prevent the inactivation of the endogenous restriction factor SAMHD1 and protect this long-lived CD4+ T-memory cell population from HIV infection.	ruxolitinib	57-68	Janus kinase 1	Homo sapiens	32-36
30145050-3	2018	Here, we describe the identification of the novel orally bioavailable JAK inhibitor 18, peficitinib (also known as ASP015K), which showed moderate selectivity for JAK3 over JAK1, JAK2, and TYK2 in enzyme assays.	peficitinib	88-99	Janus kinase 1	Homo sapiens	173-177
30145050-5	2018	Furthermore, we determined the crystal structures of JAK1, JAK2, JAK3, and TYK2 in a complex with peficitinib, and revealed that the 1H-pyrrolo[2,3-b]pyridine-5-carboxamide scaffold of peficitinib forms triple hydrogen bonds with the hinge region.	peficitinib	98-109	Janus kinase 1	Homo sapiens	53-57
30145050-5	2018	Furthermore, we determined the crystal structures of JAK1, JAK2, JAK3, and TYK2 in a complex with peficitinib, and revealed that the 1H-pyrrolo[2,3-b]pyridine-5-carboxamide scaffold of peficitinib forms triple hydrogen bonds with the hinge region.	1H-pyrrolo[2,3-b]pyridine-5-carboxamide	133-172	Janus kinase 1	Homo sapiens	53-57
30145050-5	2018	Furthermore, we determined the crystal structures of JAK1, JAK2, JAK3, and TYK2 in a complex with peficitinib, and revealed that the 1H-pyrrolo[2,3-b]pyridine-5-carboxamide scaffold of peficitinib forms triple hydrogen bonds with the hinge region.	peficitinib	185-196	Janus kinase 1	Homo sapiens	53-57
30145050-5	2018	Furthermore, we determined the crystal structures of JAK1, JAK2, JAK3, and TYK2 in a complex with peficitinib, and revealed that the 1H-pyrrolo[2,3-b]pyridine-5-carboxamide scaffold of peficitinib forms triple hydrogen bonds with the hinge region.	Hydrogen	210-218	Janus kinase 1	Homo sapiens	53-57
30145050-6	2018	Interestingly, the binding modes of peficitinib in the ATP-binding pockets differed among JAK1, JAK2, JAK3, and TYK2.	peficitinib	36-47	Janus kinase 1	Homo sapiens	90-94
30145050-6	2018	Interestingly, the binding modes of peficitinib in the ATP-binding pockets differed among JAK1, JAK2, JAK3, and TYK2.	Adenosine Triphosphate	55-58	Janus kinase 1	Homo sapiens	90-94
30145050-7	2018	WaterMap analysis of the crystal structures suggests that unfavorable water molecules are the likely reason for the difference in orientation of the 1H-pyrrolo[2,3-b]pyridine-5-carboxamide scaffold to the hinge region among JAKs.	Water	70-75	Janus kinase 1	Homo sapiens	224-228
30145050-7	2018	WaterMap analysis of the crystal structures suggests that unfavorable water molecules are the likely reason for the difference in orientation of the 1H-pyrrolo[2,3-b]pyridine-5-carboxamide scaffold to the hinge region among JAKs.	1H-pyrrolo[2,3-b]pyridine-5-carboxamide	149-188	Janus kinase 1	Homo sapiens	224-228
30006916-2	2018	Baricitinib is an oral, selective JAK 1 and 2 inhibitor which has been shown to be effective in the treatment of RA in several clinical trials.	baricitinib	0-11	Janus kinase 1	Homo sapiens	34-45
30185657-4	2018	Herein, we found that CSA drives SCC proliferation and tumor growth through IL-22 and JAK/STAT pathway induction.	Cyclosporine	22-25	Janus kinase 1	Homo sapiens	86-89
30010187-2	2018	Ruxolitinib is a JAK1/2 inhibitor that may control myelofibrosis (MF)-related splenomegaly and symptoms and can be prescribed regardless of age.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	17-23
30245189-4	2018	Since ruxolitinib, a JAK1/JAK2 inhibitor, suppresses NF-kB expression, we conducted a phase 1 dose-escalation study to determine the safety and efficacy of ruxolitinib in previously treated lower-risk MDS patients with evidence of NF-kB activation.	ruxolitinib	6-17	Janus kinase 1	Homo sapiens	21-25
30590943-14	2018	JAK1/JAK2 inhibitor ruxolitinib is approved for hydroxyurea resistant/intolerant patients.	ruxolitinib	20-31	Janus kinase 1	Homo sapiens	0-4
30590943-14	2018	JAK1/JAK2 inhibitor ruxolitinib is approved for hydroxyurea resistant/intolerant patients.	Hydroxyurea	48-59	Janus kinase 1	Homo sapiens	0-4
30949000-0	2018	Successful treatment of atopic dermatitis with the JAK1 inhibitor oclacitinib.	oclacitinib	66-77	Janus kinase 1	Homo sapiens	51-55
30949000-1	2018	We report the first case of atopic dermatitis successfully treated with the oral Janus kinase-1 (JAK1) inhibitor oclacitinib.	oclacitinib	113-124	Janus kinase 1	Homo sapiens	81-95
30949000-1	2018	We report the first case of atopic dermatitis successfully treated with the oral Janus kinase-1 (JAK1) inhibitor oclacitinib.	oclacitinib	113-124	Janus kinase 1	Homo sapiens	97-101
30185657-5	2018	We in turn inhibited SCC growth with an FDA-approved JAK1/2 inhibitor, ruxolitinib.	ruxolitinib	71-82	Janus kinase 1	Homo sapiens	53-59
30185657-8	2018	JAK/STAT pathway genes were highly expressed in tumors from a cohort of CSA-exposed OTRs and in SCC with high risk for metastasis.	Cyclosporine	72-75	Janus kinase 1	Homo sapiens	0-3
30185657-10	2018	In nude mice engrafted with human A431 cells, IL-22 and CSA treatment increased tumor growth and upregulated IL-22 receptor, JAK1, and STAT1/3 expression.	Cyclosporine	56-59	Janus kinase 1	Homo sapiens	125-129
29945795-3	2018	Selective JAK1/2 inhibitor, ruxolitinib (3), and pan-HDAC inhibitor vorinostat (4) were linked together by a single nitrogen atom to create a new series of compounds with very potent JAK2 and HDAC6 inhibition with selectivity against HDAC1.	Nitrogen	116-124	Janus kinase 1	Homo sapiens	10-16
30078086-1	2018	The objective of this study was to evaluate structural damage progression based on clinical response in rheumatoid arthritis patients with no or limited prior disease-modifying anti-rheumatic drug treatment receiving the Janus kinase (JAK)1/JAK2 inhibitor baricitinib 4 mg, methotrexate (MTX), or the combination.	baricitinib	256-267	Janus kinase 1	Homo sapiens	221-240
30207045-6	2018	In this study, as a JAK1 and JAK3 inhibitor, tofacitinib has been proposed for the treatment of refractory pemphigus patients.	tofacitinib	45-56	Janus kinase 1	Homo sapiens	20-24
29681434-2	2018	We evaluated the JAK1/JAK2 inhibitor ruxolitinib plus pemetrexed/cisplatin first-line in patients with stage IIIB/IV or recurrent nonsquamous NSCLC with systemic inflammation (modified Glasgow prognostic score [mGPS] 1/2).	ruxolitinib	37-48	Janus kinase 1	Homo sapiens	17-21
30001163-1	2018	INTRODUCTION: Treatment with ruxolitinib, a selective JAK1/2 inhibitor, has significantly improved the lives of patients with myelofibrosis.	ruxolitinib	29-40	Janus kinase 1	Homo sapiens	54-60
30043249-1	2018	The oral Janus associated kinase (JAK1/2) inhibitor ruxolitinib has been available for treatment of patients with intermediate or high-risk myelofibrosis in Europe since 2012.	ruxolitinib	52-63	Janus kinase 1	Homo sapiens	34-40
30114348-5	2018	Currently ruxolitinib, a JAK1/JAK2 inhibitor, is also approved for PV patients with hydroxyurea resistance or intolerance.	ruxolitinib	10-21	Janus kinase 1	Homo sapiens	25-29
30159126-5	2018	Therefore in this study we investigated whether inhibiting both JAK1/2 and CDK4/6, using LEE011 and ruxolitinib respectively is effective in NKTL.	ribociclib	89-95	Janus kinase 1	Homo sapiens	64-70
30159126-5	2018	Therefore in this study we investigated whether inhibiting both JAK1/2 and CDK4/6, using LEE011 and ruxolitinib respectively is effective in NKTL.	ruxolitinib	100-111	Janus kinase 1	Homo sapiens	64-70
29616317-2	2018	Ruxolitinib, a JAK1/2 inhibitor, is the lone therapy approved for MF, offering a clear symptom and spleen benefit at the expense of treatment-related cytopenias.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-21
29616317-3	2018	Pacritinib (PAC), a multi-kinase inhibitor with specificity for JAK2, FLT3, and IRAK1 but sparing JAK1, has demonstrated clinical activity in MF with minimal myelosuppression.	11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene	0-10	Janus kinase 1	Homo sapiens	98-102
29076110-1	2018	BACKGROUND AND OBJECTIVES: Upadacitinib is a janus kinase (JAK) 1 inhibitor being developed for the treatment of rheumatoid arthritis (RA) and other inflammatory diseases.	upadacitinib	27-39	Janus kinase 1	Homo sapiens	45-65
29672897-0	2018	Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: A phase 1, randomized, placebo-controlled, dose-escalation study.	Abrocitinib	42-53	Janus kinase 1	Homo sapiens	16-30
29672897-1	2018	AIMS: To determine the safety, tolerability, pharmacokinetics and pharmacodynamics of the Janus kinase 1-selective inhibitor, PF-04965842.	Abrocitinib	126-137	Janus kinase 1	Homo sapiens	90-104
29870712-7	2018	In addition, DHHL suppressed IL-4-induced STAT-6 and JAK-1 tyrosine phosphorylation, suggesting that this compound inhibited M2 polarization by suppressing the JAK-STAT signaling pathway.	Tyrosine	59-67	Janus kinase 1	Homo sapiens	53-58
29675680-2	2018	This randomized phase 2 trial evaluated the efficacy and safety of the addition of ruxolitinib, a JAK1/JAK2 inhibitor, to capecitabine in patients with HER2-negative advanced breast cancer and high systemic inflammation (modified Glasgow Prognostic Score [mGPS] >= 1).	ruxolitinib	83-94	Janus kinase 1	Homo sapiens	98-102
29134648-1	2018	Population pharmacokinetic (popPK) modeling was used to characterize the PK profile of the oral Janus kinase (JAK)1/JAK2 inhibitor, baricitinib, in 18 patients with Mendelian interferonopathies who are enrolled in a compassionate use program.	baricitinib	132-143	Janus kinase 1	Homo sapiens	96-115
29508247-1	2018	Background Ruxolitinib, a Janus kinase 1 (JAK1)/JAK2 inhibitor, plus capecitabine improved overall survival (OS) vs capecitabine in a subgroup analysis of patients with metastatic pancreatic cancer and systemic inflammation (C-reactive protein [CRP] >13 mg/dL) in the randomized phase II RECAP study.	ruxolitinib	11-22	Janus kinase 1	Homo sapiens	42-46
30058088-13	2018	JAK1/JAK2 inhibitor ruxolitinib is approved for hydroxyurea resistant/intolerant patients.	ruxolitinib	20-31	Janus kinase 1	Homo sapiens	0-4
29693289-14	2018	Finally, we proved that ATB increased phosphorylated levels of AKT, JAK1, and STAT3, and those increases were all reversed by miR-494 overexpression.	atb	24-27	Janus kinase 1	Homo sapiens	68-72
30058088-13	2018	JAK1/JAK2 inhibitor ruxolitinib is approved for hydroxyurea resistant/intolerant patients.	Hydroxyurea	48-59	Janus kinase 1	Homo sapiens	0-4
30043749-2	2018	Baricitinib is an oral selective Janus kinase (JAK)1 and JAK2 inhibitor that we hypothesised might have therapeutic benefit in patients with systemic lupus erythematosus.	baricitinib	0-11	Janus kinase 1	Homo sapiens	33-52
30123428-7	2018	Next, we investigated the effects of ruxolitinib, an inhibitor of both JAK1 and JAK2, which phosphorylates and activates STAT3.	ruxolitinib	37-48	Janus kinase 1	Homo sapiens	71-75
29934865-11	2018	CONCLUSION: JAK1/2 inhibition with ruxolitinib represents a viable option for treatment of refractory CMC, if HSCT is not considered.	ruxolitinib	35-46	Janus kinase 1	Homo sapiens	12-18
29695516-0	2018	Phase 1 study of the PI3Kdelta inhibitor INCB040093 +- JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma.	INCB039110	70-80	Janus kinase 1	Homo sapiens	55-59
29789426-3	2018	Herein we identified that the Janus kinase 1 (JAK1) interacts with Sirt1 and catalyzes its phosphorylation at the tyrosine residues of 280 and 301, both of which are highly conserved and located in the histone deacetylase catalytic domain of Sirt1.	Tyrosine	114-122	Janus kinase 1	Homo sapiens	30-44
29789426-3	2018	Herein we identified that the Janus kinase 1 (JAK1) interacts with Sirt1 and catalyzes its phosphorylation at the tyrosine residues of 280 and 301, both of which are highly conserved and located in the histone deacetylase catalytic domain of Sirt1.	Tyrosine	114-122	Janus kinase 1	Homo sapiens	46-50
29649002-0	2018	JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.	baricitinib	23-34	Janus kinase 1	Homo sapiens	0-4
29622655-6	2018	Surprisingly, we found that ruxolitinib, an FDA approved agent targeting JAK1 and JAK2, did not lead to the same anti-myeloma effects.	ruxolitinib	28-39	Janus kinase 1	Homo sapiens	73-77
29908669-1	2018	BACKGROUND: Upadacitinib is a selective inhibitor of Janus kinase 1 and was efficacious in phase 2 studies in patients with moderate-to-severe rheumatoid arthritis.	upadacitinib	12-24	Janus kinase 1	Homo sapiens	53-67
29645296-2	2018	The JAK1/2 inhibitor Ruxolitinib has remarkable clinical efficacy, including spleen reduction, improvement of constitutional symptoms, and bone marrow (BM) fibrosis reversal.	ruxolitinib	21-32	Janus kinase 1	Homo sapiens	4-10
29908670-1	2018	BACKGROUND: Phase 2 studies with upadacitinib, a selective Janus kinase 1 (JAK1) inhibitor, have shown safety and efficacy in the treatment of patients with active rheumatoid arthritis.	upadacitinib	33-45	Janus kinase 1	Homo sapiens	59-73
29908670-1	2018	BACKGROUND: Phase 2 studies with upadacitinib, a selective Janus kinase 1 (JAK1) inhibitor, have shown safety and efficacy in the treatment of patients with active rheumatoid arthritis.	upadacitinib	33-45	Janus kinase 1	Homo sapiens	75-79
31723782-5	2018	Ruxolitinib, a Janus Kinase (JAK) 1/JAK2 inhibitor, has demonstrated efficacy in patients with both myelofibrosis (MF) and polycythemia vera and is well tolerated.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-35
29942363-7	2018	Of note, the success of tofacitinib has spurred the development of JAK1, JAK2 and other JAK3-selective small molecule inhibitors, some of which have also entered the clinical setting, whereas other JAK inhibitors are currently being evaluated in RA clinical trials.	tofacitinib	24-35	Janus kinase 1	Homo sapiens	67-71
29459227-4	2018	SiRNA silencing of JAK1, STAT3 and NOX4 diminished the hypoxia-mediated effect while a role of HIF1alpha could be clearly ruled out by the response to hypoxia-mimetics and competition experiments with a plasmid harboring the oxygen-dependent degradation domain of HIF1alpha.	Oxygen	225-231	Janus kinase 1	Homo sapiens	19-23
29785143-4	2018	Although JAK2 inhibitors, such as the JAK1/2 inhibitor ruxolitinib and the JAK2/FLT3/CSF1R/IRAK1 inhibitor pacritinib suppress abnormal clone expansion in myelofibrosis, ruxolitinib does not appear to prevent or reverse bone-marrow fibrosis in most patients.	ruxolitinib	55-66	Janus kinase 1	Homo sapiens	38-44
28762476-3	2018	Upadacitinib is a Janus kinase 1 inhibitor currently being evaluated in phase III rheumatoid arthritis trials.	upadacitinib	0-12	Janus kinase 1	Homo sapiens	18-32
29761158-0	2018	Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer.	ruxolitinib	18-29	Janus kinase 1	Homo sapiens	43-49
29761158-2	2018	Ruxolitinib is an orally bioavailable receptor tyrosine inhibitor targeting JAK1 and JAK2.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	76-80
29761158-2	2018	Ruxolitinib is an orally bioavailable receptor tyrosine inhibitor targeting JAK1 and JAK2.	Tyrosine	47-55	Janus kinase 1	Homo sapiens	76-80
29254929-5	2018	We have examined whether persistent vessel wall inflammation is maintained by lesional T cells, including the newly identified tissue-resident memory T cells, and whether such T cells are sensitive to the cytokine-signaling inhibitor tofacitinib, a Janus kinase (JAK) inhibitor targeting JAK3 and JAK1.	tofacitinib	234-245	Janus kinase 1	Homo sapiens	297-301
29468276-10	2018	The JAK1/2 inhibitor ruxolitinib also seems to be effective across a range of patient ages.	ruxolitinib	21-32	Janus kinase 1	Homo sapiens	4-10
29452839-0	2018	Development of selective inhibitors for the treatment of rheumatoid arthritis: (R)-3-(3-(Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor.	(r)-3-(3-(methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)-3-oxopropanenitrile	79-170	Janus kinase 1	Homo sapiens	176-180
29452839-1	2018	A series of 3(R)-aminopyrrolidine derivatives were designed and synthesized for JAK1-selective inhibitors through the modification of tofacitinib"s core structure, (3R,4R)-3-amino-4-methylpiperidine.	3(r)-aminopyrrolidine	12-33	Janus kinase 1	Homo sapiens	80-84
29452839-1	2018	A series of 3(R)-aminopyrrolidine derivatives were designed and synthesized for JAK1-selective inhibitors through the modification of tofacitinib"s core structure, (3R,4R)-3-amino-4-methylpiperidine.	tofacitinib	134-145	Janus kinase 1	Homo sapiens	80-84
29452839-1	2018	A series of 3(R)-aminopyrrolidine derivatives were designed and synthesized for JAK1-selective inhibitors through the modification of tofacitinib"s core structure, (3R,4R)-3-amino-4-methylpiperidine.	(3r,4r)-3-amino-4-methylpiperidine	164-198	Janus kinase 1	Homo sapiens	80-84
29452839-4	2018	Compound 6 showed improved selectivity for JAK1 compared to that of tofacitinib (IC50 11, 2.4 x 102, 2.8 x 103, and 1.1 x 102 nM for JAK1, JAK2, JAK3, and TYK2, respectively).	tofacitinib	68-79	Janus kinase 1	Homo sapiens	133-137
29522138-2	2018	Thrombocytopenia is a poor prognostic feature and limits use of Janus kinase 1 (JAK1)/Janus kinase 2 (JAK2) inhibitor ruxolitinib.	ruxolitinib	118-129	Janus kinase 1	Homo sapiens	64-78
29687421-1	2018	Baricitinib (Olumiant ) is an oral, targeted synthetic DMARD that inhibits JAK1 and JAK2, which are implicated in the pathogenesis of rheumatoid arthritis (RA).	baricitinib	0-11	Janus kinase 1	Homo sapiens	75-79
29351986-0	2018	A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma.	ruxolitinib	49-60	Janus kinase 1	Homo sapiens	29-33
29351986-3	2018	In this phase II study we assessed the safety and efficacy of ruxolitinib, an oral JAK1/2 inhibitor, in patients with relapsed/refractory Hodgkin lymphoma.	ruxolitinib	62-73	Janus kinase 1	Homo sapiens	83-89
29731870-6	2018	Furthermore, piceatannol (a JAK1 inhibitor) or small interfering RNA against STAT3 reduced the extent of the increased expression of MMP-11 induced by IGF-1 in SGC-7901 cells.	3,3',4,5'-tetrahydroxystilbene	13-24	Janus kinase 1	Homo sapiens	28-32
29731870-7	2018	Piceatannol treatment induced the dose-dependent decline in the enhancement of STAT3 phosphorylation induced by IGF-1, indicating that the JAK1/STAT3 pathway may be implicated in the elevated expression of MMP-11 induced by IGF-1 in SGC-7901 cells.	3,3',4,5'-tetrahydroxystilbene	0-11	Janus kinase 1	Homo sapiens	139-143
29750040-2	2018	This Phase Ib study evaluated ruxolitinib, a potent JAK1/2 inhibitor, in combination with gemcitabine with or without nab-paclitaxel in patients with advanced solid tumors.	ruxolitinib	30-41	Janus kinase 1	Homo sapiens	52-58
29494851-7	2018	These results provided insights into the effects of dasatinib on JAK/STAT signaling in NK cells in vivo and the mechanisms underlying NK cell activation induced by dasatinib therapy.	Dasatinib	52-61	Janus kinase 1	Homo sapiens	65-68
29515238-6	2018	Regarding key differences of therapy recommendations, both recombinant interferon alpha and the JAK1/JAK2 inhibitor ruxolitinib are recommended as second-line therapies for PV patients who are intolerant or have inadequate response to hydroxyurea.	ruxolitinib	116-127	Janus kinase 1	Homo sapiens	96-100
29515238-6	2018	Regarding key differences of therapy recommendations, both recombinant interferon alpha and the JAK1/JAK2 inhibitor ruxolitinib are recommended as second-line therapies for PV patients who are intolerant or have inadequate response to hydroxyurea.	Hydroxyurea	235-246	Janus kinase 1	Homo sapiens	96-100
29805309-8	2018	Here, we show that liver cancer cells also exhibit heterogeneous sensitivities to sorafenib induced cell death, which co-relates with the STAT3-Y705 phosphorylation levels and JAK1/2 expression levels in Hep3B, Huh7 and HepG2 cells.	Sorafenib	82-91	Janus kinase 1	Homo sapiens	176-182
29805309-10	2018	Finally, both inhibitors of STAT3 SH2 domain (S3i-201) or STAT3 upstream kinases JAKs (JAK inhibitor I) could synergistically enhance sorafenib induced cell death.	Sorafenib	134-143	Janus kinase 1	Homo sapiens	81-85
29666307-6	2018	IL-2-JAK1/3 signaling pathways thus increased the abundance of nutrient transporters, nutrient sensors, and critical oxygen-sensing molecules.	Oxygen	117-123	Janus kinase 1	Homo sapiens	5-9
29235894-2	2018	A few years ago, the first-in-class JAK1/JAK2 inhibitor ruxolitinib, demonstrated reductions in both constitutional symptoms and splenomegaly, leading to the US FDA approval.	ruxolitinib	56-67	Janus kinase 1	Homo sapiens	36-40
29266308-0	2018	The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis.	pyrazofurin	91-93	Janus kinase 1	Homo sapiens	75-79
29436642-1	2018	The Janus kinase (JAK)1 and JAK2 inhibitor, ruxolitinib, and the active form of vitamin D (calcitriol) were previously reported to possess anticancer effects in breast cancer.	Calcitriol	91-101	Janus kinase 1	Homo sapiens	4-23
29263442-0	2018	Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis.	N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	33-44	Janus kinase 1	Homo sapiens	48-52
28969943-7	2018	The Jak 1/2 inhibitor ruxolitinib, the mTOR inhibitor rapamycin and the PI3 kinase inhibitor LY294002 all prevented the potentiation of cell death by IL-13.	ruxolitinib	22-33	Janus kinase 1	Homo sapiens	4-11
29566740-0	2018	Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes.	GLPG0634	10-20	Janus kinase 1	Homo sapiens	34-39
29544547-2	2018	The oral Janus kinase (JAK) 1/JAK2 inhibitor ruxolitinib has been shown to improve splenomegaly, symptom burden, and overall survival in patients with intermediate-2 or high-risk MF compared with placebo or best available therapy (BAT).	ruxolitinib	45-56	Janus kinase 1	Homo sapiens	9-29
29189896-1	2018	Ruxolitinib is a JAK1/2 inhibitor that is effective in managing symptoms and splenomegaly related to myelofibrosis (MF).	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	17-23
29480036-7	2018	Ruxolitinib, a potent oral JAK1/JAK2 inhibitor remains the only Food and Drug Administration (FDA)-approved medicinal therapy for the treatment of MF.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	27-31
29311136-1	2018	Momelotinib (MMB), a small-molecule inhibitor of Janus kinase (JAK)1/2 and of activin A receptor type 1 (ACVR1), is in clinical development for the treatment of myeloproliferative neoplasms.	N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	0-11	Janus kinase 1	Homo sapiens	49-70
29311136-1	2018	Momelotinib (MMB), a small-molecule inhibitor of Janus kinase (JAK)1/2 and of activin A receptor type 1 (ACVR1), is in clinical development for the treatment of myeloproliferative neoplasms.	N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	13-16	Janus kinase 1	Homo sapiens	49-70
29311136-7	2018	The major circulating human metabolite, M21 (a morpholino lactam), is a potent inhibitor of JAK1/2 and ACVR1 in vitro.	morpholino lactam	47-64	Janus kinase 1	Homo sapiens	92-98
29298069-0	2018	Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.	Abrocitinib	18-105	Janus kinase 1	Homo sapiens	133-137
29471605-9	2018	Tofacitinib is an oral, small molecule that inhibits JAK1, JAK3 and in a lesser extent, JAK2.	tofacitinib	0-11	Janus kinase 1	Homo sapiens	53-57
29472557-2	2018	The lack of complete response in most patients treated with the JAK1/2 inhibitor ruxolitinib indicates the need for identifying novel therapeutic strategies.	ruxolitinib	81-92	Janus kinase 1	Homo sapiens	64-70
29298069-0	2018	Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.	Abrocitinib	107-118	Janus kinase 1	Homo sapiens	133-137
29298069-4	2018	Through modification of the 3-aminopiperidine linker in tofacitinib, we discovered highly selective JAK1 inhibitors with nanomolar potency in a human whole blood assay.	Piperidin-3-amine	28-45	Janus kinase 1	Homo sapiens	100-104
29298069-4	2018	Through modification of the 3-aminopiperidine linker in tofacitinib, we discovered highly selective JAK1 inhibitors with nanomolar potency in a human whole blood assay.	tofacitinib	56-67	Janus kinase 1	Homo sapiens	100-104
29056075-0	2018	An updated review of the JAK1/2 inhibitor (ruxolitinib) in the Philadelphia-negative myeloproliferative neoplasms.	ruxolitinib	43-54	Janus kinase 1	Homo sapiens	25-31
29162613-3	2018	In the present study, we investigated whether ruxolitinib, a small drug acting as a JAK1/2 inhibitor and currently used in the treatment of myeloproliferative neoplasms, may also counteract the repressing effects of IL-6 toward hepatic detoxifying systems.	ruxolitinib	46-57	Janus kinase 1	Homo sapiens	84-90
28956263-1	2018	Ruxolitinib, a potent JAK1/JAK2 inhibitor, was found to be superior to the best available therapy (BAT) in controlling hematocrit, reducing splenomegaly, and improving symptoms in the phase 3 RESPONSE study of patients with polycythemia vera with splenomegaly who experienced an inadequate response to or adverse effects from hydroxyurea.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	22-26
29128627-0	2018	Inhibition of JAK1 by microRNA-708 promotes SH-SY5Y neuronal cell survival after oxygen and glucose deprivation and reoxygenation.	Oxygen	81-87	Janus kinase 1	Homo sapiens	14-18
29399328-6	2018	Ten years after the beginning of clinical trials, only two drugs have been approved by the US Food and Drug Administration: one JAK2/JAK1 inhibitor (ruxolitinib) in intermediate-2 and high-risk myelofibrosis and hydroxyurea-resistant or -intolerant polycythemia vera and one JAK1/JAK3 inhibitor (tofacitinib) in methotrexate-resistant rheumatoid arthritis.	ruxolitinib	149-160	Janus kinase 1	Homo sapiens	133-137
29127481-2	2018	Once the JAKs are activated, a cascade of further signaling events is triggered involving phosphorylation of selected receptor chain tyrosines, binding of signal transducer and activator of transcription (STAT) proteins and phosphorylation of these STATs.	Tyrosine	133-142	Janus kinase 1	Homo sapiens	9-13
29741513-5	2018	Considerable advancements have been made in the understanding of MPN pathogenesis, in particular recognition of the driver mutations JAK2 V617F, CALR, and MPL, which has led to the development of ruxolitinib, an inhibitor of Janus kinase 1 (JAK1) and JAK2 that has transformed therapy for myelofibrosis.	ruxolitinib	196-207	Janus kinase 1	Homo sapiens	225-239
29741513-5	2018	Considerable advancements have been made in the understanding of MPN pathogenesis, in particular recognition of the driver mutations JAK2 V617F, CALR, and MPL, which has led to the development of ruxolitinib, an inhibitor of Janus kinase 1 (JAK1) and JAK2 that has transformed therapy for myelofibrosis.	ruxolitinib	196-207	Janus kinase 1	Homo sapiens	241-245
29162613-0	2018	The JAK1/2 Inhibitor Ruxolitinib Reverses Interleukin-6-Mediated Suppression of Drug-Detoxifying Proteins in Cultured Human Hepatocytes.	ruxolitinib	21-32	Janus kinase 1	Homo sapiens	4-10
29849942-5	2018	We investigated the therapeutic potential of ruxolitinib, a JAK1/JAK2 inhibitor that has been FDA-approved for the treatment of myelofibrosis, to treat ovarian cancer either alone or in combination with conventional chemotherapy agents.	ruxolitinib	45-56	Janus kinase 1	Homo sapiens	60-64
29056075-1	2018	Ruxolitinib (Rux), a JAK1/2 inhibitor, has been approved for patients with myelofibrosis and in polycythemia vera with inadequate response/intolerance to hydroxycarbamide.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	21-27
29056075-1	2018	Ruxolitinib (Rux), a JAK1/2 inhibitor, has been approved for patients with myelofibrosis and in polycythemia vera with inadequate response/intolerance to hydroxycarbamide.	ruxolitinib	0-3	Janus kinase 1	Homo sapiens	21-27
29202299-0	2018	Repression of interferon beta-regulated cytokines by the JAK1/2 inhibitor ruxolitinib in inflammatory human macrophages.	ruxolitinib	74-85	Janus kinase 1	Homo sapiens	57-63
29202299-1	2018	Ruxolitinib is a Janus kinase (JAK) 1/2 inhibitor, currently used in the treatment of myeloproliferative neoplasms.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	17-39
30079384-9	2018	We present an index case of a patient with T-PLL with a clonal JAK1 V658F mutation that responded to ruxolitinib therapy.	ruxolitinib	101-112	Janus kinase 1	Homo sapiens	63-67
28986762-1	2018	Ruxolitinib, a potent JAK1/JAK2 inhibitor, improved splenomegaly and myelofibrosis-associated symptoms and prolonged survival compared with placebo and best available therapy in the phase 3 COMFORT studies.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	22-26
29214116-1	2017	Background: Ruxolitinib is a potent inhibitor of JAK1/2 with proven efficacy in myelofibrosis.	ruxolitinib	12-23	Janus kinase 1	Homo sapiens	49-53
30069628-1	2018	Ruxolitinib, formerly known as INCB018424 or INC424, is a potent and selective oral inhibitor of Janus kinase (JAK) 1 and JAK2.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	97-117
30069628-1	2018	Ruxolitinib, formerly known as INCB018424 or INC424, is a potent and selective oral inhibitor of Janus kinase (JAK) 1 and JAK2.	ruxolitinib	31-41	Janus kinase 1	Homo sapiens	97-117
30069628-1	2018	Ruxolitinib, formerly known as INCB018424 or INC424, is a potent and selective oral inhibitor of Janus kinase (JAK) 1 and JAK2.	ruxolitinib	45-51	Janus kinase 1	Homo sapiens	97-117
29042365-2	2017	Current treatment options for MPNs include cytoreduction by hydroxyurea and JAK1/2 inhibition by ruxolitinib, both of which are not curative.	ruxolitinib	97-108	Janus kinase 1	Homo sapiens	76-82
29139090-1	2017	Tofacitinib (Xeljanz ) is a potent, selective JAK inhibitor that preferentially inhibits Janus kinase (JAK) 1 and JAK3.	tofacitinib	0-11	Janus kinase 1	Homo sapiens	89-109
28891251-1	2017	Baricitinib is an oral inhibitor of Janus kinases (JAKs), selective for JAK1 and 2.	baricitinib	0-11	Janus kinase 1	Homo sapiens	51-55
28891251-1	2017	Baricitinib is an oral inhibitor of Janus kinases (JAKs), selective for JAK1 and 2.	baricitinib	0-11	Janus kinase 1	Homo sapiens	72-82
29098608-4	2017	The only approved therapy for MF, JAK1/2 inhibitor ruxolitinib, can ameliorate splenomegaly, improve symptoms, and prolong survival in some patients.	ruxolitinib	51-62	Janus kinase 1	Homo sapiens	34-38
29139090-1	2017	Tofacitinib (Xeljanz ) is a potent, selective JAK inhibitor that preferentially inhibits Janus kinase (JAK) 1 and JAK3.	tofacitinib	13-20	Janus kinase 1	Homo sapiens	89-109
29074595-3	2017	MAJIC (ISRCTN61925716) is a randomized phase 2 trial of ruxolitinib (JAK1/2 inhibitor) vs best available therapy (BAT) in ET and polycythemia vera patients resistant or intolerant to HC.	ruxolitinib	56-67	Janus kinase 1	Homo sapiens	69-75
28879797-7	2017	Amorfrutin A also inhibited activation of the upstream kinases Janus-activated kinase 1 (JAK1), JAK2 and Src signaling pathways.	amorfrutin A	0-12	Janus kinase 1	Homo sapiens	63-87
28879797-7	2017	Amorfrutin A also inhibited activation of the upstream kinases Janus-activated kinase 1 (JAK1), JAK2 and Src signaling pathways.	amorfrutin A	0-12	Janus kinase 1	Homo sapiens	89-93
28722170-9	2017	This effect was inhibited by the JAK1/2 inhibitor of the JAK/STAT3 pathway ruxolitinib.	ruxolitinib	75-86	Janus kinase 1	Homo sapiens	33-39
28757617-5	2017	Nilotinib also suppressed endothelial cell proliferation, migration and tube-formation and bound to a distinct set of target-kinases, relevant to angiogenesis and atherosclerosis, including angiopoietin receptor-1 TEK, ABL-2, JAK1 and MAP-kinases.	nilotinib	0-9	Janus kinase 1	Homo sapiens	226-230
28484265-7	2017	The combination of the GC dexamethasone and the JAK1/2 inhibitor ruxolitinib altered the balance between pro- and anti-apoptotic factors in samples with IL7-dependent GC resistance, but not in samples with IL7-independent GC resistance.	ruxolitinib	65-76	Janus kinase 1	Homo sapiens	48-54
28994166-11	2017	Ruxolitinib is a selective inhibitor of JAK1 and JAK2 kinases and the JAK-STAT signaling pathway.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	40-44
28960447-4	2017	AZD1480 and CYT387 are novel JAK1/2 inhibitors that have been used in clinical trials for treating various hematologic cancers in humans.	AZD 1480	0-7	Janus kinase 1	Homo sapiens	29-35
28960447-4	2017	AZD1480 and CYT387 are novel JAK1/2 inhibitors that have been used in clinical trials for treating various hematologic cancers in humans.	N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	12-18	Janus kinase 1	Homo sapiens	29-35
29228628-7	2017	Luminespib decreased the phosphorylation of mutant STAT3 at Y705, whereas JAK1/JAK2 inhibitor ruxolitinib had reduced efficacy on mutant STAT3 phosphorylation.	ruxolitinib	94-105	Janus kinase 1	Homo sapiens	74-78
28838249-5	2017	Here we review the pharmacology and clinical trial data for efficacy and safety of filgotinib, an investigational selective JAK1 inhibitor.	GLPG0634	83-93	Janus kinase 1	Homo sapiens	124-128
28953386-4	2017	A preferred pyrazole substituted pyrrolopyrimidine, 24, inhibits JAK1 and HDACs 1, 2, 3, 6, and 10 with IC50 values of less than 20 nM, is <100 nM potent against JAK2 and HDAC11, and is selective for the JAK family against a panel of 97 kinases.	pyrazole	12-20	Janus kinase 1	Homo sapiens	65-69
28953386-4	2017	A preferred pyrazole substituted pyrrolopyrimidine, 24, inhibits JAK1 and HDACs 1, 2, 3, 6, and 10 with IC50 values of less than 20 nM, is <100 nM potent against JAK2 and HDAC11, and is selective for the JAK family against a panel of 97 kinases.	pyrrolopyrimidine	33-50	Janus kinase 1	Homo sapiens	65-69
28622463-0	2017	Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials.	GLPG0634	60-70	Janus kinase 1	Homo sapiens	84-89
28622463-14	2017	CONCLUSION: Selective inhibition of JAK-1 with filgotinib shows initial efficacy in RA with an encouraging safety profile in these exploratory studies.	GLPG0634	47-57	Janus kinase 1	Homo sapiens	36-41
28277287-3	2017	The discovery of a JAK2 point mutation (JAK2 V617F) as the main cause of polycythemia vera lead to the development and FDA approval of a JAK1/2 inhibitor, ruxolitinib, in 2011.	ruxolitinib	155-166	Janus kinase 1	Homo sapiens	137-143
28953386-3	2017	Herein the core features of ruxolitinib (1), a marketed JAK1/2 inhibitor, have been merged with the HDAC inhibitor vorinostat (2), leading to new molecules that are bispecific targeted JAK/HDAC inhibitors.	ruxolitinib	28-39	Janus kinase 1	Homo sapiens	56-62
29262601-2	2017	Ruxolitinib is a pyrrolo[2.3-d]pyrimidine derivative with inhibitory activity against JAK1 and JAK2, moderate activity against TYK2, and minor activity against JAK3.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	86-90
29262601-2	2017	Ruxolitinib is a pyrrolo[2.3-d]pyrimidine derivative with inhibitory activity against JAK1 and JAK2, moderate activity against TYK2, and minor activity against JAK3.	Pyrrolo(2,3-d)pyrimidine	17-41	Janus kinase 1	Homo sapiens	86-90
29085766-4	2017	These descriptors correlate with the anti-RA activity with R2 values for JAK3, JAK2 and JAK1 are 0.9811, 0.8620 and 0.9740, respectively.	Radium	42-44	Janus kinase 1	Homo sapiens	88-92
28503781-0	2017	Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib.	upadacitinib	136-148	Janus kinase 1	Homo sapiens	121-125
29025600-3	2017	Furthermore, we show that primary ALL mononuclear cells harboring the JAK2 R938Q mutation display reduced sensitivity to the JAK1/2 ATP-competitive inhibitor ruxolitinib in vitro, compared to ALL cells that carry a more common JAK2 pseudokinase domain mutation.	Adenosine Triphosphate	132-135	Janus kinase 1	Homo sapiens	125-131
29025600-3	2017	Furthermore, we show that primary ALL mononuclear cells harboring the JAK2 R938Q mutation display reduced sensitivity to the JAK1/2 ATP-competitive inhibitor ruxolitinib in vitro, compared to ALL cells that carry a more common JAK2 pseudokinase domain mutation.	ruxolitinib	158-169	Janus kinase 1	Homo sapiens	125-131
28829236-1	2017	INTRODUCTION: Tofacitinib is a pan JAK inhibitor with specificity for JAK3 over JAK1 over JAK2, which is approved in many countries for the treatment of rheumatoid arthritis (RA), including the United States and the European Union, either as monotherapy or in combination with conventional synthetic disease modifying anti-arthritis drugs (csDMARDs).	tofacitinib	14-25	Janus kinase 1	Homo sapiens	80-84
28838249-7	2017	Expert opinion: The selectivity of filgotinib for JAK1 may have theoretical advantages in terms of limiting toxicity.	GLPG0634	35-45	Janus kinase 1	Homo sapiens	50-54
28729401-9	2017	The selective JAK1 inhibitor filgotinib effectively suppressed STAT3 activation and OSMR expression, and cotargeting inhibition of the oncogenic pathway and JAK1 reversed resistance to targeted drugs.	GLPG0634	29-39	Janus kinase 1	Homo sapiens	14-18
28823882-4	2017	OBJECTIVE: To evaluate the efficacy of the JAK 1/3 inhibitor tofacitinib in the treatment of vitiligo.	tofacitinib	61-72	Janus kinase 1	Homo sapiens	43-48
28962635-2	2017	This analysis evaluated the long-term survival benefit with ruxolitinib, a Janus kinase (JAK)1/JAK2 inhibitor, in patients with intermediate-2 (int-2) or high-risk MF.	ruxolitinib	60-71	Janus kinase 1	Homo sapiens	75-94
29051788-12	2017	For example, the JAK1 blocker filgotinib was tested in Crohn"s disease, whereas the JAK1/3 inhibitor tofacitinib was tested in clinical trials for both Crohn"s disease and ulcerative colitis.	tofacitinib	101-112	Janus kinase 1	Homo sapiens	84-88
28794380-2	2017	We herein present the case of a post-polycythemia vera (PV) myelofibrosis patient with massive splenomegaly who developed laboratory TLS after treatment with ruxolitinib, a potent JAK1/JAK2 inhibitor.	ruxolitinib	158-169	Janus kinase 1	Homo sapiens	180-184
28737053-5	2017	Expert opinion: Baricitinib is an oral targeted synthetic (ts) disease-modifying antirheumatic drug (DMARD) that mainly inhibits JAK1 and JAK2.	baricitinib	16-27	Janus kinase 1	Homo sapiens	129-133
29026328-5	2017	However, the combination of rhIL-6 and ruxolitinib, a JAK1/JAK2-selective inhibitor, was a less effective inhibitor of STAT protein activation.	ruxolitinib	39-50	Janus kinase 1	Homo sapiens	54-58
28824063-2	2017	Ruxolitinib (RUXO), a novel JAK1/2 inhibitor, can be used as a bridging therapy until allo-SCT can be performed to reduce TRM.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	28-34
28824063-2	2017	Ruxolitinib (RUXO), a novel JAK1/2 inhibitor, can be used as a bridging therapy until allo-SCT can be performed to reduce TRM.	ruxolitinib	13-17	Janus kinase 1	Homo sapiens	28-34
28649004-5	2017	STAT signaling inhibition by the JAK1/2 inhibitor ruxolitinib mimicked MACC1 knockdown-mediated molecular signatures and apoptosis sensitization to Fas activation.	ruxolitinib	50-61	Janus kinase 1	Homo sapiens	33-39
28656237-0	2017	Matrine increases the inhibitory effects of afatinib on H1975 cells via the IL-6/JAK1/STAT3 signaling pathway.	Afatinib	44-52	Janus kinase 1	Homo sapiens	81-85
28684419-6	2017	Enhancement is accompanied by an increase in signal transducer and activator of transcription 5 (STAT5) phosphorylation and is abrogated by treatment with C188-9, a STAT3/5 inhibitor, or with ruxolitinib, a Janus kinase 1/2 (JAK1/2) inhibitor.	C188-9	155-161	Janus kinase 1	Homo sapiens	225-231
28684419-6	2017	Enhancement is accompanied by an increase in signal transducer and activator of transcription 5 (STAT5) phosphorylation and is abrogated by treatment with C188-9, a STAT3/5 inhibitor, or with ruxolitinib, a Janus kinase 1/2 (JAK1/2) inhibitor.	ruxolitinib	192-203	Janus kinase 1	Homo sapiens	225-231
28622623-0	2017	A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia.	N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	19-30	Janus kinase 1	Homo sapiens	41-45
28622623-1	2017	Momelotinib is a potent inhibitor of JAK1 and JAK2 that demonstrated efficacy in patients with primary and secondary myelofibrosis.	N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	0-11	Janus kinase 1	Homo sapiens	37-41
28619982-8	2017	Moreover, the JAK1/2 inhibitor ruxolitinib restored sensitivity to the BCL2 inhibitor venetoclax in AML patient cells ex vivo in different model systems and in vivo in an AML xenograft mouse model.	ruxolitinib	31-42	Janus kinase 1	Homo sapiens	14-20
29296813-6	2017	In vitro screening using a panel of tyrosine kinase inhibitors against 14 different kinase alterations identified the ABL1-inhibitor, dasatinib, as a potent inhibitor of ABL-class fusions (ABL1, ABL2, CSF1R, PDGFRB), whereas the JAK1/JAK2 inhibitor ruxolitinib, was most effective against JAK-STAT-activating alterations (JAK1, JAK2, JAK3, IL7R, IL2RB), but not TYK2.	Dasatinib	134-143	Janus kinase 1	Homo sapiens	229-233
29296813-6	2017	In vitro screening using a panel of tyrosine kinase inhibitors against 14 different kinase alterations identified the ABL1-inhibitor, dasatinib, as a potent inhibitor of ABL-class fusions (ABL1, ABL2, CSF1R, PDGFRB), whereas the JAK1/JAK2 inhibitor ruxolitinib, was most effective against JAK-STAT-activating alterations (JAK1, JAK2, JAK3, IL7R, IL2RB), but not TYK2.	Dasatinib	134-143	Janus kinase 1	Homo sapiens	322-326
28619982-8	2017	Moreover, the JAK1/2 inhibitor ruxolitinib restored sensitivity to the BCL2 inhibitor venetoclax in AML patient cells ex vivo in different model systems and in vivo in an AML xenograft mouse model.	venetoclax	86-96	Janus kinase 1	Homo sapiens	14-20
28550731-8	2017	In addition, xanthotoxin significantly reduced the phosphorylation at signal transducers and activators of transcription 1 (STAT1, Ser 727 and Tyr 701) and STAT3 (Tyr 705), as well as Janus kinase (JAK) 1 and 2 in LPS-induced RAW 264.7 macrophages.	Methoxsalen	13-24	Janus kinase 1	Homo sapiens	184-210
28790099-0	2017	GSK2586184, a JAK1 selective inhibitor, in two patients with ulcerative colitis.	GSK2586184	0-10	Janus kinase 1	Homo sapiens	14-18
28790099-2	2017	Tofacitinib inhibits cytokine signalling through blockade of JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2).	tofacitinib	0-11	Janus kinase 1	Homo sapiens	61-65
28790099-7	2017	The JAK1 selective inhibitor GSK2586184 was well tolerated and induced clinical and endoscopic response in two patients with moderate-to-severe UC.	GSK2586184	29-39	Janus kinase 1	Homo sapiens	4-8
28478401-9	2017	Treatment with combined JAK1/JAK2 inhibitors or with JAK2 inhibitors in combination with HSP90 inhibitors was more effective than monotherapy with JAK2 inhibitors in bleomycin-induced pulmonary fibrosis and in adTBR-induced dermal fibrosis.	Bleomycin	166-175	Janus kinase 1	Homo sapiens	24-28
28478401-9	2017	Treatment with combined JAK1/JAK2 inhibitors or with JAK2 inhibitors in combination with HSP90 inhibitors was more effective than monotherapy with JAK2 inhibitors in bleomycin-induced pulmonary fibrosis and in adTBR-induced dermal fibrosis.	adtbr	210-215	Janus kinase 1	Homo sapiens	24-28
28853089-0	2017	Role of JAK1, JAK2, and JAK3 in Functional Stimulation of Mesenchymal Precursor Cells by Alkaloid Songorine.	Alkaloids	89-97	Janus kinase 1	Homo sapiens	8-12
28382662-6	2017	The oral JAK1/JAK3 inhibitor, tofacitinib, is currently approved for rheumatoid arthritis and is in clinical trials for other chronic inflammatory disorders.	tofacitinib	30-41	Janus kinase 1	Homo sapiens	9-13
28673391-4	2017	The Food and Drug Administration approved the JAK1/JAK2 inhibitor, ruxolitinib, for the treatment of myelofibrosis and polycythemia vera.	ruxolitinib	67-78	Janus kinase 1	Homo sapiens	46-50
28039266-8	2017	Transient blockade of CD11b+ cell expansion using a JAK 1/2 Inhibitor (AZD1480) impaired mobilization of these cells and was associated with a reduction in tumor volume, maintenance of a low-grade tumor phenotype, and prolongation in survival.Conclusions: We demonstrate that impaired recruitment of CD11b+ myeloid cells with a JAK1/2 inhibitor inhibits glioma progression in vivo and prolongs survival in a murine glioma model.	AZD 1480	71-78	Janus kinase 1	Homo sapiens	52-59
28322434-2	2017	A 2014 study implicated the JAK1/JAK2 inhibitor, ruxolitinib in short-term treatment of alopecia, however little information exists about the long-term use in otherwise healthy individuals in the community setting.	ruxolitinib	49-60	Janus kinase 1	Homo sapiens	28-32
28721333-1	2017	We present the case of a 79-year-old man who showed multiple pulmonary nodules on chest computed tomography (CT) after being treated for 6 months with ruxolitinib, an inhibitor of Janus kinase (JAK) 1 and 2, to treat primary myelofibrosis.	ruxolitinib	151-162	Janus kinase 1	Homo sapiens	180-206
28760302-1	2017	The unprecedented success of the Janus kinase (JAK) 1/2 inhibitor ruxolitinib in myelofibrosis (MF) provided much-needed impetus for clinical drug development for the Philadelphia chromosome-negative myeloproliferative neoplasms.	ruxolitinib	66-77	Janus kinase 1	Homo sapiens	33-53
28677798-10	2017	In addition, JAK1 knockdown showed similar effects of miR-448 on the metastasis of PDAC cells.	pdac	83-87	Janus kinase 1	Homo sapiens	13-17
28677798-12	2017	Taken together, these findings suggest that miR-448 functions as a tumor suppressor in the development of PDAC through targeting the JAK1/STAT3 pathway.	pdac	106-110	Janus kinase 1	Homo sapiens	133-137
28500170-1	2017	Since its approval in 2011, the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib has evolved to become the centerpiece of therapy for myelofibrosis (MF), and its use in patients with hydroxyurea resistant or intolerant polycythemia vera (PV) is steadily increasing.	ruxolitinib	68-79	Janus kinase 1	Homo sapiens	50-56
28158411-8	2017	GSK2586184, a Janus kinase 1 selective inhibitor, induced clinical and endoscopic response in ulcerative colitis; however, the study was discontinued at an early stage due to liver toxicity observed in systemic lupus patients receiving the drug.	GSK2586184	0-10	Janus kinase 1	Homo sapiens	14-28
28158411-9	2017	Filgotinib, a Janus kinase 1 selective inhibitor investigated in treatment of Crohn"s disease, was superior to placebo.	GLPG0634	0-10	Janus kinase 1	Homo sapiens	14-28
28039266-8	2017	Transient blockade of CD11b+ cell expansion using a JAK 1/2 Inhibitor (AZD1480) impaired mobilization of these cells and was associated with a reduction in tumor volume, maintenance of a low-grade tumor phenotype, and prolongation in survival.Conclusions: We demonstrate that impaired recruitment of CD11b+ myeloid cells with a JAK1/2 inhibitor inhibits glioma progression in vivo and prolongs survival in a murine glioma model.	AZD 1480	71-78	Janus kinase 1	Homo sapiens	328-334
27993828-0	2017	Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).	GLPG0634	0-10	Janus kinase 1	Homo sapiens	49-53
27993828-1	2017	OBJECTIVES: To evaluate the efficacy and safety of different doses of filgotinib, an oral Janus kinase 1 inhibitor, as monotherapy in patients with active rheumatoid arthritis (RA) and previous inadequate response to methotrexate (MTX).	GLPG0634	70-80	Janus kinase 1	Homo sapiens	90-104
27993829-0	2017	Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).	GLPG0634	0-10	Janus kinase 1	Homo sapiens	39-43
27993829-1	2017	OBJECTIVES: To evaluate the efficacy and safety of different doses and regimens of filgotinib, an oral Janus kinase 1 inhibitor, as add-on treatment to methotrexate (MTX) in patients with active rheumatoid arthritis (RA) and inadequate response to MTX.	GLPG0634	83-93	Janus kinase 1	Homo sapiens	103-117
28410228-5	2017	Moreover, a high sensitivity to the JAK1/2 inhibitor ruxolitinib was observed in S646P mutant model.	ruxolitinib	53-64	Janus kinase 1	Homo sapiens	36-42
28441920-4	2017	NS-018 and INCB039110, selective inhibitors of JAK2 and JAK1, respectively, are also discussed.	NS-018	0-6	Janus kinase 1	Homo sapiens	56-60
28441920-4	2017	NS-018 and INCB039110, selective inhibitors of JAK2 and JAK1, respectively, are also discussed.	INCB039110	11-21	Janus kinase 1	Homo sapiens	56-60
28302714-0	2017	Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	22-26
28318222-2	2017	Here, we report that not only is PF-956980 a pan-JAK ATP-competitive inhibitor but it also causes selective reduction of endogenous JAK2 and JAK3 protein levels in human primary immune cells (in a time-dependent manner), leaving the other JAK family members (JAK1 and TYK2) unchanged.	pyrazofurin	33-35	Janus kinase 1	Homo sapiens	259-263
29228564-1	2017	Inhibition of the constitutively activated JAK/STAT pathway in JAK2V617F mutated cells by the JAK1/JAK2 inhibitor ruxolitinib resulted in clinical benefits in patients with myeloproliferative neoplasms.	ruxolitinib	114-125	Janus kinase 1	Homo sapiens	43-46
29228564-1	2017	Inhibition of the constitutively activated JAK/STAT pathway in JAK2V617F mutated cells by the JAK1/JAK2 inhibitor ruxolitinib resulted in clinical benefits in patients with myeloproliferative neoplasms.	ruxolitinib	114-125	Janus kinase 1	Homo sapiens	94-98
28332364-9	2017	Moreover, the expressions of STAT1, JAK1, and c-Met in H460 cells were decreased by SIM-89 treatment, and c-Met phosphorylation was suppressed in A549, H441, H1299, and B16F10 cells by the treatment.	sim-89	84-90	Janus kinase 1	Homo sapiens	36-40
27889820-1	2017	Ruxolitinib, a JAK1 and JAK2 inhibitor, has been tested and approved for the treatment of primary and secondary myelofibrosis (MF).	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-19
27740634-2	2017	Ruxolitinib is an oral Janus-activated kinase 1 (JAK1)/JAK2 inhibitor approved for the treatment of patients with myelofibrosis based on the results of two randomized clinical trials.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	23-47
27740634-2	2017	Ruxolitinib is an oral Janus-activated kinase 1 (JAK1)/JAK2 inhibitor approved for the treatment of patients with myelofibrosis based on the results of two randomized clinical trials.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	49-53
27458171-4	2017	Capz also inhibited activation of the upstream kinases JAK1/2 and c-Src.	capsazepine	0-4	Janus kinase 1	Homo sapiens	55-61
28356514-12	2017	Finally, ruxolitinib, a JAK1/2 inhibitor, was effective in vivo in a xenograft ALK- ALCL model.	ruxolitinib	9-20	Janus kinase 1	Homo sapiens	24-30
28053127-7	2017	Suppression of JAK1/2 by ruxolitinib prevented STAT3-mediated transcription of ZEB1, SNAI1 and OSMR, as well as the emergence of a mesenchymal/CSC phenotype.	ruxolitinib	25-36	Janus kinase 1	Homo sapiens	15-21
28188131-2	2017	Results from a phase 2 study for the treatment of MF with the Janus kinase 1/2 (JAK1/2) inhibitor momelotinib (MMB) demonstrated that MMB treatment ameliorated anemia, which was unexpected for a JAK1/2 inhibitor, because erythropoietin-mediated JAK2 signaling is essential for erythropoiesis.	N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	98-109	Janus kinase 1	Homo sapiens	80-86
28188131-2	2017	Results from a phase 2 study for the treatment of MF with the Janus kinase 1/2 (JAK1/2) inhibitor momelotinib (MMB) demonstrated that MMB treatment ameliorated anemia, which was unexpected for a JAK1/2 inhibitor, because erythropoietin-mediated JAK2 signaling is essential for erythropoiesis.	N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	111-114	Janus kinase 1	Homo sapiens	80-86
28188131-2	2017	Results from a phase 2 study for the treatment of MF with the Janus kinase 1/2 (JAK1/2) inhibitor momelotinib (MMB) demonstrated that MMB treatment ameliorated anemia, which was unexpected for a JAK1/2 inhibitor, because erythropoietin-mediated JAK2 signaling is essential for erythropoiesis.	N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	134-137	Janus kinase 1	Homo sapiens	80-86
28579852-3	2017	However, more recently, the discovery of JAK2 mutations has also led to the development of small-molecule JAK1/2 inhibitors, the first of which, ruxolitinib, has been approved for the treatment of MF in the United States and Europe.	ruxolitinib	145-156	Janus kinase 1	Homo sapiens	106-112
27723271-1	2017	OBJECTIVE: We undertook this phase III study to evaluate baricitinib, an orally administered JAK-1/JAK-2 inhibitor, as monotherapy or combined with methotrexate (MTX) compared to MTX monotherapy in patients with active rheumatoid arthritis (RA) who had received no or minimal conventional synthetic disease-modifying antirheumatic drugs (DMARDs) and who were naive to biologic DMARDs.	baricitinib	57-68	Janus kinase 1	Homo sapiens	93-98
27832516-1	2017	Ruxolitinib is a potent JAK1/JAK2 inhibitor that has demonstrated durable improvements in splenomegaly, symptoms, and overall survival in controlled clinical trials in patients with myelofibrosis.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	24-28
28028027-1	2017	There has been a major revolution in the management of patients with myeloproliferative neoplasms (MPN), and in particular those with myelofibrosis and extensive splenomegaly and symptomatic burden, after the introduction of the JAK1 and JAK2 inhibitor ruxolitinib.	ruxolitinib	253-264	Janus kinase 1	Homo sapiens	229-233
28260257-1	2017	Ruxolitinib is a dual janus kinase 1 (JAK1)/JAK2 inhibitor used to treat splenomegaly and symptoms associated with myelofibrosis (MF).	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	22-36
28260257-1	2017	Ruxolitinib is a dual janus kinase 1 (JAK1)/JAK2 inhibitor used to treat splenomegaly and symptoms associated with myelofibrosis (MF).	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	38-42
28228106-1	2017	BACKGROUND: The randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial evaluated the JAK1/JAK2 inhibitor ruxolitinib in patients with intermediate-2/high-risk myelofibrosis.	ruxolitinib	120-131	Janus kinase 1	Homo sapiens	100-104
28199814-1	2017	BACKGROUND: Baricitinib is an oral, reversible inhibitor of the Janus kinases JAK1 and JAK2 that may have therapeutic value in patients with rheumatoid arthritis.	baricitinib	12-23	Janus kinase 1	Homo sapiens	78-82
27983880-1	2017	INTRODUCTION: Ruxolitinib is a potent and selective JAK1/JAK2 inhibitor that has shown superiority as compared to available conventional chemotherapies, in terms of reduction in splenomegaly and improvement of symptoms and quality of life.	ruxolitinib	14-25	Janus kinase 1	Homo sapiens	52-56
27785927-0	2017	Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.	N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	0-11	Janus kinase 1	Homo sapiens	30-36
27785927-4	2017	The JAK1/2 inhibitor momelotinib unexpectedly resulted in reduction of anemia in MF patients during Phase I/II trials.	N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	21-32	Janus kinase 1	Homo sapiens	4-10
27930945-2	2017	Ruxolitinib, an oral JAK1/2 inhibitor, is highly effective in ameliorating systemic symptoms and reducing splenomegaly.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	21-27
27916398-1	2017	BACKGROUND: In the pivotal RESPONSE study, ruxolitinib, a Janus kinase (JAK)1 and JAK2 inhibitor, was superior to best available therapy at controlling haematocrit and improving splenomegaly and symptoms in patients with polycythaemia vera with splenomegaly who were inadequately controlled with hydroxyurea.	ruxolitinib	43-54	Janus kinase 1	Homo sapiens	58-77
27882812-2	2017	Ruxolitinib, a JAK1/2 inhibitor, is currently the only drug approved for the treatment of patients with intermediate or high risk MF.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-21
26705936-7	2017	MCF-7 cells cocultured with M2 TAM showed activated JAK1/STAT3 and Raf/MEK/JNK pathways contributing to tyrosine and serine phophorylation of STAT3, respectively.	tam	31-34	Janus kinase 1	Homo sapiens	52-56
26705936-7	2017	MCF-7 cells cocultured with M2 TAM showed activated JAK1/STAT3 and Raf/MEK/JNK pathways contributing to tyrosine and serine phophorylation of STAT3, respectively.	Tyrosine	104-112	Janus kinase 1	Homo sapiens	52-56
28674362-0	2017	The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation.	ruxolitinib	79-90	Janus kinase 1	Homo sapiens	61-67
28674362-3	2017	We describe how treatment with a JAK1/2 inhibitor, ruxolitinib, led to the rapid amelioration of marrow fibrosis, erythrocytosis and thrombocytopenia in a 77-year-old man with post-PV MF who carried a JAK2 exon 12 mutation (JAK2H538QK539L).	ruxolitinib	51-62	Janus kinase 1	Homo sapiens	33-39
27988142-1	2017	BACKGROUND: Filgotinib (GLPG0634, GS-6034) is a once-daily, orally administered, Janus kinase 1 (JAK1)-selective inhibitor.	GLPG0634	12-22	Janus kinase 1	Homo sapiens	81-95
27988142-1	2017	BACKGROUND: Filgotinib (GLPG0634, GS-6034) is a once-daily, orally administered, Janus kinase 1 (JAK1)-selective inhibitor.	GLPG0634	12-22	Janus kinase 1	Homo sapiens	97-101
27923824-9	2017	These results demonstrate that ruxolitinib"s nonselective inhibition of JAK1/2 results in profound NK-cell dysfunction by blocking downstream pSTAT5, hence providing a persuasive rationale for the development of selective JAK2 inhibitors for immunotherapeutic applications.	ruxolitinib	31-42	Janus kinase 1	Homo sapiens	72-78
27634203-1	2017	Momelotinib, a small-molecule inhibitor of Janus kinase 1 and Janus kinase 2, has demonstrated efficacy in myelofibrosis patients with 300 mg, once-daily dosing.	N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	0-11	Janus kinase 1	Homo sapiens	43-57
27286739-3	2016	In this study, we examine the expression of the interleukin-6/Janus kinase/STAT3 (IL-6/JAK/STAT3) pathway components in PA and ca-ex-PA.	ca-ex-pa	127-135	Janus kinase 1	Homo sapiens	87-90
27659251-5	2017	Although there is a high sequence homology and structural identity of JAK1 and JAK2, such as a very similar binding mode of inhibitors at the ATPbinding site of enzymes, obvious differences surrounding the JAK1 and JAK2 ATP-binding sites provide a platform for the rational design of JAK2- and JAK1-specific inhibitors.	atpbinding	142-152	Janus kinase 1	Homo sapiens	70-74
27659251-5	2017	Although there is a high sequence homology and structural identity of JAK1 and JAK2, such as a very similar binding mode of inhibitors at the ATPbinding site of enzymes, obvious differences surrounding the JAK1 and JAK2 ATP-binding sites provide a platform for the rational design of JAK2- and JAK1-specific inhibitors.	Adenosine Triphosphate	142-145	Janus kinase 1	Homo sapiens	70-74
27997540-8	2016	Our analysis revealed that mutations in JAK1 and KRAS, two genes encoding components of the interleukin 7 receptor (IL7R) signaling pathway, were associated with steroid resistance and poor outcome.	Steroids	162-169	Janus kinase 1	Homo sapiens	40-44
27997540-13	2016	We found that expressing mutant IL7R, JAK1, or NRAS, or wild-type NRAS or AKT, specifically induced steroid resistance without affecting sensitivity to vincristine or L-asparaginase.	Steroids	100-107	Janus kinase 1	Homo sapiens	38-42
27286739-8	2016	CONCLUSION: The IL-6/JAK/STAT3 pathway is overexpressed in PA, and this overexpression was even more pronounced in ca-ex-PA, with a shift in the JAKs mediating STAT3 phosphorylation.	ca-ex-pa	115-123	Janus kinase 1	Homo sapiens	21-24
27286739-9	2016	Future studies are needed to clarify whether PA and ca-ex-PA could be treated with targeted therapy directed against components of the IL-6/JAK/STAT3 pathway.	ca-ex-pa	52-60	Janus kinase 1	Homo sapiens	140-143
27286739-7	2016	Overexpression of phosphorylated JAK1 (p-JAK1) and cyclin D1 was significantly overexpressed in ductal cells compared with myoepithelial cells in PA. A shift from p-JAK1 to p-JAK2 and p-Tyk2 overexpression was seen between PA and ca-ex-PA, combined with a high p-STAT3 expression in the latter.	ca-ex-pa	230-238	Janus kinase 1	Homo sapiens	33-37
27157043-7	2016	In a CMML patient with splenomegaly, who was treated with the JAK1/2 inhibitor ruxolitinib off label, we can demonstrate a spleen response and the disappearance of constitutional symptoms which was associated with a decrease in autonomous CFU-GM formation ex vivo.	ruxolitinib	79-90	Janus kinase 1	Homo sapiens	62-68
27389975-0	2016	A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy.	upadacitinib	21-28	Janus kinase 1	Homo sapiens	42-47
27389975-1	2016	OBJECTIVE: To compare the efficacy and safety of ABT-494, a novel selective JAK-1 inhibitor, with placebo in patients with moderate-to-severe rheumatoid arthritis (RA) and an inadequate response or intolerance to at least 1 anti-tumor necrosis factor (anti-TNF) agent.	upadacitinib	49-56	Janus kinase 1	Homo sapiens	76-81
27390150-0	2016	Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate.	upadacitinib	23-30	Janus kinase 1	Homo sapiens	44-49
27390150-1	2016	OBJECTIVE: To evaluate the efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in patients with moderate-to-severe rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX).	upadacitinib	50-57	Janus kinase 1	Homo sapiens	71-76
27272171-0	2016	Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis.	upadacitinib	45-52	Janus kinase 1	Homo sapiens	72-77
27272171-1	2016	BACKGROUND: ABT-494 is a potent and selective Janus kinase (JAK) 1 inhibitor being developed for the treatment of several autoimmune disorders, with potential for an improved safety profile compared with non-selective JAK inhibitors.	upadacitinib	12-19	Janus kinase 1	Homo sapiens	46-66
27774820-4	2016	Areas covered: Current pharmacologic therapy of MF revolves around the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib, which dramatically improves constitutional symptoms and splenomegaly in the majority of patients, and improves overall survival (OS).	ruxolitinib	107-118	Janus kinase 1	Homo sapiens	89-95
27579615-4	2016	The JAK1/2 inhibitor ruxolitinib blocked STAT3-phosphorylation and partially improved DEX-mediated killing of stimulated CLL cells in vitro but not in CLL patients in vivo.	ruxolitinib	21-32	Janus kinase 1	Homo sapiens	4-10
27788604-11	2016	The Z"-LYTE  kinase assay showed a reduction in the activities of JAK1, JAK3 and TYK2 by pirfenidone.	pirfenidone	89-100	Janus kinase 1	Homo sapiens	66-70
27086927-6	2016	Importantly, Ruxolitinib, a JAK1 inhibitor, could rescue the phenotypic changes induced by miR-23a, -27a and -24 inhibitors.	ruxolitinib	13-24	Janus kinase 1	Homo sapiens	28-32
27799566-1	2016	Janus kinases (JAKs) classically signal by activating STAT transcription factors but can also regulate gene expression by epigenetically phosphorylating histone H3 on tyrosine 41 (H3Y41-P).	Tyrosine	167-175	Janus kinase 1	Homo sapiens	15-19
27579615-4	2016	The JAK1/2 inhibitor ruxolitinib blocked STAT3-phosphorylation and partially improved DEX-mediated killing of stimulated CLL cells in vitro but not in CLL patients in vivo.	Dexamethasone	86-89	Janus kinase 1	Homo sapiens	4-10
27827355-0	2016	Development of a high-throughput crystal structure-determination platform for JAK1 using a novel metal-chelator soaking system.	Metals	97-102	Janus kinase 1	Homo sapiens	78-82
27919027-7	2016	Clinically used AMPK activators metformin and salicylate enhanced the inhibitory phosphorylation of endogenous JAK1 and inhibited STAT3 phosphorylation in primary vascular endothelial cells.	Metformin	32-41	Janus kinase 1	Homo sapiens	111-115
27919027-7	2016	Clinically used AMPK activators metformin and salicylate enhanced the inhibitory phosphorylation of endogenous JAK1 and inhibited STAT3 phosphorylation in primary vascular endothelial cells.	Salicylates	46-56	Janus kinase 1	Homo sapiens	111-115
27827355-1	2016	Crystals of phosphorylated JAK1 kinase domain were initially generated in complex with nucleotide (ADP) and magnesium.	Adenosine Diphosphate	99-102	Janus kinase 1	Homo sapiens	27-31
27827355-1	2016	Crystals of phosphorylated JAK1 kinase domain were initially generated in complex with nucleotide (ADP) and magnesium.	Magnesium	108-117	Janus kinase 1	Homo sapiens	27-31
27555284-0	2016	The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3.	triazole-pyrrolopyrimidine	32-58	Janus kinase 1	Homo sapiens	112-116
27555284-3	2016	We discovered a potent and highly selective inhibitor of JAK2 over JAK1 and -3 based on the structure of 4-(2,5-triazole)-pyrrolopyrimidine.	4-(2,5-triazole)-pyrrolopyrimidine	105-139	Janus kinase 1	Homo sapiens	67-78
27244086-0	2016	Molecular docking, 3D QSAR and dynamics simulation studies of imidazo-pyrrolopyridines as janus kinase 1 (JAK 1) inhibitors.	imidazo-pyrrolopyridines	62-86	Janus kinase 1	Homo sapiens	90-104
27577235-9	2016	Results of phase III clinical trials using a JAK1/2 inhibitor, baricitinib, have shown feasible efficacy and tolerable safety.	baricitinib	63-74	Janus kinase 1	Homo sapiens	45-51
27577235-11	2016	In addition, clinical phase III trials using filgotinib and ABT-494, specific JAK1 inhibitors, are currently underway.	GLPG0634	45-55	Janus kinase 1	Homo sapiens	78-82
27577235-11	2016	In addition, clinical phase III trials using filgotinib and ABT-494, specific JAK1 inhibitors, are currently underway.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	60-63	Janus kinase 1	Homo sapiens	78-82
27690665-4	2016	Areas covered: Several JAK inhibitors such as tofacitinib and baricitinib are oral synthetic DMARD that inhibit JAK1, 2 and 3.	tofacitinib	46-57	Janus kinase 1	Homo sapiens	112-125
27690665-4	2016	Areas covered: Several JAK inhibitors such as tofacitinib and baricitinib are oral synthetic DMARD that inhibit JAK1, 2 and 3.	baricitinib	62-73	Janus kinase 1	Homo sapiens	112-125
27771575-5	2016	The results have highlighted spirocyclic pyrrolopyrimidines with submicromolar JAK1 IC50 values and a preference for JAK1 over JAK2 as potential starting points in developing a novel class of JAK1 inhibitors.	spirocyclic pyrrolopyrimidines	29-59	Janus kinase 1	Homo sapiens	79-83
27055521-0	2016	Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus.	GSK2586184	84-94	Janus kinase 1	Homo sapiens	69-73
27055521-1	2016	We aimed to evaluate the pharmacodynamics, efficacy, safety and tolerability of the JAK1 inhibitor GSK2586184 in adults with systemic lupus erythematosus (SLE).	GSK2586184	99-109	Janus kinase 1	Homo sapiens	84-88
27244086-0	2016	Molecular docking, 3D QSAR and dynamics simulation studies of imidazo-pyrrolopyridines as janus kinase 1 (JAK 1) inhibitors.	imidazo-pyrrolopyridines	62-86	Janus kinase 1	Homo sapiens	106-111
27244086-3	2016	Docking, 3D quantitative structure activity relationship (3D-QSAR) and molecular dynamics (MD) studies were performed on a series of Imidazo-pyrrolopyridine derivatives reported as JAK 1 inhibitors.	imidazo-pyrrolopyridine	133-156	Janus kinase 1	Homo sapiens	181-186
27910962-4	2016	Baricitinib (LY-3009104, INCB-028050), a new potent and selective tyrosine-protein kinase JAK1/JAK2 inhibitor, has shown clinical efficacy in patients with RA refractory to aggressive standard-of-care treatment (with both conventional DMARDs and bDMARDs) when administered orally at 4 mg q.d.	baricitinib	0-11	Janus kinase 1	Homo sapiens	90-94
27910962-4	2016	Baricitinib (LY-3009104, INCB-028050), a new potent and selective tyrosine-protein kinase JAK1/JAK2 inhibitor, has shown clinical efficacy in patients with RA refractory to aggressive standard-of-care treatment (with both conventional DMARDs and bDMARDs) when administered orally at 4 mg q.d.	baricitinib	13-23	Janus kinase 1	Homo sapiens	90-94
27910962-4	2016	Baricitinib (LY-3009104, INCB-028050), a new potent and selective tyrosine-protein kinase JAK1/JAK2 inhibitor, has shown clinical efficacy in patients with RA refractory to aggressive standard-of-care treatment (with both conventional DMARDs and bDMARDs) when administered orally at 4 mg q.d.	baricitinib	25-36	Janus kinase 1	Homo sapiens	90-94
27268955-8	2016	In early clinical trials, the pentoxifylline derivative CTP-499, the CCR2 inhibitor CCX140-B, the CCL2 inhibitor emapticap pegol and the JAK1/JAK2 inhibitor baricitinib were the most promising drugs for diabetic kidney disease.	baricitinib	157-168	Janus kinase 1	Homo sapiens	137-141
27738655-6	2016	We showed that in vitro this antiviral state could be reverted by combining VSV-GP with the JAK1/2-inhibitor ruxolitinib.	ruxolitinib	109-120	Janus kinase 1	Homo sapiens	92-96
27729820-5	2016	Ruxolitinib, a JAK 1 and 2 inhibitor, has already proven to be efficient in relieving symptoms in primary myelofibrosis and PV.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-26
27699253-4	2016	Here, we investigated the use of the oral JAK1/2 inhibitor ruxolitinib in the treatment of patients with moderate-to-severe AA.	ruxolitinib	59-70	Janus kinase 1	Homo sapiens	42-48
27427830-5	2016	Five phase 3 trials of Baricitinib, a JAK1 and JAK2 inhibitor, have been performed and showed high clinical efficacy in patients with active RA and naive to sDMARDs or an inadequate response to sDMARDs, MTX or bDMARDs.	baricitinib	23-34	Janus kinase 1	Homo sapiens	38-42
27460897-3	2016	The JAK inhibitor SHR0302 is a synthetic molecule that potently inhibits all members of the JAK family, particularly JAK1.	ivarmacitinib	18-25	Janus kinase 1	Homo sapiens	117-121
27272942-6	2016	The increased IL-7 was secreted by mesenchymal stem cells (MSC) in the bone marrow, which may protect leukemic cells from apoptosis induced by imatinib through JAK1/STAT5 signaling pathway.	Imatinib Mesylate	143-151	Janus kinase 1	Homo sapiens	160-164
27572962-2	2016	The US FDA -approved JAK1-3 inhibitor tofacitinib also potently inhibits PRK1 in vitro.	tofacitinib	38-49	Janus kinase 1	Homo sapiens	21-25
27163538-3	2016	Tofacitinib, an oral Janus kinase inhibitor that targets Jak1/Jak3 dependent Stat activation, has been assessed as a substitute for calcineurin inhibitor therapy after low-to-moderate risk kidney transplantation in 3 randomized trials.	tofacitinib	0-11	Janus kinase 1	Homo sapiens	57-61
30209928-0	2016	[Sodium Aescinate Induced Apoptosis of BGC-823 and AGS Cells by Inhibiting JAK-1/STAT-1 Signaling Pathway].	sodium aescinate	1-17	Janus kinase 1	Homo sapiens	75-80
30209928-4	2016	Conclusion: Sodium aescinate inhibit the proliferation and induce apoptosis in the gastric cancer BGC-823 cells and AGS cells, and this process can be implemented by inhibiting the JAK-1/STAT-1 signaling pathway.	sodium aescinate	12-28	Janus kinase 1	Homo sapiens	181-186
27774135-0	2016	Design, Synthesis, and Antitumor Evaluation of 4-Amino-(1H)-pyrazole Derivatives as JAKs Inhibitors.	4-amino-(1h)-pyrazole	47-68	Janus kinase 1	Homo sapiens	84-88
27774135-2	2016	Herein, we designed and synthesized a series of 4-amino-(1H)-pyrazole derivatives as potent JAKs inhibitors for cancer treatment.	4-amino-(1h)-pyrazole	48-69	Janus kinase 1	Homo sapiens	92-96
27774135-6	2016	It is worth noting that both 3f and 11b showed more potent antiproliferative activities than the approved JAKs inhibitor Ruxolitinib.	ruxolitinib	121-132	Janus kinase 1	Homo sapiens	106-110
27570458-7	2016	In clinical trials, the JAK1/JAK2 inhibitor ruxolitinib - the first therapy approved for MF worldwide - improved disease-related splenomegaly and symptoms independent of JAK2 (V617F) mutational status, and prolonged survival compared with placebo or standard therapy in patients with advanced MF.	ruxolitinib	44-55	Janus kinase 1	Homo sapiens	24-28
27473820-12	2016	Tofacitinib is a pan-JAK inhibitor that is approved by the FDA for the treatment of rheumatoid arthritis and ruxolitinib is a JAK1/2 inhibitor that is approved for the treatment of polycythemia vera and myelofibrosis.	ruxolitinib	109-120	Janus kinase 1	Homo sapiens	126-132
26979390-2	2016	In this issue, ruxolitinib, a JAK1 and -2 inhibitory drug, is shown to induce objective responses in chronic myelomonocytic leukemia patients.	ruxolitinib	15-26	Janus kinase 1	Homo sapiens	30-41
27502249-7	2016	Ruxolitinib, a JAK1/2 inhibitor approved for intermediate-2/high-risk myelofibrosis, was recently employed in SR-GvHD with encouraging overall response rates.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-21
26858309-1	2016	PURPOSE: To conduct a phase I clinical trial exploring the safety and efficacy of ruxolitinib, a JAK1/2 inhibitor, for chronic myelomonocytic leukemia (CMML).	ruxolitinib	82-93	Janus kinase 1	Homo sapiens	97-103
27137359-0	2016	Design, synthesis and preliminary biological evaluation of 4-aminopyrazole derivatives as novel and potent JAKs inhibitors.	1H-Pyrazol-4-amine	59-74	Janus kinase 1	Homo sapiens	107-111
26769332-2	2016	OBJECTIVE: To evaluate the safety and efficacy of the oral selective JAK1 inhibitor INCB039110 in stable, chronic plaque psoriasis.	INCB039110	84-94	Janus kinase 1	Homo sapiens	69-73
27102499-1	2016	RESPONSE is an open-label phase 3 study evaluating the Janus kinase 1/Janus kinase 2 inhibitor ruxolitinib versus best available therapy for efficacy/safety in hydroxyurea-resistant or intolerant patients with polycythemia vera.	Hydroxyurea	160-171	Janus kinase 1	Homo sapiens	55-69
27175602-14	2016	Quercetin reduced the expression of phospho-JAK1 and phospho-STAT3 and decreased STAT3-dependent luciferase reporter gene activity in the BT-474 cells.	Quercetin	0-9	Janus kinase 1	Homo sapiens	44-48
27211272-1	2016	Ruxolitinib is a Janus kinase (JAK) (JAK1/JAK2) inhibitor that has demonstrated superiority over placebo and best available therapy (BAT) in the Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment (COMFORT) studies.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	37-41
27261178-0	2016	Novel JAK1-selective benzimidazole inhibitors with enhanced membrane permeability.	benzimidazole	21-34	Janus kinase 1	Homo sapiens	6-10
27261178-1	2016	The previously identified Janus kinase 1 (JAK1)-selective inhibitor, 1-(2-aminoethyl)-2-(piperidin-4-yl)-1H-benzo[d]imidazole-5-carboxamide (2), suffered from low cell permeability, which resulted in poor pharmacokinetic properties.	1-(2-aminoethyl)-2-(piperidin-4-yl)-1H-benzo(d)imidazole-5-carboxamide	69-139	Janus kinase 1	Homo sapiens	26-40
27261178-1	2016	The previously identified Janus kinase 1 (JAK1)-selective inhibitor, 1-(2-aminoethyl)-2-(piperidin-4-yl)-1H-benzo[d]imidazole-5-carboxamide (2), suffered from low cell permeability, which resulted in poor pharmacokinetic properties.	1-(2-aminoethyl)-2-(piperidin-4-yl)-1H-benzo(d)imidazole-5-carboxamide	69-139	Janus kinase 1	Homo sapiens	42-46
27259268-6	2016	Overexpression of constitutively active STAT3 partly reversed the anti cancer effects of (-)-oleocanthal, which inhibited STAT3 activation by decreasing the activities of JAK1 and JAK2 and increasing the activity of SHP-1.	oleocanthal	89-104	Janus kinase 1	Homo sapiens	171-175
27137359-2	2016	We designed and synthesized a novel series of 4-aminopyrazole derivatives, which showed inhibitory potency against various JAKs.	1H-Pyrazol-4-amine	46-61	Janus kinase 1	Homo sapiens	123-127
27371847-0	2016	[Astaxanthin inhibits proliferation and promotes apoptosis of A549 lung cancer cells via blocking JAK1/STAT3 pathway].	astaxanthine	1-12	Janus kinase 1	Homo sapiens	98-102
27017614-5	2016	Ruxolitinib, an oral JAK1/JAK2 inhibitor, is approved in the USA for the treatment of patients with intermediate- or high-risk MF and patients with PV who have had an inadequate response to or are intolerant of hydroxyurea.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	21-25
26800231-0	2016	A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis.	baricitinib	31-42	Janus kinase 1	Homo sapiens	52-72
26800231-2	2016	OBJECTIVES: To evaluate the safety and efficacy of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis in a randomized, double-blind, placebo-controlled, dose-ranging phase 2b study.	baricitinib	51-62	Janus kinase 1	Homo sapiens	72-92
27371847-6	2016	Western blotting showed that astaxanthin up-regulated the expression of Bax and down-regulated the expressions of Bcl-2, STAT3 and JAK1.	astaxanthine	29-40	Janus kinase 1	Homo sapiens	131-135
27371847-7	2016	Conclusion Astaxanthin functions as a potent inhibitor of A549 lung cancer cell growth by targeting JAK1/STAT3 signaling pathway.	astaxanthine	11-22	Janus kinase 1	Homo sapiens	100-104
27045723-4	2016	In Filgotinib group, the specific inhibitor of Janus kinase 1 (JAK1), Filgotinib, was used to detect the role of JAK1/signal transducer and activator of transcription 1 (STAT1) signaling pathway in LPS challenge, and the aqueous physiological buffer group was used as the control.	GLPG0634	3-13	Janus kinase 1	Homo sapiens	47-61
31360077-6	2016	Ruxolitinib is an orally available small-molecule tyrosine kinase inhibitor that is a potent and selective inhibitor of JAK1/JAK2.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	120-124
26910327-0	2016	The Selective JAK1/3-Inhibitor R507 Mitigates Obliterative Airway Disease Both With Systemic Administration and Aerosol Inhalation.	r507	31-35	Janus kinase 1	Homo sapiens	14-18
26927423-0	2016	Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors.	(benz)imidazole pyridones	42-67	Janus kinase 1	Homo sapiens	71-75
26927423-5	2016	Concurrent crystallography-driven exploration of the ribose pocket and the solvent front led to analogs with optimized kinome and JAK1 selectivities over the JAK2 isoform by targeting several residues unique to JAK1, such as Arg-879 and Glu-966.	Ribose	53-59	Janus kinase 1	Homo sapiens	130-134
26927423-5	2016	Concurrent crystallography-driven exploration of the ribose pocket and the solvent front led to analogs with optimized kinome and JAK1 selectivities over the JAK2 isoform by targeting several residues unique to JAK1, such as Arg-879 and Glu-966.	Ribose	53-59	Janus kinase 1	Homo sapiens	211-215
26927423-5	2016	Concurrent crystallography-driven exploration of the ribose pocket and the solvent front led to analogs with optimized kinome and JAK1 selectivities over the JAK2 isoform by targeting several residues unique to JAK1, such as Arg-879 and Glu-966.	Arginine	225-228	Janus kinase 1	Homo sapiens	211-215
26927423-5	2016	Concurrent crystallography-driven exploration of the ribose pocket and the solvent front led to analogs with optimized kinome and JAK1 selectivities over the JAK2 isoform by targeting several residues unique to JAK1, such as Arg-879 and Glu-966.	Glutamic Acid	237-240	Janus kinase 1	Homo sapiens	211-215
26785220-0	2016	Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study.	GSK2586184	42-52	Janus kinase 1	Homo sapiens	27-31
26785220-1	2016	BACKGROUND: GSK2586184 is a selective oral Janus kinase (JAK)1 inhibitor being evaluated as a treatment for moderate-to-severe plaque-type psoriasis.	GSK2586184	12-22	Janus kinase 1	Homo sapiens	43-62
27053336-0	2016	Piperlongumine inhibits gastric cancer cells via suppression of the JAK1,2/STAT3 signaling pathway.	piperlonguminine	0-14	Janus kinase 1	Homo sapiens	68-74
27053336-5	2016	In addition, PL reduced the phosphorylation of Janus kinase (JAK)1, JAK2 and signal transducer and activator of transcription (STAT)3 in a concentration-dependent manner, as indicated by western blot analysis, and decreased the expression of STAT3-dependent tumor-associated genes in GC cells, as revealed by PCR analysis.	piperlonguminine	13-15	Janus kinase 1	Homo sapiens	47-66
26981780-1	2016	We determined whether the myelofibrosis drug ruxolitinib, an inhibitor of Janus kinases 1/2 (JAK1 and JAK2), could interact with the multiple sclerosis drug dimethyl-fumarate (DMF) to kill tumor cells; studies used the in vivo active form of the drug, mono-methyl fumarate (MMF).	Dimethyl Fumarate	157-174	Janus kinase 1	Homo sapiens	74-91
26981780-1	2016	We determined whether the myelofibrosis drug ruxolitinib, an inhibitor of Janus kinases 1/2 (JAK1 and JAK2), could interact with the multiple sclerosis drug dimethyl-fumarate (DMF) to kill tumor cells; studies used the in vivo active form of the drug, mono-methyl fumarate (MMF).	Dimethyl Fumarate	157-174	Janus kinase 1	Homo sapiens	93-97
26981780-1	2016	We determined whether the myelofibrosis drug ruxolitinib, an inhibitor of Janus kinases 1/2 (JAK1 and JAK2), could interact with the multiple sclerosis drug dimethyl-fumarate (DMF) to kill tumor cells; studies used the in vivo active form of the drug, mono-methyl fumarate (MMF).	Dimethyl Fumarate	176-179	Janus kinase 1	Homo sapiens	74-91
26981780-1	2016	We determined whether the myelofibrosis drug ruxolitinib, an inhibitor of Janus kinases 1/2 (JAK1 and JAK2), could interact with the multiple sclerosis drug dimethyl-fumarate (DMF) to kill tumor cells; studies used the in vivo active form of the drug, mono-methyl fumarate (MMF).	Dimethyl Fumarate	176-179	Janus kinase 1	Homo sapiens	93-97
26981780-1	2016	We determined whether the myelofibrosis drug ruxolitinib, an inhibitor of Janus kinases 1/2 (JAK1 and JAK2), could interact with the multiple sclerosis drug dimethyl-fumarate (DMF) to kill tumor cells; studies used the in vivo active form of the drug, mono-methyl fumarate (MMF).	citraconic acid	252-272	Janus kinase 1	Homo sapiens	74-91
26981780-1	2016	We determined whether the myelofibrosis drug ruxolitinib, an inhibitor of Janus kinases 1/2 (JAK1 and JAK2), could interact with the multiple sclerosis drug dimethyl-fumarate (DMF) to kill tumor cells; studies used the in vivo active form of the drug, mono-methyl fumarate (MMF).	citraconic acid	252-272	Janus kinase 1	Homo sapiens	93-97
26981780-1	2016	We determined whether the myelofibrosis drug ruxolitinib, an inhibitor of Janus kinases 1/2 (JAK1 and JAK2), could interact with the multiple sclerosis drug dimethyl-fumarate (DMF) to kill tumor cells; studies used the in vivo active form of the drug, mono-methyl fumarate (MMF).	citraconic acid	274-277	Janus kinase 1	Homo sapiens	74-91
26981780-1	2016	We determined whether the myelofibrosis drug ruxolitinib, an inhibitor of Janus kinases 1/2 (JAK1 and JAK2), could interact with the multiple sclerosis drug dimethyl-fumarate (DMF) to kill tumor cells; studies used the in vivo active form of the drug, mono-methyl fumarate (MMF).	citraconic acid	274-277	Janus kinase 1	Homo sapiens	93-97
27045723-4	2016	In Filgotinib group, the specific inhibitor of Janus kinase 1 (JAK1), Filgotinib, was used to detect the role of JAK1/signal transducer and activator of transcription 1 (STAT1) signaling pathway in LPS challenge, and the aqueous physiological buffer group was used as the control.	GLPG0634	3-13	Janus kinase 1	Homo sapiens	63-67
27045723-4	2016	In Filgotinib group, the specific inhibitor of Janus kinase 1 (JAK1), Filgotinib, was used to detect the role of JAK1/signal transducer and activator of transcription 1 (STAT1) signaling pathway in LPS challenge, and the aqueous physiological buffer group was used as the control.	GLPG0634	70-80	Janus kinase 1	Homo sapiens	47-61
27045723-4	2016	In Filgotinib group, the specific inhibitor of Janus kinase 1 (JAK1), Filgotinib, was used to detect the role of JAK1/signal transducer and activator of transcription 1 (STAT1) signaling pathway in LPS challenge, and the aqueous physiological buffer group was used as the control.	GLPG0634	70-80	Janus kinase 1	Homo sapiens	63-67
26755644-2	2016	However, the lack of complete response in most patients treated with the JAK1/2 inhibitor, ruxolitinib, indicates the need for identifying pathways that cooperate with JAK2.	ruxolitinib	91-102	Janus kinase 1	Homo sapiens	73-79
26717494-4	2016	Over the last decade, the molecular pathogenesis of MPNs has been elucidated considerably, and the Janus kinase (JAK) 1/2 inhibitor ruxolitinib is the first drug specifically approved by the US Food and Drug Administration to treat patients with intermediate-risk and high-risk myelofibrosis.	ruxolitinib	132-143	Janus kinase 1	Homo sapiens	99-119
26493563-5	2016	OS was 91% (95% CI, 69% to 98%) for those who experienced clinical improvement and 32% (95% CI, 8% to 59%) for those who developed LT on JAK1/2 inhibitors.	Osmium	0-2	Janus kinase 1	Homo sapiens	137-141
26846873-3	2016	Ruxolitinib, a potent JAK1/2 inhibitor, initially approved for myelofibrosis, was recently approved for patients with polycythemia vera refractory or intolerant to hydroxycarbamide.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	22-28
26834213-1	2016	OBJECTIVE: To evaluate efficacy and safety, baricitinib [Janus kinase (JAK) 1/JAK2 inhibitor] was compared with placebo in Japanese patients with active rheumatoid arthritis (RA) despite background treatment with methotrexate (MTX).	baricitinib	44-55	Janus kinase 1	Homo sapiens	57-77
26701727-8	2016	Furthermore,the sensitivity to the treatment of a JAK1/2 inhibitor, ruxolitinib, was observed in JAK1S703I mutant PDX model, but not in other non-activating mutant or wild type models.	ruxolitinib	68-79	Janus kinase 1	Homo sapiens	50-56
26855781-2	2016	According to the literature, Ruxolitinib, a JAK1/JAK2 inhibitor, has been shown to reduce symptoms related to proinflammatory cytokine release in other myeloproliferative neoplasms.	ruxolitinib	29-40	Janus kinase 1	Homo sapiens	44-48
26811457-5	2016	In the present study the JAK1/2 inhibitor ruxolitinib reduced phosphorylation of STAT3 and STAT6 and expression of c-Myc in the HL cell line HDLM-2.	ruxolitinib	42-53	Janus kinase 1	Homo sapiens	25-31
27840748-1	2016	The Janus kinase (JAK) 1 and 2 inhibitor, ruxolitinib, was recently approved in Japan and has been effective in many patients with myelofibrosis (MF).	ruxolitinib	42-53	Janus kinase 1	Homo sapiens	4-30
26701356-2	2016	High-throughput screening against TYK2 and JAK1-3 provided aminoindazole derivative 1 as a hit compound.	1H-Indazol-3-amine	59-72	Janus kinase 1	Homo sapiens	43-47
26682735-6	2016	Six compounds were identified and confirmed in vitro, with an indazole-based hit exhibiting promising selectivity for JAK2 vs JAK1.	Indazoles	62-70	Janus kinase 1	Homo sapiens	126-130
26586478-6	2016	Concomitantly targeting the TGF-beta type I receptor (TbetaRI) kinase with SB505124 and JAK1-2 with ruxolitinib suppresses JAK1 phosphorylation and blocks proliferative cross-talk between human pancreatic cancer cells (PCCs) and human endothelial cells (ECs), and these anti-proliferative effects were mimicked by JAK1 silencing in ECs.	ruxolitinib	100-111	Janus kinase 1	Homo sapiens	88-92
26586478-6	2016	Concomitantly targeting the TGF-beta type I receptor (TbetaRI) kinase with SB505124 and JAK1-2 with ruxolitinib suppresses JAK1 phosphorylation and blocks proliferative cross-talk between human pancreatic cancer cells (PCCs) and human endothelial cells (ECs), and these anti-proliferative effects were mimicked by JAK1 silencing in ECs.	ruxolitinib	100-111	Janus kinase 1	Homo sapiens	123-127
26586478-6	2016	Concomitantly targeting the TGF-beta type I receptor (TbetaRI) kinase with SB505124 and JAK1-2 with ruxolitinib suppresses JAK1 phosphorylation and blocks proliferative cross-talk between human pancreatic cancer cells (PCCs) and human endothelial cells (ECs), and these anti-proliferative effects were mimicked by JAK1 silencing in ECs.	ruxolitinib	100-111	Janus kinase 1	Homo sapiens	123-127
26693854-0	2016	Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions.	GLPG0634	56-66	Janus kinase 1	Homo sapiens	41-45
26614408-0	2016	Identification of azabenzimidazoles as potent JAK1 selective inhibitors.	1H-imidazo(4,5-b)pyridine	18-35	Janus kinase 1	Homo sapiens	46-50
26614408-1	2016	We have identified a class of azabenzimidazoles as potent and selective JAK1 inhibitors.	1H-imidazo(4,5-b)pyridine	30-47	Janus kinase 1	Homo sapiens	72-76
26693854-1	2016	OBJECTIVE: The selective Janus kinase 1 inhibitor filgotinib (GLPG0634), which is currently in clinical development for the treatment of rheumatoid arthritis (RA) and Crohn"s disease, demonstrated encouraging safety and efficacy profiles in RA patients after 4 weeks of daily dosing.	GLPG0634	50-60	Janus kinase 1	Homo sapiens	25-39
26648193-4	2015	In this article, we present our recommendations for the practical management of myelofibrosis with ruxolitinib, a selective inhibitor of both JAK1 and JAK2.	ruxolitinib	99-110	Janus kinase 1	Homo sapiens	142-146
26482169-0	2015	Comment on: "Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modelling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection".	GLPG0634	79-89	Janus kinase 1	Homo sapiens	114-118
26482170-0	2015	Author"s Reply to Srinivas: "Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection".	GLPG0634	94-104	Janus kinase 1	Homo sapiens	129-133
26562526-6	2015	JI069 inhibited gp130 signaling by inducing dissociation between gp130 and JAK1.	ji069	0-5	Janus kinase 1	Homo sapiens	75-79
26433906-10	2015	A recent phase 3 trial has shown the superiority of the JAK1/2 inhibitor ruxolitinib in comparison to best available treatment in HU-intolerant or -resistant patients.	ruxolitinib	73-84	Janus kinase 1	Homo sapiens	56-62
26623653-2	2015	Targeted therapy with Ruxolitinib, a JAK1/2-specific inhibitor, achieves symptomatic improvement but does not eliminate the neoplastic clone.	ruxolitinib	22-33	Janus kinase 1	Homo sapiens	37-41
26455550-3	2015	Most importantly, myricetin interacts with oncoproteins such as protein kinase B (PKB) (Akt), Fyn, MEK1, and JAK1-STAT3 (Janus kinase-signal transducer and activator of transcription 3), and it attenuates the neoplastic transformation of cancer cells.	myricetin	18-27	Janus kinase 1	Homo sapiens	109-113
26372653-0	2015	Structure activity optimization of 6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyrazines as Jak1 kinase inhibitors.	6H-pyrrolo(2,3-e)(1,2,4)triazolo(4,3-a)pyrazine	35-83	Janus kinase 1	Homo sapiens	87-91
26375873-5	2015	In addition, resveratrol inhibited the phosphorylation of JAK1, JAK2, and Tyk2 and their downstream mediators, including STAT3 and STAT5.	Resveratrol	13-24	Janus kinase 1	Homo sapiens	58-62
26443624-1	2015	The development of the dual Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib for the treatment of myeloproliferative neoplasms (MPNs) has led to studies of ruxolitinib in other clinical contexts, including JAK-mutated acute lymphoblastic leukemia (ALL).	ruxolitinib	64-75	Janus kinase 1	Homo sapiens	46-52
26443624-1	2015	The development of the dual Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib for the treatment of myeloproliferative neoplasms (MPNs) has led to studies of ruxolitinib in other clinical contexts, including JAK-mutated acute lymphoblastic leukemia (ALL).	ruxolitinib	155-166	Janus kinase 1	Homo sapiens	46-52
26552452-4	2015	The JAK1/2 inhibitor, ruxolitinib, was the first JAK inhibitor approved for patients with intermediate- to high-risk myelofibrosis and its effects in improving symptoms and survival benefits were demonstrated by randomized controlled trials.	ruxolitinib	22-33	Janus kinase 1	Homo sapiens	4-10
26356819-1	2015	The JAK/STAT pathway is constitutively activated in myeloproliferative neoplasms and can be inhibited by ruxolitinib, a selective JAK1/2 inhibitor.	ruxolitinib	105-116	Janus kinase 1	Homo sapiens	130-136
26351728-0	2015	Benzimidazole Derivatives as Potent JAK1-Selective Inhibitors.	benzimidazole	0-13	Janus kinase 1	Homo sapiens	36-40
26362333-1	2015	Ruxolitinib (Jakavi( ), Jakafi( )) is an orally administered, first-in-class Janus Kinase (JAK) 1 and 2 inhibitor that was recently approved for the treatment of patients with polycythaemia vera (PV) who have responded inadequately to or are intolerant of hydroxyurea.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	77-103
26362333-2	2015	By inhibiting JAK 1 and 2, ruxolitinib reduces hyperactive JAK-signal transducers and activators of transcription (STAT) signalling that is implicated in the pathogenesis of PV.	ruxolitinib	27-38	Janus kinase 1	Homo sapiens	14-25
25976292-1	2015	BACKGROUND: Ruxolitinib, an orally bioavailable JAK1/JAK2 inhibitor, may treat cancers with CRLF2 and/or JAK pathway mutations.	ruxolitinib	12-23	Janus kinase 1	Homo sapiens	48-52
26351728-4	2015	In this study, as part of our continued efforts to develop a selective JAK1 inhibitor, a series of 1,2-disubstituted benzimidazole-5-carboxamide derivatives was prepared and their inhibitory activities against all four JAK isozymes were evaluated.	1,2-disubstituted benzimidazole-5-carboxamide	99-144	Janus kinase 1	Homo sapiens	71-75
26351728-5	2015	A clear structure-activity relationship was observed with respect to JAK1 selectivity; this highlighted the importance of hydrogen bond donors at both N(1) and R2 positions located within a specific distance from the benzimidazole core.	Hydrogen	122-130	Janus kinase 1	Homo sapiens	69-73
26351728-5	2015	A clear structure-activity relationship was observed with respect to JAK1 selectivity; this highlighted the importance of hydrogen bond donors at both N(1) and R2 positions located within a specific distance from the benzimidazole core.	benzimidazole	217-230	Janus kinase 1	Homo sapiens	69-73
26351728-6	2015	One of the synthesized compounds, 1-(2-aminoethyl)-2-(piperidin-4-yl)-1H-benzo[d]imidazole-5-carboxamide (5c), showed remarkable JAK1 selectivity (63-fold vs JAK2, 25-fold vs JAK3, and 74-fold vs Tyk2).	1-(2-aminoethyl)-2-(piperidin-4-yl)-1H-benzo(d)imidazole-5-carboxamide	34-104	Janus kinase 1	Homo sapiens	129-133
26351728-7	2015	Molecular docking revealed that the 2-aminoethyl and piperidin-4-yl substituents of 5c function as probes to differentiate the ATP-binding site of JAK1 from that of JAK2, resulting in preferential JAK1 binding.	2-aminoethyl and piperidin-4-yl	36-67	Janus kinase 1	Homo sapiens	147-151
26351728-7	2015	Molecular docking revealed that the 2-aminoethyl and piperidin-4-yl substituents of 5c function as probes to differentiate the ATP-binding site of JAK1 from that of JAK2, resulting in preferential JAK1 binding.	2-aminoethyl and piperidin-4-yl	36-67	Janus kinase 1	Homo sapiens	197-201
26351728-7	2015	Molecular docking revealed that the 2-aminoethyl and piperidin-4-yl substituents of 5c function as probes to differentiate the ATP-binding site of JAK1 from that of JAK2, resulting in preferential JAK1 binding.	Adenosine Triphosphate	127-130	Janus kinase 1	Homo sapiens	147-151
26351728-7	2015	Molecular docking revealed that the 2-aminoethyl and piperidin-4-yl substituents of 5c function as probes to differentiate the ATP-binding site of JAK1 from that of JAK2, resulting in preferential JAK1 binding.	Adenosine Triphosphate	127-130	Janus kinase 1	Homo sapiens	197-201
26232434-0	2015	Parafibromin Is a Component of IFN-gamma-Triggered Signaling Pathways That Facilitates JAK1/2-Mediated Tyrosine Phosphorylation of STAT1.	Tyrosine	103-111	Janus kinase 1	Homo sapiens	87-91
26231159-3	2015	Stimulation with IFNalpha/beta leads to the tyrosine phosphorylation of the JAK1 and Tyk2 receptor-associated kinases with subsequent STATs activation, transmitting signals from the cell surface receptor to the nucleus.	Tyrosine	44-52	Janus kinase 1	Homo sapiens	76-80
26152731-7	2015	Tofacitinib, a small product targeting JAK, inhibits phosphorylation of JAK1 and JAK3, subsequent Stat1 and expression of Stat1-inducible genes, which contribute to efficient propagation of its anti-inflammatory effects for the treatment of RA.	tofacitinib	0-11	Janus kinase 1	Homo sapiens	72-76
25980454-4	2015	Ruxolitinib is an oral JAK1/JAK2 inhibitor that has been evaluated in Phase II and III clinical trials in patients with PV, who are intolerant of or resistant to hydroxyurea.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	23-27
26059596-2	2015	To identify JAK inhibitors, we focused on the 1H-pyrrolo[2,3-b]pyridine derivative 3, which exhibited moderate JAK3 and JAK1 inhibitory activities.	pyrrolo(2, 3-b)pyridine	46-71	Janus kinase 1	Homo sapiens	120-124
25681059-0	2015	Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection.	GLPG0634	65-75	Janus kinase 1	Homo sapiens	100-104
25681059-1	2015	BACKGROUND AND OBJECTIVES: Filgotinib (GLPG0634) is a selective inhibitor of Janus kinase 1 (JAK1) currently in development for the treatment of rheumatoid arthritis and Crohn"s disease.	GLPG0634	27-37	Janus kinase 1	Homo sapiens	77-91
25681059-1	2015	BACKGROUND AND OBJECTIVES: Filgotinib (GLPG0634) is a selective inhibitor of Janus kinase 1 (JAK1) currently in development for the treatment of rheumatoid arthritis and Crohn"s disease.	GLPG0634	27-37	Janus kinase 1	Homo sapiens	93-97
25915176-1	2015	Ruxolitinib, a JAK1 and JAK2 inhibitor, has been tested and approved for the treatment of primary and secondary myelofibrosis.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-19
25959371-4	2015	Furthermore, this probe was applied to establish the selectivity profile of the JAK1/2 inhibitor momelotinib that is currently evaluated in clinical phase 3 studies.	N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	97-108	Janus kinase 1	Homo sapiens	80-86
26059596-3	2015	Optimization of 3 identified the tricyclic imidazo-pyrrolopyridinone derivative 19, which exhibited potent JAK3 and JAK1 inhibitory activities (IC50=1.1 nM, 1.5 nM, respectively) with favorable metabolic stability.	tricyclic imidazo-pyrrolopyridinone	33-68	Janus kinase 1	Homo sapiens	116-120
26166037-0	2015	Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells.	Homoharringtonine	0-17	Janus kinase 1	Homo sapiens	64-68
25736380-8	2015	Inhibition of FGFR signaling and to a lesser extent JAK1/2 signaling profoundly enhanced OSU-03012/sildenafil lethality.	OSU 03012	89-98	Janus kinase 1	Homo sapiens	52-56
25736380-8	2015	Inhibition of FGFR signaling and to a lesser extent JAK1/2 signaling profoundly enhanced OSU-03012/sildenafil lethality.	Sildenafil Citrate	99-109	Janus kinase 1	Homo sapiens	52-56
25818476-7	2015	Finally, we demonstrated that JAK1, JAK2, and STAT1 were indispensable for the actual enhancement of PG production in response to IFN-gamma stimulation.	Prostaglandins	101-103	Janus kinase 1	Homo sapiens	30-34
26288713-4	2015	The first of these agents to be approved was ruxolitinib, a JAK1/JAK2 inhibitor, which has been shown to improve both spleen size and symptoms in patients with MF.	ruxolitinib	45-56	Janus kinase 1	Homo sapiens	60-64
26166037-0	2015	Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells.	Gefitinib	93-102	Janus kinase 1	Homo sapiens	64-68
26167286-1	2015	BACKGROUND: Ruxolitinib, a novel inhibitor of Janus kinases 1 and 2, was recently approved for the treatment of myelofibrosis but, recently, attention has been drawn to potential side effects and especially opportunistic infections and virus reactivations.	ruxolitinib	12-23	Janus kinase 1	Homo sapiens	46-67
25931145-4	2015	We demonstrate that strong stimuli (e.g. intact Escherichia coli or LPS in addition to IL-1beta) induce IL-12p70 via a ROS/RELA/CDK9 pathway that is inhibited by simultaneous JAK1/STAT3 signalling.	ros	119-122	Janus kinase 1	Homo sapiens	175-179
25926026-3	2015	This new methodology was further applied in a highly efficient synthesis of JAK 1/2 inhibitor (R)-ruxolitinib.	3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile	94-109	Janus kinase 1	Homo sapiens	76-83
25644746-5	2015	The JAK1/JAK2 inhibitor ruxolitinib is approved for the treatment of myelofibrosis and is currently under clinical development for polycythemia vera.	ruxolitinib	24-35	Janus kinase 1	Homo sapiens	4-8
26121980-7	2015	Analysis of gene-expression with cytotoxicity identified JAK1 expression to be a significant predictor of triptolide sensitivity.	triptolide	106-116	Janus kinase 1	Homo sapiens	57-61
25315076-2	2015	In the phase 3 Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment (COMFORT) studies, ruxolitinib, a potent Janus kinase 1 (JAK1)/JAK2 inhibitor, provided substantial improvements in splenomegaly, symptoms, quality-of-life measures and overall survival compared with placebo or best available therapy.	ruxolitinib	99-110	Janus kinase 1	Homo sapiens	121-135
25315076-2	2015	In the phase 3 Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment (COMFORT) studies, ruxolitinib, a potent Janus kinase 1 (JAK1)/JAK2 inhibitor, provided substantial improvements in splenomegaly, symptoms, quality-of-life measures and overall survival compared with placebo or best available therapy.	ruxolitinib	99-110	Janus kinase 1	Homo sapiens	137-141
26131691-18	2015	While the JAK1/2 inhibitor ruxolitinib is effective, a $43,200 annual cost precludes widespread adoption.	ruxolitinib	27-38	Janus kinase 1	Homo sapiens	10-16
25398374-0	2015	The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.	tofacitinib	18-29	Janus kinase 1	Homo sapiens	50-54
26056473-2	2015	Ruxolitinib, a JAK1/JAK2 tyrosine kinase inhibitor, is now widely used for first- and second-line therapy in persons with MPN-MF, especially those with disease-related splenomegaly, intermediate- or high-risk disease, and constitutional symptoms.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-19
25824483-1	2015	Ruxolitinib (INCB018424) is the first JAK1/JAK2 inhibitor approved for treatment of myelofibrosis.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	38-42
25824483-1	2015	Ruxolitinib (INCB018424) is the first JAK1/JAK2 inhibitor approved for treatment of myelofibrosis.	ruxolitinib	13-23	Janus kinase 1	Homo sapiens	38-42
25917087-6	2015	The results indicate that, through Gi and JAK1 and 2 kinases activation, CXCL12 signaling cooperates to build the IS and to maintain adhesive contacts between APC and T cells, required for continuous TCR signaling.	is	114-116	Janus kinase 1	Homo sapiens	42-52
26316485-1	2015	Ruxolitinib, a JAK1 and JAK2 inhibitor drug, has recently been approved for the treatment of patients with high- or intermediate-risk myelofibrosis with symptomatic splenomegaly.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-19
25724932-0	2015	DRESS syndrome and reversible liver function abnormalities in patients with systemic lupus erythematosus treated with the highly selective JAK-1 inhibitor GSK2586184.	GSK2586184	155-165	Janus kinase 1	Homo sapiens	139-144
25515354-7	2015	In randomized controlled phase 3 studies, the JAK1/JAK2 inhibitor ruxolitinib provided rapid and lasting improvement in MF-related splenomegaly and symptom burden as well as a survival advantage compared with placebo or best available therapy.	ruxolitinib	66-77	Janus kinase 1	Homo sapiens	46-50
25762644-5	2015	Conversely, STAT3 silencing or JAK1-2 inhibition with ruxolitinib blocks CM-enhanced EC proliferation.	ruxolitinib	54-65	Janus kinase 1	Homo sapiens	31-35
25762644-8	2015	Thus, targeting JAK1-2 with ruxolitinib blocks a final pathway that is common to multiple pro-angiogenic factors, suppresses EC-mediated PCC proliferation, and may be useful in PDACs with a strong pro-angiogenic signature.	ruxolitinib	28-39	Janus kinase 1	Homo sapiens	16-20
25870379-3	2015	Biological advances in MPN have translated into the rapid development of novel therapeutics, culminating in the approval of the first treatment for MF, the JAK1/JAK2 inhibitor ruxolitinib.	ruxolitinib	176-187	Janus kinase 1	Homo sapiens	156-160
25511866-1	2015	Momelotinib (a JAK1 and JAK2 inhibitor) induces both anaemia and spleen responses in myelofibrosis (MF).	N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	0-11	Janus kinase 1	Homo sapiens	15-19
25616577-1	2015	In the phase III COMFORT-I study, the Janus kinase 1 (JAK1)/JAK2 inhibitor ruxolitinib provided significant improvements in splenomegaly, key symptoms, and quality-of-life measures and was associated with an overall survival benefit relative to placebo in patients with intermediate-2 or high-risk myelofibrosis.	ruxolitinib	75-86	Janus kinase 1	Homo sapiens	38-52
25616577-1	2015	In the phase III COMFORT-I study, the Janus kinase 1 (JAK1)/JAK2 inhibitor ruxolitinib provided significant improvements in splenomegaly, key symptoms, and quality-of-life measures and was associated with an overall survival benefit relative to placebo in patients with intermediate-2 or high-risk myelofibrosis.	ruxolitinib	75-86	Janus kinase 1	Homo sapiens	54-58
25441108-0	2015	A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia.	ruxolitinib	62-73	Janus kinase 1	Homo sapiens	26-51
25441108-1	2015	BACKGROUND: Ruxolitinib is a potent and specific JAK1/JAK2 inhibitor recently approved for the treatment of myelofibrosis.	ruxolitinib	12-23	Janus kinase 1	Homo sapiens	49-53
26137574-0	2015	Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib.	baricitinib	74-85	Janus kinase 1	Homo sapiens	57-63
25810010-2	2015	AZD1480, an orally active pharmacologic inhibitor of JAK1/JAK2, has been tested in several cancer models.	AZD 1480	0-7	Janus kinase 1	Homo sapiens	53-57
25638222-1	2015	Ruxolitinib is a potent Janus kinase (JAK) 1/JAK2 inhibitor that has demonstrated rapid and durable improvements in splenomegaly and symptoms and a survival benefit in 2 phase 3 trials in patients with myelofibrosis.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	24-44
26137574-4	2015	METHODS: A patient with AA was enrolled in a clinical trial to examine the efficacy of baricitinib, a JAK1/2 inhibitor, to treat concomitant CANDLE syndrome.	baricitinib	87-98	Janus kinase 1	Homo sapiens	102-108
24733674-0	2015	Cantharidin inhibits angiogenesis by suppressing VEGF-induced JAK1/STAT3, ERK and AKT signaling pathways.	Cantharidin	0-11	Janus kinase 1	Homo sapiens	62-66
25431052-1	2015	OBJECTIVES: To investigate baricitinib (LY3009104, formerly INCB028050), a novel, oral inhibitor of JAK1/JAK2 in patients with moderate to severe rheumatoid arthritis (RA) despite treatment with methotrexate.	baricitinib	27-38	Janus kinase 1	Homo sapiens	100-104
25431052-1	2015	OBJECTIVES: To investigate baricitinib (LY3009104, formerly INCB028050), a novel, oral inhibitor of JAK1/JAK2 in patients with moderate to severe rheumatoid arthritis (RA) despite treatment with methotrexate.	baricitinib	40-49	Janus kinase 1	Homo sapiens	100-104
25576658-4	2015	Moreover, resveratrol pretreatment up-regulated the phosphorylated forms of JAK1 and STAT3, as well as suppressor of cytokine signaling (SOCS)3 protein expression in LPS activated cells, demonstrating that the JAK-STAT signaling pathway is involved in the anti-inflammatory effect exerted by resveratrol.	Resveratrol	10-21	Janus kinase 1	Homo sapiens	76-80
25256963-2	2015	Ruxolitinib, a janus-activated kinase (JAK) 1/2 inhibitor, has proven to be beneficial in reduction of splenomegaly, improvement of constitutional symptoms, and possibly in overall survival.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-47
25601187-1	2015	Ruxolitinib (Jakavi( ), Jakafi( )) is an orally administered inhibitor of Janus kinases (JAK) 1 and 2 used in the management of patients with myelofibrosis.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	74-101
26356267-1	2015	BACKGROUND/AIMS: The JAK1/JAK2 tyrosine kinase inhibitor ruxolitinib is widely used for the treatment of myeloproliferative neoplasm-associated myelofibrosis and other malignancies.	ruxolitinib	57-68	Janus kinase 1	Homo sapiens	21-25
25504635-2	2015	The purpose of this study was to assess the preclinical efficacy of the JAK1/2 inhibitor AZD1480, both as a single agent and in combination with the MEK inhibitor selumetinib, against JAK-mutated patient-derived xenografts.	AZD 1480	89-96	Janus kinase 1	Homo sapiens	72-76
25629741-1	2015	BACKGROUND: Ruxolitinib, a Janus kinase (JAK) 1 and 2 inhibitor, was shown to have a clinical benefit in patients with polycythemia vera in a phase 2 study.	ruxolitinib	12-23	Janus kinase 1	Homo sapiens	27-53
25482928-3	2015	Treatment with cucurbitacin-I depleted p-STAT3, p-STAT5, p-JAK1 and p-JAK2 levels, inhibited cell proliferation, and induced G2/M accumulation, DNA endoreduplication, and multipolar mitotic spindles.	cucurbitacin I	15-29	Janus kinase 1	Homo sapiens	59-63
26315837-0	2015	Isoliquiritigenin Inhibits Interferon-gamma-Inducible Genes Expression in Hepatocytes through Down-Regulating Activation of JAK1/STAT1, IRF3/MyD88, ERK/MAPK, JNK/MAPK and PI3K/Akt Signaling Pathways.	isoliquiritigenin	0-17	Janus kinase 1	Homo sapiens	124-128
25559089-4	2015	Protein kinases are highly attractive targets for drug discovery, as evidenced by the approval of almost 30 kinase inhibitors in oncology, and the successful development of the dual JAK1/2 (Janus kinase 1/2) inhibitor ruxolitinib for inflammatory indications.	ruxolitinib	218-229	Janus kinase 1	Homo sapiens	182-188
26367195-1	2015	The first-in-class JAK1/JAK2 inhibitor ruxolitinib inhibits JAK/STAT signaling, inducing durable reductions in splenomegaly and constitutional symptoms in patients with myelofibrosis.	ruxolitinib	39-50	Janus kinase 1	Homo sapiens	19-23
26389774-3	2015	Ruxolitinib, a JAK1 and 2 inhibitor, is the only currently approved agent.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-25
25757677-1	2015	The JAK1 and JAK2 inhibitor ruxolitinib has approved indications in myelofibrosis, a BCR-AB1-negative myeloproliferative neoplasm associated with progressive bone marrow fibrosis and shortened survival.	ruxolitinib	28-39	Janus kinase 1	Homo sapiens	4-8
25453808-3	2014	Incorporation of amino group to 3-position of the cyclopentane ring resulted in a series of JAK3 inhibitors (4g-4j) that potently inhibited IFNgamma production in an IL2-induced whole blood assay and displayed high functional selectivity for JAK3-JAK1 pathway relative to JAK2.	Cyclopentanes	50-62	Janus kinase 1	Homo sapiens	247-251
25387665-5	2015	RESULTS: JTE-052 inhibited the JAK1, JAK2, JAK3, and tyrosine kinase (Tyk)2 enzymes in an adenosine triphosphate (ATP)-competitive manner and inhibited cytokine signaling evoked by IL-2, IL-6, IL-23, granulocyte/macrophage colony-stimulating factor, and IFN-alpha.	Adenosine Triphosphate	114-117	Janus kinase 1	Homo sapiens	31-35
25586607-2	2015	Targeting of the JAK-STAT pathway has been the intense focus of therapeutic development and led to the approval of the JAK1/2 inhibitor, ruxolitinib.	ruxolitinib	137-148	Janus kinase 1	Homo sapiens	119-125
25387665-5	2015	RESULTS: JTE-052 inhibited the JAK1, JAK2, JAK3, and tyrosine kinase (Tyk)2 enzymes in an adenosine triphosphate (ATP)-competitive manner and inhibited cytokine signaling evoked by IL-2, IL-6, IL-23, granulocyte/macrophage colony-stimulating factor, and IFN-alpha.	delgocitinib	9-16	Janus kinase 1	Homo sapiens	31-35
25387665-5	2015	RESULTS: JTE-052 inhibited the JAK1, JAK2, JAK3, and tyrosine kinase (Tyk)2 enzymes in an adenosine triphosphate (ATP)-competitive manner and inhibited cytokine signaling evoked by IL-2, IL-6, IL-23, granulocyte/macrophage colony-stimulating factor, and IFN-alpha.	Adenosine Triphosphate	90-112	Janus kinase 1	Homo sapiens	31-35
25453808-4	2014	Further modifications led to the discovery of an orally bioavailable (2-fluoro-2-methylcyclopentyl)amino analogue 5g which is a nanomolar inhibitor of both JAK3 and TYK2, functionally selective for the JAK3-JAK1 pathway versus JAK2, and active in a human whole blood assay.	2-fluoro-2-methylcyclopentyl	70-98	Janus kinase 1	Homo sapiens	207-211
25501025-1	2014	Ruxolitinib, a Janus kinase (JAK)-1 and JAK-2 inhibitor, is the first-in-class drug to be licensed in the United States for the treatment of high- and intermediate-risk myelofibrosis (MF).	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-35
25320076-3	2014	The lead compound, CIMO, suppresses proliferation of HCC cells and achieves this effect by reducing both constitutive and inducible phosphorylation of JAK1, JAK2, and STAT3.	cimo	19-23	Janus kinase 1	Homo sapiens	151-155
25696866-2	2014	Furthermore, the oral JAK1/JAK2 inhibitor ruxolitinib, rationally designed to target activated JAK2 signaling in MPN, has been approved by the Food and Drug Administration (FDA) of the United States for the past 3 years for the treatment of intermediate- and advanced-phase myelofibrosis.	ruxolitinib	42-53	Janus kinase 1	Homo sapiens	22-26
25520049-3	2014	Ruxolitinib, a JAK-1/2 inhibitor, is effective at controlling splenomegaly and constitutional symptoms, but has limited benefit in reversing bone marrow fibrosis or inducing complete or partial remissions.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-22
24965573-0	2014	The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers.	baricitinib	54-65	Janus kinase 1	Homo sapiens	75-82
24965573-1	2014	Baricitinib (also known as LY3009104 or INCB028050), a novel and potent small molecule inhibitor of Janus kinase family of enzymes (JAKs) with selectivity for JAK1 and JAK2, is currently in clinical development for the treatment of rheumatoid arthritis (RA) and other inflammatory disorders.	baricitinib	0-11	Janus kinase 1	Homo sapiens	132-136
24965573-1	2014	Baricitinib (also known as LY3009104 or INCB028050), a novel and potent small molecule inhibitor of Janus kinase family of enzymes (JAKs) with selectivity for JAK1 and JAK2, is currently in clinical development for the treatment of rheumatoid arthritis (RA) and other inflammatory disorders.	baricitinib	0-11	Janus kinase 1	Homo sapiens	159-163
24965573-1	2014	Baricitinib (also known as LY3009104 or INCB028050), a novel and potent small molecule inhibitor of Janus kinase family of enzymes (JAKs) with selectivity for JAK1 and JAK2, is currently in clinical development for the treatment of rheumatoid arthritis (RA) and other inflammatory disorders.	baricitinib	27-36	Janus kinase 1	Homo sapiens	132-136
24965573-1	2014	Baricitinib (also known as LY3009104 or INCB028050), a novel and potent small molecule inhibitor of Janus kinase family of enzymes (JAKs) with selectivity for JAK1 and JAK2, is currently in clinical development for the treatment of rheumatoid arthritis (RA) and other inflammatory disorders.	baricitinib	27-36	Janus kinase 1	Homo sapiens	159-163
24013646-3	2014	In this study, the function of JAKs in DCs was investigated with tofacitinib.	tofacitinib	65-76	Janus kinase 1	Homo sapiens	31-35
24013646-11	2014	CONCLUSIONS: Tofacitinib, a JAK1/JAK3 inhibitor, affected the activities of human DCs.	tofacitinib	13-24	Janus kinase 1	Homo sapiens	28-32
25043171-2	2014	Ruxolitinib, the first-in-class oral small molecule JAK1/2 inhibitor, has demonstrated clinical efficacy and shown a potential overall survival benefit in two randomized phase III clinical trials.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	52-58
25369270-0	2014	Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.	triazolopyridines	0-17	Janus kinase 1	Homo sapiens	31-35
25369270-3	2014	Having identified JAK1 as a possible new target for arthritis at Galapagos, the compound library was screened against JAK1, resulting in the identification of a triazolopyridine-based series of inhibitors represented by 3.	CP-808844	161-177	Janus kinase 1	Homo sapiens	18-22
25390891-7	2014	More specifically, the JAK1/2 inhibitor Ruxolitinib enhances the growth of viruses that are sensitive to IFN due to (i) loss of function of the viral IFN antagonist (due to mutation or species-specific constraints) or (ii) mutations/host cell constraints that slow virus spread such that it can be controlled by the IFN response.	ruxolitinib	40-51	Janus kinase 1	Homo sapiens	23-29
25131802-0	2014	Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program.	AZD 1480	41-48	Janus kinase 1	Homo sapiens	66-87
25131802-1	2014	BACKGROUND: AZD1480 is an ATP competitive inhibitor of Janus kinases 1 and 2 (JAK1, 2) that has been shown to inhibit the growth of solid tumor models.	AZD 1480	12-19	Janus kinase 1	Homo sapiens	55-76
25131802-1	2014	BACKGROUND: AZD1480 is an ATP competitive inhibitor of Janus kinases 1 and 2 (JAK1, 2) that has been shown to inhibit the growth of solid tumor models.	AZD 1480	12-19	Janus kinase 1	Homo sapiens	78-82
25131802-1	2014	BACKGROUND: AZD1480 is an ATP competitive inhibitor of Janus kinases 1 and 2 (JAK1, 2) that has been shown to inhibit the growth of solid tumor models.	Adenosine Triphosphate	26-29	Janus kinase 1	Homo sapiens	55-76
25131802-1	2014	BACKGROUND: AZD1480 is an ATP competitive inhibitor of Janus kinases 1 and 2 (JAK1, 2) that has been shown to inhibit the growth of solid tumor models.	Adenosine Triphosphate	26-29	Janus kinase 1	Homo sapiens	78-82
25217444-3	2014	The Jak inhibitor tofacitinib (CP-690,550) which is an approved drug for rheumatoid arthritis was originally introduced as a selective Jak3 inhibitor, however, it also inhibits Jak1 and Jak2.	tofacitinib	18-29	Janus kinase 1	Homo sapiens	177-181
25217444-3	2014	The Jak inhibitor tofacitinib (CP-690,550) which is an approved drug for rheumatoid arthritis was originally introduced as a selective Jak3 inhibitor, however, it also inhibits Jak1 and Jak2.	tofacitinib	31-37	Janus kinase 1	Homo sapiens	177-181
25232526-2	2014	Tofacitinib, an orally administered Janus kinase (JAK) inhibitor, decreases T-cell activation, pro-inflammatory cytokine production, and cytokine signaling by inhibiting binding of type I cytokine receptors family and gamma-chain cytokines to paired JAK1/JAK3 receptors.	tofacitinib	0-11	Janus kinase 1	Homo sapiens	250-254
25369270-3	2014	Having identified JAK1 as a possible new target for arthritis at Galapagos, the compound library was screened against JAK1, resulting in the identification of a triazolopyridine-based series of inhibitors represented by 3.	CP-808844	161-177	Janus kinase 1	Homo sapiens	118-122
25369270-4	2014	Optimization within this chemical series led to identification of GLPG0634 (65, filgotinib), a selective JAK1 inhibitor currently in phase 2B development for RA and phase 2A development for Crohn"s disease (CD).	GLPG0634	80-90	Janus kinase 1	Homo sapiens	105-109
25193869-3	2014	The in vitro treatment of splenic and peripheral blood MF CD34(+) cells with the JAK1/2/3 inhibitor, AZD1480, reduced the absolute number of CD34(+), CD34(+)CD90(+), and CD34(+)CXCR4(+) cells as well as assayable hematopoietic progenitor cells (HPCs) irrespective of the JAK2 and calreticulin mutational status.	AZD 1480	101-108	Janus kinase 1	Homo sapiens	81-89
25526003-1	2014	Ruxolitinib, a small molecule JAK-1/2 inhibitor, was approved by the U.S. Food and Drug Administration (FDA) in November 2011, as the first therapeutic for the treatment of intermediate and high-risk myelofibrosis.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	30-37
25101566-4	2014	The phosphorylation of Janus-activated kinases (JAKs) 1 and 2 and Src was also suppressed by lupeol.	lupeol	93-99	Janus kinase 1	Homo sapiens	23-61
25226283-5	2014	DCE and CS can trigger S-glutathionylation of various substrates, including the transcription factor STAT3 and JAK1/2 proteins.	dehydrocostus lactone	0-3	Janus kinase 1	Homo sapiens	111-117
25226283-5	2014	DCE and CS can trigger S-glutathionylation of various substrates, including the transcription factor STAT3 and JAK1/2 proteins.	costunolide	8-10	Janus kinase 1	Homo sapiens	111-117
25197973-7	2014	Ruxolitinib was then docked into the ligand-binding pocket of a previously solved JAK1 structure.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	82-86
25197973-8	2014	From the docking result, Ruxolitinib also binds JAK1 as a type I inhibitor, with more interactions and a higher shape complementarity with the ligand-binding pocket of JAK1 compared to that of c-Src.	ruxolitinib	25-36	Janus kinase 1	Homo sapiens	48-52
25197973-8	2014	From the docking result, Ruxolitinib also binds JAK1 as a type I inhibitor, with more interactions and a higher shape complementarity with the ligand-binding pocket of JAK1 compared to that of c-Src.	ruxolitinib	25-36	Janus kinase 1	Homo sapiens	168-172
24814730-8	2014	Similarly, the synthetic allopregnanolone analog, ganaxolone (GNX), repressed GAT-2, JAK-1 and STAT-1 expression in activated macrophage lineage cells (p<0.05).	Pregnanolone	25-41	Janus kinase 1	Homo sapiens	85-90
25129481-8	2014	Notably, three patients treated with oral ruxolitinib, an inhibitor of JAK1 and JAK2, achieved near-complete hair regrowth within 5 months of treatment, suggesting the potential clinical utility of JAK inhibition in human AA.	ruxolitinib	42-53	Janus kinase 1	Homo sapiens	71-75
24818516-7	2014	JAK inhibitors differ in isoform specificity profiles, with good efficacy achievable by selective inhibition of either JAK1 (filgotinib or INCB-039110) or JAK3 (decernotinib).	GLPG0634	125-135	Janus kinase 1	Homo sapiens	119-123
25180155-5	2014	Eventually, he was treated with ruxolitinib, an FDA-approved JAK1/2 inhibitor, which resulted in dramatic improvement of his blood counts.	ruxolitinib	32-43	Janus kinase 1	Homo sapiens	61-67
24814730-8	2014	Similarly, the synthetic allopregnanolone analog, ganaxolone (GNX), repressed GAT-2, JAK-1 and STAT-1 expression in activated macrophage lineage cells (p<0.05).	ganaxolone	50-60	Janus kinase 1	Homo sapiens	85-90
24814730-8	2014	Similarly, the synthetic allopregnanolone analog, ganaxolone (GNX), repressed GAT-2, JAK-1 and STAT-1 expression in activated macrophage lineage cells (p<0.05).	ganaxolone	62-65	Janus kinase 1	Homo sapiens	85-90
24778152-6	2014	Incubation of CLL cells with the JAK1/2 inhibitor ruxolitinib inhibited IgM-induced STAT3 phosphorylation and induced apoptosis of IgM-stimulated but not unstimulated CLL cells in a dose- and time-dependent manner.	ruxolitinib	50-61	Janus kinase 1	Homo sapiens	33-39
24867113-5	2014	Ruxolitinib, a Janus kinase (JAK) 1 and 2 inhibitor, is the first therapy to be approved by the U.S. Food and Drug Administration for intermediate- or high-risk MF.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-41
24813092-8	2014	Two of the five tumors displayed significantly altered kinase activity in the TMZ resistant xenolines and network modeling indicated PKC, JAK1, PI3K, CDK2, and VEGFR as potential mediators of this resistance.	Temozolomide	78-81	Janus kinase 1	Homo sapiens	138-142
24766055-8	2014	Resultant research in targeting the JAK/STAT pathway led to the approval of ruxolitinib, a JAK1/JAK2 inhibitor with activity in MPNs.	ruxolitinib	76-87	Janus kinase 1	Homo sapiens	91-95
24614195-9	2014	In conclusion, CTP-HBcAg(18-27)-Tapasin fusion protein could enhance not only the percentages of CTLs but also induce robust specific CTL activity and inhibits hepatitis B virus replication in vivo, which was associated with activation of the JAK/STAT signaling pathway.	Cytidine Triphosphate	15-18	Janus kinase 1	Homo sapiens	243-246
24523387-9	2014	Oxalate treatment also activated the IL-2Rbeta signaling pathway (JAK1/STAT5 phosphorylation).	Oxalates	0-7	Janus kinase 1	Homo sapiens	66-70
24764577-8	2014	Moreover, the JAK1/2 inhibitor ruxolitinib potently inhibited the anti-CD3-dependent production of IFN-gamma, a marker of the differentiation of Th cells along the tumor-inhibitory Th1 pathway.	ruxolitinib	31-42	Janus kinase 1	Homo sapiens	14-20
24583800-6	2014	The JAK1/2 inhibitor ruxolitinib and the JAK3 inhibitor tofacitinib were recently approved for the treatment of myelofibrosis and rheumatoid arthritis, respectively, and additional ATP-competitive JAK inhibitors are in clinical development.	ruxolitinib	21-32	Janus kinase 1	Homo sapiens	4-10
24458439-1	2014	The JAK1/JAK2 inhibitor ruxolitinib produced significant reductions in splenomegaly and symptomatic burden and improved survival in patients with myelofibrosis (MF), irrespective of their JAK2 mutation status, in 2 phase III studies against placebo (COMFORT-I) and best available therapy (COMFORT-II).	ruxolitinib	24-35	Janus kinase 1	Homo sapiens	4-8
24333736-6	2014	Treatment with the protein tyrosine phosphatase (PTP) inhibitor pervanadate treatment reversed the CPS-induced down-regulation of JAK1/2 and STAT3, thereby suggesting the involvement of a PTP.	pervanadate	64-75	Janus kinase 1	Homo sapiens	130-136
24398382-0	2014	Linear propargylic alcohol functionality attached to the indazole-7-carboxamide as a JAK1-specific linear probe group.	propargylic alcohol	7-26	Janus kinase 1	Homo sapiens	85-89
24386992-2	2014	In EP-2634185 Sareum claims 5-anilino-2-(2-halophenyl)-oxazole-4-carboxamide derivatives which are shown to be nanomolar potency Tyk2 inhibitors with 10 - 100-fold selectivity over JAK1, JAK2 and JAK3.	5-anilino-2-(2-halophenyl)-oxazole-4-carboxamide	28-76	Janus kinase 1	Homo sapiens	181-185
24258498-0	2014	A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.	ruxolitinib	19-30	Janus kinase 1	Homo sapiens	40-44
24258498-3	2014	Ruxolitinib, an oral JAK1/JAK2 inhibitor, is active in preclinical models of PV.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	21-25
24292520-1	2014	The Janus-activated kinase 1 (JAK1) and JAK2 inhibitor ruxolitinib is effective in decreasing symptomatic splenomegaly and myelofibrosis (MF)-related symptoms.	ruxolitinib	55-66	Janus kinase 1	Homo sapiens	4-28
24589536-2	2014	SUMMARY: Ruxolitinib, an oral tyrosine kinase inhibitor that targets the Janus-associated kinases (JAKs) 1 and 2, has been recently approved for the treatment of patients with intermediate- or high-risk myelofibrosis.	ruxolitinib	9-20	Janus kinase 1	Homo sapiens	73-112
24589536-10	2014	CONCLUSION: By directly targeting both JAK1 and JAK2 through small-molecule inhibition, ruxolitinib elicits a reduction in splenomegaly and disease-related symptoms in patients with intermediate- or high-risk myelofibrosis while maintaining an acceptable toxicity profile and a low treatment-discontinuation rate.	ruxolitinib	88-99	Janus kinase 1	Homo sapiens	39-43
24398382-0	2014	Linear propargylic alcohol functionality attached to the indazole-7-carboxamide as a JAK1-specific linear probe group.	1H-Indazole-7-carboxamide	57-79	Janus kinase 1	Homo sapiens	85-89
24398382-2	2014	In this study, through pairwise comparison and 3D alignment of the JAK isozyme structures bound to the same inhibitor molecule, we reasoned that an alkynol functionality would serve as an isozyme-specific probe group, which would enable the resulting inhibitor to differentiate the ATP-binding site of JAK1 from those of other isozymes.	alkynol	148-155	Janus kinase 1	Homo sapiens	302-306
24398382-2	2014	In this study, through pairwise comparison and 3D alignment of the JAK isozyme structures bound to the same inhibitor molecule, we reasoned that an alkynol functionality would serve as an isozyme-specific probe group, which would enable the resulting inhibitor to differentiate the ATP-binding site of JAK1 from those of other isozymes.	Adenosine Triphosphate	282-285	Janus kinase 1	Homo sapiens	302-306
24398382-3	2014	The 3-alkynolyl-5-(4"-indazolyl)indazole-7-carboxamide derivatives were thus prepared, and in vitro evaluation of their inhibitory activity against the JAK isozymes revealed that the propargyl alcohol functionality endowed the 5-(4"-indazolyl)indazole-7-carboxamide scaffold with JAK1 selectivity over other JAK isozymes, particularly JAK2.	3-alkynolyl-5-(4"-indazolyl)indazole-7-carboxamide	4-54	Janus kinase 1	Homo sapiens	280-284
24398382-3	2014	The 3-alkynolyl-5-(4"-indazolyl)indazole-7-carboxamide derivatives were thus prepared, and in vitro evaluation of their inhibitory activity against the JAK isozymes revealed that the propargyl alcohol functionality endowed the 5-(4"-indazolyl)indazole-7-carboxamide scaffold with JAK1 selectivity over other JAK isozymes, particularly JAK2.	propargyl alcohol	183-200	Janus kinase 1	Homo sapiens	280-284
24398382-3	2014	The 3-alkynolyl-5-(4"-indazolyl)indazole-7-carboxamide derivatives were thus prepared, and in vitro evaluation of their inhibitory activity against the JAK isozymes revealed that the propargyl alcohol functionality endowed the 5-(4"-indazolyl)indazole-7-carboxamide scaffold with JAK1 selectivity over other JAK isozymes, particularly JAK2.	5-(4"-indazolyl)indazole-7-carboxamide	16-54	Janus kinase 1	Homo sapiens	280-284
24501543-7	2014	The JAK1/JAK2 inhibitor ruxolitinib is effective in improving splenomegaly, MF-related symptoms, and quality-of-life measures.	ruxolitinib	24-35	Janus kinase 1	Homo sapiens	4-8
24261748-1	2014	Selective JAK1 inhibitors based on a 3-aminopyrazole-4-carboxamide scaffold.	3-Amino-1H-pyrazole-4-carboxamide	37-66	Janus kinase 1	Homo sapiens	10-14
24754420-8	2014	Ruxolitinib, an oral selective inhibitor of JAK1 and JAK2 kinases, has shown high efficacy in patients with high-risk PMF (or with myelofibrosis following polycythemia vera or essential thrombocythemia) to ameliorate disease symptoms and to reduce splenomegaly in randomized trials COMFORT-I and COMFORT-II.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	44-48
24763226-8	2014	Moreover, uPAR-mediated growth and motility is partially abolished upon treatment with the Jak1/Jak2 inhibitor INCB018424.	ruxolitinib	111-121	Janus kinase 1	Homo sapiens	91-95
23387973-8	2014	Among genes up-regulated by Y15 and temozolomide more significantly than by each agent alone were: COX7B; interferon, gamma-inducible transcript: IFI16; DDIT4; GADD45G and down-regulated: KIF3A, AKT1; ABL; JAK1, GLI3 and ALDH1A3.	Temozolomide	36-48	Janus kinase 1	Homo sapiens	206-210
24419350-2	2014	Ruxolitinib and tofacitinib are JAK1/2 inhibitors that are FDA approved for rheumatoid arthritis and myelofibrosis, respectively, but their therapeutic application for treatment of HIV infection was unexplored.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	32-36
24419350-2	2014	Ruxolitinib and tofacitinib are JAK1/2 inhibitors that are FDA approved for rheumatoid arthritis and myelofibrosis, respectively, but their therapeutic application for treatment of HIV infection was unexplored.	tofacitinib	16-27	Janus kinase 1	Homo sapiens	32-36
24583775-0	2014	4-Amino-pyrrolopyridine-5-carboxamide: a novel scaffold for JAK1-selective inhibitors.	4-amino-pyrrolopyridine-5-carboxamide	0-37	Janus kinase 1	Homo sapiens	60-64
24583775-2	2014	In this study, a novel 4-amino-1H-pyrrolo[2,3-b]pyridine-5-carboxamide scaffold was designed through structural modification of the potent JAK1-selective inhibitor, C2-methyl imidazopyrrolopyridine.	SCHEMBL12876743	23-70	Janus kinase 1	Homo sapiens	139-143
24583775-2	2014	In this study, a novel 4-amino-1H-pyrrolo[2,3-b]pyridine-5-carboxamide scaffold was designed through structural modification of the potent JAK1-selective inhibitor, C2-methyl imidazopyrrolopyridine.	c2-methyl imidazopyrrolopyridine	165-197	Janus kinase 1	Homo sapiens	139-143
24583775-3	2014	Among the series studied, the 4-(2-aminoethyl)amino-pyrrolopyridine derivative, 2j, exhibited a significant 24.7-fold JAK1/JAK2 selectivity along with reasonable inhibitory activity against JAK1 (IC50=2.2 microM).	4-(2-aminoethyl)amino-pyrrolopyridine	30-67	Janus kinase 1	Homo sapiens	118-122
24583775-3	2014	Among the series studied, the 4-(2-aminoethyl)amino-pyrrolopyridine derivative, 2j, exhibited a significant 24.7-fold JAK1/JAK2 selectivity along with reasonable inhibitory activity against JAK1 (IC50=2.2 microM).	4-(2-aminoethyl)amino-pyrrolopyridine	30-67	Janus kinase 1	Homo sapiens	190-194
25027606-6	2014	Tofacitinib, an oral inhibitor of JAK3, JAK1, and, to a lesser degree, JAK2, approved for the treatment of rheumatoid arthritis in several countries, has demonstrated positive results in psoriasis in phase II studies.	tofacitinib	0-11	Janus kinase 1	Homo sapiens	40-44
27128228-1	2014	Hepatic and renal impairment studies were conducted with ruxolitinib, a JAK1&2 inhibitor that is cleared predominantly by metabolism.	ruxolitinib	57-68	Janus kinase 1	Homo sapiens	72-82
24368888-1	2013	PURPOSE: Ruxolitinib is an oral Janus kinase (JAK) 1/JAK2 inhibitor approved in the US for the treatment of intermediate-or high-risk myelofibrosis (MF).	ruxolitinib	9-20	Janus kinase 1	Homo sapiens	32-52
24147573-1	2014	A series of pyrrolo[2,3-d]pyrimidine derivatives have previously been claimed as Janus kinase (JAK) 1 selective inhibitors.	Pyrrolo(2,3-d)pyrimidine	12-36	Janus kinase 1	Homo sapiens	81-101
24883332-4	2014	Tofacitinib, an oral or topically administered JAK1 and JAK3 inhibitor, and ruxolitinib, a topical JAK1 and JAK2 inhibitor, have been most extensively studied in psoriasis, and both improved clinical symptoms of psoriasis.	tofacitinib	0-11	Janus kinase 1	Homo sapiens	47-51
24883332-4	2014	Tofacitinib, an oral or topically administered JAK1 and JAK3 inhibitor, and ruxolitinib, a topical JAK1 and JAK2 inhibitor, have been most extensively studied in psoriasis, and both improved clinical symptoms of psoriasis.	ruxolitinib	76-87	Janus kinase 1	Homo sapiens	99-103
24195509-11	2014	The inhibition of JAK1 phosphorylation seemed sufficient to allow INCB018424-mediated apoptosis.	ruxolitinib	66-76	Janus kinase 1	Homo sapiens	18-22
24756798-1	2014	Ruxolitinib, formerly known as INCB018424 or INC424, is a potent and selective oral inhibitor of JAK1 and JAK2.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	97-101
24756798-1	2014	Ruxolitinib, formerly known as INCB018424 or INC424, is a potent and selective oral inhibitor of JAK1 and JAK2.	ruxolitinib	31-41	Janus kinase 1	Homo sapiens	97-101
24756798-1	2014	Ruxolitinib, formerly known as INCB018424 or INC424, is a potent and selective oral inhibitor of JAK1 and JAK2.	ruxolitinib	45-51	Janus kinase 1	Homo sapiens	97-101
24158701-3	2013	EXPERIMENTAL DESIGN: JAK1 and JAK2 were inhibited by AZD1480 or siRNAs, and the effect of inhibition of JAK gene family on SCLC cell viability was evaluated.	AZD 1480	53-60	Janus kinase 1	Homo sapiens	21-25
24238036-3	2013	In 2 randomized phase III studies, the Janus kinase (JAK) 1/JAK2 inhibitor ruxolitinib significantly improved splenomegaly and disease-related symptoms compared with placebo (Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment [COMFORT-I]) or best available therapy (COMFORT-II) in patients with intermediate-2 or high-risk MF.	ruxolitinib	75-86	Janus kinase 1	Homo sapiens	39-59
24174625-1	2013	Ruxolitinib is a potent Janus kinase (JAK)1/JAK2 inhibitor that has demonstrated rapid reductions in splenomegaly and marked improvement in disease-related symptoms and quality of life in patients with myelofibrosis (MF).	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	24-43
23968543-6	2013	The JAK inhibitors CP-690,550 and INCB028050 both suppressed activation of JAK-1/-2/-3 and downstream STAT-1/-3/-5, as well as the expression levels of target proinflammatory genes (MCP-I, SAA1/2) in oncostatin-M (OSM)-stimulated rheumatoid synovial fibroblasts.	tofacitinib	19-25	Janus kinase 1	Homo sapiens	75-80
23968543-6	2013	The JAK inhibitors CP-690,550 and INCB028050 both suppressed activation of JAK-1/-2/-3 and downstream STAT-1/-3/-5, as well as the expression levels of target proinflammatory genes (MCP-I, SAA1/2) in oncostatin-M (OSM)-stimulated rheumatoid synovial fibroblasts.	baricitinib	34-44	Janus kinase 1	Homo sapiens	75-80
24501689-9	2013	In stark contrast, we showed that ruxolitinib, a JAK1/JAK2-selective tyrosine kinase inhibitor used to treat patients with myelofibrosis, dramatically impaired JAK1-STAT signaling downstream of all IHCA-associated gp130 mutants.	ruxolitinib	34-45	Janus kinase 1	Homo sapiens	49-53
24056820-0	2013	Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib.	ruxolitinib	93-104	Janus kinase 1	Homo sapiens	58-62
24056820-1	2013	UNLABELLED: Ruxolitinib, a JAK1/JAK2 inhibitor, is currently the only pharmacological agent approved for the treatment of myelofibrosis.	ruxolitinib	12-23	Janus kinase 1	Homo sapiens	27-31
24326545-10	2013	In parallel, clinical trials have been initiated involving the Jak2/3 (Janus kinase-2/3) inhibitor tofacitinib and Jak1/2 inhibitor ruxolitinib to block IL-15 signaling.	ruxolitinib	132-143	Janus kinase 1	Homo sapiens	115-121
24501689-9	2013	In stark contrast, we showed that ruxolitinib, a JAK1/JAK2-selective tyrosine kinase inhibitor used to treat patients with myelofibrosis, dramatically impaired JAK1-STAT signaling downstream of all IHCA-associated gp130 mutants.	ruxolitinib	34-45	Janus kinase 1	Homo sapiens	160-164
24042009-0	2013	Design and evaluation of novel 8-oxo-pyridopyrimidine Jak1/2 inhibitors.	8-oxo-pyridopyrimidine	31-53	Janus kinase 1	Homo sapiens	54-58
24021352-6	2013	Its 3-O-Me product, i.e. 8-hydroxy-5-isopropyl-3-methoxy-7-methylbenzo[cd]indol-2(1H)-one, named 3-O-methylthespesilactam, of which the structure was identified by NMR investigations and single-crystal X-ray diffraction analysis, was discovered as a new type of small-molecule anticancer pan-JAK inhibitor against A2058 human melanoma cells, and selective and potent inhibitor of JAK1 and TYK2.	3-o-me	4-10	Janus kinase 1	Homo sapiens	380-384
24021352-6	2013	Its 3-O-Me product, i.e. 8-hydroxy-5-isopropyl-3-methoxy-7-methylbenzo[cd]indol-2(1H)-one, named 3-O-methylthespesilactam, of which the structure was identified by NMR investigations and single-crystal X-ray diffraction analysis, was discovered as a new type of small-molecule anticancer pan-JAK inhibitor against A2058 human melanoma cells, and selective and potent inhibitor of JAK1 and TYK2.	8-hydroxy-5-isopropyl-3-methoxy-7-methylbenzo[cd]indol-2(	25-82	Janus kinase 1	Homo sapiens	380-384
24021352-6	2013	Its 3-O-Me product, i.e. 8-hydroxy-5-isopropyl-3-methoxy-7-methylbenzo[cd]indol-2(1H)-one, named 3-O-methylthespesilactam, of which the structure was identified by NMR investigations and single-crystal X-ray diffraction analysis, was discovered as a new type of small-molecule anticancer pan-JAK inhibitor against A2058 human melanoma cells, and selective and potent inhibitor of JAK1 and TYK2.	1h)-one	82-89	Janus kinase 1	Homo sapiens	380-384
24021352-6	2013	Its 3-O-Me product, i.e. 8-hydroxy-5-isopropyl-3-methoxy-7-methylbenzo[cd]indol-2(1H)-one, named 3-O-methylthespesilactam, of which the structure was identified by NMR investigations and single-crystal X-ray diffraction analysis, was discovered as a new type of small-molecule anticancer pan-JAK inhibitor against A2058 human melanoma cells, and selective and potent inhibitor of JAK1 and TYK2.	3-o-methylthespesilactam	97-121	Janus kinase 1	Homo sapiens	380-384
24042009-1	2013	A highly ligand efficient, novel 8-oxo-pyridopyrimidine containing inhibitor of Jak1 and Jak2 isoforms with a pyridone moiety as the hinge-binding motif was discovered.	8-oxo-pyridopyrimidine	33-55	Janus kinase 1	Homo sapiens	80-84
24042009-1	2013	A highly ligand efficient, novel 8-oxo-pyridopyrimidine containing inhibitor of Jak1 and Jak2 isoforms with a pyridone moiety as the hinge-binding motif was discovered.	Pyridones	110-118	Janus kinase 1	Homo sapiens	80-84
23627915-3	2013	Tofacitinib is an oral janus kinase (JAK) inhibitor that inhibits JAK family kinase members, in particular JAK1 and JAK3, achieving a broad limitation of inflammation by interfering with several cytokine receptors.	tofacitinib	0-11	Janus kinase 1	Homo sapiens	107-111
24030211-2	2013	Here, we evaluated VSV oncolysis of a panel of human head and neck cancer cells and showed that VSV resistance in SCC25 and SCC15 cells could be reversed with Janus kinase (JAK) 1/2 inhibitors (JAK inhibitor I and ruxolitinib).	ruxolitinib	214-225	Janus kinase 1	Homo sapiens	159-179
24082147-3	2013	SOCS3, the major negative regulator of STAT3, is induced by tyrosine-phosphorylated STAT3 and terminates STAT3 phosphorylation about 2 h after initial exposure of cells to members of the IL-6 family of cytokines by binding cooperatively to the common receptor subunit gp130 and JAKs 1 and 2.	Tyrosine	60-68	Janus kinase 1	Homo sapiens	244-290
24283870-1	2013	Ruxolitinib, an oral JAK1 and JAK2 inhibitor, is approved in the US for patients with intermediate or high-risk myelofibrosis (MF), a chronic neoplasm associated with aberrant myeloproliferation, progressive bone marrow fibrosis, splenomegaly, and burdensome symptoms.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	21-25
23891156-4	2013	Reduced phosphorylation of STAT proteins and lower expression levels of the cellular janus kinases Jak1 and Tyk2 were observed in these cell populations, which may account for the impaired JAK-STAT signaling and reduced antiviral responses to rIFNlambda.	rifnlambda	243-253	Janus kinase 1	Homo sapiens	99-103
24083419-3	2013	Ruxolitinib (INC424, INCB18424, Jakafi, Jakavi), a JAK1 and JAK2 inhibitor, was approved in November 2011 by the US FDA for the treatment of intermediate- or high-risk MF, and more recently in Europe and Canada for the treatment of MF-related splenomegaly or symptoms.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	51-55
24290217-7	2013	Of much interest, a combination of everolimus and the JAK1/2 inhibitor, ruxolitinib, showed strong synergism in inducing cell cycle arrest and blockade of cell proliferation.	ruxolitinib	72-83	Janus kinase 1	Homo sapiens	54-60
23639230-5	2013	Also, PTX inhibited phosphorylation of the upstream kinases JAK1 and JAK2 and increased the expression of pSHP2 phosphatase.	Pentoxifylline	6-9	Janus kinase 1	Homo sapiens	60-64
23791841-2	2013	Chromosomal sequencing revealed a new Jak1 (p.Ser645Pro) point mutation at the conserved serine of the pseudokinase domain, corresponding to a somatic human mutation (p.Ser646Phe) inducing a constitutive activation of the Janus kinase (JAK)/STAT pathway.	Serine	89-95	Janus kinase 1	Homo sapiens	38-42
23454584-3	2013	cAMP-increasing agents rapidly inhibited activation of JAK1 and its substrate STAT3.	Cyclic AMP	0-4	Janus kinase 1	Homo sapiens	55-59
23672349-2	2013	Here, we report post-hoc analyses of the impact of ruxolitinib, a potent and selective JAK1 and JAK2 inhibitor, on disease-related symptoms and HRQoL in MF patients from the large phase 3 COMFORT-II study (N = 219).	ruxolitinib	51-62	Janus kinase 1	Homo sapiens	87-91
22748021-0	2013	Progesterone activates Janus Kinase 1/2 and activators of transcription 1 (JAK1-2/STAT1) pathway in human spermatozoa.	Progesterone	0-12	Janus kinase 1	Homo sapiens	75-81
22748021-6	2013	Progesterone (5 mum) leads to phosphorylation of JAK1, JAK2 and STAT1 in a time-dependent manner.	Progesterone	0-12	Janus kinase 1	Homo sapiens	49-53
22748021-8	2013	We conclude that in human spermatozoa, the JAK1/2 pathway is activated upon capacitation and is further modulated by progesterone; the biological processes controlled by this pathway in sperm need to be elucidated.	Progesterone	117-129	Janus kinase 1	Homo sapiens	43-49
23570265-4	2013	Tofacitinib is a novel synthetic DMARD that selectively inhibits Janus kinases (JAKs), particularly JAK1 and JAK3.	tofacitinib	0-11	Janus kinase 1	Homo sapiens	80-84
23570265-4	2013	Tofacitinib is a novel synthetic DMARD that selectively inhibits Janus kinases (JAKs), particularly JAK1 and JAK3.	tofacitinib	0-11	Janus kinase 1	Homo sapiens	100-104
23670175-2	2013	Of these, the JAK1/2 inhibitor, ruxolitinib (INCB018424, Incyte Corporation) was recently approved for the treatment of patients with myelofibrosis (MF).	ruxolitinib	32-43	Janus kinase 1	Homo sapiens	14-20
23459451-2	2013	We conducted a Phase 1/2 trial of CYT387, a potent JAK1/2 inhibitor, in patients with high- or intermediate-risk primary or post-polycythemia vera/essential thrombocythemia MF.	N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	34-40	Janus kinase 1	Homo sapiens	51-57
22717332-4	2013	IFN-alpha potently induced nitric oxide synthase (iNOS) and nitric oxide (NO) release and down-regulated haem oxygenase-1 (HO-1) expression, which could be dampened by Janus kinase 1 (JAK1) and c-Jun NH2-terminal kinase (JNK) inhibition, respectively.	nitric	27-33	Janus kinase 1	Homo sapiens	168-182
23656643-7	2013	A patient with CNL carrying a JAK-activating CSF3R mutation had marked clinical improvement after the administration of the JAK1/2 inhibitor ruxolitinib.	ruxolitinib	141-152	Janus kinase 1	Homo sapiens	124-130
23406773-4	2013	Ruxolitinib is an oral JAK1 and JAK2 inhibitor that has recently been approved for the treatment of myelofibrosis and has been tested against other hematologic malignancies.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	23-27
23367873-2	2013	Progression in the field has taken a recent step forward with the approval of ruxolitinib (Jakafi), a selective inhibitor of JAK1/2 and very recently tofacitinib (Xeljanz), a pan-JAK inhibitor.	ruxolitinib	78-89	Janus kinase 1	Homo sapiens	125-131
23367873-12	2013	EXPERT OPINION: JAK inhibitor therapy is entering a significant new era with the advent on the market of the JAK1/2 inhibitor ruxolitinib and the pan-JAK inhibitor tofacitinib, with unprecedented speed of development.	ruxolitinib	126-137	Janus kinase 1	Homo sapiens	109-115
22875628-2	2013	Here we assess the JAK1/2 inhibitor ruxolitinib as therapy for patients with JAK2-rearrangement associated myeloproliferative neoplasms (MPN).	ruxolitinib	36-47	Janus kinase 1	Homo sapiens	19-25
22717332-4	2013	IFN-alpha potently induced nitric oxide synthase (iNOS) and nitric oxide (NO) release and down-regulated haem oxygenase-1 (HO-1) expression, which could be dampened by Janus kinase 1 (JAK1) and c-Jun NH2-terminal kinase (JNK) inhibition, respectively.	nitric	27-33	Janus kinase 1	Homo sapiens	184-188
24252238-7	2013	Ruxolitinib (Jakafi), a non-selective inhibitor of JAK1 & 2, has been approved by FDA for patients with intermediate to high risk primary or secondary myelofibrosis.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	51-55
23515130-5	2013	Tofacitinib is one of the first JAK inhibitors tested and mainly interacts with JAK1 and JAK3.	tofacitinib	0-11	Janus kinase 1	Homo sapiens	80-84
24252238-7	2013	Ruxolitinib (Jakafi), a non-selective inhibitor of JAK1 & 2, has been approved by FDA for patients with intermediate to high risk primary or secondary myelofibrosis.	Adenosine Monophosphate	57-60	Janus kinase 1	Homo sapiens	51-55
23847256-1	2013	BACKGROUND: AZD1480 is a novel agent that inhibits Janus-associated kinases 1 and 2 (JAK1 and JAK2).	AZD 1480	12-19	Janus kinase 1	Homo sapiens	85-89
24319228-5	2013	The JAK1/JAK2 inhibitor ruxolitinib is approved for treatment of MF in North America and Europe and other lead JAK inhibitors discussed herein (fedratinib [SAR302503], momelotinib [CYT387], and pacritinib [SB1518]), have entered advanced phases of trial investigation.	ruxolitinib	24-35	Janus kinase 1	Homo sapiens	4-8
23236554-4	2013	We show that the tyrosine phosphorylation of PKR induced by either bacterial RNA or poly I:C is impaired in mutant cells lacking TYK2, JAK1, or JAK2 kinases.	Tyrosine	17-25	Janus kinase 1	Homo sapiens	135-139
23214979-2	2013	We optimized a new inhibitor scaffold, 3-amido-5-cyclopropylpyrrolopyrazines, to a potent example with reasonable kinome selectivity, including selectivity for JAK3 versus JAK1, and good biopharmaceutical properties.	3-amido-5-cyclopropylpyrrolopyrazines	39-76	Janus kinase 1	Homo sapiens	172-176
23124025-10	2013	As evidence of differential regulation of gene function by IL-4 and IL-13, we further report that MAO-A-mediated reactive oxygen species generation is influenced by different Jaks.	Reactive Oxygen Species	113-136	Janus kinase 1	Homo sapiens	175-179
23307549-10	2013	Ruxolitinib is a small-molecule inhibitor of JAK1 and JAK2 and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	45-49
23061804-1	2012	Ruxolitinib is a selective inhibitor of Janus kinases (JAK) 1 and 2, which are involved in the signalling pathway of various cytokines and growth factors essential to haematopoiesis.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	40-67
23107482-0	2012	Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2.	imidazo-pyrrolopyridine	45-68	Janus kinase 1	Homo sapiens	69-73
23107482-1	2012	Herein we describe our successful efforts in obtaining C-2 substituted imidazo-pyrrolopyridines with improved JAK1 selectivity relative to JAK2 by targeting an amino acid residue that differs between the two isoforms (JAK1: E966; JAK2: D939).	imidazo-pyrrolopyridines	71-95	Janus kinase 1	Homo sapiens	110-114
23107482-1	2012	Herein we describe our successful efforts in obtaining C-2 substituted imidazo-pyrrolopyridines with improved JAK1 selectivity relative to JAK2 by targeting an amino acid residue that differs between the two isoforms (JAK1: E966; JAK2: D939).	imidazo-pyrrolopyridines	71-95	Janus kinase 1	Homo sapiens	218-222
22939972-0	2012	Depletion of cellular glutathione modulates LIF-induced JAK1-STAT3 signaling in cardiac myocytes.	Glutathione	22-33	Janus kinase 1	Homo sapiens	56-60
22939972-3	2012	Therefore, the present study was undertaken to directly test the hypothesis that JAK1 signaling by the IL-6-type cytokines in cardiac myocytes is impaired by glutathione (GSH) depletion, since this tripeptide is one of the major anti-oxidant molecules and redox-buffers in cells.	Glutathione	158-169	Janus kinase 1	Homo sapiens	81-85
22939972-3	2012	Therefore, the present study was undertaken to directly test the hypothesis that JAK1 signaling by the IL-6-type cytokines in cardiac myocytes is impaired by glutathione (GSH) depletion, since this tripeptide is one of the major anti-oxidant molecules and redox-buffers in cells.	Glutathione	171-174	Janus kinase 1	Homo sapiens	81-85
23372833-6	2013	In addition, resveratrol suppressed constitutively active STAT3 in all the cell lines and inhibited JAK2 phosphorylation but had no effect on other upstream mediators of STAT3 activation, such as PTEN, TYK2, and JAK1.	Resveratrol	13-24	Janus kinase 1	Homo sapiens	212-216
23391678-0	2013	Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	21-35
23391678-5	2013	In November 2011, ruxolitinib, an inhibitor of JAK1 and JAK2, was approved by the US Food and Drug Administration for the treatment of intermediate- or high-risk MF, including primary MF, post-PV MF, and post-ET MF.	ruxolitinib	18-29	Janus kinase 1	Homo sapiens	47-51
23186315-3	2012	AREAS COVERED: This review describes the pathogenesis, clinical features and current treatment of MF, clinical data for ruxolitinib, a potent oral JAK1/JAK2 inhibitor and the only therapy approved for the treatment of MF, and agents in development for the treatment of MF.	ruxolitinib	120-131	Janus kinase 1	Homo sapiens	147-151
22939972-3	2012	Therefore, the present study was undertaken to directly test the hypothesis that JAK1 signaling by the IL-6-type cytokines in cardiac myocytes is impaired by glutathione (GSH) depletion, since this tripeptide is one of the major anti-oxidant molecules and redox-buffers in cells.	tripeptide K-26	198-208	Janus kinase 1	Homo sapiens	81-85
22939972-7	2012	Addition of glutathione monoethyl ester, which is cleaved intracellularly to GSH, prevented attenuation of LIF-induced JAK1 and STAT3 activation, as did the reductant N-acetyl-cysteine.	S-ethyl glutathione	12-39	Janus kinase 1	Homo sapiens	119-123
22939972-7	2012	Addition of glutathione monoethyl ester, which is cleaved intracellularly to GSH, prevented attenuation of LIF-induced JAK1 and STAT3 activation, as did the reductant N-acetyl-cysteine.	Glutathione	77-80	Janus kinase 1	Homo sapiens	119-123
22972985-8	2012	Finally, pharmacologic inhibition of IFNgammaR signaling with inhibitors of JAK1/JAK2, which are mediators of IFNgammaR signaling, results in the decreased expression of CXCR3 and reduced GVHD and improved survival after allo-HSCT and this effect is mediated by altered trafficking of Tconv to GVHD target organs.	tconv	285-290	Janus kinase 1	Homo sapiens	76-80
22172707-5	2012	Following treatment with 5-FU, JAK1 and STAT5 immunoreactivities were decreased in MCF-7 cells in comparison with both gemcitabine-treated and non-treated groups.	Fluorouracil	25-29	Janus kinase 1	Homo sapiens	31-35
22763125-6	2012	We also found that PTP-MEG2 DA mutant preferentially associated with Janus kinase 1 (JAK1) but not with other JAK kinases (Tyk2 and JAK2) present in ECs and regulated JAK1 tyrosine phosphorylation.	Tyrosine	172-180	Janus kinase 1	Homo sapiens	69-83
23042420-13	2012	Ruxolitinib is the first JAK1/2 inhibitor approved by the Food and Drug Administration (FDA) for the treatment of patients with intermediate- or high-risk MF.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	25-31
23055361-3	2012	Most data are available on the JAK inhibitors, the so called "ATP mimetics" for the treatment of MF.	Adenosine Triphosphate	62-65	Janus kinase 1	Homo sapiens	31-34
23055361-4	2012	Recent data from two large phase-III studies showed that the JAK1 /2 inhibitor Ruxolitinib is very effective in the reduction of spleen size and the improvement of quality of life in MF patients.	ruxolitinib	79-90	Janus kinase 1	Homo sapiens	61-65
22971156-6	2012	EXPERT OPINION: The recent disclosure of the clinical efficacy of a selective JAK1 inhibitor (GLPG-0634) in rheumatoid arthritis and detailed disclosure of the some potent and highly selective JAK1 inhibitors provide a clear stimulus for further activity in this area.	GLPG0634	94-103	Janus kinase 1	Homo sapiens	78-82
22971156-6	2012	EXPERT OPINION: The recent disclosure of the clinical efficacy of a selective JAK1 inhibitor (GLPG-0634) in rheumatoid arthritis and detailed disclosure of the some potent and highly selective JAK1 inhibitors provide a clear stimulus for further activity in this area.	GLPG0634	94-103	Janus kinase 1	Homo sapiens	193-197
22763125-6	2012	We also found that PTP-MEG2 DA mutant preferentially associated with Janus kinase 1 (JAK1) but not with other JAK kinases (Tyk2 and JAK2) present in ECs and regulated JAK1 tyrosine phosphorylation.	Tyrosine	172-180	Janus kinase 1	Homo sapiens	167-171
23051187-0	2012	Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	21-25
23051187-3	2012	Ruxolitinib is the first JAK1 and JAK2 inhibitor to be approved by the US Food and Drug Administration.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	25-29
23051187-7	2012	The JAK1 and JAK2 inhibitor ruxolitinib has shown promising results in pre-clinical and clinical trials.	ruxolitinib	28-39	Janus kinase 1	Homo sapiens	4-8
22961117-6	2012	Inhibition of the signal transducer and activator of transcription 3 tyrosine phosphorylation was found to be achieved through suppression of JAK1 and JAK2.	Tyrosine	69-77	Janus kinase 1	Homo sapiens	142-146
23170143-3	2012	Recent studies have shown that cerulein-activated nicotinamide adenine dinucleotide phosphate oxidase elicits reactive oxygen species, which trigger the phosphorylation of the JAK1, STAT1, and STAT3 proteins and induce the production of inflammatory cytokines, such as tumor necrosis factor-alpha, interleukin (IL)-1beta, and IL-6, in pancreatic acinar cells.	Reactive Oxygen Species	110-133	Janus kinase 1	Homo sapiens	176-180
22281165-2	2012	INCB018424, a small molecule inhibitor of JAK1 and JAK2, inhibits cytokine-induced JAK/signal transducers and activators of transcription signaling and the resultant production of inflammatory proteins (eg, IL-17).	ruxolitinib	0-10	Janus kinase 1	Homo sapiens	42-46
22891040-4	2012	Afatinib activated interleukin-6 receptor (IL-6R)/JAK1/STAT3 signaling via autocrine IL-6 secretion in both cells.	Afatinib	0-8	Janus kinase 1	Homo sapiens	50-54
22891040-5	2012	Inhibition of IL-6R/JAK1/STAT3 signaling pathway increased the sensitivity to afatinib.	Afatinib	78-86	Janus kinase 1	Homo sapiens	20-24
22891040-7	2012	Blockade of IL-6R/JAK1 significantly increased the sensitivity to afatinib through inhibition of afatinib-induced STAT3 activation augmented by the interaction with fibroblasts, suggesting a critical role of paracrine IL-6R/JAK1/STAT3 loop between fibroblasts and cancer cells in the development of drug resistance.	Afatinib	66-74	Janus kinase 1	Homo sapiens	18-22
22891040-7	2012	Blockade of IL-6R/JAK1 significantly increased the sensitivity to afatinib through inhibition of afatinib-induced STAT3 activation augmented by the interaction with fibroblasts, suggesting a critical role of paracrine IL-6R/JAK1/STAT3 loop between fibroblasts and cancer cells in the development of drug resistance.	Afatinib	66-74	Janus kinase 1	Homo sapiens	224-228
22891040-7	2012	Blockade of IL-6R/JAK1 significantly increased the sensitivity to afatinib through inhibition of afatinib-induced STAT3 activation augmented by the interaction with fibroblasts, suggesting a critical role of paracrine IL-6R/JAK1/STAT3 loop between fibroblasts and cancer cells in the development of drug resistance.	Afatinib	97-105	Janus kinase 1	Homo sapiens	18-22
22891040-7	2012	Blockade of IL-6R/JAK1 significantly increased the sensitivity to afatinib through inhibition of afatinib-induced STAT3 activation augmented by the interaction with fibroblasts, suggesting a critical role of paracrine IL-6R/JAK1/STAT3 loop between fibroblasts and cancer cells in the development of drug resistance.	Afatinib	97-105	Janus kinase 1	Homo sapiens	224-228
22891040-8	2012	The enhancement of afatinib sensitivity by inhibition of IL-6R/JAK1/STAT3 signaling was confirmed in in vivo PC9-GR xenograft model.	Afatinib	19-27	Janus kinase 1	Homo sapiens	63-67
22891040-9	2012	Similar to afatinib, de novo resistance to dacomitinib in H1975 and PC9-GR cells was also mediated by dacomitinib-induced JAK1/STAT3 activation.	dacomitinib	43-54	Janus kinase 1	Homo sapiens	122-126
22891040-9	2012	Similar to afatinib, de novo resistance to dacomitinib in H1975 and PC9-GR cells was also mediated by dacomitinib-induced JAK1/STAT3 activation.	dacomitinib	102-113	Janus kinase 1	Homo sapiens	122-126
22261016-3	2012	The new small drug molecule and JAK1/3 inhibitor, tofacitinib, is currently being tested in phase II and III clinical trials for rheumatoid arthritis, psoriasis and in organ transplantation.	tofacitinib	50-61	Janus kinase 1	Homo sapiens	32-38
22763125-6	2012	We also found that PTP-MEG2 DA mutant preferentially associated with Janus kinase 1 (JAK1) but not with other JAK kinases (Tyk2 and JAK2) present in ECs and regulated JAK1 tyrosine phosphorylation.	Tyrosine	172-180	Janus kinase 1	Homo sapiens	85-89
22698084-1	2012	Herein we report the discovery of the C-2 methyl substituted imidazopyrrolopyridine series and its optimization to provide potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.	imidazopyrrolopyridine	61-83	Janus kinase 1	Homo sapiens	154-158
22812580-0	2012	Evaluation of WO2012037132 - a novel scaffold for selective JAK1 inhibition.	wo2012037132	14-26	Janus kinase 1	Homo sapiens	60-64
22812580-1	2012	Novel 1-anilino-4-phenylphthalazine derivatives, compositions containing them, and their use as JAK1 inhibitors and for the treatment of cancer, inflammatory and autoimmune diseases are claimed.	1-anilino-4-phenylphthalazine	6-35	Janus kinase 1	Homo sapiens	96-100
22718840-0	2012	Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.	ruxolitinib	84-95	Janus kinase 1	Homo sapiens	64-68
22718840-1	2012	Ruxolitinib is JAK1/JAK2 inhibitor with established clinical benefit in myelofibrosis (MF).	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-19
22852872-6	2012	In November 2011, the US Food and Drug Administration approved the use of the JAK1- and JAK2-selective inhibitor ruxolitinib for the treatment of patients with intermediate or high-risk myelofibrosis, including PMF, post-PV MF, and post-ET MF.	ruxolitinib	113-124	Janus kinase 1	Homo sapiens	78-82
22700718-1	2012	The discovery of JAK2617F mutation paved the way for the development of small molecule inhibitors of JAK1/2 resulting in first approved JAK1/2 inhibitor, ruxolitinib, for the treatment of patients with myelofibrosis (MF).	ruxolitinib	154-165	Janus kinase 1	Homo sapiens	101-107
22700718-1	2012	The discovery of JAK2617F mutation paved the way for the development of small molecule inhibitors of JAK1/2 resulting in first approved JAK1/2 inhibitor, ruxolitinib, for the treatment of patients with myelofibrosis (MF).	ruxolitinib	154-165	Janus kinase 1	Homo sapiens	136-142
22894574-2	2012	One additional treatment may be tofacitinib (CP-690,550), an oral inhibitor of Janus kinases 1, 2, and 3 with in vitro functional specificity for kinases 1 and 3 over kinase 2, which is expected to block signaling involving gamma chain-containing cytokines including interleukins 2, 4, 7, 9, 15, and 21.	tofacitinib	32-43	Janus kinase 1	Homo sapiens	79-104
22894574-2	2012	One additional treatment may be tofacitinib (CP-690,550), an oral inhibitor of Janus kinases 1, 2, and 3 with in vitro functional specificity for kinases 1 and 3 over kinase 2, which is expected to block signaling involving gamma chain-containing cytokines including interleukins 2, 4, 7, 9, 15, and 21.	tofacitinib	45-51	Janus kinase 1	Homo sapiens	79-104
23238141-2	2012	Ruxolitinib (INCB018424, Jakafi) is a potent dual JAK1 and JAK2 inhibitor.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	50-54
23238141-2	2012	Ruxolitinib (INCB018424, Jakafi) is a potent dual JAK1 and JAK2 inhibitor.	ruxolitinib	13-23	Janus kinase 1	Homo sapiens	50-54
22555804-4	2012	Inhibitor 2 (E)-2-cyano-N-[(S)-1-phenylethyl]-3-(pyridin-2-yl)acrylamide was the most effective in inhibition of JAK/STAT3 signaling and at doses >= 25 muM significantly reduced the level of phosphorylated JAK1, JAK2 and STAT3 (at Tyr705) and downregulated the expression of known STAT3 targets.	(e)-2-cyano-n-[(s)-1-phenylethyl]-3-(pyridin-2-yl)acrylamide	12-72	Janus kinase 1	Homo sapiens	209-213
22544377-1	2012	On November 16, 2011, the U.S. Food and Drug Administration (FDA) granted full approval to ruxolitinib, (Jakafi; Incyte Corp.), an inhibitor of the Janus kinases 1 and 2, for the treatment of patients with intermediate- or high-risk myelofibrosis, including primary myelofibrosis, postpolycythemia vera myelofibrosis, and postessential thrombocythemia myelofibrosis.	ruxolitinib	91-102	Janus kinase 1	Homo sapiens	148-169
22474318-6	2012	Ruxolitinib (Jakafi; Incyte) is a small-molecule inhibitor of JAK1/2 that has proved to be effective at reducing splenomegaly and ameliorating symptoms in myeloproliferative neoplasms.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	62-68
22402124-5	2012	IL-2 challenge enhanced tyrosine phosphorylation of Janus-activated kinase (JAK)1-3 and STAT5, and induced JAK1 and JAK2 to associate with STAT5 in IL-2-dependent ATL cells.	Tyrosine	24-32	Janus kinase 1	Homo sapiens	76-83
22528658-3	2012	IL-5 binding to IL-5R on target cells induces rapid tyrosine phosphorylation and activation of various cellular proteins, including JAK1/JAK2 and STAT1/STAT5.	Tyrosine	52-60	Janus kinase 1	Homo sapiens	132-136
22394507-6	2012	Exposure to quercetin resulted in the reduction of GP130, JAK1 and STAT3 activation by IL-6, as well as a marked decrease of the proliferative and migratory properties of glioblastoma cells induced by IL-6.	Quercetin	12-21	Janus kinase 1	Homo sapiens	58-62
22406175-0	2012	STAT6 and JAK1 are essential for IL-4-mediated suppression of prostaglandin production in human follicular dendritic cells: opposing roles of phosphorylated and unphosphorylated STAT6.	Prostaglandins	62-75	Janus kinase 1	Homo sapiens	10-14
22406175-7	2012	IL-4 induced tyrosine phosphorylation of STAT1, 3, and 6, but only JAK1-STAT6 pathway was responsible for the prevention of COX-2 augmentation and PG production.	Prostaglandins	147-149	Janus kinase 1	Homo sapiens	67-71
22279053-1	2012	On November 16, 2011, the Food and Drug Administration approved ruxolitinib (a JAK1 and JAK2 inhibitor) for use in the treatment of high and intermediate risk myelofibrosis.	ruxolitinib	64-75	Janus kinase 1	Homo sapiens	79-83
22375970-2	2012	We evaluated the efficacy and safety of ruxolitinib, a potent and selective Janus kinase (JAK) 1 and 2 inhibitor, as compared with the best available therapy, in patients with myelofibrosis.	ruxolitinib	40-51	Janus kinase 1	Homo sapiens	76-102
22375971-1	2012	BACKGROUND: Ruxolitinib, a selective inhibitor of Janus kinase (JAK) 1 and 2, has clinically significant activity in myelofibrosis.	ruxolitinib	12-23	Janus kinase 1	Homo sapiens	50-76
22038826-6	2012	Acutely, curcumin inhibited Stat1 binding to the GAS cis-element, prevented Stat1 nuclear translocation, and reduced Jak1 phosphorylation and phosphorylation of Stat1 at Tyr(701).	Curcumin	9-17	Janus kinase 1	Homo sapiens	117-121
22252297-9	2012	In HEK293T cells, CP-690,550 less effectively suppressed JAK1-mediated STAT3 phosphorylation compared with JAK3.	tofacitinib	18-24	Janus kinase 1	Homo sapiens	57-61
22252297-10	2012	These results suggest that CP-690,550 has a different effects among JAKs and STATs, thereby affecting helper T cell differentiation, and murine autoimmune disease models.	tofacitinib	27-33	Janus kinase 1	Homo sapiens	68-72
22333600-9	2012	Furthermore, lentiviral-mediated JAK1-overexpressing cells were more sensitive to enzastaurin than control cells.	enzastaurin	82-93	Janus kinase 1	Homo sapiens	33-37
22333600-10	2012	CONCLUSION: Our results suggested that the JAK1 pathway may be used as a single predictive biomarker for enzastaurin treatment.	enzastaurin	105-116	Janus kinase 1	Homo sapiens	43-47
23119228-7	2012	Discovery of the JAK2V617F mutation paved the way for drug discovery in MF, and the first JAK1/2 inhibitor, ruxolitinib, has been approved by FDA and Health Canada.	ruxolitinib	108-119	Janus kinase 1	Homo sapiens	90-96
23055694-7	2012	Tofacitinib, a JAK1/3 inhibitor, was shown to be efficacious in two Phase III trials, while VX-509, a JAK3 inhibitor, showed promising results in a Phase II trial.	tofacitinib	0-11	Janus kinase 1	Homo sapiens	15-21
22830345-4	2012	Ruxolitinib (previously known as INCB018424; Incyte Corporation, Wilmington, Delaware, USA) is a rationally designed potent oral JAK1 and JAK2 inhibitor that has undergone clinical trials in patients with PV, ET, and PMF.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	129-133
22905257-1	2012	We previously showed that oxidative stress inhibits leukemia inhibitory factor (LIF) signaling by targeting JAK1, and the catalytic domains of JAK 1 and 2 have a cysteine-based redox switch.	Cysteine	162-170	Janus kinase 1	Homo sapiens	143-154
22661199-4	2012	CONCLUSION: These findings indicate that the STAT6 phosphorylation/activation induced by IL-13 is mediated by an activation of JAK1 in cultured hBSMCs.	hbsmcs	144-150	Janus kinase 1	Homo sapiens	127-131
22108298-8	2012	Piceatannol also inhibits JAK-1, which is a key member of the STAT pathway that is crucial in controlling cellular activities in response to extracellular cytokines and is a COX-2-inducible enzyme involved in inflammation and carcinogenesis.	3,3',4,5'-tetrahydroxystilbene	0-11	Janus kinase 1	Homo sapiens	26-31
22149883-9	2012	Among the H-iridoids tested, H-geniposide inhibited constitutive STAT3 activation through inhibiting upstream JAK1 and c-Src.	h-geniposide	29-41	Janus kinase 1	Homo sapiens	110-114
23056499-3	2012	Here, we tested the efficacy of a JAK1/2- inhibitor, AZD1480, in the in vitro and in vivo growth of thyroid cancer cell lines expressing oncogenic RET.	AZD 1480	53-60	Janus kinase 1	Homo sapiens	34-38
21257798-1	2011	INCB018424 phosphate, a potent inhibitor of JAK enzymes with selectivity for JAK1&2, is in development for the treatment of myelofibrosis (MF).	Ruxolitinib phosphate	0-20	Janus kinase 1	Homo sapiens	77-87
22319590-7	2012	Interestingly, treatment of NSCLC cells with the JAK1/2 inhibitor ruxolitinib has no effect on cell proliferation and viability in two-dimensional culture, but inhibits growth in soft agar and xenograft assays.	ruxolitinib	66-77	Janus kinase 1	Homo sapiens	49-55
22399854-1	2012	Ruxolitinib is an orally bioavailable, selective Janus kinase (JAK) 1 and 2 inhibitor approved for the treatment of myelofibrosis (MF), a bone marrow disease in which the JAK pathway is dysregulated, leading to impaired hematopoiesis and immune function.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	49-75
22399854-2	2012	By inhibiting JAK1 and JAK2, ruxolitinib modulates cytokine-stimulated intracellular signaling.	ruxolitinib	29-40	Janus kinase 1	Homo sapiens	14-18
21880948-5	2011	The kinase JAK1 is enriched in membrane fractions and is activated during human sperm capacitation as suggested by its increase in phosphotyrosine content.	Phosphotyrosine	131-146	Janus kinase 1	Homo sapiens	11-15
21325634-7	2011	Second, curcumin suppressed activation of signal transducer and activator of transcription-3 as indicated by decreased phosphorylation at both tyrosine(705) and serine(727) and inhibition of janus kinase-1 phosphorylation.	Curcumin	8-16	Janus kinase 1	Homo sapiens	191-205
21788946-4	2011	CYT387 is a novel, orally bioavailable JAK1/2 inhibitor, which has recently been described.	N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	0-6	Janus kinase 1	Homo sapiens	39-45
22027691-4	2011	AZD1480 treatment effectively blocks constitutive and stimulus-induced JAK1, JAK2, and STAT-3 phosphorylation in both human and murine glioma cells, and leads to a decrease in cell proliferation and induction of apoptosis.	AZD 1480	0-7	Janus kinase 1	Homo sapiens	71-75
21965659-7	2011	Importantly, we identified a cluster of three membrane-proximal betac lysine residues (Lys(457), Lys(461), and Lys(467)) whose presence was required for both JAK1/2 binding to betac and receptor ubiquitination.	Lysine	70-76	Janus kinase 1	Homo sapiens	158-162
21965659-7	2011	Importantly, we identified a cluster of three membrane-proximal betac lysine residues (Lys(457), Lys(461), and Lys(467)) whose presence was required for both JAK1/2 binding to betac and receptor ubiquitination.	Lysine	87-90	Janus kinase 1	Homo sapiens	158-162
21965659-7	2011	Importantly, we identified a cluster of three membrane-proximal betac lysine residues (Lys(457), Lys(461), and Lys(467)) whose presence was required for both JAK1/2 binding to betac and receptor ubiquitination.	Lysine	97-100	Janus kinase 1	Homo sapiens	158-162
21965659-7	2011	Importantly, we identified a cluster of three membrane-proximal betac lysine residues (Lys(457), Lys(461), and Lys(467)) whose presence was required for both JAK1/2 binding to betac and receptor ubiquitination.	Lysine	97-100	Janus kinase 1	Homo sapiens	158-162
21691275-1	2011	SB1518 is an innovative pyrimidine-based macrocycle that shows a unique kinase profile with selective inhibition of Janus Kinase-2 (JAK2; IC50=23 and 19 nM for JAK2(WT) and JAK2(V617F), respectively) within the JAK family (IC50=1280, 520 and 50 nM for JAK1, JK3 and TYK2, respectively) and fms-like tyrosine kinase-3 (FLT3; IC50=22 nM).	11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene	0-6	Janus kinase 1	Homo sapiens	252-256
22034658-1	2011	Ruxolitinib (INCB018424) is a JAK1 and JAK2 inhibitor recently evaluated for the treatment of myelofibrosis (MF) in early- and advanced-phase clinical trials.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	30-34
22034658-1	2011	Ruxolitinib (INCB018424) is a JAK1 and JAK2 inhibitor recently evaluated for the treatment of myelofibrosis (MF) in early- and advanced-phase clinical trials.	ruxolitinib	13-23	Janus kinase 1	Homo sapiens	30-34
22146225-1	2011	Ruxolitinib is an orally available, ATP-competitive inhibitor, selective for tyrosine-protein kinases JAK1 and JAK2 and is the most advanced JAK1/JAK2 inhibitor in development for the treatment of myeloproliferative neoplasms.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	102-106
22146225-1	2011	Ruxolitinib is an orally available, ATP-competitive inhibitor, selective for tyrosine-protein kinases JAK1 and JAK2 and is the most advanced JAK1/JAK2 inhibitor in development for the treatment of myeloproliferative neoplasms.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	141-145
22146225-1	2011	Ruxolitinib is an orally available, ATP-competitive inhibitor, selective for tyrosine-protein kinases JAK1 and JAK2 and is the most advanced JAK1/JAK2 inhibitor in development for the treatment of myeloproliferative neoplasms.	Adenosine Triphosphate	36-39	Janus kinase 1	Homo sapiens	102-106
22146225-2	2011	The suggested mechanism of action of ruxolitinib is attenuation of cytokine signaling via the inhibition of JAK1 and JAK2 (wild-type or mutated forms), resulting in antiproliferative and proapoptotic effects.	ruxolitinib	37-48	Janus kinase 1	Homo sapiens	108-112
21635221-2	2011	In a recently completed Phase I?II study, ruxolitinib, a selective orally available JAK1 and JAK2 inhibitor, has shown efficacy in patients with advanced myelofibrosis.	ruxolitinib	42-53	Janus kinase 1	Homo sapiens	84-88
22362131-11	2011	Recently, the positive results of the first in class of the JAK1/JAK2 inhibitors, ruxolitinib (formerly INCB18242), from 2 large phase III studies were presented and are discussed herein.	ruxolitinib	82-93	Janus kinase 1	Homo sapiens	60-64
21919691-0	2011	Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	19-25
21919691-1	2011	Ruxolitinib (INCB018424) is the first potent, selective, oral inhibitor of JAK1 and 2 being developed for clinical use.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	75-85
21919691-1	2011	Ruxolitinib (INCB018424) is the first potent, selective, oral inhibitor of JAK1 and 2 being developed for clinical use.	ruxolitinib	13-23	Janus kinase 1	Homo sapiens	75-85
21677670-3	2011	We hypothesized that local inhibition of cytokine signaling using topical administration of INCB018424, a small molecule inhibitor of JAK1 and JAK2, would provide benefit similar to systemic cytokine neutralization.	ruxolitinib	92-102	Janus kinase 1	Homo sapiens	134-138
21635221-8	2011	Ruxolitinib, a potent JAK1 and JAK2 inhibitor, known to decrease spleen size and alleviate constitutional symptoms in myelofibrosis, represents a potentially promising agent for the treatment of leukemias by inhibiting the JAK?STAT signaling.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	22-26
21289371-0	2011	Oral administration of penta-O-galloyl-beta-D-glucose suppresses triple-negative breast cancer xenograft growth and metastasis in strong association with JAK1-STAT3 inhibition.	penta-o-galloyl-beta-d-glucose	23-53	Janus kinase 1	Homo sapiens	154-158
21679692-6	2011	Adenovirus-based expression of Jak1 inactive mutant demonstrated that Jak1 mediates ZO-2 tyrosine phosphorylation.	Tyrosine	89-97	Janus kinase 1	Homo sapiens	31-35
21679692-6	2011	Adenovirus-based expression of Jak1 inactive mutant demonstrated that Jak1 mediates ZO-2 tyrosine phosphorylation.	Tyrosine	89-97	Janus kinase 1	Homo sapiens	70-74
21289371-2	2011	Extending on our recent work, we hypothesize that the herbal compound 1,2,3,4,6-penta-O-galloyl-beta-D-glucose (PGG) can inhibit the growth and metastasis of TNBCa xenograft and target Janus-activated kinase (JAK)-signal transducer and activator of transcription (STAT) 3-signaling axis.	beta-penta-O-galloyl-glucose	70-110	Janus kinase 1	Homo sapiens	209-212
21289371-2	2011	Extending on our recent work, we hypothesize that the herbal compound 1,2,3,4,6-penta-O-galloyl-beta-D-glucose (PGG) can inhibit the growth and metastasis of TNBCa xenograft and target Janus-activated kinase (JAK)-signal transducer and activator of transcription (STAT) 3-signaling axis.	beta-penta-O-galloyl-glucose	112-115	Janus kinase 1	Homo sapiens	209-212
21289371-7	2011	In cell culture of MDA-MB-231 cells, PGG decreased pSTAT3 and its downstream target proteins, decreased its upstream kinase pJAK1 and induced the expression of SHP1, a JAK1 upstream tyrosine phosphatase, within as early as 1 h of exposure.	beta-penta-O-galloyl-glucose	37-40	Janus kinase 1	Homo sapiens	125-129
21289371-10	2011	Mechanistically, PGG-induced inhibition of JAK1-STAT3 axis may contribute to the observed in vivo efficacy and the effects on the cellular processes.	beta-penta-O-galloyl-glucose	17-20	Janus kinase 1	Homo sapiens	43-47
21393331-0	2011	Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.	Adenosine Triphosphate	58-61	Janus kinase 1	Homo sapiens	10-14
21420464-4	2011	Interestingly, CK inhibited phosphorylation of STAT3 and its upstream activators, the Janus activated kinase 1 (JAK1), but not JAK2.	ginsenoside M1	15-17	Janus kinase 1	Homo sapiens	86-110
21420464-4	2011	Interestingly, CK inhibited phosphorylation of STAT3 and its upstream activators, the Janus activated kinase 1 (JAK1), but not JAK2.	ginsenoside M1	15-17	Janus kinase 1	Homo sapiens	112-116
21420464-8	2011	Overall, our findings demonstrate that JAK1/STAT3 signaling mediates CK-induced apoptosis in U266 cells and also suggest the chemopreventive potential of CK for treatment of multiple myeloma.	ginsenoside M1	69-71	Janus kinase 1	Homo sapiens	39-43
21393331-4	2011	We further used this library of JAK1 mutation-positive cell lines to assess their sensitivity to ATP-competitive inhibitors.	Adenosine Triphosphate	97-100	Janus kinase 1	Homo sapiens	32-36
21393331-5	2011	RESULTS: While most JAK1 mutants were sensitive to ATP-competitive JAK inhibitors, mutations targeting Phe958 and Pro960 in the hinge region of the kinase domain rendered JAK1 constitutively active but also resistant to all tested JAK inhibitors.	Adenosine Triphosphate	51-54	Janus kinase 1	Homo sapiens	20-24
20478313-2	2010	Although the crystal structures of active JAK1 and JAK2 kinase domains have been reported recently with the clinical compound CP-690550, the structures of both TYK2 and JAK3 with CP-690550 have remained outstanding.	tofacitinib	126-135	Janus kinase 1	Homo sapiens	42-46
21439476-6	2011	Specific inhibition of the "analog-sensitive" mutant AS-Jak1 but not AS-Jak3 by the ATP-competitive analog 1NM-PP1 abrogated IL-2 signaling, corroborating the data with the selective Jak3 inhibitor.	Adenosine Triphosphate	84-87	Janus kinase 1	Homo sapiens	56-60
21439476-6	2011	Specific inhibition of the "analog-sensitive" mutant AS-Jak1 but not AS-Jak3 by the ATP-competitive analog 1NM-PP1 abrogated IL-2 signaling, corroborating the data with the selective Jak3 inhibitor.	1-tert-butyl-3-naphthalen-1-ylmethyl-1H-pyrazolo(3,4-d)pyrimidin-4-ylemine	107-114	Janus kinase 1	Homo sapiens	56-60
21439476-7	2011	Jak1 thus plays a dominant role over Jak3 and these data challenge the notion that selective ATP-competitive Jak3 kinase inhibitors will be effective.	Adenosine Triphosphate	93-96	Janus kinase 1	Homo sapiens	0-4
21216930-5	2011	Inhibition of JAK1 with small molecules or RNA interference resulted in loss of STAT3 tyrosine phosphorylation and inhibition of cell growth.	Tyrosine	86-94	Janus kinase 1	Homo sapiens	14-18
20878062-11	2010	RNA transcript analyses showed decreased EGF-R and KRas expression in vivo, following indomethacin treatment, which also included KRas, PI3K, JAK1, STAT3 and c-jun, mRNAs in cultured tumor cells.	Indomethacin	86-98	Janus kinase 1	Homo sapiens	142-146
20570727-4	2010	IL-13 stimulates intracellular ROS synthesis within 5min via IL-13Ralpha1-JAK1-STAT6- and IL-13Ralpha2-MEK1/2-ERK1/2-dependent activation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-1 (NOX-1).	Reactive Oxygen Species	31-34	Janus kinase 1	Homo sapiens	74-78
20843246-3	2010	INCB018424 is a potent and selective Janus kinase 1 (JAK1) and JAK2 inhibitor.	ruxolitinib	0-10	Janus kinase 1	Homo sapiens	37-51
20843246-3	2010	INCB018424 is a potent and selective Janus kinase 1 (JAK1) and JAK2 inhibitor.	ruxolitinib	0-10	Janus kinase 1	Homo sapiens	53-57
21198544-6	2011	gamma-Tocotrienol also inhibited the activation of Src, JAK1 and JAK2 implicated in STAT3 activation.	plastochromanol 8	0-17	Janus kinase 1	Homo sapiens	56-60
21277633-0	2011	IL-4 and IL-13 suppress prostaglandins production in human follicular dendritic cells by repressing COX-2 and mPGES-1 expression through JAK1 and STAT6.	Prostaglandins	24-38	Janus kinase 1	Homo sapiens	137-141
21277633-8	2011	Although IL-4 induced tyrosine phosphorylation of JAK1 and TYK2, RNA interference experiments revealed that only JAK1 was responsible for the IL-4-stimulated STAT6 phosphorylation.	Tyrosine	22-30	Janus kinase 1	Homo sapiens	50-54
21277633-9	2011	Knocking down JAK1 and STAT6 ablated the inhibitory effect of IL-4 on COX-2 expression and significantly reduced production of PGE(2) and prostacyclin.	Dinoprostone	127-133	Janus kinase 1	Homo sapiens	14-18
21277633-9	2011	Knocking down JAK1 and STAT6 ablated the inhibitory effect of IL-4 on COX-2 expression and significantly reduced production of PGE(2) and prostacyclin.	Epoprostenol	138-150	Janus kinase 1	Homo sapiens	14-18
21277633-13	2011	These results stress the essential roles of JAK1 and STAT6 in the early signaling pathway of IL-4 and IL-13 leading to suppression of COX-2 expression and repression of PG production by HK cells.	Prostaglandins	169-171	Janus kinase 1	Homo sapiens	44-48
21079613-4	2011	However, most patients treated with a JAK2 (TG101348) or JAK1/2 (INCB018424) inhibitor experienced substantial improvement in constitutional symptoms and reduction in spleen size; the mechanism of action for INCB018424 includes anti-JAK1-mediated downregulation of proinflammatory cytokines.	ruxolitinib	65-75	Janus kinase 1	Homo sapiens	57-63
21079613-4	2011	However, most patients treated with a JAK2 (TG101348) or JAK1/2 (INCB018424) inhibitor experienced substantial improvement in constitutional symptoms and reduction in spleen size; the mechanism of action for INCB018424 includes anti-JAK1-mediated downregulation of proinflammatory cytokines.	ruxolitinib	65-75	Janus kinase 1	Homo sapiens	57-61
21079613-4	2011	However, most patients treated with a JAK2 (TG101348) or JAK1/2 (INCB018424) inhibitor experienced substantial improvement in constitutional symptoms and reduction in spleen size; the mechanism of action for INCB018424 includes anti-JAK1-mediated downregulation of proinflammatory cytokines.	ruxolitinib	208-218	Janus kinase 1	Homo sapiens	57-63
21079613-4	2011	However, most patients treated with a JAK2 (TG101348) or JAK1/2 (INCB018424) inhibitor experienced substantial improvement in constitutional symptoms and reduction in spleen size; the mechanism of action for INCB018424 includes anti-JAK1-mediated downregulation of proinflammatory cytokines.	ruxolitinib	208-218	Janus kinase 1	Homo sapiens	57-61
21625597-2	2011	We report that, in human THP-1 cell line, they inhibit IL-6-elicited tyrosine phosphorylation of STAT3 and its DNA binding activity with EC(50) of 10 microM with concomitant down-regulation of the phosphorylation of the tyrosine Janus kinases JAK1, JAK2 and Tyk2.	Tyrosine	69-77	Janus kinase 1	Homo sapiens	243-247
21106455-0	2010	Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3.	diamino-1,2,4-triazole	0-22	Janus kinase 1	Homo sapiens	72-76
21106455-2	2010	Presented is the design and synthesis of 1,2,4-triazoles, and the evaluation of their inhibitory activity against the Janus associated kinases TYK2 and JAKs 1-3.	1,2,4-triazole	41-56	Janus kinase 1	Homo sapiens	152-156
19937797-3	2010	We found that betulinic acid inhibited constitutive activation of STAT3, Src kinase, JAK1 and JAK2.	betulinic acid	14-28	Janus kinase 1	Homo sapiens	85-89
20053498-4	2010	The activation of c-Src, JAK1 and JAK2 implicated in STAT3 activation, were also suppressed by this saponin.	Saponins	100-107	Janus kinase 1	Homo sapiens	25-29
20167604-3	2010	Upon IL-7</protein-id> binding, both chains are driven in cholesterol- and sphingomyelin-rich rafts where associated signaling proteins Jak1, Jak3, STAT1, -3, and -5 are found to be phosphorylated.	Cholesterol	58-69	Janus kinase 1	Homo sapiens	136-140
20506062-0	2010	Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	25-29
20506062-1	2010	Ruxolitinib (INCB-018424) is a potent, orally available, selective inhibitor of both JAK1 and JAK2 of the JAK-STAT signaling pathway, being developed by Incyte Corp and Novartis AG.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	85-89
20506062-1	2010	Ruxolitinib (INCB-018424) is a potent, orally available, selective inhibitor of both JAK1 and JAK2 of the JAK-STAT signaling pathway, being developed by Incyte Corp and Novartis AG.	ruxolitinib	13-24	Janus kinase 1	Homo sapiens	85-89
20167604-3	2010	Upon IL-7</protein-id> binding, both chains are driven in cholesterol- and sphingomyelin-rich rafts where associated signaling proteins Jak1, Jak3, STAT1, -3, and -5 are found to be phosphorylated.	Sphingomyelins	75-88	Janus kinase 1	Homo sapiens	136-140
20371721-7	2010	These data indicate that the inhibition of STAT3 activity by sorafenib involves both the inhibition of upstream kinases (JAK1 and JAK2) of STAT3 and increased phosphatase activity.	Sorafenib	61-70	Janus kinase 1	Homo sapiens	121-125
20442315-9	2010	Western blot analysis of the xenograft tumor tissues showed that HO-3867 inhibited pSTAT3 (Tyr705 and Ser727) and JAK1 and increased apoptotic markers cleaved caspase-3 and poly ADP ribose polymerase.	Holmium	65-67	Janus kinase 1	Homo sapiens	114-118
20130243-0	2010	Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.	ruxolitinib	63-73	Janus kinase 1	Homo sapiens	46-52
20672017-6	2010	From this screen, we have identified novel signaling molecules, such as JAK1, STAT1, cortactin (CTTN), FER, p130Cas (BCAR1), SRC and FYN as tyrosine phosphorylated in human MM cell lines.	Tyrosine	140-148	Janus kinase 1	Homo sapiens	72-76
19710367-4	2009	We provide evidence that AD412 inhibited the JAK1/3-dependent phosphorylations of Akt, STAT5a/b, and ERK1/2 in IL-2-stimulated CTL-L2 cells.	3-(1-(4-chlorobenzyl)indol-3-yl)-N-(pyridin-4-yl)propanamide	25-30	Janus kinase 1	Homo sapiens	45-49
19945455-3	2010	Stimulation of WISH cells with the cyclic peptide showed tyrosine phosphorylation of Jak1 and Tyk2 kinases, tyrosine and serine phosphorylation of STAT1 and STAT3 transcription factors and activation of p38 MAPK pathway, although phosphorylation levels or kinetics were in some conditions different to those obtained under IFN-alpha2b stimulus.	Tyrosine	57-65	Janus kinase 1	Homo sapiens	85-89
20072651-0	2010	INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.	INCB 16562	0-9	Janus kinase 1	Homo sapiens	13-19
20072651-2	2010	INCB16562 was developed as a novel, selective, and orally bioavailable small-molecule inhibitor of JAK1 and JAK2 markedly selective over JAK3.	INCB 16562	0-9	Janus kinase 1	Homo sapiens	99-103
20072651-9	2010	Taken together, these data suggest that INCB16562 is a potent JAK1/2 inhibitor and that mitigation of JAK/STAT signaling by targeting JAK1 and JAK2 will be beneficial in the treatment of myeloma patients, particularly in combination with other agents.	INCB 16562	40-49	Janus kinase 1	Homo sapiens	62-68
20072651-9	2010	Taken together, these data suggest that INCB16562 is a potent JAK1/2 inhibitor and that mitigation of JAK/STAT signaling by targeting JAK1 and JAK2 will be beneficial in the treatment of myeloma patients, particularly in combination with other agents.	INCB 16562	40-49	Janus kinase 1	Homo sapiens	62-66
19887489-9	2009	CONCLUSIONS: These data showed that administration of the dual JAK1/2 inhibitor INCB16562 reduces malignant cell burden, normalizes spleen size and architecture, suppresses inflammatory cytokines, improves weight gain, and extends survival in a rodent model of JAK2V617F-driven hematologic malignancy.	INCB 16562	80-89	Janus kinase 1	Homo sapiens	63-69
19928918-10	2010	Moreover, phosphorylation of PKC-delta, JAK-1, and JAK-2, which are the upstream event for the activation of STAT1, are also inhibited by EGCG in IFN-gamma-stimulated human oral cancer cells.	epigallocatechin gallate	138-142	Janus kinase 1	Homo sapiens	40-45
20006573-7	2010	Concomitantly, TNFalpha induced phosphorylation of STAT1 at Tyr-701 by JAK1 facilitates its nuclear translocation and activation of CD40 through p300 recruitment and core Histone-3 acetylation.	Tyrosine	60-63	Janus kinase 1	Homo sapiens	71-75
19706767-6	2009	Addition of DTT or glutathione prevents the JAK cross-linking and blocks the inhibitory effects of HJB on IL-6-induced STAT3 activation, suggesting that HJB may react with cystein residues of JAKs to form covalent bonds that inactivate JAKs.	Dithiothreitol	12-15	Janus kinase 1	Homo sapiens	192-196
19762238-0	2009	Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs).	phenylaminopyrimidines	0-22	Janus kinase 1	Homo sapiens	55-59
19762238-1	2009	A series of phenylaminopyrimidines has been identified as inhibitors of Janus kinases (JAKs).	phenylaminopyrimidines	12-34	Janus kinase 1	Homo sapiens	87-91
19762238-2	2009	Development of this initial series led to the potent JAK2/JAK1 inhibitor CYT387 (N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-benzamide).	N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	73-79	Janus kinase 1	Homo sapiens	58-62
19762238-2	2009	Development of this initial series led to the potent JAK2/JAK1 inhibitor CYT387 (N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-benzamide).	N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	81-159	Janus kinase 1	Homo sapiens	58-62
19706767-6	2009	Addition of DTT or glutathione prevents the JAK cross-linking and blocks the inhibitory effects of HJB on IL-6-induced STAT3 activation, suggesting that HJB may react with cystein residues of JAKs to form covalent bonds that inactivate JAKs.	Glutathione	19-30	Janus kinase 1	Homo sapiens	192-196
19706767-6	2009	Addition of DTT or glutathione prevents the JAK cross-linking and blocks the inhibitory effects of HJB on IL-6-induced STAT3 activation, suggesting that HJB may react with cystein residues of JAKs to form covalent bonds that inactivate JAKs.	Dithiothreitol	12-15	Janus kinase 1	Homo sapiens	236-240
19706767-6	2009	Addition of DTT or glutathione prevents the JAK cross-linking and blocks the inhibitory effects of HJB on IL-6-induced STAT3 activation, suggesting that HJB may react with cystein residues of JAKs to form covalent bonds that inactivate JAKs.	Glutathione	19-30	Janus kinase 1	Homo sapiens	236-240
19295546-0	2009	CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.	N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	0-6	Janus kinase 1	Homo sapiens	20-24
19706767-6	2009	Addition of DTT or glutathione prevents the JAK cross-linking and blocks the inhibitory effects of HJB on IL-6-induced STAT3 activation, suggesting that HJB may react with cystein residues of JAKs to form covalent bonds that inactivate JAKs.	Cysteine	172-179	Janus kinase 1	Homo sapiens	192-196
19295546-6	2009	Overall, our data indicate that the JAK1/JAK2 selective inhibitor CYT387 has potential for efficacious treatment of MPN harboring mutated JAK2 and MPL alleles.	N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	66-72	Janus kinase 1	Homo sapiens	36-40
19295546-2	2009	CYT387 is an ATP-competitive small molecule that potently inhibits JAK1/JAK2 kinases (IC(50)=11 and 18 nM, respectively), with significantly less activity against other kinases, including JAK3 (IC(50)=155 nM).	N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	0-6	Janus kinase 1	Homo sapiens	67-71
19295546-2	2009	CYT387 is an ATP-competitive small molecule that potently inhibits JAK1/JAK2 kinases (IC(50)=11 and 18 nM, respectively), with significantly less activity against other kinases, including JAK3 (IC(50)=155 nM).	Adenosine Triphosphate	13-16	Janus kinase 1	Homo sapiens	67-71
18664717-0	2008	Ceramide accelerates ultraviolet-induced MMP-1 expression through JAK1/STAT-1 pathway in cultured human dermal fibroblasts.	Ceramides	0-8	Janus kinase 1	Homo sapiens	66-70
19951532-7	2009	The phosphorylation of JAK1 was enhanced after the NB4 cells treated with As2O3.	Arsenic Trioxide	74-79	Janus kinase 1	Homo sapiens	23-27
19951532-9	2009	The effect of As2O3 inhibiting NB4 cells proliferation was weaker in the JAK1 siRNA transfected group.	Arsenic Trioxide	14-19	Janus kinase 1	Homo sapiens	73-77
19951532-10	2009	The inhibiting rate of 4 micromol/L As2O3 on NB4 cells proliferation of JAK1 siRNA group was 49.12% being lower than that of the non-specific siRNA group (74.58%) and control group (72.33%).	Arsenic Trioxide	36-41	Janus kinase 1	Homo sapiens	72-76
19951532-11	2009	After NB4 cells transfected with JAK1 plasmid, the JAK1 expression level in wild-type and mutant type plasmid groups were significantly higher than those in the empty plasmid group, moreover the effect of As2O3 inhibiting proliferation was stronger in wild-type plasmid group.	Arsenic Trioxide	205-210	Janus kinase 1	Homo sapiens	33-37
19951532-11	2009	After NB4 cells transfected with JAK1 plasmid, the JAK1 expression level in wild-type and mutant type plasmid groups were significantly higher than those in the empty plasmid group, moreover the effect of As2O3 inhibiting proliferation was stronger in wild-type plasmid group.	Arsenic Trioxide	205-210	Janus kinase 1	Homo sapiens	51-55
19951532-12	2009	The inhibiting rate of 4 micromol/L As2O3 on NB4 cells proliferation of wild-type plasmid group was 69.53% being higher than that of the mutant type JAK1 plasmid group (37.26%) and the empty plasmid group (39.61%).	Arsenic Trioxide	36-41	Janus kinase 1	Homo sapiens	149-153
19951532-15	2009	Arsenic trioxide inhibits the proliferation of NB4 cells through activating the JAK1.	Arsenic Trioxide	0-16	Janus kinase 1	Homo sapiens	80-84
19951532-16	2009	P21 is up-regulated after arsenic trioxide activated the JAK1 to inhibit the proliferation of NB4 cells.	Arsenic Trioxide	26-42	Janus kinase 1	Homo sapiens	57-61
19139102-4	2009	Mutation of the FERM domain of JAK1, which is critical for cytokine receptor association, or of the single tyrosine of IL-9Ralpha involved in STAT recruitment abolished this activity, indicating that JAK1 mutants need to associate with a functional IL-9Ralpha to activate STAT factors.	Tyrosine	107-115	Janus kinase 1	Homo sapiens	200-204
18995957-0	2009	Myricetin directly targets JAK1 to inhibit cell transformation.	myricetin	0-9	Janus kinase 1	Homo sapiens	27-31
18995957-7	2009	Myricetin inhibited the phosphorylation of JAK1 and increased the autophosphorylation of EGF receptor (EGFR).	myricetin	0-9	Janus kinase 1	Homo sapiens	43-47
18995957-9	2009	Affinity data further demonstrated that myricetin had a higher affinity for JAK1 than STAT3.	myricetin	40-49	Janus kinase 1	Homo sapiens	76-80
19014879-9	2009	CONCLUSIONS: IFNalpha determines the binding of PEA3 to JAK1 and its tyrosine phosphorylation.	Tyrosine	69-77	Janus kinase 1	Homo sapiens	56-60
19635391-4	2009	Exposure of BE(2)-C cells to the heavy metals CdCl(2) and HgCl(2) and to the mitochondrial complex I inhibitor rotenone inhibited interleukin-6, interferon-gamma and ciliary neurotrophic factor-mediated Jak/STAT signaling, reduced Jak1 and Jak2 auto-phosphorylation and induced Jak tyrosine nitration.	Rotenone	111-119	Janus kinase 1	Homo sapiens	231-235
19385051-5	2009	EGF also induced the phosphorylation of EGFR, ERK, and STAT-3, and these effects were inhibited by the EGFR inhibitor, AG1478.To investigate the involvement of the STAT-3 pathway on EGF-induced MMP-9 expression, we pretreatedSKBR3 cells with JAK1, JAK2, and JAK3 inhibitors prior to EGF treatment.	RTKI cpd	119-125	Janus kinase 1	Homo sapiens	242-246
19231233-6	2009	Expressions of proteins and mRNAs of cytokines were determined by ELISA and RT-PCR, respectively, activities of MAP kinases, PKC, JAK1/2, and STAT1 on tyrosine 701 and serine 727 by immunoblotting, the DNA-binding activity of the transcription factors by electrophoretic mobility shift assay.	Tyrosine	151-159	Janus kinase 1	Homo sapiens	130-136
19231233-7	2009	IFNgamma-stimulated mast cells showed increase in expressions of proteins and mRNAs of inflammatory cytokines, phosphorylations of MAP kinases, PKCalpha and betaI, JAK1/2, and STAT1 on tyrosine 701 and serine 727.	Tyrosine	185-193	Janus kinase 1	Homo sapiens	164-170
19361440-4	2009	Both inhibitors bound in a similar manner to JAK1, namely buried deep within a constricted ATP-binding site, thereby providing a basis for the potent inhibition of JAK1.	Adenosine Triphosphate	91-94	Janus kinase 1	Homo sapiens	45-49
19361440-4	2009	Both inhibitors bound in a similar manner to JAK1, namely buried deep within a constricted ATP-binding site, thereby providing a basis for the potent inhibition of JAK1.	Adenosine Triphosphate	91-94	Janus kinase 1	Homo sapiens	164-168
19361440-5	2009	As expected, the mode of inhibitor binding in JAK1 was very similar to that observed in JAK2, highlighting the challenges in developing JAK-specific inhibitors that target the ATP-binding site.	Adenosine Triphosphate	176-179	Janus kinase 1	Homo sapiens	46-50
19361440-6	2009	Nevertheless, differences surrounding the JAK1 and JAK2 ATP-binding sites were apparent, thereby providing a platform for the rational design of JAK2- and JAK1-specific inhibitors.	Adenosine Triphosphate	56-59	Janus kinase 1	Homo sapiens	155-159
18922133-2	2009	In addition to their role in phosphorylation of receptor tyrosine residues and downstream signalling substrates, JAKs have recently been implicated in controlling expression of cytokine receptors, predominantly by masking critical motifs involved in endocytosis and lysosomal targeting.	Tyrosine	57-65	Janus kinase 1	Homo sapiens	113-117
18664717-7	2008	The activation of ceramide pathway by C(2)-ceramide enhanced phosphorylation of signal transducer and activators of transcription-1 (STAT-1), whereas ceramide-induced MMP-1 expression was potently prevented by piceatannol; Janus kinase (JAK1) inhibtor; and WHI-P131, a specific inhibitor of JAK3; but not by AG490, JAK 2 inhbitor, in human dermal fibroblasts.	Ceramides	18-26	Janus kinase 1	Homo sapiens	237-241
18664717-8	2008	We also found that UV induced the phosphorylation of STAT-1, and UV-induced MMP-1 expression was significantly decreased by JAK1 inhibitor, piceatannol.	3,3',4,5'-tetrahydroxystilbene	140-151	Janus kinase 1	Homo sapiens	124-128
18664717-9	2008	Overall, we demonstrate that induction of intracellular ceramide by UV may activate MMP-1 gene expression via JAK1/STAT-1 pathway.	Ceramides	56-64	Janus kinase 1	Homo sapiens	110-114
18596134-6	2008	Combined results from EMSA and western blot analysis revealed the inhibitory ability of 15d-PGJ(2), but not of synthetic PPARgamma ligands, on IFN-gamma-induced tyrosine phosphorylation of JAK1, JAK2, STAT1 and nuclear STAT1 translocation and DNA binding.	15d-pgj	88-95	Janus kinase 1	Homo sapiens	189-193
18596134-6	2008	Combined results from EMSA and western blot analysis revealed the inhibitory ability of 15d-PGJ(2), but not of synthetic PPARgamma ligands, on IFN-gamma-induced tyrosine phosphorylation of JAK1, JAK2, STAT1 and nuclear STAT1 translocation and DNA binding.	Tyrosine	161-169	Janus kinase 1	Homo sapiens	189-193
18682290-6	2008	We also demonstrate, in Jak1, phosphorylation of Y(939), a corresponding tyrosine residue with Y(913), negatively regulated Jak1 signaling pathway.	Tyrosine	73-81	Janus kinase 1	Homo sapiens	24-28
18682290-6	2008	We also demonstrate, in Jak1, phosphorylation of Y(939), a corresponding tyrosine residue with Y(913), negatively regulated Jak1 signaling pathway.	Tyrosine	73-81	Janus kinase 1	Homo sapiens	124-128
18413761-0	2008	Triterpenoid CDDO-methyl ester inhibits the Janus-activated kinase-1 (JAK1)--&gt;signal transducer and activator of transcription-3 (STAT3) pathway by direct inhibition of JAK1 and STAT3.	triterpenoid TP-222	0-12	Janus kinase 1	Homo sapiens	70-74
18413761-3	2008	The present studies show that CDDO-Me blocks interleukin-6 (IL-6)-induced and constitutive activation of the Janus-activated kinase 1 (JAK1) in cells.	bardoxolone methyl	30-37	Janus kinase 1	Homo sapiens	109-133
18413761-3	2008	The present studies show that CDDO-Me blocks interleukin-6 (IL-6)-induced and constitutive activation of the Janus-activated kinase 1 (JAK1) in cells.	bardoxolone methyl	30-37	Janus kinase 1	Homo sapiens	135-139
18413761-4	2008	In support of a direct mechanism, CDDO-Me forms adducts with JAK1 at Cys(1077) in the kinase domain and inhibits JAK1 activity.	bardoxolone methyl	34-41	Janus kinase 1	Homo sapiens	61-65
18413761-4	2008	In support of a direct mechanism, CDDO-Me forms adducts with JAK1 at Cys(1077) in the kinase domain and inhibits JAK1 activity.	bardoxolone methyl	34-41	Janus kinase 1	Homo sapiens	113-117
18413761-4	2008	In support of a direct mechanism, CDDO-Me forms adducts with JAK1 at Cys(1077) in the kinase domain and inhibits JAK1 activity.	Cysteine	69-72	Janus kinase 1	Homo sapiens	61-65
18413761-7	2008	These findings indicate that CDDO-Me inhibits activation of the JAK1--&gt;STAT3 pathway by forming adducts with both JAK1 and STAT3.	bardoxolone methyl	29-36	Janus kinase 1	Homo sapiens	64-68
18413761-7	2008	These findings indicate that CDDO-Me inhibits activation of the JAK1--&gt;STAT3 pathway by forming adducts with both JAK1 and STAT3.	bardoxolone methyl	29-36	Janus kinase 1	Homo sapiens	117-121
18381062-2	2008	Here, I showed that coumermycin-induced chemical heterodimerization of Jak1 and Jak3 but not homodimerization of Jak1 or Jak3 induces cell proliferation of an IL-2R-reconstituted cell line.	coumermycin	20-31	Janus kinase 1	Homo sapiens	71-75
18346458-7	2008	Superimposition of the interface residues suggested that substitution of Asp 99 (Jak3) into Glu 101 (Jak1) generated steric hindrance and a Tyr 91 to Phe 93 switch altered the shape of catalytic cleft which collectively prohibited the inhibitor binding.	Glutamic Acid	92-95	Janus kinase 1	Homo sapiens	101-105
18346458-8	2008	Furthermore, in-silico mutagenesis of these two residues back to Asp and Tyr enabled Jak1 to accommodate WHI-P131.	Aspartic Acid	65-68	Janus kinase 1	Homo sapiens	85-89
18346458-8	2008	Furthermore, in-silico mutagenesis of these two residues back to Asp and Tyr enabled Jak1 to accommodate WHI-P131.	Tyrosine	73-76	Janus kinase 1	Homo sapiens	85-89
18413761-0	2008	Triterpenoid CDDO-methyl ester inhibits the Janus-activated kinase-1 (JAK1)--&gt;signal transducer and activator of transcription-3 (STAT3) pathway by direct inhibition of JAK1 and STAT3.	triterpenoid TP-222	0-12	Janus kinase 1	Homo sapiens	172-176
18413761-0	2008	Triterpenoid CDDO-methyl ester inhibits the Janus-activated kinase-1 (JAK1)--&gt;signal transducer and activator of transcription-3 (STAT3) pathway by direct inhibition of JAK1 and STAT3.	bardoxolone methyl	13-30	Janus kinase 1	Homo sapiens	70-74
18413761-0	2008	Triterpenoid CDDO-methyl ester inhibits the Janus-activated kinase-1 (JAK1)--&gt;signal transducer and activator of transcription-3 (STAT3) pathway by direct inhibition of JAK1 and STAT3.	bardoxolone methyl	13-30	Janus kinase 1	Homo sapiens	172-176
17592174-13	2007	The inhibition of JAK1, JAK3, STAT5, ERK1/2, and Akt phosphorylation caused by DHA, SA, and PA is associated with an alteration of CD25 expression at the cell surface.	sa	84-86	Janus kinase 1	Homo sapiens	18-22
18281483-3	2008	All three cytokines induced tyrosine phosphorylation of Jak1 and Jak3 in CTCL cell lines and native leukemic (Sezary) cells.	Tyrosine	28-36	Janus kinase 1	Homo sapiens	56-60
17645497-0	2007	Auranofin blocks interleukin-6 signalling by inhibiting phosphorylation of JAK1 and STAT3.	Auranofin	0-9	Janus kinase 1	Homo sapiens	75-79
17645497-10	2007	Thiol-group-reactive proteins may be involved in AF-induced suppression of JAK1/STAT3 phosphorylation.	Sulfhydryl Compounds	0-5	Janus kinase 1	Homo sapiens	75-79
17948269-4	2007	Importantly, inhibition of IL-10-induced STAT3 activation and IL-10-suppressive action by a prolonged exposure to cycloheximide (CHX) was observed to occur also in human monocytes and was caused by a defective IL-10-mediated activation of Jak1 and Tyk2 kinases.	Cycloheximide	114-127	Janus kinase 1	Homo sapiens	239-243
17948269-4	2007	Importantly, inhibition of IL-10-induced STAT3 activation and IL-10-suppressive action by a prolonged exposure to cycloheximide (CHX) was observed to occur also in human monocytes and was caused by a defective IL-10-mediated activation of Jak1 and Tyk2 kinases.	Cycloheximide	129-132	Janus kinase 1	Homo sapiens	239-243
18052729-11	2007	However, GM-CSF-induced downregulation of Tyk2 and Jak1 tyrosine phosphorylation as well as Tyk2 protein levels likely contributed to the reduced Stat1 tyrosine phosphorylation.	Tyrosine	56-64	Janus kinase 1	Homo sapiens	51-55
17919239-6	2007	AG490, a JAK inhibitor, blocked JAK1 phosphorylation accompanied by inhibition of PI3K and Akt activation as well as alpha1(I) collagen mRNA expression, indicating a JAK1-dependent mechanism.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	0-5	Janus kinase 1	Homo sapiens	32-36
17919239-6	2007	AG490, a JAK inhibitor, blocked JAK1 phosphorylation accompanied by inhibition of PI3K and Akt activation as well as alpha1(I) collagen mRNA expression, indicating a JAK1-dependent mechanism.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	0-5	Janus kinase 1	Homo sapiens	166-170
17785825-8	2007	Treatment of cells with kaempferol did not affect activation of Src kinase by IL-4 but did prevent the phosphorylation of JAK1 and JAK3.	kaempferol	24-34	Janus kinase 1	Homo sapiens	122-126
17592174-8	2007	PA, SA, DHA, and EPA decreased JAK1, JAK3, STAT5, and Akt phosphorylation induced by IL-2, but OA and LA did not cause any effect.	Protactinium	0-2	Janus kinase 1	Homo sapiens	31-35
17592174-8	2007	PA, SA, DHA, and EPA decreased JAK1, JAK3, STAT5, and Akt phosphorylation induced by IL-2, but OA and LA did not cause any effect.	sa	4-6	Janus kinase 1	Homo sapiens	31-35
17592174-13	2007	The inhibition of JAK1, JAK3, STAT5, ERK1/2, and Akt phosphorylation caused by DHA, SA, and PA is associated with an alteration of CD25 expression at the cell surface.	Protactinium	92-94	Janus kinase 1	Homo sapiens	18-22
17592174-8	2007	PA, SA, DHA, and EPA decreased JAK1, JAK3, STAT5, and Akt phosphorylation induced by IL-2, but OA and LA did not cause any effect.	Dihydroalprenolol	8-11	Janus kinase 1	Homo sapiens	31-35
17592174-8	2007	PA, SA, DHA, and EPA decreased JAK1, JAK3, STAT5, and Akt phosphorylation induced by IL-2, but OA and LA did not cause any effect.	Eicosapentaenoic Acid	17-20	Janus kinase 1	Homo sapiens	31-35
17385713-0	2007	Evidence that IL-6-type cytokine signaling in cardiomyocytes is inhibited by oxidative stress: parthenolide targets JAK1 activation by generating ROS.	parthenolide	95-107	Janus kinase 1	Homo sapiens	116-120
17592174-13	2007	The inhibition of JAK1, JAK3, STAT5, ERK1/2, and Akt phosphorylation caused by DHA, SA, and PA is associated with an alteration of CD25 expression at the cell surface.	Dihydroalprenolol	79-82	Janus kinase 1	Homo sapiens	18-22
17550976-2	2007	We now report marked PRL-induced tyrosine phosphorylation of Jak1, in addition to Jak2, in a series of human breast cancer cell lines, including T47D, MCF7, and SKBR3.	Tyrosine	33-41	Janus kinase 1	Homo sapiens	61-65
17550976-7	2007	Instead, PRL activated Jak1 through a Jak2-dependent mechanism, based on disruption of PRL activation of Jak1 after Jak2 suppression by 1) lentiviral delivery of Jak2 short hairpin RNA, 2) adenoviral delivery of dominant-negative Jak2, and 3) AG490 pharmacological inhibition.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	243-248	Janus kinase 1	Homo sapiens	23-27
17550976-8	2007	Finally, suppression of Jak1 by lentiviral delivery of Jak1 short hairpin RNA blocked PRL activation of ERK and signal transducer and activator of transcription (Stat)3 and suppressed PRL activation of Jak2, Stat5a, Stat5b, and Akt, as well as tyrosine phosphorylation of PRLR.	Tyrosine	244-252	Janus kinase 1	Homo sapiens	24-28
17550976-8	2007	Finally, suppression of Jak1 by lentiviral delivery of Jak1 short hairpin RNA blocked PRL activation of ERK and signal transducer and activator of transcription (Stat)3 and suppressed PRL activation of Jak2, Stat5a, Stat5b, and Akt, as well as tyrosine phosphorylation of PRLR.	Tyrosine	244-252	Janus kinase 1	Homo sapiens	55-59
17703129-6	2007	Moreover, we hypothesize that hyperactivation of the JAK kinases, particularly JAK2, mismatched STAT3 serine-tyrosine phosphorylation or heightened STAT3 transcriptional activity, and SOCS3 induction may ultimately prove detrimental.	Serine	102-108	Janus kinase 1	Homo sapiens	53-56
17703129-6	2007	Moreover, we hypothesize that hyperactivation of the JAK kinases, particularly JAK2, mismatched STAT3 serine-tyrosine phosphorylation or heightened STAT3 transcriptional activity, and SOCS3 induction may ultimately prove detrimental.	Tyrosine	109-117	Janus kinase 1	Homo sapiens	53-56
17385713-3	2007	Activation of Janus kinase 1 (JAK1) tyrosine kinase was markedly reduced by parthenolide.	parthenolide	76-88	Janus kinase 1	Homo sapiens	14-28
17385713-3	2007	Activation of Janus kinase 1 (JAK1) tyrosine kinase was markedly reduced by parthenolide.	parthenolide	76-88	Janus kinase 1	Homo sapiens	30-34
17385713-4	2007	Pretreatment with parthenolide inhibited JAK1-mediated phosphorylation of the LIF receptor subunits LIF receptor (LIFR) alpha and glycoprotein 130 (gp130), and reduced the LIF-induced increase in JAK1 association with both components.	parthenolide	18-30	Janus kinase 1	Homo sapiens	41-45
17385713-4	2007	Pretreatment with parthenolide inhibited JAK1-mediated phosphorylation of the LIF receptor subunits LIF receptor (LIFR) alpha and glycoprotein 130 (gp130), and reduced the LIF-induced increase in JAK1 association with both components.	parthenolide	18-30	Janus kinase 1	Homo sapiens	196-200
17385713-7	2007	Pretreatment with the antioxidant, N-acetyl-L-cysteine, completely suppressed the effect of parthenolide on JAK1 and STAT3.	Acetylcysteine	35-54	Janus kinase 1	Homo sapiens	108-112
17385713-7	2007	Pretreatment with the antioxidant, N-acetyl-L-cysteine, completely suppressed the effect of parthenolide on JAK1 and STAT3.	parthenolide	92-104	Janus kinase 1	Homo sapiens	108-112
17385713-8	2007	From these results, we conclude ROS generation in cardiomyocytes blocks STAT3 signaling of the IL-6-type cytokines by targeting JAK1.	Reactive Oxygen Species	32-35	Janus kinase 1	Homo sapiens	128-132
17341659-7	2007	Interestingly, JAK1 inhibitor only in combination with silibinin resulted in a complete reduction in Stat3 phosphorylation at Tyr705, activated caspase-9 and caspase-3, and caused strong PARP cleavage and apoptotic death of DU145 cells.	Silybin	55-64	Janus kinase 1	Homo sapiens	15-19
17397165-1	2007	Herein, we describe the design and surface-binding characterization of a de novo designed peptide, JAK1, which undergoes surface-induced folding at the hydroxyapatite (HA)-solution interface.	Durapatite	152-166	Janus kinase 1	Homo sapiens	99-103
17570252-0	2007	Exenatide blocks JAK1-STAT1 in pancreatic beta cells.	Exenatide	0-9	Janus kinase 1	Homo sapiens	17-21
17397165-2	2007	JAK1 is designed to be unstructured in buffered saline solution, yet undergo HA-induced folding that is largely governed by the periodic positioning of gamma-carboxyglutamic acid (Gla) residues within the primary sequence of the peptide.	Sodium Chloride	48-54	Janus kinase 1	Homo sapiens	0-4
17397165-2	2007	JAK1 is designed to be unstructured in buffered saline solution, yet undergo HA-induced folding that is largely governed by the periodic positioning of gamma-carboxyglutamic acid (Gla) residues within the primary sequence of the peptide.	1-Carboxyglutamic Acid	152-178	Janus kinase 1	Homo sapiens	0-4
17397165-2	2007	JAK1 is designed to be unstructured in buffered saline solution, yet undergo HA-induced folding that is largely governed by the periodic positioning of gamma-carboxyglutamic acid (Gla) residues within the primary sequence of the peptide.	1-Carboxyglutamic Acid	180-183	Janus kinase 1	Homo sapiens	0-4
17290288-0	2007	Interferons induce tyrosine phosphorylation of the eIF2alpha kinase PKR through activation of Jak1 and Tyk2.	Tyrosine	19-27	Janus kinase 1	Homo sapiens	94-98
17290288-5	2007	Moreover, we provide strong evidence that both the induction of eIF2alpha phosphorylation and inhibition of protein synthesis by IFN are impaired in cells lacking Jak1 or Tyk2, which corresponds to a lack of induction of PKR tyrosine phosphorylation.	Tyrosine	225-233	Janus kinase 1	Homo sapiens	163-167
16544577-7	2006	Compared with controls, DHA changed the localization of IL-2R, STAT5a and STAT5b in lipid rafts and suppressed the expression of JAK1, JAK3 and tyrosine phosphotyrosine in soluble membrane fractions.	dehydroacetic acid	24-27	Janus kinase 1	Homo sapiens	129-133
17121792-3	2007	The signaling pathways employed by cmvIL-10 were investigated, and the classic IL-10R/JAK1/Stat3 pathway was found to be activated in monocytes.	cmvil-10	35-43	Janus kinase 1	Homo sapiens	86-90
16920889-6	2007	Inhibition of JAK1/STAT-3 pathways by piceatannol or ERK1/2 by the MAPK/ERK kinase 1/2 inhibitor U0126 blunted the increase in total protein synthesis.	3,3',4,5'-tetrahydroxystilbene	38-49	Janus kinase 1	Homo sapiens	14-18
16920889-6	2007	Inhibition of JAK1/STAT-3 pathways by piceatannol or ERK1/2 by the MAPK/ERK kinase 1/2 inhibitor U0126 blunted the increase in total protein synthesis.	U 0126	97-102	Janus kinase 1	Homo sapiens	14-18
17016659-9	2006	In JAK1 and ISGF3gamma-silenced Hep3B cells, the apoptosis induction and caspase-8 activation levels by IFN, even in combination with 5-FU, were abrogated.	Fluorouracil	134-138	Janus kinase 1	Homo sapiens	3-7
16595158-5	2006	This was accomplished by preventing the IFN-alpha-induced tyrosine phosphorylation of STAT-1 and STAT-2 through the inactivation of the upstream receptor associated tyrosine kinases, JAK-1 and Tyk-2.	Tyrosine	58-66	Janus kinase 1	Homo sapiens	183-188
16448461-5	2006	H2O2 was increased while glutathione was decreased; these changes were prevented by AG490, suggesting a Janus kinases (JAK)-mediated process.	Hydrogen Peroxide	0-4	Janus kinase 1	Homo sapiens	119-122
16448461-5	2006	H2O2 was increased while glutathione was decreased; these changes were prevented by AG490, suggesting a Janus kinases (JAK)-mediated process.	Glutathione	25-36	Janus kinase 1	Homo sapiens	119-122
16982750-9	2006	PD98059 also increased back the expression of the MAD2 cell cycle checkpoint protein that was down-regulated during "all JAKs inhibitor"-mediated endoreduplication.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	0-7	Janus kinase 1	Homo sapiens	121-125
16843830-3	2006	We found that divalent cadmium (CdCl2) inhibited ciliary neurotrophic factor (CNTF)-mediated Jak1 and Jak2 tyrosine kinase signaling in human BE(2)-C neuroblastoma cells.	Cadmium	23-30	Janus kinase 1	Homo sapiens	93-97
16843830-3	2006	We found that divalent cadmium (CdCl2) inhibited ciliary neurotrophic factor (CNTF)-mediated Jak1 and Jak2 tyrosine kinase signaling in human BE(2)-C neuroblastoma cells.	Cadmium Chloride	32-37	Janus kinase 1	Homo sapiens	93-97
16474838-0	2006	The mutation in the ATP-binding region of JAK1, identified in human uterine leiomyosarcomas, results in defective interferon-gamma inducibility of TAP1 and LMP2.	Adenosine Triphosphate	20-23	Janus kinase 1	Homo sapiens	42-46
15978943-5	2005	Treatment of HL-205 and HL-525 cells with DMSO and HL-205 cells with PMA-induced JAK1 phosphorylation, JAK1/STAT1 association, formation of STAT1-STAT2 heterodimers, and the binding of the active IFN stimulating growth factor 3 (ISGF3) to the IFN-stimulated response element (ISRE) fragment isolated from the 2-5A synthetase promoter.	Dimethyl Sulfoxide	42-46	Janus kinase 1	Homo sapiens	81-85
16324217-17	2005	When IFN-alpha binds its receptor, two receptor associated tyrosine kinases, Tyk2 and Jak1 become activated by phosphorylation, and phosphorylate Stat1 and Stat2 on conserved tyrosine residues 13.	Tyrosine	59-67	Janus kinase 1	Homo sapiens	86-90
16044161-3	2005	Such effects of curcumin appear to result from suppression of the constitutively active STAT3 through inhibition of Janus kinase 1 (JAK1).	Curcumin	16-24	Janus kinase 1	Homo sapiens	116-130
16044161-3	2005	Such effects of curcumin appear to result from suppression of the constitutively active STAT3 through inhibition of Janus kinase 1 (JAK1).	Curcumin	16-24	Janus kinase 1	Homo sapiens	132-136
16044161-5	2005	Altogether, our findings suggest a novel function for curcumin, acting as a suppressor of JAK-1 and STAT3 activation in PEL cells, leading to inhibition of proliferation and induction of caspase-dependent apoptosis.	Curcumin	54-62	Janus kinase 1	Homo sapiens	90-95
15978943-5	2005	Treatment of HL-205 and HL-525 cells with DMSO and HL-205 cells with PMA-induced JAK1 phosphorylation, JAK1/STAT1 association, formation of STAT1-STAT2 heterodimers, and the binding of the active IFN stimulating growth factor 3 (ISGF3) to the IFN-stimulated response element (ISRE) fragment isolated from the 2-5A synthetase promoter.	Dimethyl Sulfoxide	42-46	Janus kinase 1	Homo sapiens	103-107
15894543-3	2005	We investigated the functionality of the Jak1 SH2 domain by stably reconstituting Jak1-defective human fibrosarcoma cells U4C with endogenous amounts of Jak1 in which the crucial arginine residue Arg466 within the SH2 domain has been replaced by lysine.	Arginine	179-187	Janus kinase 1	Homo sapiens	41-45
15659558-7	2005	We observed induced phosphorylation on several well documented as well as novel tyrosine phosphorylation sites on proteins involved in IFNalpha signal transduction, such as Tyk2, JAK1, and IFNAR subunits.	Tyrosine	80-88	Janus kinase 1	Homo sapiens	179-183
15939634-10	2005	These findings suggest that hypoxia induces the expression of JAK1, JAK2, JAK3 and phospho-STAT1 and -STAT3 in PASMC.	pasmc	111-116	Janus kinase 1	Homo sapiens	62-66
15582995-9	2005	The Met-Janus kinase 1-STAT3 signaling pathway may be a major signaling pathway for DCP-induced cell proliferation.	dcp	84-87	Janus kinase 1	Homo sapiens	8-22
14978237-7	2004	ICAM-1 promoter activities induced by the overexpression of wild-type JAK1- and PLC-gamma2 were blocked by the PLCgamma2 mutant or the dominant-negative PKCalpha (Lys--&gt;Arg), c-Src (Lys--&gt;Met), or STAT1 (Y701M) mutants, but not by dominant-negative STAT3 (DN) mutants.	Lysine	163-166	Janus kinase 1	Homo sapiens	70-74
15123634-2	2004	In this study we demonstrated that inhibitors of histone deacetylase (HDAC) activity, butyrate, trichostatin A, and suberoylanilide hydroxamic acid, prevented IFNgamma-induced JAK1 activation, STAT1 phosphorylation, its nuclear translocation, and STAT1-dependent gene activation.	Butyrates	86-94	Janus kinase 1	Homo sapiens	176-180
15123634-2	2004	In this study we demonstrated that inhibitors of histone deacetylase (HDAC) activity, butyrate, trichostatin A, and suberoylanilide hydroxamic acid, prevented IFNgamma-induced JAK1 activation, STAT1 phosphorylation, its nuclear translocation, and STAT1-dependent gene activation.	trichostatin A	96-110	Janus kinase 1	Homo sapiens	176-180
15123634-2	2004	In this study we demonstrated that inhibitors of histone deacetylase (HDAC) activity, butyrate, trichostatin A, and suberoylanilide hydroxamic acid, prevented IFNgamma-induced JAK1 activation, STAT1 phosphorylation, its nuclear translocation, and STAT1-dependent gene activation.	Vorinostat	116-147	Janus kinase 1	Homo sapiens	176-180
14978237-4	2004	Tyrosine phosphorylation of Janus kinases (JAK) 1/2 was induced by IFN-gamma but not by TPA.	Tyrosine	0-8	Janus kinase 1	Homo sapiens	28-51
14978237-6	2004	IFN-gamma-induced tyrosine phosphorylation of phospholipase C (PLC)-gamma was inhibited by AG 490 (a JAK inhibitor), and the association between JAK1/2 and PLC-gamma was increased after IFN-gamma treatment, indicating the activation of PLC-gamma via JAK1/2 phosphorylation.	Tyrosine	18-26	Janus kinase 1	Homo sapiens	145-151
14978237-7	2004	ICAM-1 promoter activities induced by the overexpression of wild-type JAK1- and PLC-gamma2 were blocked by the PLCgamma2 mutant or the dominant-negative PKCalpha (Lys--&gt;Arg), c-Src (Lys--&gt;Met), or STAT1 (Y701M) mutants, but not by dominant-negative STAT3 (DN) mutants.	Arginine	172-175	Janus kinase 1	Homo sapiens	70-74
14978237-6	2004	IFN-gamma-induced tyrosine phosphorylation of phospholipase C (PLC)-gamma was inhibited by AG 490 (a JAK inhibitor), and the association between JAK1/2 and PLC-gamma was increased after IFN-gamma treatment, indicating the activation of PLC-gamma via JAK1/2 phosphorylation.	Tyrosine	18-26	Janus kinase 1	Homo sapiens	145-149
14978237-7	2004	ICAM-1 promoter activities induced by the overexpression of wild-type JAK1- and PLC-gamma2 were blocked by the PLCgamma2 mutant or the dominant-negative PKCalpha (Lys--&gt;Arg), c-Src (Lys--&gt;Met), or STAT1 (Y701M) mutants, but not by dominant-negative STAT3 (DN) mutants.	Lysine	185-188	Janus kinase 1	Homo sapiens	70-74
14970177-3	2004	Here we show that vIL-6 is N-linked glycosylated at N78 and N89 and demonstrate that N-linked glycosylation at site N89 of vIL-6 markedly enhances binding to gp130, signaling through the JAK1-STAT1/3 pathway and functions in a cytokine-dependent cell proliferation bioassay.	vil-6	18-23	Janus kinase 1	Homo sapiens	187-191
14970177-3	2004	Here we show that vIL-6 is N-linked glycosylated at N78 and N89 and demonstrate that N-linked glycosylation at site N89 of vIL-6 markedly enhances binding to gp130, signaling through the JAK1-STAT1/3 pathway and functions in a cytokine-dependent cell proliferation bioassay.	vil-6	123-128	Janus kinase 1	Homo sapiens	187-191
14647450-7	2004	However, inhibition of Jak1 expression also decreased IFN-alpha-induced tyrosine phosphorylation of ErbB3.	Tyrosine	72-80	Janus kinase 1	Homo sapiens	23-27
12941469-3	2003	Exposure of human neuroblastoma cells, BE(2)-C, first to tyrosine phosphatase inhibitors (either phenylarsine oxide or PTP inhibitor-2) prevented Jak1, STAT1 and STAT3 activation elicited subsequently by either CNTF or interferon-gamma.	oxophenylarsine	97-115	Janus kinase 1	Homo sapiens	146-150
14555918-6	2003	STAT activation is strongly associated with tyrosine phosphorylation by tyrosine kinases, namely Jak1, Jak2, Jak3, and Tyk2.	Tyrosine	44-52	Janus kinase 1	Homo sapiens	97-101
12771930-4	2003	Signalling cascade studies revealed that IL-10 stimulated tyrosine phosphorylation of JAK1 and TYK2 receptor kinases and tyrosine phosphorylation of IL-10E1.	Tyrosine	58-66	Janus kinase 1	Homo sapiens	86-90
12837923-7	2003	JAK1 and JNK1 were two of the genes shown by the arrays to be down-regulated in RU486-treated endometrial explants.	Mifepristone	80-85	Janus kinase 1	Homo sapiens	0-4
12802285-2	2003	IL-10E1 signaling involves tyrosine phosphorylation of the IL-10R JAK1 (Janus kinase) and TYK2 (tyrosine kinase) receptor kinases and tyrosine phosphorylation of two tyrosine moieties (Y57 and Y62) of a LIM domain of the IL-10E1 protein.	Tyrosine	27-35	Janus kinase 1	Homo sapiens	66-70
12738762-6	2003	The up-regulation of Fer and its dissociation from Jak1 were accompanied by an augmented association of activated Fer with Stat3 and by a concomitant increase in the tyrosine phosphorylation of Stat3.	Tyrosine	166-174	Janus kinase 1	Homo sapiens	51-55
12584205-4	2003	We show that 15-deoxy-Delta12,14-prostaglandin J(2) (15d-PGJ(2)) and rosiglitazone reduce the phosphorylation of STAT1 and STAT3 as well as Janus kinase 1 (JAK1) and JAK2 in activated astrocytes and microglia.	14-prostaglandin j	30-48	Janus kinase 1	Homo sapiens	140-154
12584205-4	2003	We show that 15-deoxy-Delta12,14-prostaglandin J(2) (15d-PGJ(2)) and rosiglitazone reduce the phosphorylation of STAT1 and STAT3 as well as Janus kinase 1 (JAK1) and JAK2 in activated astrocytes and microglia.	14-prostaglandin j	30-48	Janus kinase 1	Homo sapiens	156-160
12584205-4	2003	We show that 15-deoxy-Delta12,14-prostaglandin J(2) (15d-PGJ(2)) and rosiglitazone reduce the phosphorylation of STAT1 and STAT3 as well as Janus kinase 1 (JAK1) and JAK2 in activated astrocytes and microglia.	2-(ETHOXYMETHYL)-4-(4-FLUOROPHENYL)-3-[2-(2-HYDROXYPHENOXY)PYRIMIDIN-4-YL]ISOXAZOL-5(2H)-ONE	57-60	Janus kinase 1	Homo sapiens	140-154
12584205-4	2003	We show that 15-deoxy-Delta12,14-prostaglandin J(2) (15d-PGJ(2)) and rosiglitazone reduce the phosphorylation of STAT1 and STAT3 as well as Janus kinase 1 (JAK1) and JAK2 in activated astrocytes and microglia.	2-(ETHOXYMETHYL)-4-(4-FLUOROPHENYL)-3-[2-(2-HYDROXYPHENOXY)PYRIMIDIN-4-YL]ISOXAZOL-5(2H)-ONE	57-60	Janus kinase 1	Homo sapiens	156-160
12584205-4	2003	We show that 15-deoxy-Delta12,14-prostaglandin J(2) (15d-PGJ(2)) and rosiglitazone reduce the phosphorylation of STAT1 and STAT3 as well as Janus kinase 1 (JAK1) and JAK2 in activated astrocytes and microglia.	Rosiglitazone	69-82	Janus kinase 1	Homo sapiens	140-154
12584205-4	2003	We show that 15-deoxy-Delta12,14-prostaglandin J(2) (15d-PGJ(2)) and rosiglitazone reduce the phosphorylation of STAT1 and STAT3 as well as Janus kinase 1 (JAK1) and JAK2 in activated astrocytes and microglia.	Rosiglitazone	69-82	Janus kinase 1	Homo sapiens	156-160
12551917-7	2003	We provide evidence that JAK1, like JAK2, phosphorylates Tyr-439 and Tyr-494 in SH2-Bbeta and that PDGF receptor phosphorylates SH2-Bbeta on Tyr-439.	Tyrosine	69-72	Janus kinase 1	Homo sapiens	25-29
12589807-2	2003	Making use of Jak-1 or STAT-1 deficient cell lines, we demonstrated that the apoptotic process induced by butyrate is independent of the presence of these proteins.	Butyrates	106-114	Janus kinase 1	Homo sapiens	14-19
12551917-7	2003	We provide evidence that JAK1, like JAK2, phosphorylates Tyr-439 and Tyr-494 in SH2-Bbeta and that PDGF receptor phosphorylates SH2-Bbeta on Tyr-439.	Tyrosine	57-60	Janus kinase 1	Homo sapiens	25-29
12551917-7	2003	We provide evidence that JAK1, like JAK2, phosphorylates Tyr-439 and Tyr-494 in SH2-Bbeta and that PDGF receptor phosphorylates SH2-Bbeta on Tyr-439.	Tyrosine	69-72	Janus kinase 1	Homo sapiens	25-29
12559972-2	2003	Since transphosphorylation of the two kinases is presumed to occur after receptor engagement we examined the phosphorylation by recombinant JAK3 of a peptide substrate corresponding to the JAK1 activation loop (KAIETDKEYYTVKD), which has two adjacent tyrosines.	Tyrosine	251-260	Janus kinase 1	Homo sapiens	189-193
12559972-5	2003	Kinetic analysis of the reactions of singly phosphorylated JAK1 activation loop peptides showed that phosphorylating the first or second tyrosine decreased the k(cat)/K(m) for the phosphorylation of the other 115- and 26-fold, respectively.	Tyrosine	137-145	Janus kinase 1	Homo sapiens	59-63
11960349-3	2002	The reduced IL-6-mediated STAT3 tyrosine phosphorylation after pre-treatment with TGF-beta1 was associated with apoptosis and coincided with the degradation of certain cellular proteins, including JAK1 and -2 and Tyk2, without affecting the ERK expression and phosphorylation.	Tyrosine	32-40	Janus kinase 1	Homo sapiens	197-208
12044887-5	2002	Regulation of inducible ICAM-1 expression by taxifolin was at transcriptional level by inhibiting the activation of signal transducers and activators of transcription (STAT)1 and protein tyrosine phosphorylation of Janus kinase (JAK)1 suggesting that the JAK-STAT pathway may be the molecular site of action of taxifolin.	taxifolin	45-54	Janus kinase 1	Homo sapiens	229-234
12177620-5	2002	METHODS: The tyrosine phosphorylation (P-tyr) states of the Janus kinases (Jaks) and signal transducers and activators of transcription (STAT) proteins were examined by immunoprecipitation and immunoblot.	Tyrosine	13-21	Janus kinase 1	Homo sapiens	75-79
12177620-5	2002	METHODS: The tyrosine phosphorylation (P-tyr) states of the Janus kinases (Jaks) and signal transducers and activators of transcription (STAT) proteins were examined by immunoprecipitation and immunoblot.	Tyrosine	13-16	Janus kinase 1	Homo sapiens	75-79
11882386-3	2002	In the human cell line (SH-SY5Y), STAT1 and STAT3 activation by CNTF-like cytokines showed tyrosine phosphorylation peaking at 0.5 h and inactivating within 2 h. Tyrosine phosphorylation of the receptor-associated tyrosine kinases Jak1 and Jak2 showed a similar time course of activation and inactivation in response to CNTF.	Tyrosine	162-170	Janus kinase 1	Homo sapiens	231-235
12018856-2	2002	Although STAT1 activation is primarily induced upon tyrosine phosphorylation by Jak1 and Jak2 (the IFN-gamma receptor-associated tyrosine kinases), the full activation of STAT1 is thought to involve serine phosphorylation by unidentified protein kinases.	Tyrosine	52-60	Janus kinase 1	Homo sapiens	80-84
11960349-6	2002	It was shown that in AML cells cultured in the presence of Z-VAD-fmk, TGF-beta1 pretreatment resulted in a reduction of JAK1 phosphorylation upon IL-6 stimulation.	benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone	59-68	Janus kinase 1	Homo sapiens	120-124
11442760-8	2001	The kinase upstream of signal transducer and activator of transcription 3, Janus kinase 1, was constitutively tyrosine-phosphorylated in WM9 cells and did not respond to interleukin-6 with increased phosphorylation.	Tyrosine	110-118	Janus kinase 1	Homo sapiens	75-89
11751854-9	2002	However, SH2-B beta bound to both and was tyrosyl-phosphorylated by JAK1.	cyclo(tyrosyl-tyrosyl)	42-49	Janus kinase 1	Homo sapiens	68-72
11751854-11	2002	APS also decreased tyrosyl phosphorylation of JAK1, but did not affect the activity or tyrosyl phosphorylation of JAK3.	Adenosine Phosphosulfate	0-3	Janus kinase 1	Homo sapiens	46-50
11751854-11	2002	APS also decreased tyrosyl phosphorylation of JAK1, but did not affect the activity or tyrosyl phosphorylation of JAK3.	cyclo(tyrosyl-tyrosyl)	19-26	Janus kinase 1	Homo sapiens	46-50
11751854-12	2002	Overexpressed APS bound to and was tyrosyl-phosphorylated by all three JAKs.	Adenosine Phosphosulfate	14-17	Janus kinase 1	Homo sapiens	71-75
11751854-12	2002	Overexpressed APS bound to and was tyrosyl-phosphorylated by all three JAKs.	cyclo(tyrosyl-tyrosyl)	35-42	Janus kinase 1	Homo sapiens	71-75
11438544-6	2001	In addition to PI3K and Akt, JAK1, JAK2, and the tyrosine 440 STAT1 docking residue of IFNGR1 are required for STAT1 to be phosphorylated on serine.	Serine	141-147	Janus kinase 1	Homo sapiens	29-33
11438544-7	2001	Taken together, these results suggest that the following events lead to the activation of STAT1 upon IFN gamma stimulation: 1) PI3K and Akt are activated by the occupied receptor and Tyr-440 is phosphorylated by the activated JAKs; 2) STAT1 docks to Tyr-440; and 3) Tyr-701 is phosphorylated by the JAKs and Ser-727 is phosphorylated by a kinase downstream of Akt.	Tyrosine	183-186	Janus kinase 1	Homo sapiens	226-230
11438544-7	2001	Taken together, these results suggest that the following events lead to the activation of STAT1 upon IFN gamma stimulation: 1) PI3K and Akt are activated by the occupied receptor and Tyr-440 is phosphorylated by the activated JAKs; 2) STAT1 docks to Tyr-440; and 3) Tyr-701 is phosphorylated by the JAKs and Ser-727 is phosphorylated by a kinase downstream of Akt.	Tyrosine	183-186	Janus kinase 1	Homo sapiens	299-303
11438544-7	2001	Taken together, these results suggest that the following events lead to the activation of STAT1 upon IFN gamma stimulation: 1) PI3K and Akt are activated by the occupied receptor and Tyr-440 is phosphorylated by the activated JAKs; 2) STAT1 docks to Tyr-440; and 3) Tyr-701 is phosphorylated by the JAKs and Ser-727 is phosphorylated by a kinase downstream of Akt.	Tyrosine	250-253	Janus kinase 1	Homo sapiens	226-230
11438544-7	2001	Taken together, these results suggest that the following events lead to the activation of STAT1 upon IFN gamma stimulation: 1) PI3K and Akt are activated by the occupied receptor and Tyr-440 is phosphorylated by the activated JAKs; 2) STAT1 docks to Tyr-440; and 3) Tyr-701 is phosphorylated by the JAKs and Ser-727 is phosphorylated by a kinase downstream of Akt.	Tyrosine	250-253	Janus kinase 1	Homo sapiens	299-303
11438544-7	2001	Taken together, these results suggest that the following events lead to the activation of STAT1 upon IFN gamma stimulation: 1) PI3K and Akt are activated by the occupied receptor and Tyr-440 is phosphorylated by the activated JAKs; 2) STAT1 docks to Tyr-440; and 3) Tyr-701 is phosphorylated by the JAKs and Ser-727 is phosphorylated by a kinase downstream of Akt.	Tyrosine	250-253	Janus kinase 1	Homo sapiens	226-230
11438544-7	2001	Taken together, these results suggest that the following events lead to the activation of STAT1 upon IFN gamma stimulation: 1) PI3K and Akt are activated by the occupied receptor and Tyr-440 is phosphorylated by the activated JAKs; 2) STAT1 docks to Tyr-440; and 3) Tyr-701 is phosphorylated by the JAKs and Ser-727 is phosphorylated by a kinase downstream of Akt.	Tyrosine	250-253	Janus kinase 1	Homo sapiens	299-303
11438544-7	2001	Taken together, these results suggest that the following events lead to the activation of STAT1 upon IFN gamma stimulation: 1) PI3K and Akt are activated by the occupied receptor and Tyr-440 is phosphorylated by the activated JAKs; 2) STAT1 docks to Tyr-440; and 3) Tyr-701 is phosphorylated by the JAKs and Ser-727 is phosphorylated by a kinase downstream of Akt.	Serine	308-311	Janus kinase 1	Homo sapiens	226-230
11438544-7	2001	Taken together, these results suggest that the following events lead to the activation of STAT1 upon IFN gamma stimulation: 1) PI3K and Akt are activated by the occupied receptor and Tyr-440 is phosphorylated by the activated JAKs; 2) STAT1 docks to Tyr-440; and 3) Tyr-701 is phosphorylated by the JAKs and Ser-727 is phosphorylated by a kinase downstream of Akt.	Serine	308-311	Janus kinase 1	Homo sapiens	299-303
11751854-14	2002	These results suggest that 1) SH2-B beta specifically activates JAK2, 2) APS negatively regulates both JAK2 and JAK1, and 3) both SH2-B beta and APS may serve as adapter proteins for all three JAKs independent of any role they have in JAK activity.	Adenosine Phosphosulfate	73-76	Janus kinase 1	Homo sapiens	112-116
11751854-14	2002	These results suggest that 1) SH2-B beta specifically activates JAK2, 2) APS negatively regulates both JAK2 and JAK1, and 3) both SH2-B beta and APS may serve as adapter proteins for all three JAKs independent of any role they have in JAK activity.	Adenosine Phosphosulfate	73-76	Janus kinase 1	Homo sapiens	193-197
11751854-14	2002	These results suggest that 1) SH2-B beta specifically activates JAK2, 2) APS negatively regulates both JAK2 and JAK1, and 3) both SH2-B beta and APS may serve as adapter proteins for all three JAKs independent of any role they have in JAK activity.	Adenosine Phosphosulfate	73-76	Janus kinase 1	Homo sapiens	64-67
11751854-14	2002	These results suggest that 1) SH2-B beta specifically activates JAK2, 2) APS negatively regulates both JAK2 and JAK1, and 3) both SH2-B beta and APS may serve as adapter proteins for all three JAKs independent of any role they have in JAK activity.	Adenosine Phosphosulfate	145-148	Janus kinase 1	Homo sapiens	112-116
11751854-14	2002	These results suggest that 1) SH2-B beta specifically activates JAK2, 2) APS negatively regulates both JAK2 and JAK1, and 3) both SH2-B beta and APS may serve as adapter proteins for all three JAKs independent of any role they have in JAK activity.	Adenosine Phosphosulfate	145-148	Janus kinase 1	Homo sapiens	193-197
11751854-14	2002	These results suggest that 1) SH2-B beta specifically activates JAK2, 2) APS negatively regulates both JAK2 and JAK1, and 3) both SH2-B beta and APS may serve as adapter proteins for all three JAKs independent of any role they have in JAK activity.	Adenosine Phosphosulfate	145-148	Janus kinase 1	Homo sapiens	64-67
12661403-7	2002	The connections of IL-2R or IL-12R with their ligands recruit receptor-associated cytoplasmic proteins from the JAK family (JAK1/JAK3 or JAK2/TYK2, respectively), which catalyze the phosphorylation of themselves and intrinsic tyrosine residues on the receptor, creating STAT docking sites.	Tyrosine	226-234	Janus kinase 1	Homo sapiens	112-115
12661403-7	2002	The connections of IL-2R or IL-12R with their ligands recruit receptor-associated cytoplasmic proteins from the JAK family (JAK1/JAK3 or JAK2/TYK2, respectively), which catalyze the phosphorylation of themselves and intrinsic tyrosine residues on the receptor, creating STAT docking sites.	Tyrosine	226-234	Janus kinase 1	Homo sapiens	124-128
11468294-4	2001	Substitution of Tyr(107) to alanine, a residue conserved among Jaks and involved in hydrophobic core interactions of the proposed beta-grasp domain, abrogated binding of full-length Jak1 to gp130 in COS-7 transfectants.	carbonyl sulfide	199-202	Janus kinase 1	Homo sapiens	182-186
11369622-3	2001	This study reports that SDF-1alpha can stimulate the tyrosine phosphorylation of Janus kinase 2 (JAK2) and other members of the JAK/signal transduction and activation of transcription (STAT) family, including JAK1, tyrosine kinase 2, STAT2, and STAT4 in the human progenitor cell line, CTS.	Tyrosine	53-61	Janus kinase 1	Homo sapiens	209-213
11294841-7	2001	The results obtained showed an activation of Janus kinases (JAK1, JAK2, and TYK2) leading to a tyrosine phosphorylation of the gp130 and LIFR.	Tyrosine	95-103	Janus kinase 1	Homo sapiens	60-64
11160325-6	2001	Fes appears to be a downstream kinase from Jak1/Jak3 in this process.	Iron	0-3	Janus kinase 1	Homo sapiens	43-47
11162588-1	2001	We have previously shown that interferon-alpha (IFN alpha)-dependent tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1) is impaired by serine phosphorylation of IRS-1 due to the reduced ability of serine phosphorylated IRS-1 to serve as a substrate for Janus kinase 1 (JAK1).	Serine	211-217	Janus kinase 1	Homo sapiens	267-281
11162588-1	2001	We have previously shown that interferon-alpha (IFN alpha)-dependent tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1) is impaired by serine phosphorylation of IRS-1 due to the reduced ability of serine phosphorylated IRS-1 to serve as a substrate for Janus kinase 1 (JAK1).	Serine	211-217	Janus kinase 1	Homo sapiens	283-287
11162588-1	2001	We have previously shown that interferon-alpha (IFN alpha)-dependent tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1) is impaired by serine phosphorylation of IRS-1 due to the reduced ability of serine phosphorylated IRS-1 to serve as a substrate for Janus kinase 1 (JAK1).	Tyrosine	69-77	Janus kinase 1	Homo sapiens	267-281
11162588-1	2001	We have previously shown that interferon-alpha (IFN alpha)-dependent tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1) is impaired by serine phosphorylation of IRS-1 due to the reduced ability of serine phosphorylated IRS-1 to serve as a substrate for Janus kinase 1 (JAK1).	Tyrosine	69-77	Janus kinase 1	Homo sapiens	283-287
11162588-4	2001	Importantly, only FRAP-dependent IRS-1(511-772) serine phosphorylation inhibited by 50% subsequent JAK1-dependent tyrosine phosphorylation of IRS-1.	Serine	48-54	Janus kinase 1	Homo sapiens	99-103
11162588-1	2001	We have previously shown that interferon-alpha (IFN alpha)-dependent tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1) is impaired by serine phosphorylation of IRS-1 due to the reduced ability of serine phosphorylated IRS-1 to serve as a substrate for Janus kinase 1 (JAK1).	Serine	149-155	Janus kinase 1	Homo sapiens	267-281
11162588-4	2001	Importantly, only FRAP-dependent IRS-1(511-772) serine phosphorylation inhibited by 50% subsequent JAK1-dependent tyrosine phosphorylation of IRS-1.	Tyrosine	114-122	Janus kinase 1	Homo sapiens	99-103
11162588-1	2001	We have previously shown that interferon-alpha (IFN alpha)-dependent tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1) is impaired by serine phosphorylation of IRS-1 due to the reduced ability of serine phosphorylated IRS-1 to serve as a substrate for Janus kinase 1 (JAK1).	Serine	149-155	Janus kinase 1	Homo sapiens	283-287
11162588-6	2001	Taken together, these data indicate that FRAP, but not p70(s6k), is a likely physiologic IRS-1 serine kinase that negatively regulates JAK1-dependent IRS-1 tyrosine phosphorylation and suggests that FRAP may modulate IRS-dependent cytokine signaling.	Tyrosine	156-164	Janus kinase 1	Homo sapiens	135-139
10993906-6	2000	STAM2 is downstream of the Jak family of kinases since coexpression of STAM2 with Jak1 or Jak2 but not an unrelated Tec family kinase, Etk, resulted in its tyrosine phosphorylation.	Tyrosine	156-164	Janus kinase 1	Homo sapiens	27-30
11133764-4	2001	In cotransfection experiments, JAB/SOCS1/SSI-1 associates with both Jak1 and Jak3; however, JAB/SOCS1/SSI-1 had a greater effect on Jak1 tyrosine phosphorylation and kinase activity.	Tyrosine	137-145	Janus kinase 1	Homo sapiens	132-136
11163041-5	2001	The induction of protein tyrosine phosphorylation of proteins including PTKs, janus kinase (JAK)1, and JAK2, was examined by Western blotting and immunoprecipitation.	Tyrosine	25-33	Janus kinase 1	Homo sapiens	78-97
11163041-7	2001	RESULTS: IFN 1 (Interferon) induced tyrosine phosphorylation of multiple substrates, particularly that of 75,000; 90,000; 130,000; and 160,000 molecular weight proteins including JAK1 and JAK2 in cultured HCE cells.	Tyrosine	36-44	Janus kinase 1	Homo sapiens	179-183
11163041-11	2001	CONCLUSIONS: Tyrosine phosphorylation of proteins including JAK1 and JAK2 is essential for IFN-gamma-induction of MHC class II expression, but not critical for that of ICAM-1 expression in cultured HCE cells.	Tyrosine	13-21	Janus kinase 1	Homo sapiens	60-64
10993906-6	2000	STAM2 is downstream of the Jak family of kinases since coexpression of STAM2 with Jak1 or Jak2 but not an unrelated Tec family kinase, Etk, resulted in its tyrosine phosphorylation.	Tyrosine	156-164	Janus kinase 1	Homo sapiens	82-86
11046056-8	2000	Jak1 was inhibited at the level of tyrosine phosphorylation, indicating that inhibition occurred at least in part upstream of Stats in the Jak-Stat pathway.	Tyrosine	35-43	Janus kinase 1	Homo sapiens	0-4
10875931-4	2000	Tyrosine kinases, Jak1 and Jak3, involved in IL-4 signaling can associate with SHIP, yet only Jak1 can tyrosine-phosphorylate SHIP when co-expressed.	Tyrosine	103-111	Janus kinase 1	Homo sapiens	18-22
10982844-5	2000	Nuclear presence of tyrosine-phosphorylated STAT1 could be restored in Jak1-deficient cells by leptomycin B, an inhibitor of nuclear export.	Tyrosine	20-28	Janus kinase 1	Homo sapiens	71-75
10982844-5	2000	Nuclear presence of tyrosine-phosphorylated STAT1 could be restored in Jak1-deficient cells by leptomycin B, an inhibitor of nuclear export.	leptomycin B	95-107	Janus kinase 1	Homo sapiens	71-75
10982844-8	2000	Impaired binding of the transcriptional coactivator CBP to tyrosine-phosphorylated STAT1 derived from Jak1-deficient cells offers a model for the intermolecular regulation of the nuclear export sequence.	Tyrosine	59-67	Janus kinase 1	Homo sapiens	102-106
11096454-5	2000	The receptor blockade by mAb 51.44 and 234.28 resulted in the inhibition of IFN-alpha2a and IFN-beta-induced tyrosine phosphorylation of Jak1, Tyk2, Stat1/2/3, and IFNAR-1/2 and inhibition of IFN-stimulated gene factor 3 (ISGF3) formation.	Tyrosine	109-117	Janus kinase 1	Homo sapiens	137-141
10875931-4	2000	Tyrosine kinases, Jak1 and Jak3, involved in IL-4 signaling can associate with SHIP, yet only Jak1 can tyrosine-phosphorylate SHIP when co-expressed.	Tyrosine	103-111	Janus kinase 1	Homo sapiens	94-98
10747872-5	2000	Moreover, tyrosine phosphorylation of STAT3, JAK1, and JAK2 was increased upon IGF-I stimulation of endogenous IGF-IR in 293T cells transfected with the respective STAT or JAK expression vector.	Tyrosine	10-18	Janus kinase 1	Homo sapiens	45-49
10918594-3	2000	Analysis of the early signals triggered by IFN-alpha and IFN-beta demonstrated that the two IFNs were similarly effective in inducing tyrosine phosphorylation of the Jak-1 and Tyk-2 kinases and the transcription factors Stat-1 and Stat-2.	Tyrosine	134-142	Janus kinase 1	Homo sapiens	166-171
10747872-7	2000	Dominant-negative JAK1 or JAK2 was able to block the IGF-IR-mediated tyrosine phosphorylation of STAT3 in 293T cells.	Tyrosine	69-77	Janus kinase 1	Homo sapiens	18-22
10586107-5	1999	Type I IFN induces the phosphorylation of STAT1 and STAT2 proteins by tyrosine phosphorylation involving the type I IFN receptor-associated tyrosine kinases TYK2 and JAK1.	Tyrosine	70-78	Janus kinase 1	Homo sapiens	166-170
10660600-1	2000	Degenerate polymerase chain reaction against conserved kinase catalytic subdomains identified 15 tyrosine and serine-threonine kinases expressed in surgically removed prostatic carcinoma tissues, including six receptor kinases (PDGFBR, IGF1-R, VEGFR2, MET, RYK, and EPH-A1), six non-receptor kinases (ABL, JAK1, JAK2, TYK2, PLK-1, and EMK), and three novel kinases.	Tyrosine	97-105	Janus kinase 1	Homo sapiens	306-310
10666284-4	2000	Moreover, tyrosine phosphorylation of Jak1 in response to IFN-alpha was unaffected at the early phase of infection, suggesting that oligomerization of the receptor subunits proceeded normally.	Tyrosine	10-18	Janus kinase 1	Homo sapiens	38-42
10488146-0	1999	JAK1-dependent phosphorylation of insulin receptor substrate-1 (IRS-1) is inhibited by IRS-1 serine phosphorylation.	Serine	93-99	Janus kinase 1	Homo sapiens	0-4
10488146-3	1999	In addition, we demonstrate that serine phosphorylation of IRS-1 renders it a poorer substrate for JAK1 (Janus kinase-1).	Serine	33-39	Janus kinase 1	Homo sapiens	99-103
10488146-8	1999	Taken together, these data indicate that serine phosphorylation of IRS-1 prevents its subsequent tyrosine phosphorylation by JAK1 and suggest that IRS-1 serine phosphorylation may play a counter-regulatory role in pathways outside the insulin signaling system.	Tyrosine	97-105	Janus kinase 1	Homo sapiens	125-129
10488146-3	1999	In addition, we demonstrate that serine phosphorylation of IRS-1 renders it a poorer substrate for JAK1 (Janus kinase-1).	Serine	33-39	Janus kinase 1	Homo sapiens	105-119
10488146-8	1999	Taken together, these data indicate that serine phosphorylation of IRS-1 prevents its subsequent tyrosine phosphorylation by JAK1 and suggest that IRS-1 serine phosphorylation may play a counter-regulatory role in pathways outside the insulin signaling system.	Serine	153-159	Janus kinase 1	Homo sapiens	125-129
10488146-8	1999	Taken together, these data indicate that serine phosphorylation of IRS-1 prevents its subsequent tyrosine phosphorylation by JAK1 and suggest that IRS-1 serine phosphorylation may play a counter-regulatory role in pathways outside the insulin signaling system.	Serine	41-47	Janus kinase 1	Homo sapiens	125-129
10404396-5	1999	It is clear that PRL activates the tyrosine phosphorylation of several proteins, including members of a novel family of protein tyrosine kinases, the Janus Kinases (JAKs).	Tyrosine	35-43	Janus kinase 1	Homo sapiens	165-169
10433356-6	1999	STAT3 binds to these sites via its SH2 (Src homology 2) domain, and is, in turn, tyrosine-phosphorylated by the receptor-associated JAKs.	Tyrosine	81-89	Janus kinase 1	Homo sapiens	132-136
10409622-9	1999	A glutathione S-transferase fusion protein of the cytoplasmic domain of IL-13Ralpha was phosphorylated on tyrosine in vitro by JAK1, JAK3, and Tyk2, although the tyrosine phosphorylation events mediated by Tyk2 and JAK3 were not detectable using anti-phosphotyrosine antibodies.	Tyrosine	106-114	Janus kinase 1	Homo sapiens	127-131
10373548-5	1999	Tyrosine phosphorylation of SOCS-3 was observed upon coexpression with Jak1 and Jak2 but only weakly with Jak3.	Tyrosine	0-8	Janus kinase 1	Homo sapiens	71-75
10373548-7	1999	Moreover, following IL-2 stimulation of T cells, SOCS-3 was able to interact with the IL-2 receptor complex, and in particular tyrosine phosphorylated Jak1 and IL-2Rbeta.	Tyrosine	127-135	Janus kinase 1	Homo sapiens	151-155
10502458-2	1999	In addition, growth hormone (GH) stimulates tyrosine phosphorylation of Jak1 and Jak3 in certain cell lines, while the effect on Tyk2 has not been analysed.	Tyrosine	44-52	Janus kinase 1	Homo sapiens	72-76
10037026-2	1999	Wild type Jak3 was able to tyrosine phosphorylate a kinase-dead Jak1 (Jak1E908).	Tyrosine	27-35	Janus kinase 1	Homo sapiens	64-68
10080544-1	1999	Binding of interferon-gamma (IFN-gamma) to its heterodimeric receptor induces activation of the tyrosine kinases JAK1 and JAK2 followed by tyrosine phosphorylation of STAT1alpha.	Tyrosine	96-104	Janus kinase 1	Homo sapiens	113-117
10224470-7	1999	RESULTS: We show that binding of IFN-gamma to human eosinophils initiated a series of events that resulted in the rapid tyrosine phosphorylation of not only the IFN-gammaRalpha chain but also Jak1, Jak2, and Stat1alpha.	Tyrosine	120-128	Janus kinase 1	Homo sapiens	192-196
9935235-9	1999	Furthermore, stimulation of IMC-2 cells with rG-CSF induced rapid activation of tyrosine-phosphorylated JAK1, suggesting that the G-CSF signal may be transduced into the cells through G-CSFR.	Tyrosine	80-88	Janus kinase 1	Homo sapiens	104-108
10229853-4	1999	We demonstrate that HCMV inhibits IFN-alpha-stimulated MHC class I, IFN regulatory factor-1, MxA and 2",5-oligoadenylate synthetase gene expression, transcription factor activation, and signaling in infected fibroblasts and endothelial cells by decreasing the expression of Janus kinase 1 and p48, two essential components of the IFN-alpha signal transduction pathway.	hcmv	20-24	Janus kinase 1	Homo sapiens	274-288
10408379-3	1999	JAK1 but not JAK2 was tyrosine phosphorylated in response to sublytic C5b-9.	Tyrosine	22-30	Janus kinase 1	Homo sapiens	0-4
10233717-6	1999	In vitro analyses using synthetic peptides of this region showed that the tyrosine kinase Janus kinase 1 (JAK1), as well as IRS-1 and IRS-2 bind to the I4R motif irrespective of the polymorphism or a tyrosine phosphorylation.	Tyrosine	74-82	Janus kinase 1	Homo sapiens	90-104
10233717-6	1999	In vitro analyses using synthetic peptides of this region showed that the tyrosine kinase Janus kinase 1 (JAK1), as well as IRS-1 and IRS-2 bind to the I4R motif irrespective of the polymorphism or a tyrosine phosphorylation.	Tyrosine	74-82	Janus kinase 1	Homo sapiens	106-110
10037026-2	1999	Wild type Jak3 was able to tyrosine phosphorylate a kinase-dead Jak1 (Jak1E908).	Tyrosine	27-35	Janus kinase 1	Homo sapiens	70-78
10037026-6	1999	By comparison only IL2Rbeta was recognized and tyrosine phosphorylated by wild-type Jak1.	Tyrosine	47-55	Janus kinase 1	Homo sapiens	84-88
9278334-8	1997	Furthermore, the tyrosine phosphorylation of STAT1 and the tyrosine kinases JAK1 and JAK2 was enhanced significantly in RGD-adherent monocytes compared with control cells.	Tyrosine	17-25	Janus kinase 1	Homo sapiens	76-80
9849880-0	1998	Constitutive association of JAK1 and STAT5 in pro-B cells is dissolved by interleukin-4-induced tyrosine phosphorylation of both proteins.	Tyrosine	96-104	Janus kinase 1	Homo sapiens	28-32
9794795-7	1998	It is concluded that Jak1 is required for the tyrosine phosphorylation of SHP2.	Tyrosine	46-54	Janus kinase 1	Homo sapiens	21-25
9774657-6	1998	We also found that Jak1 interacts with p85 in the absence of IL-2Rbeta and that IL-2Rbeta and Jak1 cooperate for the efficient recruitment and tyrosine phosphorylation of p85.	Tyrosine	143-151	Janus kinase 1	Homo sapiens	94-98
9788278-6	1998	In this study, we report that PDGF- and CNTF-induced OL progenitors responded with a rapid tyrosine phosphorylation of JAK1, JAK2, STAT1alpha/beta, and STAT3.	Tyrosine	91-99	Janus kinase 1	Homo sapiens	119-123
9520455-1	1998	Interleukin 2 (IL-2) rapidly induces tyrosine phosphorylation of intracellular substrates, including the IL-2 receptor beta chain (IL-2Rbeta), Janus kinase 1 (Jak1), Jak3, signal transducer/activator of transcription proteins, and Shc, but the mechanism underlying dephosphorylation of these proteins is not known.	Tyrosine	37-45	Janus kinase 1	Homo sapiens	143-157
9520455-1	1998	Interleukin 2 (IL-2) rapidly induces tyrosine phosphorylation of intracellular substrates, including the IL-2 receptor beta chain (IL-2Rbeta), Janus kinase 1 (Jak1), Jak3, signal transducer/activator of transcription proteins, and Shc, but the mechanism underlying dephosphorylation of these proteins is not known.	Tyrosine	37-45	Janus kinase 1	Homo sapiens	159-163
9520455-3	1998	We have found that IL-2 induces association of SHP-1 with the IL-2 receptor complex, and that once SHP-1 is recruited to the activated receptor it is able to decrease tyrosine phosphorylation of IL-2Rbeta and the associated tyrosine kinases Jak1 and Jak3.	Tyrosine	167-175	Janus kinase 1	Homo sapiens	241-245
9452436-4	1998	G-CSF-dependent tyrosyl phosphorylation of Jak1 and Jak2 occurred in all three cell lines.	cyclo(tyrosyl-tyrosyl)	16-23	Janus kinase 1	Homo sapiens	43-47
9637709-1	1998	PDGF stimulates tyrosine phosphorylation of Janus kinase 1 (JAK1) and the signal transducer and activator of transcription 1 (STAT1alpha).	Tyrosine	16-24	Janus kinase 1	Homo sapiens	44-58
9637709-1	1998	PDGF stimulates tyrosine phosphorylation of Janus kinase 1 (JAK1) and the signal transducer and activator of transcription 1 (STAT1alpha).	Tyrosine	16-24	Janus kinase 1	Homo sapiens	60-64
9610741-6	1998	Upon stimulation with IL-6/sIL-6R, the gp130, cytoplasmic Janus kinases JAK1 and JAK2 were tyrosine phosphorylated.	Tyrosine	91-99	Janus kinase 1	Homo sapiens	72-76
9516124-7	1998	IL-5 stimulation resulted in tyrosine phosphorylation of JAK2, JAK1, betac, and STAT5.	Tyrosine	29-37	Janus kinase 1	Homo sapiens	63-67
9516124-9	1998	Furthermore, tyrosine phosphorylation of JAK1 was dependent on the activation of JAK2.	Tyrosine	13-21	Janus kinase 1	Homo sapiens	41-45
9452495-6	1998	MK stimulates tyrosine phosphorylation of JAK1, JAK2, and STAT1alpha.	Tyrosine	14-22	Janus kinase 1	Homo sapiens	42-46
9382798-0	1997	Janus kinases in interleukin-2-mediated signaling: JAK1 and JAK3 are differentially regulated by tyrosine phosphorylation.	Tyrosine	97-105	Janus kinase 1	Homo sapiens	51-55
9382798-2	1997	Many cytokines activate receptor-associated Janus kinases (JAKs) that promote tyrosine phosphorylation of signal transducers and activators of transcription (STAT) factors.	Tyrosine	78-86	Janus kinase 1	Homo sapiens	59-63
9382798-3	1997	Although JAK activation has been correlated with phosphorylation, the role of this tyrosine phosphorylation in the regulation of JAK1 and JAK3 remains unclear.	Tyrosine	83-91	Janus kinase 1	Homo sapiens	129-133
9382798-5	1997	RESULTS: We targeted two conserved tyrosine residues within the activation loop of the JAK1 and JAK3 kinase domains for substitution with phenylalanines.	Tyrosine	35-43	Janus kinase 1	Homo sapiens	87-91
9382798-5	1997	RESULTS: We targeted two conserved tyrosine residues within the activation loop of the JAK1 and JAK3 kinase domains for substitution with phenylalanines.	Phenylalanine	138-152	Janus kinase 1	Homo sapiens	87-91
9382798-6	1997	In an overexpression system, the catalytic function of JAK1 strictly required the presence of the first of these tyrosines, Y1033.	Tyrosine	113-122	Janus kinase 1	Homo sapiens	55-59
9382798-6	1997	In an overexpression system, the catalytic function of JAK1 strictly required the presence of the first of these tyrosines, Y1033.	y1033	124-129	Janus kinase 1	Homo sapiens	55-59
9382798-11	1997	CONCLUSIONS: JAK1 and JAK3 are differentially regulated by specific tyrosines within their respective activation loops.	Tyrosine	68-77	Janus kinase 1	Homo sapiens	13-17
9199317-2	1997	The Janus family of tyrosine kinases (Jak1, Jak2, Jak3, and Tyk2) is required for cytokine-induced tyrosine phosphorylation and dimerization of the Stat proteins.	Tyrosine	20-28	Janus kinase 1	Homo sapiens	38-42
9202126-6	1997	Interaction of JAB with Jak1, Jak2 or Jak3 markedly reduces their tyrosine-kinase activity and suppresses the tyrosine-phosphorylation and activation of STATs.	Tyrosine	66-74	Janus kinase 1	Homo sapiens	24-28
9212064-1	1997	Several different Janus kinases (JAKs) and signal transducers and activation of transcription (STATs) have been implicated in mediating the biological responses induced by PRL, based on their ligand-dependent tyrosine phosphorylation and activation.	Tyrosine	209-217	Janus kinase 1	Homo sapiens	33-37
9159166-7	1997	Disruption of the Jak1-binding proline-rich Box1 region of IL-4Ralpha abolished signaling by this chimeric receptor.	Proline	31-38	Janus kinase 1	Homo sapiens	18-22
9199189-6	1997	In contrast, IL-4 stimulated tyrosine phosphorylation of JAK1, JAK2 and tyk2 in this cell line.	Tyrosine	29-37	Janus kinase 1	Homo sapiens	57-61
9135582-2	1997	We have identified that hPL rapidly stimulated the tyrosine phosphorylation of at least 7 proteins including Janus Kinases (JAK1 and JAK2) and a signal transducer and activator of transcription protein (Stat3).	Tyrosine	51-59	Janus kinase 1	Homo sapiens	124-128
9162019-4	1997	This sustained STAT5 activation can be blocked by protein kinase inhibitors, which is consistent with the ability of the proteasome inhibitor to stabilize IL-2-induced tyrosine phosphorylation of Jak1 and Jak3.	Tyrosine	168-176	Janus kinase 1	Homo sapiens	196-200
9178903-5	1997	Furthermore, Jak1 but not Jak2 induces tyrosine phosphorylation of Btk, but not Tec.	Tyrosine	39-47	Janus kinase 1	Homo sapiens	13-17
9178903-6	1997	These observations suggest that upon cytokine stimulation JAKs activate Tec/Btk or induce their dimerization resulting in endogenous tyrosine phosphorylation.	Tyrosine	133-141	Janus kinase 1	Homo sapiens	58-62
9209327-7	1997	JAK1 and STAT5 were constitutively tyrosine-phosphorylated but the DNA binding activity of STAT5 was not induced.	Tyrosine	35-43	Janus kinase 1	Homo sapiens	0-4
9045682-0	1997	Jak1 expression is required for mediating interleukin-4-induced tyrosine phosphorylation of insulin receptor substrate and Stat6 signaling molecules.	Tyrosine	64-72	Janus kinase 1	Homo sapiens	0-4
9209410-4	1997	Furthermore, we revealed that two proline residues in the box1 region, which is conserved in the IL-2 receptor beta chain and the alpha chains of the cytokine receptors, are essentially involved in association with Jak1.	Proline	34-41	Janus kinase 1	Homo sapiens	215-219
9045682-1	1997	The Jak1, Jak2, Jak3, and Fes tyrosine kinases have been demonstrated to undergo tyrosine phosphorylation in response to interleukin (IL)-4 stimulation in different cell systems.	Tyrosine	30-38	Janus kinase 1	Homo sapiens	4-8
9045682-7	1997	Reconstitution of Jak1 expression in E1C3 cells restored the ability of IL-4 to induce IRS and Stat6 tyrosine phosphorylation.	Tyrosine	101-109	Janus kinase 1	Homo sapiens	18-22
9045682-8	1997	These results provide evidence that Jak1 expression is required for mediating tyrosine phosphorylation and activation of crucial molecules involved in IL-4 signal transduction.	Tyrosine	78-86	Janus kinase 1	Homo sapiens	36-40
9036989-6	1997	Treatment of cells with wortmannin also inhibited the phosphorylation of the p85 subunit of PI 3"-kinase and the type I IFN-regulated activation of the Map kinase, but had no inhibitory effect on the IFN-alpha-induced activation of Tyk-2 and Jak-1 kinases nor on the activation of Stat-1, Stat-2, and Stat-3.	Wortmannin	24-34	Janus kinase 1	Homo sapiens	242-247
9013940-0	1997	The IL-4-induced tyrosine phosphorylation of the insulin receptor substrate is dependent on JAK1 expression in human fibrosarcoma cells.	Tyrosine	17-25	Janus kinase 1	Homo sapiens	92-96
9047382-3	1997	In signaling from gp130, a common signal transducer for the IL-6 family cytokines, STAT3, a transcription factor that contains an SH2 domain, is recruited by phosphotyrosines on gp130 and is subsequently phosphorylated by gp130-associated JAKs.	Phosphotyrosine	158-174	Janus kinase 1	Homo sapiens	239-243
9013940-1	1997	It has been shown that IL-4 induces the tyrosine phosphorylation of JAK1 and JAK3 in the majority of hemopoietic cell types, and JAK2 and TYK2 in several other types.	Tyrosine	40-48	Janus kinase 1	Homo sapiens	68-72
9013940-3	1997	To determine whether JAKs play a role in activating a signal transduction pathway different from the classical JAK/STAT pathway, we analyzed the ability of huIL-4 to stimulate the tyrosine phosphorylation of one of its major cellular substrates, the insulin receptor substrate (IRS).	Tyrosine	180-188	Janus kinase 1	Homo sapiens	21-25
9013940-4	1997	Using human fibrosarcoma cell lines with mutations in JAK1, JAK2, and TYK2, we found that expression of functional JAK1, but not TYK2 or JAK2, is essential for IL-4-induced tyrosine phosphorylation of IRS.	Tyrosine	173-181	Janus kinase 1	Homo sapiens	115-119
8759739-3	1996	We have previously demonstrated that IFN-gamma-induced class II expression in glial cells involves activation of both tyrosine kinase and protein kinase C. IFN-gamma induces tyrosine phosphorylation of the tyrosine kinases Jak1 and Jak2 and of Stat1 alpha.	Tyrosine	118-126	Janus kinase 1	Homo sapiens	223-227
8940193-4	1996	There was low level tyrosine phosphorylation of JAKs 1, 2, and 3 in Bcr/Abl-transformed cells, but no detectable complex formation with Bcr/Abl, and activation of STAT5 by P210 was not blocked by two different dominant-negative JAK mutants.	Tyrosine	20-28	Janus kinase 1	Homo sapiens	48-64
8887543-5	1996	The activated Eyk kinases specifically stimulate tyrosine phosphorylation of STAT1, STAT3 and JAK1.	Tyrosine	49-57	Janus kinase 1	Homo sapiens	94-98
8892755-6	1996	Our results demonstrate that c-JH1 and c-JH2 associate with each other and c-JH2 can be tyrosine-phosphorylated by c-JAK1 and by c-JH(1 + 2).	Tyrosine	88-96	Janus kinase 1	Homo sapiens	117-121
8628273-1	1996	Binding of alpha interferon (IFNalpha) to its receptors induces rapid tyrosine phosphorylation of the receptor subunits IFNaR1 and IFNaR2, the TYK2 and JAK1 tyrosine kinases, and the Stat1 and Stat2 transcription factors.	Tyrosine	70-78	Janus kinase 1	Homo sapiens	152-156
8700538-1	1996	Interferon-alpha induces the rapid tyrosine phosphorylation of a number of molecules, including the cognate receptors, JAK-family kinases (Jak1 and tyk2), and latent transcription factors (STATs 1 and 2).	Tyrosine	35-43	Janus kinase 1	Homo sapiens	139-143
8647212-5	1996	Using MOLT-4 transfectants with the mutant beta chains, we found that two conserved proline residues within the box 1 region are essentially involved in association with Jak1.	Proline	84-91	Janus kinase 1	Homo sapiens	170-174
8864852-6	1996	Interleukin 4, but not insulin, stimulated the tyrosine phosphorylation of JAK1 and, to a lesser extent, JAK2.	Tyrosine	47-55	Janus kinase 1	Homo sapiens	75-79
8683106-10	1996	Finally, IL-2 induced tyrosine phosphorylation of JAK1 and JAK3, while IL-12 induced phosphorylation of JAK2 and TYK2 in both preactivated primary NK and NK3.3 cells.	Tyrosine	22-30	Janus kinase 1	Homo sapiens	50-54
8780896-1	1996	Janus kinase (JAK) family protein tyrosine kinases are constituents of a signaling path leading to tyrosine phosphorylation and activation of signal transducer and activator of transcription (STAT) family transcription factors.	Tyrosine	34-42	Janus kinase 1	Homo sapiens	14-17
8621573-3	1996	One of these signaling events involves the tyrosine phosphorylation of STATs (signal transducers and activators of transcription), a process believed to require the activation of a tyrosine kinase of the JAK family.	Tyrosine	43-51	Janus kinase 1	Homo sapiens	204-207
8625884-4	1996	The JAKs, a family of intracellular kinases, and the STATs, a family of transcription factors, have both previously been shown to be tyrosine phosphorylated and activated in response to various cytokines, interferons, and growth factors in cells of non-skeletal origin.	Tyrosine	133-141	Janus kinase 1	Homo sapiens	4-8
8605323-7	1996	IL-2 stimulation of the transduced cell line resulted in appropriate tyrosine phosphorylation of both Jak1 and Jak3.	Tyrosine	69-77	Janus kinase 1	Homo sapiens	102-106
8550631-6	1996	In addition, Pro-267 is required for JAK-1 binding.	Proline	13-16	Janus kinase 1	Homo sapiens	37-42
8657115-5	1996	IFNalpha-stimulated tyrosine phosphorylation of Jak1 and the alpha subunit of the IFN-alpha receptor were unaffected by phorbol 12-myristate 13-acetate (PMA).	Tyrosine	20-28	Janus kinase 1	Homo sapiens	48-52
8608222-2	1996	G-CSF induces tyrosine phosphorylation of Jak1, Jak2, STAT1, and STAT3.	Tyrosine	14-22	Janus kinase 1	Homo sapiens	42-46
8671609-4	1996	Mutational analysis revealed that one of the proline residues, particularly Pro352 and Pro355, in the membrane-proximal proline-rich sequence (Pro352-Pro353-X-Pro355) of the cytoplasmic domain of IL-5R alpha is required for cell proliferation, and for both JAK1 and JAK2 activation.	Proline	45-52	Janus kinase 1	Homo sapiens	257-261
8671609-4	1996	Mutational analysis revealed that one of the proline residues, particularly Pro352 and Pro355, in the membrane-proximal proline-rich sequence (Pro352-Pro353-X-Pro355) of the cytoplasmic domain of IL-5R alpha is required for cell proliferation, and for both JAK1 and JAK2 activation.	Proline	120-127	Janus kinase 1	Homo sapiens	257-261
8671609-5	1996	In addition, transfectants expressing chimeric receptors which consist of the extracellular domain of IL-5R alpha and the cytoplasmic domain of beta c responded to IL-5 for proliferation and tyrosine phosphorylation of JAK1.	Tyrosine	191-199	Janus kinase 1	Homo sapiens	219-223
8671609-7	1996	These results indicate that activation of JAK1, JAK2 and STAT5 is critical to coupling IL-5-induced tyrosine phosphorylation and ultimately mitogenesis, and that Pro352 and Pro355 in the proline-rich sequence appear to play more essential roles in cell growth and in both JAK1/STAT5 and JAK2/STAT5 activation than Pro353 does.	Tyrosine	100-108	Janus kinase 1	Homo sapiens	42-46
8550573-1	1996	Binding of interferon alpha (IFN alpha) to its receptor induces activation of the Tyk-2 and Jak-1 tyrosine kinases and tyrosine phosphorylation of multiple downstream signaling elements, including the Stat components of the interferon-stimulated gene factor 3 (ISGF-3).	Tyrosine	98-106	Janus kinase 1	Homo sapiens	92-97
8770944-0	1996	PDGF stimulates tyrosine phosphorylation of JAK 1 protein tyrosine kinase in human mesangial cells.	Tyrosine	16-24	Janus kinase 1	Homo sapiens	44-49
8770944-12	1996	Antiphosphotyrosine immunoblotting of JAK 1 immunoprecipitates from PDGF-stimulated mesangial cell lysate showed increased tyrosine phosphorylation of this tyrosine kinase.	Tyrosine	11-19	Janus kinase 1	Homo sapiens	38-43
8770944-15	1996	The data also provide the first evidence that PDGF stimulates tyrosine phosphorylation of JAK 1, the cytoplasmic tyrosine kinase stimulated by many other cytokines to activate transcription via STATs.	Tyrosine	62-70	Janus kinase 1	Homo sapiens	90-95
7594533-7	1995	In addition, IL-4 and IL-7 induced the rapid tyrosine phosphorylation of JAK3 and JAK1, and IL-4 activated both JAK3 and JAK1 phosphotransferase activity.	Tyrosine	45-53	Janus kinase 1	Homo sapiens	82-86
8536716-6	1995	Finally, insulin appears to induce the tyrosine phosphorylation of JAK1, but does not modify the tyrosine phosphorylation state of JAK2.	Tyrosine	39-47	Janus kinase 1	Homo sapiens	67-71
7591091-2	1995	The changes in gene expression brought about by gamma interferon are thought to involve transient increases in the activities of cellular protein tyrosine kinases, including the Janus kinases Jak1 and Jak2, leading to tyrosine phosphorylation of the transcription factor Stat1.	Tyrosine	146-154	Janus kinase 1	Homo sapiens	192-196
7579336-1	1995	The protein tyrosine kinases JAK1 and JAK2 are phosphorylated tyrosine after the interaction of granulocyte colony-stimulating factor (G-CSF) with its transmembrane receptor.	Tyrosine	12-20	Janus kinase 1	Homo sapiens	29-33
7591091-3	1995	To investigate the mechanisms accounting for the impaired responses to gamma interferon, a model system for examining overall changes in protein tyrosine phosphorylation, activation of Jak1 and Jak2 and phosphorylation of Stat1 was developed in phorbol 12-myristate 13-acetate-differentiated U-937 cells.	Tetradecanoylphorbol Acetate	245-276	Janus kinase 1	Homo sapiens	185-189
7657660-3	1995	Co-expression of Stat1 with Tyk2, Jak1, or Jak2 resulted in the specific tyrosine phosphorylation of Stat1 at Tyr701, the residue phosphorylated in mammalian cells stimulated with interferon gamma.	Tyrosine	73-81	Janus kinase 1	Homo sapiens	34-38
7591091-5	1995	Increased labeling of these proteins occurred to similar extents in control cells and in cells that had been infected with L. donovani for 16 h. Jak1, Jak2, and Stat1 were immunoprecipitated from control and interferon-treated cells, and tyrosine phosphorylation of these proteins, detected by antiphosphotyrosine immunoblotting was used to measured their activation.	Tyrosine	238-246	Janus kinase 1	Homo sapiens	145-149
7591091-6	1995	Tyrosine phosphorylation of Jak1, Jak2, and Stat1 increased markedly, in a dose-dependent manner, in U-937 cells incubated with gamma interferon.	Tyrosine	0-8	Janus kinase 1	Homo sapiens	28-32
7591091-7	1995	In contrast, in cells infected with L. donovani, tyrosine phosphorylation of Jak1, Jak2, and Stat1 was markedly impaired.	Tyrosine	49-57	Janus kinase 1	Homo sapiens	77-81
7579387-4	1995	In fibroblasts, the activation of the STAT proteins is accompanied by tyrosine phosphorylation of Tyk2 and JAK1.	Tyrosine	70-78	Janus kinase 1	Homo sapiens	107-111
7569929-2	1995	In murine pre-B lymphocytes transformed with A-MuLV, the Janus kinases (Jaks) Jak1 and Jak3 exhibited constitutive tyrosine kinase activity, and the STAT proteins (signal transducers and activators of transcription) normally activated by interleukin-4 and interleukin-7 were tyrosine-phosphorylated in the absence of these cytokines.	Tyrosine	115-123	Janus kinase 1	Homo sapiens	72-76
7569929-2	1995	In murine pre-B lymphocytes transformed with A-MuLV, the Janus kinases (Jaks) Jak1 and Jak3 exhibited constitutive tyrosine kinase activity, and the STAT proteins (signal transducers and activators of transcription) normally activated by interleukin-4 and interleukin-7 were tyrosine-phosphorylated in the absence of these cytokines.	Tyrosine	115-123	Janus kinase 1	Homo sapiens	78-82
7568001-6	1995	JAK1 and JAK3 were tyrosine-phosphorylated in response to IL-2 and IL-15.	Tyrosine	19-27	Janus kinase 1	Homo sapiens	0-4
7543512-0	1995	IL-10 induces the tyrosine phosphorylation of tyk2 and Jak1 and the differential assembly of STAT1 alpha and STAT3 complexes in human T cells and monocytes.	Tyrosine	18-26	Janus kinase 1	Homo sapiens	55-59
7544000-4	1995	In this report we demonstrate that both IL-4 and IL-13 induced the tyrosine phosphorylation of 4PS and JAK1.	Tyrosine	67-75	Janus kinase 1	Homo sapiens	103-107
7543512-4	1995	IL-10 treatment of both T cells and monocytes results in the ligand-induced tyrosine phosphorylation of tyk2 and Jak1, but not Jak2 or Jak3.	Tyrosine	76-84	Janus kinase 1	Homo sapiens	113-117
7756643-4	1995	In this report we show that IL-9 induces tyrosine phosphorylation and activation of the JAK family tyrosine kinases including JAK1, JAK3, and Tyk2.	Tyrosine	41-49	Janus kinase 1	Homo sapiens	126-130
7615558-9	1995	IFN gamma clusters at least two receptor units which results in the tyrosine phosphorylation of Jak1 and Jak2, the activation of Jak2 kinase activity, and the recruitment of STAT1 alpha resulting in its activation by tyrosine phosphorylation.	Tyrosine	68-76	Janus kinase 1	Homo sapiens	96-100
7615558-9	1995	IFN gamma clusters at least two receptor units which results in the tyrosine phosphorylation of Jak1 and Jak2, the activation of Jak2 kinase activity, and the recruitment of STAT1 alpha resulting in its activation by tyrosine phosphorylation.	Tyrosine	217-225	Janus kinase 1	Homo sapiens	96-100
7608217-5	1995	Stimulation of the cells by these factors led to rapid phosphorylation of Jak1, but not Jak2 or Jak3, on tyrosine residues.	Tyrosine	105-113	Janus kinase 1	Homo sapiens	74-78
7713924-8	1995	We also demonstrate that only mouse cells expressing the human alpha subunit are able to tyrosine-phosphorylate p135tyk2 and JAK-1 and to form the ISGF3 complex in response to human IFN alpha 8.	Tyrosine	89-97	Janus kinase 1	Homo sapiens	125-130
7721895-1	1995	The tyrosine kinases JAK1 and JAK3 have been shown to undergo tyrosine phosphorylation in response to interleukin-2 (IL), IL4, IL7, and IL9, cytokines which share the common IL2 receptor gamma-chain (IL2R gamma), and evidence has been found for a preferential coupling of JAK3 to IL2R gamma and JAK1 to IL2R beta.	Tyrosine	4-12	Janus kinase 1	Homo sapiens	21-25
7721895-1	1995	The tyrosine kinases JAK1 and JAK3 have been shown to undergo tyrosine phosphorylation in response to interleukin-2 (IL), IL4, IL7, and IL9, cytokines which share the common IL2 receptor gamma-chain (IL2R gamma), and evidence has been found for a preferential coupling of JAK3 to IL2R gamma and JAK1 to IL2R beta.	Tyrosine	4-12	Janus kinase 1	Homo sapiens	295-299
7532278-4	1995	Binding of IFNs to their receptors triggers tyrosine phosphorylation and activation of the receptors, JAK family kinases, STAT1, and STAT2.	Tyrosine	44-52	Janus kinase 1	Homo sapiens	102-105
7528775-4	1995	In this report we show that IL-12 and IL-2 induce tyrosine phosphorylation of distinct members of the Janus (JAK) family of protein tyrosine kinases in human T lymphocytes.	Tyrosine	50-58	Janus kinase 1	Homo sapiens	109-112
7988557-4	1994	IFN alpha induced the tyrosine phosphorylation of JAK1 and Tyk2, but not JAK2 or JAK3.	Tyrosine	22-30	Janus kinase 1	Homo sapiens	50-54
7995951-8	1995	Pretreatment with IC resulted in the inhibition of the tyrosine phosphorylation of the tyrosine kinases, Jak1 and Jak2, both of which are involved in IFN-gamma signal transduction.	Tyrosine	55-63	Janus kinase 1	Homo sapiens	105-109
7973658-4	1994	IL-2, IL-4, IL-7 (whose receptors are known to contain gamma c), and IL-9 (whose receptor is shown here to contain gamma c) induced the tyrosine phosphorylation and activation of the Janus family tyrosine kinases Jak1 and Jak3.	Tyrosine	136-144	Janus kinase 1	Homo sapiens	213-217
7526154-1	1994	Binding of type I interferons (IFNs) to their receptors induces rapid tyrosine phosphorylation of multiple proteins, including the alpha and beta subunits of the receptor, the polypeptides that form the transcriptional activator ISGF3 alpha (Stat113, Stat84, and Stat91), and the p135tyk2 and Jak-1 tyrosine kinases.	Tyrosine	70-78	Janus kinase 1	Homo sapiens	293-298
7525556-0	1994	Differential tyrosine phosphorylation of JAK1, JAK2, and STAT1 by growth hormone and interferon-gamma in IM-9 cells.	Tyrosine	13-21	Janus kinase 1	Homo sapiens	41-45
7525556-3	1994	We demonstrate that, in the human IM-9 lymphocyte, both JAK1 and JAK2 are tyrosine-phosphorylated in response to IFN gamma, whereas only JAK2 is tyrosine-phosphorylated in response to GH.	Tyrosine	74-82	Janus kinase 1	Homo sapiens	56-60
7973659-2	1994	Stimulation with IL-2 induces the tyrosine phosphorylation and activation of the Janus kinases Jak1 and Jak3.	Tyrosine	34-42	Janus kinase 1	Homo sapiens	95-99
7973659-3	1994	Jak1 and Jak3 were found to be selectively associated with the "serine-rich" region of IL-2R beta and the carboxyl-terminal region of IL-2R gamma, respectively.	Serine	64-70	Janus kinase 1	Homo sapiens	0-4
7957877-3	1994	The results have shown that out of 4 members of JAK family tyrosine kinases (JAK1, JAK2, JAK3 and Tyk2), only JAK3 was tyrosine-phosphorylated and activated in cells of a T cell clone by stimulation with IL-7.	Tyrosine	59-67	Janus kinase 1	Homo sapiens	48-51
7929391-7	1994	The overlapping and distinct protein tyrosine phosphorylation and activation of the same JAK1 kinase in T lymphocytes strongly suggests that IL-4 and IL-9 share the common signal transduction pathways and that the specificity for each cytokine could be achieved through the unique tyrosine-phosphorylated proteins triggered by individual cytokines.	Tyrosine	37-45	Janus kinase 1	Homo sapiens	89-93
7929391-7	1994	The overlapping and distinct protein tyrosine phosphorylation and activation of the same JAK1 kinase in T lymphocytes strongly suggests that IL-4 and IL-9 share the common signal transduction pathways and that the specificity for each cytokine could be achieved through the unique tyrosine-phosphorylated proteins triggered by individual cytokines.	Tyrosine	281-289	Janus kinase 1	Homo sapiens	89-93
7957877-3	1994	The results have shown that out of 4 members of JAK family tyrosine kinases (JAK1, JAK2, JAK3 and Tyk2), only JAK3 was tyrosine-phosphorylated and activated in cells of a T cell clone by stimulation with IL-7.	Tyrosine	59-67	Janus kinase 1	Homo sapiens	77-81
7935373-6	1994	In contrast, stimulation with IL-2 or the related cytokine IL-4 resulted in the rapid, dose-dependent tyrosine phosphorylation of JAK1 and an additional 116-kDa protein.	Tyrosine	102-110	Janus kinase 1	Homo sapiens	130-134
7929242-4	1994	In addition, cells from the G1/S phase exhibited increased tyrosine phosphorylation of JAK-1 and Tyk-2 kinases and p91 by IFN-alpha as compared with asynchronized cells.	Tyrosine	59-67	Janus kinase 1	Homo sapiens	87-92
7929242-6	1994	These findings demonstrate that the levels of constitutive and inducible expression of IFN-alpha-inducible genes, activation of p91, and tyrosine phosphorylation of JAK-1 and Tyk-2 kinases are differentially influenced by the state of the cell cycle.	Tyrosine	137-145	Janus kinase 1	Homo sapiens	165-170
8022486-3	1994	Recent studies have shown that one or more of the Janus kinase family members (Jaks) associate with cytokine receptors and are tyrosine phosphorylated and activated following ligand binding.	Tyrosine	127-135	Janus kinase 1	Homo sapiens	79-83
8041779-3	1994	Tyrosine phosphorylation of JAK1 and JAK2 was induced upon IL-2 stimulation, and IL-2 activated the JAK2 kinase.	Tyrosine	0-8	Janus kinase 1	Homo sapiens	28-32
8022486-4	1994	Here we describe a new Jak family kinase, Jak-3, and demonstrate that Jak-3, and to a lesser extent Jak-1, are tyrosine phosphorylated and Jak-3 is activated in the responses to interleukin-2 and interleukin-4 in T cells and myeloid cells.	Tyrosine	111-119	Janus kinase 1	Homo sapiens	23-26
8022486-4	1994	Here we describe a new Jak family kinase, Jak-3, and demonstrate that Jak-3, and to a lesser extent Jak-1, are tyrosine phosphorylated and Jak-3 is activated in the responses to interleukin-2 and interleukin-4 in T cells and myeloid cells.	Tyrosine	111-119	Janus kinase 1	Homo sapiens	100-105
7514165-3	1994	H2O2/vanadate treatment of cells for 15 min resulted in only the tyrosine phosphorylation of Jak1 and IFN-gamma R. Only after 60 min of this treatment did we observe tyrosine phosphorylation of Jak2 and p91 and assembly of the transcription factor complex FcRF gamma that binds to the promoter of the fcgr1 gene.	Hydrogen Peroxide	0-4	Janus kinase 1	Homo sapiens	93-97
7517047-3	1994	Recent studies have shown that members of the Janus kinase (JAK) family of protein tyrosine kinases associate with the membrane proximal region, are rapidly tyrosine phosphorylated following ligand binding and their in vitro kinase activity is activated.	Tyrosine	83-91	Janus kinase 1	Homo sapiens	60-63
7514165-3	1994	H2O2/vanadate treatment of cells for 15 min resulted in only the tyrosine phosphorylation of Jak1 and IFN-gamma R. Only after 60 min of this treatment did we observe tyrosine phosphorylation of Jak2 and p91 and assembly of the transcription factor complex FcRF gamma that binds to the promoter of the fcgr1 gene.	Vanadates	5-13	Janus kinase 1	Homo sapiens	93-97
7514165-3	1994	H2O2/vanadate treatment of cells for 15 min resulted in only the tyrosine phosphorylation of Jak1 and IFN-gamma R. Only after 60 min of this treatment did we observe tyrosine phosphorylation of Jak2 and p91 and assembly of the transcription factor complex FcRF gamma that binds to the promoter of the fcgr1 gene.	Tyrosine	65-73	Janus kinase 1	Homo sapiens	93-97
33237566-1	2020	Filgotinib (Jyseleca ) is an oral, ATP-competitive, reversible JAK1 preferential inhibitor that is being developed by Galapagos NV and Gilead Sciences for the treatment of inflammatory autoimmune diseases, including inflammatory arthritis and inflammatory bowel disease.	GLPG0634	0-10	Janus kinase 1	Homo sapiens	63-67
7504784-11	1993	We find that Jak1 also becomes phosphorylated on tyrosine after cells are treated with these same three ligands, although each ligand is shown to activate at least one other different kinase.	Tyrosine	49-57	Janus kinase 1	Homo sapiens	13-17
7504784-12	1993	Jak1 may therefore be the enzyme that phosphorylates Tyr 701 in Stat91.	Tyrosine	53-56	Janus kinase 1	Homo sapiens	0-4
33826132-1	2021	BACKGROUND: Baricitinib, a selective Janus kinase 1/Janus kinase 2 inhibitor, is indicated in the European Union and Japan for the treatment of moderate-to-severe atopic dermatitis (AD) in adults who are candidates for systemic therapy.	baricitinib	12-23	Janus kinase 1	Homo sapiens	37-51
33797200-9	2021	The mechanism of MPTP inhibition was via gp130 signalling and the downstream JAK/STAT pathway.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	17-21	Janus kinase 1	Homo sapiens	77-80
33792844-11	2021	Collectively, TFA exhibited a potential protective effect against CDDP-induced testicular injury by inhibiting oxidative stress as well as TLR4/IRF3/INF-gamma, P38-MAPK/NF-kappaB-p65/TNF-alpha, and JAK1/STAT-3/ERK1/2 inflammatory signaling pathways with enhancing its in vitro cytotoxic activity.	ferulic acid	14-17	Janus kinase 1	Homo sapiens	198-202
7512720-0	1994	Tyrosine kinase JAK1 is associated with the granulocyte-colony-stimulating factor receptor and both become tyrosine-phosphorylated after receptor activation.	Tyrosine	107-115	Janus kinase 1	Homo sapiens	16-20
7512720-3	1994	We detected tyrosine phosphorylation of both the G-CSF receptor and the protein tyrosine kinase JAK1 following G-CSF binding to the human G-CSF receptor.	Tyrosine	12-20	Janus kinase 1	Homo sapiens	96-100
33971281-6	2021	Sustained treatment of MYB-TYK2-rearranged ALL cells with cerdulatinib led to enhanced and persistent JAK/STAT signaling, co-occurring with JAK1 overexpression.	4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide	58-70	Janus kinase 1	Homo sapiens	140-144
33971281-7	2021	Hyperactivation of JAK/STAT signaling and JAK1 overexpression was reversible as cerdulatinib withdrawal resulted in re-sensitization to the drug.	4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide	80-92	Janus kinase 1	Homo sapiens	42-46
33970999-6	2021	Notably, we also find that established tumors may no longer require high levels of IL-7R expression upon secondary transplantation and can progress in the absence of IL-7, but remain sensitive to inhibitors of IL-7R-mediated signaling Ruxolitinib (Jak1), AZD1208 (Pim), Dactolisib (PI3K/mTOR), Palbociclib (Cdk4/6), and Venetoclax (Bcl-2).	ruxolitinib	235-246	Janus kinase 1	Homo sapiens	248-252
33970999-6	2021	Notably, we also find that established tumors may no longer require high levels of IL-7R expression upon secondary transplantation and can progress in the absence of IL-7, but remain sensitive to inhibitors of IL-7R-mediated signaling Ruxolitinib (Jak1), AZD1208 (Pim), Dactolisib (PI3K/mTOR), Palbociclib (Cdk4/6), and Venetoclax (Bcl-2).	AZD1208	255-262	Janus kinase 1	Homo sapiens	248-252
33970999-6	2021	Notably, we also find that established tumors may no longer require high levels of IL-7R expression upon secondary transplantation and can progress in the absence of IL-7, but remain sensitive to inhibitors of IL-7R-mediated signaling Ruxolitinib (Jak1), AZD1208 (Pim), Dactolisib (PI3K/mTOR), Palbociclib (Cdk4/6), and Venetoclax (Bcl-2).	dactolisib	270-280	Janus kinase 1	Homo sapiens	248-252
33782031-1	2021	PURPOSE: The JAK1/2 inhibitor ruxolitinib has demonstrated significant benefits for patients with Myeloproliferative Neoplasms (MPNs).	ruxolitinib	30-41	Janus kinase 1	Homo sapiens	13-19
33237566-1	2020	Filgotinib (Jyseleca ) is an oral, ATP-competitive, reversible JAK1 preferential inhibitor that is being developed by Galapagos NV and Gilead Sciences for the treatment of inflammatory autoimmune diseases, including inflammatory arthritis and inflammatory bowel disease.	Adenosine Triphosphate	35-38	Janus kinase 1	Homo sapiens	63-67
33237566-2	2020	The JAK-STAT signalling pathway has been implicated in the pathogenesis of inflammatory and autoimmune diseases, and filgotinib modulates this pathway by preventing the phosphorylation and activation of STATs.	GLPG0634	117-127	Janus kinase 1	Homo sapiens	4-7
30384869-12	2018	The phosphorylation of JAK1/2 and STAT1 declined by GL.	Glycyrrhizic Acid	52-54	Janus kinase 1	Homo sapiens	23-29
29024542-1	2018	Momelotinib is a potent and selective small-molecule inhibitor of JAK1/2 that is under investigation for the treatment of myeloproliferative neoplasms.	N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	0-11	Janus kinase 1	Homo sapiens	66-72
34480250-6	2022	Western blot and qRT-PCR analysis suggested that treatment with methotrexate (MTx) dampened CoV-2-SRBD-mediated increase in JAK1/STAT3 phosphorylation, gp130, IL6, and folate-binding protein (FBP) expressions.	Methotrexate	64-76	Janus kinase 1	Homo sapiens	124-128
25682576-1	2015	BACKGROUND: In the COMFORT (COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Therapy)-I study, the Janus kinase (JAK)1/JAK2 inhibitor ruxolitinib provided significant reductions in splenomegaly, improvements in myelofibrosis (MF)-related symptoms, and a survival advantage relative to placebo in patients with intermediate-2 or high-risk MF.	ruxolitinib	140-151	Janus kinase 1	Homo sapiens	105-124
34740884-1	2022	OBJECTIVE: To characterise safety of the Janus kinase-1 preferential inhibitor filgotinib in patients with moderately to severely active rheumatoid arthritis.	GLPG0634	79-89	Janus kinase 1	Homo sapiens	41-55
29224367-2	2018	Ruxolitinib, a potent Janus kinase 1 (JAK1)/JAK2 inhibitor, led to substantial improvements in splenomegaly, MF-associated symptoms, and QoL in the phase 3 COMFORT studies, proving superior to placebo and best available therapy.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	22-36
29224367-2	2018	Ruxolitinib, a potent Janus kinase 1 (JAK1)/JAK2 inhibitor, led to substantial improvements in splenomegaly, MF-associated symptoms, and QoL in the phase 3 COMFORT studies, proving superior to placebo and best available therapy.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	38-42
26380150-3	2015	Ruxolitinib, a potent inhibitor of Janus kinase (JAK) 1 and JAK2, was associated with an overall survival benefit and improvements in splenomegaly and patient-reported outcomes in patients with myelofibrosis in the two phase 3 COMFORT studies.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	35-55
34480250-6	2022	Western blot and qRT-PCR analysis suggested that treatment with methotrexate (MTx) dampened CoV-2-SRBD-mediated increase in JAK1/STAT3 phosphorylation, gp130, IL6, and folate-binding protein (FBP) expressions.	Methotrexate	78-81	Janus kinase 1	Homo sapiens	124-128
34694880-2	2022	The Janus kinase (JAK1/2) inhibitor ruxolitinib could potentially disrupt the parasite-induced dysfunctional immune response when administered with anti-malarial therapy.	ruxolitinib	36-47	Janus kinase 1	Homo sapiens	18-24
34774741-5	2022	Among these JAK1 inhibitors, the compound 23a showed an IC50 level of 72 nM, as well as being selective against other JAKs by 12 times or more: the results of molecular docking studies suggested that the high JAK1 selectivity resulted from a key interaction between the iodine atom of compound 23a and His-885 of hJAK1.	Histidine	302-305	Janus kinase 1	Homo sapiens	118-122
34774741-5	2022	Among these JAK1 inhibitors, the compound 23a showed an IC50 level of 72 nM, as well as being selective against other JAKs by 12 times or more: the results of molecular docking studies suggested that the high JAK1 selectivity resulted from a key interaction between the iodine atom of compound 23a and His-885 of hJAK1.	Histidine	302-305	Janus kinase 1	Homo sapiens	209-213
34774741-0	2022	Synthesis and Structure-activity Relationship Studies of 1,5-Isomers of Triazole-pyrrolopyrimidine as Selective Janus Kinase 1 (JAK1) Inhibitors.	triazole-pyrrolopyrimidine	72-98	Janus kinase 1	Homo sapiens	112-126
34774741-5	2022	Among these JAK1 inhibitors, the compound 23a showed an IC50 level of 72 nM, as well as being selective against other JAKs by 12 times or more: the results of molecular docking studies suggested that the high JAK1 selectivity resulted from a key interaction between the iodine atom of compound 23a and His-885 of hJAK1.	Histidine	302-305	Janus kinase 1	Homo sapiens	313-318
34774741-0	2022	Synthesis and Structure-activity Relationship Studies of 1,5-Isomers of Triazole-pyrrolopyrimidine as Selective Janus Kinase 1 (JAK1) Inhibitors.	triazole-pyrrolopyrimidine	72-98	Janus kinase 1	Homo sapiens	128-132
34074166-2	2022	Ruxolitinib, an oral selective JAK1/2 inhibitor, has recently shown efficacy and safety in the treatment of secondary HLH, which may be an alternative to intensive chemotherapy.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	31-37
34774741-4	2022	In this study, novel 4-(1,5- or 2,5-triazole)-pyrrolopyrimidine derivatives with aromatic moieties were synthesized as JAK1 inhibitors, and an in vitro enzyme assay was used to evaluate the JAK inhibitory effects.	4-(1,5- or 2,5-triazole)-pyrrolopyrimidine	21-63	Janus kinase 1	Homo sapiens	119-123
34774741-5	2022	Among these JAK1 inhibitors, the compound 23a showed an IC50 level of 72 nM, as well as being selective against other JAKs by 12 times or more: the results of molecular docking studies suggested that the high JAK1 selectivity resulted from a key interaction between the iodine atom of compound 23a and His-885 of hJAK1.	Iodine	270-276	Janus kinase 1	Homo sapiens	12-16
34774741-5	2022	Among these JAK1 inhibitors, the compound 23a showed an IC50 level of 72 nM, as well as being selective against other JAKs by 12 times or more: the results of molecular docking studies suggested that the high JAK1 selectivity resulted from a key interaction between the iodine atom of compound 23a and His-885 of hJAK1.	Iodine	270-276	Janus kinase 1	Homo sapiens	118-122
34774741-5	2022	Among these JAK1 inhibitors, the compound 23a showed an IC50 level of 72 nM, as well as being selective against other JAKs by 12 times or more: the results of molecular docking studies suggested that the high JAK1 selectivity resulted from a key interaction between the iodine atom of compound 23a and His-885 of hJAK1.	Iodine	270-276	Janus kinase 1	Homo sapiens	209-213
34774741-5	2022	Among these JAK1 inhibitors, the compound 23a showed an IC50 level of 72 nM, as well as being selective against other JAKs by 12 times or more: the results of molecular docking studies suggested that the high JAK1 selectivity resulted from a key interaction between the iodine atom of compound 23a and His-885 of hJAK1.	Iodine	270-276	Janus kinase 1	Homo sapiens	313-318
34774741-5	2022	Among these JAK1 inhibitors, the compound 23a showed an IC50 level of 72 nM, as well as being selective against other JAKs by 12 times or more: the results of molecular docking studies suggested that the high JAK1 selectivity resulted from a key interaction between the iodine atom of compound 23a and His-885 of hJAK1.	Histidine	302-305	Janus kinase 1	Homo sapiens	12-16
34846636-1	2022	INTRODUCTION: Baricitinib, an oral Janus kinase (JAK)1/JAK2 inhibitor, is indicated in the European Union and Japan for treatment of moderate-to-severe atopic dermatitis (AD) in adults who are candidates for systemic therapy.	baricitinib	14-25	Janus kinase 1	Homo sapiens	35-54
34871917-0	2022	Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS.	upadacitinib	47-59	Janus kinase 1	Homo sapiens	22-36
34871917-1	2022	Upadacitinib is a selective janus-kinase-1 inhibitor effective in the treatment of autoimmune related diseases like rheumatoid arthritis or psoriatic arthritis.	upadacitinib	0-12	Janus kinase 1	Homo sapiens	28-42
34807428-1	2021	Abrocitinib (Cibinqo ) is an oral small-molecule inhibitor of Janus kinase 1 (JAK1) being developed by Pfizer for the treatment of moderate-to-severe atopic dermatitis (AD).	Abrocitinib	13-20	Janus kinase 1	Homo sapiens	62-76
34627950-5	2021	JAK1 inhibitor, Itacitinib adipate, dramatically inhibited high Rab1A NSCLC metastasis, in both cell line and patient derived xenograft models.	Itacitinib adipate	16-34	Janus kinase 1	Homo sapiens	0-4
34911805-2	2022	Subsequently, the use of the Janus kinase ( JAK) 1/2 inhibitor baricitinib resulted in considerable improvement in the patient"s symptoms and skin appearance.	baricitinib	63-74	Janus kinase 1	Homo sapiens	29-52
34521299-0	2022	Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI).	ruxolitinib	13-24	Janus kinase 1	Homo sapiens	34-40
34521299-1	2022	ROMEI, a prospective, observational study in patients with myelofibrosis receiving the oral JAK1/2 inhibitor ruxolitinib in real-world practice, assesses treatment adherence based on the 8-item Morisky Medication Adherence Scale (MMAS-8).	ruxolitinib	109-120	Janus kinase 1	Homo sapiens	92-98
34592416-5	2021	The PMA-treated S1P2knockout THP-1 Mphis showed decreases in IL-4/IL-13-induced phosphorylation of Janus-activated kinase (JAK) 1, JAK2, and STAT6 as well as mRNA expression of the M2 marker ARG1 compared with wild-type THP-1 Mphis.	Tetradecanoylphorbol Acetate	4-7	Janus kinase 1	Homo sapiens	99-129
34807428-1	2021	Abrocitinib (Cibinqo ) is an oral small-molecule inhibitor of Janus kinase 1 (JAK1) being developed by Pfizer for the treatment of moderate-to-severe atopic dermatitis (AD).	Abrocitinib	13-20	Janus kinase 1	Homo sapiens	78-82
34894197-0	2021	Besserung eines oralen und osophagealen Lichen ruber mucosae unter dem JAK1-Inhibitor Upadacitinib.	upadacitinib	86-98	Janus kinase 1	Homo sapiens	71-75
34169526-1	2021	Ruxolitinib is an FDA-approved orally administered Janus kinase (JAK 1/2) inhibitor that reduces cytokine-induced inflammation.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	65-72
34402699-3	2021	The number of JAKi has been growing and to date, filgotinib is the latest JAKi to be approved for use in RA.Areas coveredThis review focuses on the pharmacodynamics, pharmacokinetics, efficacy and safety of filgotinib in patients with RA.Expert opinionFilgotinib is an oral targeted synthetic disease-modifying antirheumatic drug (DMARD) that specifically inhibits JAK1.	GLPG0634	49-59	Janus kinase 1	Homo sapiens	365-369
34402699-3	2021	The number of JAKi has been growing and to date, filgotinib is the latest JAKi to be approved for use in RA.Areas coveredThis review focuses on the pharmacodynamics, pharmacokinetics, efficacy and safety of filgotinib in patients with RA.Expert opinionFilgotinib is an oral targeted synthetic disease-modifying antirheumatic drug (DMARD) that specifically inhibits JAK1.	GLPG0634	207-217	Janus kinase 1	Homo sapiens	365-369
34402699-3	2021	The number of JAKi has been growing and to date, filgotinib is the latest JAKi to be approved for use in RA.Areas coveredThis review focuses on the pharmacodynamics, pharmacokinetics, efficacy and safety of filgotinib in patients with RA.Expert opinionFilgotinib is an oral targeted synthetic disease-modifying antirheumatic drug (DMARD) that specifically inhibits JAK1.	opinionfilgotinib	245-262	Janus kinase 1	Homo sapiens	365-369
34645316-1	2021	Upadacitinib, a selective JAK 1 inhibitor, has been evaluated for efficacy and safety in the treatment of psoriatic arthritis (PsA).	upadacitinib	0-12	Janus kinase 1	Homo sapiens	26-31
34761860-0	2021	Alleviation of erosive oral and esophageal lichen planus by the JAK1 inhibitor upadacitinib.	upadacitinib	79-91	Janus kinase 1	Homo sapiens	64-68
34626199-3	2021	Dysregulation of JAK/STAT pathways and JAK2 copy number gains were observed in the four paclitaxel-resistant PDX tumors.	Paclitaxel	88-98	Janus kinase 1	Homo sapiens	17-20
34626199-5	2021	However, JAK1/2 inhibitor treatment resulted in restoration of paclitaxel sensitivity in two out of four paclitaxel-resistant PDX models and JAK1/2 inhibitor alone significantly suppressed the tumor growth in one out of the two remaining PDX models.	Paclitaxel	63-73	Janus kinase 1	Homo sapiens	9-15
34880598-3	2021	Ruxolitinib is a selective Janus kinases 1/2 inhibitor which has been shown to control acute (a) and chronic (c) GVHD while maintaining graft-versus-tumor effects.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	27-44
34097102-1	2021	A patient with rheumatoid arthritis (RA) was presented, who developed an infection with the hepatitis E virus (HEV) under treatment with the Janus kinase (JAK) 1 and 2 inhibitor baricitinib.	baricitinib	178-189	Janus kinase 1	Homo sapiens	141-167
34946023-7	2021	Our results showed that insulin-mediated reduction of UPEC infection in a high-glucose environment was not only due to the downregulation of JAK1/2 and phosphorylated STAT-1/3, but also because of the decreased expression of TLR-4 proteins and pro-inflammatory IL-6.	Glucose	79-86	Janus kinase 1	Homo sapiens	141-147
34873553-1	2021	Introduction Baricitinib is an oral synthetic Janus Kinase inhibitor that inhibits JAK1 and JAK2, and the new kid on the block in the treatment of rheumatoid arthritis (RA).	baricitinib	13-24	Janus kinase 1	Homo sapiens	83-87
34845259-0	2021	Computer aided designing of novel pyrrolopyridine derivatives as JAK1 inhibitors.	4-azaindole	34-49	Janus kinase 1	Homo sapiens	65-69
34845259-4	2021	Although JAK1 inhibitors such as Tofacitinib have been approved for medical use, the low potency and off-target effects of these inhibitors have limited their use and calls for the development of novel JAK1 inhibitors.	tofacitinib	33-44	Janus kinase 1	Homo sapiens	9-13
34845259-5	2021	In this study, we used computational methods on a series of pyrrolopyridine derivatives to design new JAK1 inhibitors.	4-azaindole	60-75	Janus kinase 1	Homo sapiens	102-106
34845259-9	2021	Of the designed compounds, seventeen of the compounds showed a higher binding energy value than the most active compound in the dataset and at least six of the compounds showed higher binding energy value than the pan JAK inhibitor Tofacitinib.	tofacitinib	232-243	Janus kinase 1	Homo sapiens	218-221
34828623-2	2021	Objectives: To evaluate the efficacy and safety of baricitinib, the first JAK 1 and 2 inhibitor approved in Europe for the treatment of adult patients with moderate-to-severe AD.	baricitinib	51-62	Janus kinase 1	Homo sapiens	74-85
34867980-4	2021	Several JAK inhibitors have entered clinical trials, including ruxolitinib, the first JAK1/2 inhibitor to become commercially available for the treatment of myelofibrosis and polycythemia vera.	ruxolitinib	63-74	Janus kinase 1	Homo sapiens	86-92
34741776-7	2022	JAK1/2 and STAT1 inhibitors could reverse the reduction of SLC7A11, GPx4 and GSH expression induced by IFN-gamma, indicating IFN-gamma induces ARPE-19 cell ferroptosis via activation of the JAK1-2/STAT1/SLC7A11 signaling pathway.	Glutathione	77-80	Janus kinase 1	Homo sapiens	0-6
34767869-3	2021	OBJECTIVE: Investigate changes in IL-23/Th17- and type I interferon-pathway biomarkers and gene responses, and measures of selectivity for TYK2 over Janus kinases (JAKs) 1-3, in patients with moderate to severe psoriasis receiving deucravacitinib.	Deucravacitinib	231-246	Janus kinase 1	Homo sapiens	164-168
34741617-0	2021	Effects of JAK1-Preferential Inhibitor Filgotinib on Circulating Biomarkers and Whole Blood Genes/Pathways of Patients With Moderately to Severely Active Crohn"s Disease.	GLPG0634	39-49	Janus kinase 1	Homo sapiens	11-15
34741617-2	2021	We profiled circulating biomarkers and whole blood transcriptional pathway activity to identify those associated with CD using data from the phase 2 FITZROY study with filgotinib, an oral preferential janus kinase-1 inhibitor.	GLPG0634	168-178	Janus kinase 1	Homo sapiens	201-215
34741776-7	2022	JAK1/2 and STAT1 inhibitors could reverse the reduction of SLC7A11, GPx4 and GSH expression induced by IFN-gamma, indicating IFN-gamma induces ARPE-19 cell ferroptosis via activation of the JAK1-2/STAT1/SLC7A11 signaling pathway.	Glutathione	77-80	Janus kinase 1	Homo sapiens	190-196
34826840-6	2021	Treatment with Baricitinib - a JAK 1/2 inhibitor - may also be beneficial for patients without or on low oxygen supplementation.	baricitinib	15-26	Janus kinase 1	Homo sapiens	31-38
34769307-8	2021	Our results suggest that JAK1 inhibition can ameliorate BRB dysfunction in T2D, and JAK1 inhibitors such as tofacitinib citrate may be re-purposed for the management of diabetic macular oedema.	tofacitinib	108-127	Janus kinase 1	Homo sapiens	84-88
34374027-2	2021	SHR0302 is an oral, highly selective, Janus kinase 1 inhibitor under investigation for inflammatory skin diseases.	ivarmacitinib	0-7	Janus kinase 1	Homo sapiens	38-52
34435525-0	2021	MiR-146b-5p targets IFI35 to inhibit inflammatory response and apoptosis via JAK1/STAT1 signalling in lipopolysaccharide-induced glomerular cells.	mir-146b-5p	0-11	Janus kinase 1	Homo sapiens	77-81
34435525-12	2021	Meanwhile, miR-146b-5p targeted IFI35 to suppress inflammatory response and cell inflammatory response and apoptosis via inactivating the JAK1/STAT1 pathway.	mir-146b-5p	11-22	Janus kinase 1	Homo sapiens	138-142
34435525-13	2021	MiR-146b-5p suppressed inflammatory response and cell apoptosis by IFI35 mediated-JAK1/STAT1 signalling in HK-2 cells, which provided a new mechanism for understanding the pathogenesis of LN.	mir-146b-5p	0-11	Janus kinase 1	Homo sapiens	82-86
34844720-0	2021	The anti-neoplastic activities of aloperine in HeLa cervical cancer cells are associated with inhibition of the IL-6-JAK1-STAT3 feedback loop.	aloperine	34-43	Janus kinase 1	Homo sapiens	117-121
34844720-12	2021	For molecular mechanisms, the expression and activation of the IL-6-JAK1-STAT3 feedback loop were markedly suppressed by ALO treatment.	aloperine	121-124	Janus kinase 1	Homo sapiens	68-72
34665696-1	2021	OBJECTIVES: To investigate the ex vivo effect of the JAK1/2 inhibitor baricitinib on expression of pro-inflammatory mediators in rheumatoid arthritis (RA) fibroblast like synoviocytes (FLS) stimulated with TNFalpha, IL-1beta and oncostatin M (OSM), and in RA synovial membrane cells (SMCs).	baricitinib	70-81	Janus kinase 1	Homo sapiens	53-59
34514729-6	2021	Crocetin suppressed the activity of upstream kinases such as Src, JAK1, and JAK2.	crocetin	0-8	Janus kinase 1	Homo sapiens	66-70
34655610-5	2022	The JAK1/2 inhibitor ruxolitinib strongly inhibited such effects on epidermal cells.	ruxolitinib	21-32	Janus kinase 1	Homo sapiens	4-10
34520107-4	2021	Ruxolitinib is a JAK-1/JAK-2 inhibitor and has showed its efficacy in suppressing IE and the immune system.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	17-22
34771643-4	2021	Tris DBA decreased cell viability, increased apoptosis, and inhibited IL-6 induced/constitutive activation of STAT3, JAK1, JAK2, and Src in HCC and MM cells.	Tromethamine	0-4	Janus kinase 1	Homo sapiens	117-121
34745769-6	2021	Mechanistically, metformin induced activation of the JAK1/2/3/STAT5 and AKT/mTOR pathways in a p38 MAPK-dependent manner rather than an AMPK-dependent manner.	Metformin	17-26	Janus kinase 1	Homo sapiens	53-61
34642693-9	2021	Treatment of SARS-CoV-2 infected RMs with baricitinib (Olumiant   ), a novel JAK1/2 inhibitor that recently received Emergency Use Authorization for the treatment of hospitalized COVID-19 patients, was remarkably effective in eliminating the influx of infiltrating, non-alveolar macrophages in the alveolar space, with a concomitant reduction of inflammatory cytokines.	baricitinib	42-53	Janus kinase 1	Homo sapiens	77-83
34721386-12	2021	In particular, we identified filgotinub and fedratinib, targeting gene JAK1, as potential drugs for AD.	Fedratinib	44-54	Janus kinase 1	Homo sapiens	71-75
34627340-5	2021	Baricitinib, an oral selective Janus kinase (JAK)1 and 2 inhibitor, may impact key cytokines implicated in the pathogenesis of JIA-uveitis or ANA-positive uveitis, representing a potential novel treatment option for disease management.	baricitinib	0-11	Janus kinase 1	Homo sapiens	31-56
34642693-9	2021	Treatment of SARS-CoV-2 infected RMs with baricitinib (Olumiant   ), a novel JAK1/2 inhibitor that recently received Emergency Use Authorization for the treatment of hospitalized COVID-19 patients, was remarkably effective in eliminating the influx of infiltrating, non-alveolar macrophages in the alveolar space, with a concomitant reduction of inflammatory cytokines.	baricitinib	55-63	Janus kinase 1	Homo sapiens	77-83
34629864-1	2021	Background: Upadacitinib, a novel selective Janus kinase 1 (JAK1) inhibitor, has been recently approved by the US FDA for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).	upadacitinib	12-24	Janus kinase 1	Homo sapiens	44-58
34629864-1	2021	Background: Upadacitinib, a novel selective Janus kinase 1 (JAK1) inhibitor, has been recently approved by the US FDA for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).	upadacitinib	12-24	Janus kinase 1	Homo sapiens	60-64
34272171-1	2021	Over the last decade, the Janus kinase (JAK) 1/2 inhibitor ruxolitinib has become widely established as the cornerstone of pharmacologic therapy for most patients with myelofibrosis (MF), providing dramatic and durable benefits in terms of splenomegaly and symptoms, and prolonging survival.	ruxolitinib	59-70	Janus kinase 1	Homo sapiens	26-48
34659493-4	2021	Upadacitinib, a JAK 1 selective molecule developed in this context has been evaluated in the SELECT phase-III study program and demonstrated a high and rapid efficacy in monotherapy as well as in combination with csDMARDs both in csDMARD-naive RA patients and in patients refractory to csDMARD and bDMARD treatments.	upadacitinib	0-12	Janus kinase 1	Homo sapiens	16-21
34471993-6	2021	Concentrations providing half-maximal inhibition (IC50) in these assays were determined for deucravacitinib and the JAK 1/2/3 inhibitors tofacitinib, upadacitinib, and baricitinib.	tofacitinib	137-148	Janus kinase 1	Homo sapiens	116-125
34471993-6	2021	Concentrations providing half-maximal inhibition (IC50) in these assays were determined for deucravacitinib and the JAK 1/2/3 inhibitors tofacitinib, upadacitinib, and baricitinib.	upadacitinib	150-162	Janus kinase 1	Homo sapiens	116-125
34471993-6	2021	Concentrations providing half-maximal inhibition (IC50) in these assays were determined for deucravacitinib and the JAK 1/2/3 inhibitors tofacitinib, upadacitinib, and baricitinib.	baricitinib	168-179	Janus kinase 1	Homo sapiens	116-125
34471993-11	2021	Simulations indicated that tofacitinib, upadacitinib, and baricitinib at steady state exhibited varying degrees of JAK 1/3 (daily average inhibition, 70-94%) and JAK 2/2 (23%-67%) inhibition at therapeutic concentrations, with Cmax values 17- to 33-fold lower than their TYK2 IC50 levels.	tofacitinib	27-38	Janus kinase 1	Homo sapiens	115-122
34471993-11	2021	Simulations indicated that tofacitinib, upadacitinib, and baricitinib at steady state exhibited varying degrees of JAK 1/3 (daily average inhibition, 70-94%) and JAK 2/2 (23%-67%) inhibition at therapeutic concentrations, with Cmax values 17- to 33-fold lower than their TYK2 IC50 levels.	upadacitinib	40-52	Janus kinase 1	Homo sapiens	115-122
34471993-11	2021	Simulations indicated that tofacitinib, upadacitinib, and baricitinib at steady state exhibited varying degrees of JAK 1/3 (daily average inhibition, 70-94%) and JAK 2/2 (23%-67%) inhibition at therapeutic concentrations, with Cmax values 17- to 33-fold lower than their TYK2 IC50 levels.	baricitinib	58-69	Janus kinase 1	Homo sapiens	115-122
34471993-13	2021	Tofacitinib, upadacitinib, and baricitinib variably inhibit JAK 1/2/3 but not TYK2.	tofacitinib	0-11	Janus kinase 1	Homo sapiens	60-69
34471993-13	2021	Tofacitinib, upadacitinib, and baricitinib variably inhibit JAK 1/2/3 but not TYK2.	upadacitinib	13-25	Janus kinase 1	Homo sapiens	60-69
34471993-13	2021	Tofacitinib, upadacitinib, and baricitinib variably inhibit JAK 1/2/3 but not TYK2.	baricitinib	31-42	Janus kinase 1	Homo sapiens	60-69
34499329-5	2021	RECENT FINDINGS: Momelotonib is a JAK1/2 and ACVR1 inhibitor that has demonstrated not only improvements in splenomegaly and symptoms, but also amelioration of anemia on the SIMPLIFY 1 and 2 clinical trial program.	momelotonib	17-28	Janus kinase 1	Homo sapiens	34-40
34157510-3	2021	Ruxolitinib, a JAK1/2 inhibitor, has recently been approved for the treatment of acute GvHD.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-21
34165774-1	2021	Ruxolitinib (RUX), a JAK1/2-inhibitor, is effective for myeloproliferative neoplasm (MPN) with both JAK2V617 F and calreticulin (CALR) mutations.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	21-25
34165774-1	2021	Ruxolitinib (RUX), a JAK1/2-inhibitor, is effective for myeloproliferative neoplasm (MPN) with both JAK2V617 F and calreticulin (CALR) mutations.	ruxolitinib	13-16	Janus kinase 1	Homo sapiens	21-25
34536415-10	2022	Moreover, an overview of the clinical course of the disease, including therapies, provides evidence for the therapeutic efficacy of the Janus kinase (JAK) 1/2 inhibitor ruxolitinib in inflammatory lung disease.	ruxolitinib	169-180	Janus kinase 1	Homo sapiens	136-158
34630428-6	2021	We investigated the impact of short-term treatment of BCL2 (venetoclax) or JAK1/2 (ruxolitinib) inhibition on recipient natural killer and T cell immunity and the subsequent effect on donor engraftment.	ruxolitinib	83-94	Janus kinase 1	Homo sapiens	75-81
34660145-3	2021	Tofacitinib is an effective JAK1 and JAK3 inhibitor that can block several cytokines such as IL-2, IL-7, and IL-6.	tofacitinib	0-11	Janus kinase 1	Homo sapiens	28-32
34498807-1	2022	Filgotinib, a preferential Janus Kinase-1 inhibitor, is approved in Europe and Japan for treatment of rheumatoid arthritis and is being developed for treatment of other chronic inflammatory diseases.	GLPG0634	0-10	Janus kinase 1	Homo sapiens	27-41
34660133-3	2021	We present a 78-year-old female with a known diagnosis of primary myelofibrosis (PMF), on ruxolitinib, a Janus kinase (JAK) 1 and 2 inhibitor, presenting with altered mental status.	ruxolitinib	90-101	Janus kinase 1	Homo sapiens	105-131
34498056-1	2021	OBJECTIVES: To explore the safety and efficacy of filgotinib (FIL), a Janus kinase 1 inhibitor, and lanraplenib (LANRA), a spleen kinase inhibitor in cutaneous lupus erythematosus (CLE).	GLPG0634	50-60	Janus kinase 1	Homo sapiens	70-84
34498056-1	2021	OBJECTIVES: To explore the safety and efficacy of filgotinib (FIL), a Janus kinase 1 inhibitor, and lanraplenib (LANRA), a spleen kinase inhibitor in cutaneous lupus erythematosus (CLE).	GLPG0634	62-65	Janus kinase 1	Homo sapiens	70-84
34552486-3	2021	The JAK1/2 inhibitor, ruxolitinib, is now considered a novel therapy in inflammatory disease, and hypercytokinemia is an important feature of CAEBV.	ruxolitinib	22-33	Janus kinase 1	Homo sapiens	4-10
34322995-0	2021	Inhibition of Janus Kinase 1 synergizes docetaxel sensitivity in prostate cancer cells.	Docetaxel	40-49	Janus kinase 1	Homo sapiens	14-28
34552976-7	2021	Furthermore, in favipiravir-treated cells, the expression of JAK1 and STAT1 was downregulated, whereas that of p-STAT1 was significantly upregulated.	favipiravir	16-27	Janus kinase 1	Homo sapiens	61-65
34586102-4	2021	Filgotinib, a selective JAK1 inhibitor, has been approved by the European Medicines Agency (EMA) for treatment of RA.	GLPG0634	0-10	Janus kinase 1	Homo sapiens	24-28
34623777-3	2021	Ruxolitinib, a JAK-1 and JAK-2 inhibitor, is documented to have potent anti-inflammatory activity by targeting several cytokines and growth factors with proposed efficacy in the cytokine storm observed in severe COVID-19 patients; therefore, this study examines the efficacy and tolerability of ruxolitinib for adult COVID-19 patients.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-20
34322995-8	2021	Furthermore, inhibition of JAK1/2 by baricitinib and ruxolitinib synergizes docetaxel sensitivity in both androgen receptor (AR)-negative DU145 and PC3 cells, but not in the AR-positive LNCaP cells.	baricitinib	37-48	Janus kinase 1	Homo sapiens	27-33
34322995-7	2021	We demonstrated that depletion of endogenous JAK1 enhanced docetaxel-induced apoptosis in PCa cells.	Docetaxel	59-68	Janus kinase 1	Homo sapiens	45-49
34322995-8	2021	Furthermore, inhibition of JAK1/2 by baricitinib and ruxolitinib synergizes docetaxel sensitivity in both androgen receptor (AR)-negative DU145 and PC3 cells, but not in the AR-positive LNCaP cells.	ruxolitinib	53-64	Janus kinase 1	Homo sapiens	27-33
34171557-3	2021	Herein, we identified that interferon-gamma (IFN-gamma), one of the most important cytokines in the immune and inflammatory response, up-regulated CD47 expression in cancer cells and this effect could be inhibited by the JAK1/2 inhibitor ruxolitinib, as well as siRNA-mediated silencing of JAK1, STAT1, and IRF1.	ruxolitinib	238-249	Janus kinase 1	Homo sapiens	221-227
34322995-8	2021	Furthermore, inhibition of JAK1/2 by baricitinib and ruxolitinib synergizes docetaxel sensitivity in both androgen receptor (AR)-negative DU145 and PC3 cells, but not in the AR-positive LNCaP cells.	Docetaxel	76-85	Janus kinase 1	Homo sapiens	27-33
34324169-0	2021	Selective Inhibition of JAK1 Primes STAT5-Driven Human Leukemia Cells for ATRA-Induced Differentiation.	Tretinoin	74-78	Janus kinase 1	Homo sapiens	24-28
34324169-3	2021	Dysregulated JAK/STAT signaling is known to drive several hematologic malignancies, and targeting JAK1 and JAK2 with the JAK1/JAK2 inhibitor ruxolitinib has led to improvement in survival in primary myelofibrosis and alleviation of vasomotor symptoms and splenomegaly in polycythemia vera and myelofibrosis.	ruxolitinib	141-152	Janus kinase 1	Homo sapiens	13-16
34324169-3	2021	Dysregulated JAK/STAT signaling is known to drive several hematologic malignancies, and targeting JAK1 and JAK2 with the JAK1/JAK2 inhibitor ruxolitinib has led to improvement in survival in primary myelofibrosis and alleviation of vasomotor symptoms and splenomegaly in polycythemia vera and myelofibrosis.	ruxolitinib	141-152	Janus kinase 1	Homo sapiens	98-102
34226674-5	2021	Restoring CD25 expression using the JAK1/3-inhibitor tofacitinib controlled TCR-induced IFNgamma secretion in vitro.	tofacitinib	53-64	Janus kinase 1	Homo sapiens	36-42
34324169-3	2021	Dysregulated JAK/STAT signaling is known to drive several hematologic malignancies, and targeting JAK1 and JAK2 with the JAK1/JAK2 inhibitor ruxolitinib has led to improvement in survival in primary myelofibrosis and alleviation of vasomotor symptoms and splenomegaly in polycythemia vera and myelofibrosis.	ruxolitinib	141-152	Janus kinase 1	Homo sapiens	121-125
34324169-5	2021	The objective of this study is to employ JAK1 inhibition (JAK1i) in the presence of ATRA as a potential therapy in non-M3 acute myeloid leukemia (AML).	Tretinoin	84-88	Janus kinase 1	Homo sapiens	41-45
34531866-8	2021	In vitro treatment of HIV-infected CD4+ T cells with physiological concentrations of JAK1/2 inhibitors, ruxolitinib and baricitinib, used in clinical settings to target inflammation, reduced latent and productive infection events when added 24 hr after infection and blocked HIV reactivation from latent cells.	ruxolitinib	104-115	Janus kinase 1	Homo sapiens	85-91
34531866-8	2021	In vitro treatment of HIV-infected CD4+ T cells with physiological concentrations of JAK1/2 inhibitors, ruxolitinib and baricitinib, used in clinical settings to target inflammation, reduced latent and productive infection events when added 24 hr after infection and blocked HIV reactivation from latent cells.	baricitinib	120-131	Janus kinase 1	Homo sapiens	85-91
34514265-4	2021	In this work, GraphGMVAE was validated by rapidly hopping the scaffold from FDA-approved upadacitinib, which is an inhibitor of human Janus kinase 1 (JAK1), to generate more potent molecules with novel chemical scaffolds.	graphgmvae	14-24	Janus kinase 1	Homo sapiens	134-148
34532638-4	2021	The JAK1/2 selective JAK inhibitor baricitinib was the first substance from this class of drugs approved by the EMA for the systemic oral treatment of AD.	baricitinib	35-46	Janus kinase 1	Homo sapiens	4-10
34532638-5	2021	The clinical development program of the JAK1 selective inhibitors upadacitinib and abrocitinib is finalized with positive results for AD.	upadacitinib	66-78	Janus kinase 1	Homo sapiens	40-44
34514265-4	2021	In this work, GraphGMVAE was validated by rapidly hopping the scaffold from FDA-approved upadacitinib, which is an inhibitor of human Janus kinase 1 (JAK1), to generate more potent molecules with novel chemical scaffolds.	graphgmvae	14-24	Janus kinase 1	Homo sapiens	150-154
34514265-4	2021	In this work, GraphGMVAE was validated by rapidly hopping the scaffold from FDA-approved upadacitinib, which is an inhibitor of human Janus kinase 1 (JAK1), to generate more potent molecules with novel chemical scaffolds.	upadacitinib	89-101	Janus kinase 1	Homo sapiens	134-148
34514265-4	2021	In this work, GraphGMVAE was validated by rapidly hopping the scaffold from FDA-approved upadacitinib, which is an inhibitor of human Janus kinase 1 (JAK1), to generate more potent molecules with novel chemical scaffolds.	upadacitinib	89-101	Janus kinase 1	Homo sapiens	150-154
34514265-6	2021	The most potent molecule has 5.0 nM activity against JAK1 kinase, which shows that the GraphGMVAE model can design molecules like how a human expert does but with high efficiency and accuracy.	graphgmvae	87-97	Janus kinase 1	Homo sapiens	53-57
34379541-5	2021	Baricitinib shows high selectivity for JAK1 and JAK2, making it appealing for the treatment of this condition.	baricitinib	0-11	Janus kinase 1	Homo sapiens	39-43
34169393-2	2021	Ruxolitinib is an FDA approved inhibitor of JAK1 and JAK2.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	44-48
34423448-2	2022	Ruxolitinib, a selective inhibitor of JAK 1 and 2, significantly reduces constitutional symptoms and spleen size compared with placebo, and has significant clinical benefits in patients with myelofibrosis.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	38-49
34910188-1	2022	OBJECTIVES: Evaluate the efficacy and safety of the Janus kinase-1 inhibitor filgotinib in Japanese patients with rheumatoid arthritis (RA) and inadequate response to methotrexate (MTX).	GLPG0634	77-87	Janus kinase 1	Homo sapiens	52-66
34445192-3	2021	Here, we present our work to repurpose a Janus kinase 1 inhibitor, ruxolitinib as a DCLK1 inhibitor, showing micromolar binding affinity and inhibitory activity.	ruxolitinib	67-78	Janus kinase 1	Homo sapiens	41-55
34352069-1	2022	OBJECTIVE: To assess the effect of filgotinib, which preferentially inhibits Janus kinase 1 (JAK1), on magnetic resonance imaging (MRI) measures of structural change in the sacroiliac (SI) joint in patients with active ankylosing spondylitis (AS) in the TORTUGA trial.	GLPG0634	35-45	Janus kinase 1	Homo sapiens	77-91
34352069-1	2022	OBJECTIVE: To assess the effect of filgotinib, which preferentially inhibits Janus kinase 1 (JAK1), on magnetic resonance imaging (MRI) measures of structural change in the sacroiliac (SI) joint in patients with active ankylosing spondylitis (AS) in the TORTUGA trial.	GLPG0634	35-45	Janus kinase 1	Homo sapiens	93-97
34352069-10	2022	CONCLUSION: The significant changes in MRI structural lesions induced by filgotinib in the SI joint by week 12 demonstrate that tissue repair can be observed very soon after starting treatment with a JAK1 preferential inhibitor.	GLPG0634	73-83	Janus kinase 1	Homo sapiens	200-204
34184542-2	2021	Material & methods: We tested ruxolitinib (a selective JAK1/2 inhibitor) efficacy in three different preclinical models of GvHD.	ruxolitinib	30-41	Janus kinase 1	Homo sapiens	55-61
34391330-9	2021	We present a patient treated with tofacitinib, 5mg twice daily, an oral JAK1/3 inhibitor, who demonstrated clinical improvement of DH and control of new lesion development.	tofacitinib	34-45	Janus kinase 1	Homo sapiens	72-78
34397713-1	2021	ABSTRACT: Baricitinib is a Janus kinase (JAK) inhibitor that selectively blocks against JAK1 and JAK2 signaling.	baricitinib	10-21	Janus kinase 1	Homo sapiens	88-92
34314383-0	2021	Curcumol may alleviate psoriasis-like inflammation by inhibiting keratinocyte proliferation and inflammatory gene expression via JAK1/STAT3 signaling.	curcumol	0-8	Janus kinase 1	Homo sapiens	129-133
34314383-5	2021	Curcumol inhibits activity of JAK1, resulting in the inhibition of STAT3, downregulation of cyclin D2, and cell cycle arrest in stimulated NHEK cells.	curcumol	0-8	Janus kinase 1	Homo sapiens	30-34
34314383-6	2021	Together, our data show that curcumol reduces proliferation and inflammatory gene expression in stimulated keratinocytes by inhibiting the JAK1/STAT3 signaling, suggesting that it might serve as a potential therapeutic option for the treatment of psoriasis.	curcumol	29-37	Janus kinase 1	Homo sapiens	139-143
34359628-8	2021	Finally, JAK1/2-STAT6 pathway inhibition by ruxolitinib, an FDA approved drug, in cell line models and in one T-LBL primary sample led to cell proliferation reduction and increased apoptosis.	ruxolitinib	44-55	Janus kinase 1	Homo sapiens	9-15
34321087-12	2021	Moreover, RSV significantly attenuated the level of IL-6 secretion, which was accompanied by less phosphorylation of the transcription factors Janus kinase 1 (JAK1) and signal transducer and activator of transcription 3 (STAT3).	Resveratrol	10-13	Janus kinase 1	Homo sapiens	143-157
34321087-12	2021	Moreover, RSV significantly attenuated the level of IL-6 secretion, which was accompanied by less phosphorylation of the transcription factors Janus kinase 1 (JAK1) and signal transducer and activator of transcription 3 (STAT3).	Resveratrol	10-13	Janus kinase 1	Homo sapiens	159-163
34118090-0	2021	Systemic Jak1 activation causes extrarenal calcitriol production and skeletal alterations provoking stunted growth.	Calcitriol	43-53	Janus kinase 1	Homo sapiens	9-13
34371735-6	2021	Ruxolitinib was designed as a molecule with low nanomolar potency selective for JAK1 and 2 enzymes, but without significant inhibition of non-JAK kinases, as well as physicochemical properties for both topical and oral administration.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	80-90
34371735-8	2021	Ruxolitinib cream represents a novel, JAK1/2 selective therapy that can be delivered directly to the skin to treat a number of cytokine-driven, inflammatory dermatoses.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	38-44
34260836-3	2021	In retrospective surveys, ruxolitinib, a Janus kinase (JAK1-JAK2) inhibitor, showed potential efficacy in patients with glucocorticoid-refractory or -dependent chronic GVHD.	ruxolitinib	26-37	Janus kinase 1	Homo sapiens	55-59
34276662-2	2021	The effect of the JAK1/2 kinase inhibitor ruxolitinib on treating steroid-refractory acute GVHD has been verified by the REACH1/2 study; however, its safety and efficacy in patients with steroid-refractory chronic GVHD (SR-cGVHD) remain unclear.	ruxolitinib	42-53	Janus kinase 1	Homo sapiens	18-24
34275303-12	2021	Furthermore, targeted synthetic drugs are used in the treatment of PsA, namely the phosphodiesterase-4 inhibitor apremilast, whose efficacy is lower, and the newly introduced JAK1/3 inhibitor tofacitinib.	tofacitinib	192-203	Janus kinase 1	Homo sapiens	175-181
34167562-7	2021	RESULTS: All NOTCH1-signaling-dependent T-ALL cell lines were sensitive to MRK-560 and its combination with ruxolitinib or imatinib in JAK1- or ABL1-dependent cell lines synergistically inhibited leukemia proliferation.	Imatinib Mesylate	123-131	Janus kinase 1	Homo sapiens	135-139
34068690-7	2021	The constitutive activation of the tyrosine kinase JAK2 is targeted by ruxolitinib, a JAK1/JAK2 tyrosine kinase inhibitor for PV patients who are resistant or intolerant to cytoreductive treatment with hydroxyurea.	ruxolitinib	71-82	Janus kinase 1	Homo sapiens	86-90
34206393-4	2021	However, IL-6 and the JAK1/2 inhibitor Ruxolitinib significantly increased angiogenic factors-endothelial nitric oxide synthase (eNOS), VEGF, and hypoxia-inducible factor-1 alpha (HIF-1alpha)-in patients with polycythemia vera (PV).	ruxolitinib	39-50	Janus kinase 1	Homo sapiens	22-28
34090625-2	2021	We assessed the efficacy and safety of filgotinib, a once-daily, oral Janus kinase 1 preferential inhibitor, for treatment of ulcerative colitis.	GLPG0634	39-49	Janus kinase 1	Homo sapiens	70-84
34097138-10	2021	Most recently, ruxolitinib, a JAK1/2 inhibitor targeting JAK-STAT signaling downstream from CSF3R, has emerged as a potentially promising new candidate for the treatment of CNL.	ruxolitinib	15-26	Janus kinase 1	Homo sapiens	30-36
34073410-4	2021	Numerous JAK inhibitors (JAKinibs) have entered clinical trials, including the JAK1/2 inhibitor Ruxolitinib approved for the treatment of MPN.	ruxolitinib	96-107	Janus kinase 1	Homo sapiens	79-85
34097573-4	2022	Flow cytometry, microscopy and other assays found that potent JAK1/2 inhibitors baricitinib and ruxolitinib reduced platelet adhesion to collagen, as well as platelet aggregation, secretion and integrin alphaIIbbeta3 activation in response to the glycoprotein VI (GPVI) agonist collagen-related peptide (CRP-XL).	baricitinib	80-91	Janus kinase 1	Homo sapiens	62-68
34097573-4	2022	Flow cytometry, microscopy and other assays found that potent JAK1/2 inhibitors baricitinib and ruxolitinib reduced platelet adhesion to collagen, as well as platelet aggregation, secretion and integrin alphaIIbbeta3 activation in response to the glycoprotein VI (GPVI) agonist collagen-related peptide (CRP-XL).	ruxolitinib	96-107	Janus kinase 1	Homo sapiens	62-68
35072287-1	2022	AIMS: Filgotinib is a potent, oral, JAK1-preferential inhibitor for the treatment of rheumatoid arthritis (RA).	GLPG0634	6-16	Janus kinase 1	Homo sapiens	36-40
34910214-0	2021	Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials.	GLPG0634	0-10	Janus kinase 1	Homo sapiens	20-24
34910214-3	2021	Filgotinib has demonstrated preferential inhibition of JAK1-dependent cytokine signaling in in vitro assays.	GLPG0634	0-10	Janus kinase 1	Homo sapiens	55-59
34349069-6	2021	Based on these findings, an investigator-initiated clinical research of a JAK1/2 inhibitor ruxolitinib for CAEBV infection was initiated in January 2019.	ruxolitinib	91-102	Janus kinase 1	Homo sapiens	74-80
35609978-1	2022	OBJECTIVES: To elucidate the mechanism of action of baricitinib, a Janus kinase (JAK) 1/2 inhibitor, and describe immunological pathways related to disease activity in adults with systemic lupus erythematosus (SLE) receiving standard background therapy in a phase II trial.	baricitinib	52-63	Janus kinase 1	Homo sapiens	67-89
35604239-0	2022	Ruxolitinib, a JAK1/2 Inhibitor as Treatment for Paraneoplastic Pemphigus: A Case Report.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	15-21
35363892-2	2022	Ruxolitinib (RUX) is the JAK1/2 inhibitor most used for treatment of MF-related splenomegaly and symptoms.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	25-31
35363892-2	2022	Ruxolitinib (RUX) is the JAK1/2 inhibitor most used for treatment of MF-related splenomegaly and symptoms.	ruxolitinib	13-16	Janus kinase 1	Homo sapiens	25-31
35603634-4	2022	Momelotinib is a JAK1/JAK2 inhibitor that also antagonizes ACVR1, leading to downregulation of hepcidin expression and increased availability of iron for erythropoiesis.	N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	0-11	Janus kinase 1	Homo sapiens	17-21
35603634-4	2022	Momelotinib is a JAK1/JAK2 inhibitor that also antagonizes ACVR1, leading to downregulation of hepcidin expression and increased availability of iron for erythropoiesis.	Iron	145-149	Janus kinase 1	Homo sapiens	17-21
35635540-1	2022	Ruxolitinib (RUX), a small molecule inhibitor of JAK1/JAK2, has been identified as the possible novel targeted agent for the treatment of hemophagocytic lymphohistiocytosis (HLH).	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	49-53
35635540-1	2022	Ruxolitinib (RUX), a small molecule inhibitor of JAK1/JAK2, has been identified as the possible novel targeted agent for the treatment of hemophagocytic lymphohistiocytosis (HLH).	ruxolitinib	13-16	Janus kinase 1	Homo sapiens	49-53
35614292-1	2022	INTRODUCTION: The phase 2 MANTA and MANTA-RAy studies were developed in consultation with global regulatory authorities to investigate potential impacts of filgotinib, a Janus kinase 1 preferential inhibitor, on semen parameters in men with active inflammatory diseases.	GLPG0634	156-166	Janus kinase 1	Homo sapiens	170-184
35597252-1	2022	BACKGROUND: The phase 3b, randomised, open-label RESPONSE-2 study in patients with inadequately controlled polycythaemia vera without splenomegaly showed superiority of the Janus kinase (JAK) 1 and JAK2 inhibitor ruxolitinib versus best available therapy for the primary endpoint of haematocrit control at week 28.	ruxolitinib	213-224	Janus kinase 1	Homo sapiens	173-193
35595725-9	2022	Imaging analysis detected phosphotyrosine STAT3 in MF patients" BM fibrocytes, and transfection of fibrocytes with STAT3-siRNA or treatment with a JAK1/2 inhibitor ruxolitinib reduced GLI1 and MMP2/9 levels.	ruxolitinib	164-175	Janus kinase 1	Homo sapiens	147-153
35599279-8	2022	RESULTS: In ARPE-19 cells exposed to high-glucose conditions, the mRNA and secretory protein levels of VEGF, p-JAK1, p-JAK2, p-STAT3, and p-STAT5 levels were significantly increased.	Glucose	42-49	Janus kinase 1	Homo sapiens	111-115
35529449-3	2022	Initially, the ligand-based pharmacophore models were generated using a set of 52 JAK1 inhibitors named C-2 methyl/hydroxyethyl imidazopyrrolopyridines derivatives.	c-2 methyl/hydroxyethyl imidazopyrrolopyridines	104-151	Janus kinase 1	Homo sapiens	82-86
35578304-2	2022	Baricitinib is a Janus kinase (JAK)1 and 2 inhibitor that was shown to have therapeutic benefit in patients with SLE in a phase II clinical trial.	baricitinib	0-11	Janus kinase 1	Homo sapiens	17-42
34978076-0	2022	Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase 2 studies.	incb054707	25-35	Janus kinase 1	Homo sapiens	0-14
34978076-2	2022	OBJECTIVES: To describe safety and efficacy results from two multicenter phase 2 trials of the JAK1 inhibitor INCB054707 in patients with moderate-to-severe HS.	incb054707	110-120	Janus kinase 1	Homo sapiens	95-99
35157370-2	2022	This phase 1, randomized, placebo-controlled trial assessed the pharmacokinetics and safety of single and multiple ascending doses up to 15 mg twice daily for 14 days of a JAK1 inhibitor, GDC-0214, in healthy volunteers (HVs; n=66).	gdc-0214	188-196	Janus kinase 1	Homo sapiens	172-176
35437207-10	2022	Dexamethasone (a corticosteroid) significantly inhibited, while ABT494 (a JAK1 inhibitor) partially inhibited, EKH"s induction of cytokines in fibroblasts.	upadacitinib	64-70	Janus kinase 1	Homo sapiens	74-78
35437207-10	2022	Dexamethasone (a corticosteroid) significantly inhibited, while ABT494 (a JAK1 inhibitor) partially inhibited, EKH"s induction of cytokines in fibroblasts.	5-Chlorotubercidin	111-114	Janus kinase 1	Homo sapiens	74-78
35368384-2	2022	The Janus kinase (JAK)1/JAK2 inhibitor ruxolitinib reduces inflammatory cytokine concentrations in disorders characterised by cytokine dysregulation, including graft-versus-host disease, myelofibrosis, and secondary hemophagocytic lymphohistiocytosis.	ruxolitinib	39-50	Janus kinase 1	Homo sapiens	4-23
35368384-3	2022	We assessed whether treatment with the JAK1/JAK2 inhibitor ruxolitinib would be beneficial in patients with COVID-19 admitted to hospital.	ruxolitinib	59-70	Janus kinase 1	Homo sapiens	39-43
35484697-1	2022	BACKGROUND: Baricitinib, an oral selective Janus Kinase (JAK) 1 and JAK 2 inhibitor, was shown to improve the signs and symptoms of moderate-to-severe atopic dermatitis (AD).	baricitinib	12-23	Janus kinase 1	Homo sapiens	43-63
35481616-0	2022	Esophageal lichen planus successfully treated with the JAK1/3 inhibitor tofacitinib.	tofacitinib	72-83	Janus kinase 1	Homo sapiens	55-61
35451191-0	2022	Arachidonic acid, a clinically adverse mediator in the ovarian cancer microenvironment, impairs JAK-STAT signaling in macrophages by perturbing lipid raft structures.	Arachidonic Acid	0-16	Janus kinase 1	Homo sapiens	96-99
35507130-8	2022	Ex vivo treatment with the JAK1/2-inhibitor ruxolitinib reduced cytokine responsiveness and normalized STAT1 phosphorylation in DN STAT3 and STAT1 GOF patient" cells.	ruxolitinib	44-55	Janus kinase 1	Homo sapiens	27-31
35368221-1	2022	BACKGROUND: Ruxolitinib cream is a topical formulation of ruxolitinib, an inhibitor of Janus kinase 1 and Janus kinase 2.	ruxolitinib	12-23	Janus kinase 1	Homo sapiens	87-101
35368221-1	2022	BACKGROUND: Ruxolitinib cream is a topical formulation of ruxolitinib, an inhibitor of Janus kinase 1 and Janus kinase 2.	ruxolitinib	58-69	Janus kinase 1	Homo sapiens	87-101
35503162-1	2022	Baricitinib (Olumiant ) is an oral small molecule inhibitor of Janus kinase (JAK)1 and JAK2, which have been implicated in the pathogenesis of atopic dermatitis (AD).	baricitinib	0-11	Janus kinase 1	Homo sapiens	63-82
35503162-1	2022	Baricitinib (Olumiant ) is an oral small molecule inhibitor of Janus kinase (JAK)1 and JAK2, which have been implicated in the pathogenesis of atopic dermatitis (AD).	baricitinib	13-21	Janus kinase 1	Homo sapiens	63-82
35266648-3	2022	Inhibition of IFNG pathway by the JAK1/2 inhibitor ruxolitinib or knocking out Stat1 gene abrogated the IFNG-induced melanogenesis.	ruxolitinib	51-62	Janus kinase 1	Homo sapiens	34-40
35382859-5	2022	The effects of Ruxolitinib (JAK1/2 inhibitor) on liver fibrosis were studied in LX-2 cells and two progressive and reversible fibrosis animal models (carbon tetrachloride (CCl4), Thioacetamide (TAA)).	ruxolitinib	15-26	Janus kinase 1	Homo sapiens	28-34
35443042-6	2022	Ruxolitinib, an oral selective JAK1/2 inhibitor, received FDA approval for the treatment of steroid-refractory acute GVHD in 2019 and remains the only agent approved for acute GVHD.	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	31-37
35437311-1	2022	Outside of clinical trials and before commercial availability for acute and chronic graft-versus-host disease (GVHD), the Janus kinase (JAK) 1/JAK2 inhibitor ruxolitinib was available to US patients with steroid-refractory GVHD through an open-label, multicenter expanded access program (EAP) sponsored by Incyte Corporation.	ruxolitinib	158-169	Janus kinase 1	Homo sapiens	122-142
35267240-0	2022	Response of rheumatoid arthritis-associated pyoderma gangrenous to the JAK1 inhibitor upadacitinib.	upadacitinib	86-98	Janus kinase 1	Homo sapiens	71-75
35346999-10	2022	Furthermore, CJ14939 also promoted oxaliplatin-induced cell death, up-regulated expression of cleaved caspase-3, and down-regulated expression of phospho-JAK1 and phospho-STAT3.	Oxaliplatin	35-46	Janus kinase 1	Homo sapiens	154-158
35100463-6	2022	The molecular mechanism of cytotoxicity observed around Fr7 against ATL cells was the degradation of JAK1 to 3 and the dephosphorylation of STAT3/5, which occurs by proteasome-dependent proteolysis, confirming that PAC directly binds to HSP90.	proanthocyanidin	215-218	Janus kinase 1	Homo sapiens	101-105
35446502-0	2022	Ansprechen eines mit rheumatoider Arthritis assoziierten Pyoderma gangraenosum auf den JAK1-Inhibitor Upadacitinib.	upadacitinib	102-114	Janus kinase 1	Homo sapiens	87-91
35365828-1	2022	OBJECTIVE: Characterize safety of the Janus kinase-1 preferential inhibitor filgotinib in Japanese patients with moderately to severely active rheumatoid arthritis.	GLPG0634	76-86	Janus kinase 1	Homo sapiens	38-52
35346999-9	2022	RESULTS: CJ14939 induced cell death, and inhibited phosphorylation of JAK1 and STAT3 in colorectal cancer cells.	cj14939	9-16	Janus kinase 1	Homo sapiens	70-74
35346999-10	2022	Furthermore, CJ14939 also promoted oxaliplatin-induced cell death, up-regulated expression of cleaved caspase-3, and down-regulated expression of phospho-JAK1 and phospho-STAT3.	cj14939	13-20	Janus kinase 1	Homo sapiens	154-158
35041155-1	2022	INTRODUCTION: Baricitinib is an oral Janus kinase (JAK)1/JAK2 inhibitor approved to treat rheumatoid arthritis (RA).	baricitinib	14-25	Janus kinase 1	Homo sapiens	37-56
35354957-0	2022	Itaconate modifies JAK1.	itaconic acid	0-9	Janus kinase 1	Homo sapiens	19-23
35235776-0	2022	Itaconate and itaconate derivatives target JAK1 to suppress alternative activation of macrophages.	itaconic acid	0-9	Janus kinase 1	Homo sapiens	43-47
35371054-4	2022	Interferon (IFN)-gamma induces IDO1 expression through the Jak/STAT1 pathway and mediates Kyn production concomitantly with Trp consumption in CLL-conditioned media, while INCB018424 (ruxolitinib), a JAK1/2 inhibitor, impaired both effects.	ruxolitinib	172-182	Janus kinase 1	Homo sapiens	59-62
35371054-4	2022	Interferon (IFN)-gamma induces IDO1 expression through the Jak/STAT1 pathway and mediates Kyn production concomitantly with Trp consumption in CLL-conditioned media, while INCB018424 (ruxolitinib), a JAK1/2 inhibitor, impaired both effects.	ruxolitinib	184-195	Janus kinase 1	Homo sapiens	59-62
35371054-4	2022	Interferon (IFN)-gamma induces IDO1 expression through the Jak/STAT1 pathway and mediates Kyn production concomitantly with Trp consumption in CLL-conditioned media, while INCB018424 (ruxolitinib), a JAK1/2 inhibitor, impaired both effects.	ruxolitinib	184-195	Janus kinase 1	Homo sapiens	200-206
35184688-9	2022	CircPIP5K1A was available to competitively combine with miR-552-3p, while whose direct target was JAK1.	mir-552-3p	56-66	Janus kinase 1	Homo sapiens	98-102
35364216-2	2022	CTP-543, a deuterated compound that selectively inhibits JAK1 and JAK2, is being developed as an oral treatment for AA.	Deuruxolitinib	0-7	Janus kinase 1	Homo sapiens	57-61
35319396-7	2022	Baricitinib, the Janus kinase (JAK) 1/2 inhibitor, is also an attractive candidate due to its properties as a potent anti-inflammatory agent and its hypothesized off-target antiviral effects against SARS-CoV-2.	baricitinib	0-11	Janus kinase 1	Homo sapiens	17-39
35337171-5	2022	Recently, the FDA approved the use of ruxolitinib, a JAK1/2 inhibitor, in the treatment of acute steroid-refractory GVHD (SR-aGVHD), highlighting the role of JAK inhibition in this immune deregulation.	ruxolitinib	38-49	Janus kinase 1	Homo sapiens	53-59
35235776-0	2022	Itaconate and itaconate derivatives target JAK1 to suppress alternative activation of macrophages.	itaconic acid	14-23	Janus kinase 1	Homo sapiens	43-47
35235776-5	2022	Examination of IL-4 signaling revealed inhibition of JAK1 and STAT6 phosphorylation by both itaconate and OI.	itaconic acid	92-101	Janus kinase 1	Homo sapiens	53-57
35235776-7	2022	Importantly, JAK1 was directly modified by itaconate derivatives at multiple residues, including cysteines 715, 816, 943, and 1130.	itaconic acid	43-52	Janus kinase 1	Homo sapiens	13-17
35235776-7	2022	Importantly, JAK1 was directly modified by itaconate derivatives at multiple residues, including cysteines 715, 816, 943, and 1130.	Cysteine	97-106	Janus kinase 1	Homo sapiens	13-17
35235776-10	2022	We therefore identify itaconate and OI as JAK1 inhibitors, suggesting a new strategy to inhibit JAK1 in M2 macrophage-driven diseases.	itaconic acid	22-31	Janus kinase 1	Homo sapiens	42-46
35235776-10	2022	We therefore identify itaconate and OI as JAK1 inhibitors, suggesting a new strategy to inhibit JAK1 in M2 macrophage-driven diseases.	itaconic acid	22-31	Janus kinase 1	Homo sapiens	96-100
35213752-9	2022	Conversely, inhibition of IL-22-induced JAK1 signalling with ABT-317 strongly attenuated morphological features of the disease but had no effect on NFkappaB-dependent cytokine production, suggesting distinct mechanisms of action by the cytokines driving psoriasis.	abt-317	61-68	Janus kinase 1	Homo sapiens	40-44
35131544-5	2022	Furthermore, propionate-induced IFIT expression is dependent on IFN type I and/or type III-mediated signalling since pre-treatment of A549 cells with Ruxolitinib, a specific JAK1/2 tyrosine kinase inhibitor, prior to stimulation with propionate, inhibited the upregulation of IFIT1 expression.	Propionates	13-23	Janus kinase 1	Homo sapiens	174-180
35131544-5	2022	Furthermore, propionate-induced IFIT expression is dependent on IFN type I and/or type III-mediated signalling since pre-treatment of A549 cells with Ruxolitinib, a specific JAK1/2 tyrosine kinase inhibitor, prior to stimulation with propionate, inhibited the upregulation of IFIT1 expression.	ruxolitinib	150-161	Janus kinase 1	Homo sapiens	174-180
35288468-1	2022	BACKGROUND: This phase I multicenter study was designed to evaluate the safety, tolerability, efficacy, and translational effects on the tumor microenvironment of itacitinib (Janus-associated kinase 1 (JAK1) inhibitor) in combination with epacadostat (indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor) or parsaclisib (phosphatidylinositol 3-kinase delta (PI3Kdelta) inhibitor).	INCB039110	163-173	Janus kinase 1	Homo sapiens	175-200
35288468-1	2022	BACKGROUND: This phase I multicenter study was designed to evaluate the safety, tolerability, efficacy, and translational effects on the tumor microenvironment of itacitinib (Janus-associated kinase 1 (JAK1) inhibitor) in combination with epacadostat (indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor) or parsaclisib (phosphatidylinositol 3-kinase delta (PI3Kdelta) inhibitor).	INCB039110	163-173	Janus kinase 1	Homo sapiens	202-206
35235887-0	2022	Piceatannol, a metabolite of resveratrol, attenuates atopic dermatitis by targeting Janus kinase 1.	3,3',4,5'-tetrahydroxystilbene	0-11	Janus kinase 1	Homo sapiens	84-98
35113547-0	2022	Identification of a Novel 2,8-Diazaspiro(4.5)decan-1-one Derivative as a Potent and Selective Dual TYK2/JAK1 Inhibitor for the Treatment of Inflammatory Bowel Disease.	2,8-diazaspiro[4.5]decan-1-one	26-56	Janus kinase 1	Homo sapiens	104-108
35113547-1	2022	In this study, we described a series of 2,8-diazaspiro(4.5)decan-1-one derivatives as selective TYK2/JAK1 inhibitors.	2,8-diazaspiro[4.5]decan-1-one	40-70	Janus kinase 1	Homo sapiens	101-105
35235887-0	2022	Piceatannol, a metabolite of resveratrol, attenuates atopic dermatitis by targeting Janus kinase 1.	Resveratrol	29-40	Janus kinase 1	Homo sapiens	84-98
35235887-10	2022	Piceatannol decreased phosphorylation of JAK-STAT protein in the TNFalpha/IFNgamma-induced HaCaT cell line.	3,3',4,5'-tetrahydroxystilbene	0-11	Janus kinase 1	Homo sapiens	41-44
35235887-11	2022	A molecular docking study showed that piceatannol strongly interacts with JAK1, suggesting a possible mode of action.	3,3',4,5'-tetrahydroxystilbene	38-49	Janus kinase 1	Homo sapiens	74-78
35186752-5	2022	RNA sequencing identified 126 genes that were regulated by both FUS-DDIT3 expression and JAK1/2 inhibition using ruxolitinib.	ruxolitinib	113-124	Janus kinase 1	Homo sapiens	89-95
35096866-1	2021	Baricitinib is a Janus kinase (JAK) inhibitor used to treat refractory rheumatoid arthritis and blocks the subtypes JAK1 and JAK2.	baricitinib	0-11	Janus kinase 1	Homo sapiens	116-120
35590143-4	2022	Treatment with the JAK1 inhibitor itacitinib resulted in a rapid resolution of aplastic anemia and a sustained recovery of hematopoiesis.	INCB039110	34-44	Janus kinase 1	Homo sapiens	19-23
34738874-0	2022	AZD3759 enhances radiation effects in non-small-cell lung cancer by a synergistic blockade of epidermal growth factor receptor and Janus kinase-1.	AZD3759	0-7	Janus kinase 1	Homo sapiens	131-145
34971577-2	2022	We aimed to evaluate the Janus kinase 1 inhibitor itacitinib versus placebo, both in combination with corticosteroids, for initial treatment of acute GVHD.	INCB039110	50-60	Janus kinase 1	Homo sapiens	25-39
35224383-6	2022	In the current study, we investigated the mechanism of binding of baricitinib, filgotinib, itacitinib, and upadacitinib to JAK1 using a combined method of molecular docking, molecular dynamics simulation, and binding free energy calculation via the molecular mechanics Poisson-Boltzmann surface area (MM-PBSA) scheme.	baricitinib	66-77	Janus kinase 1	Homo sapiens	123-127
35224383-6	2022	In the current study, we investigated the mechanism of binding of baricitinib, filgotinib, itacitinib, and upadacitinib to JAK1 using a combined method of molecular docking, molecular dynamics simulation, and binding free energy calculation via the molecular mechanics Poisson-Boltzmann surface area (MM-PBSA) scheme.	GLPG0634	79-89	Janus kinase 1	Homo sapiens	123-127
35224383-6	2022	In the current study, we investigated the mechanism of binding of baricitinib, filgotinib, itacitinib, and upadacitinib to JAK1 using a combined method of molecular docking, molecular dynamics simulation, and binding free energy calculation via the molecular mechanics Poisson-Boltzmann surface area (MM-PBSA) scheme.	INCB039110	91-101	Janus kinase 1	Homo sapiens	123-127
35224383-6	2022	In the current study, we investigated the mechanism of binding of baricitinib, filgotinib, itacitinib, and upadacitinib to JAK1 using a combined method of molecular docking, molecular dynamics simulation, and binding free energy calculation via the molecular mechanics Poisson-Boltzmann surface area (MM-PBSA) scheme.	upadacitinib	107-119	Janus kinase 1	Homo sapiens	123-127
35224383-8	2022	Due to the increased favorable intermolecular electrostatic contribution, upadacitinib is more selective to JAK1 compared to the other three inhibitors.	upadacitinib	74-86	Janus kinase 1	Homo sapiens	108-112
35224383-10	2022	Furthermore, our studies indicated that the hydrophobic residues and hydrogen bonds from the hinge region (Glu957 and Leu959) of JAK1 played an essential role in stabilizing the inhibitors.	Hydrogen	69-77	Janus kinase 1	Homo sapiens	129-133
35224383-11	2022	Protein structural network analysis reveals that the total number of links and hubs in JAK1/baricitinib (354, 48) is more significant than those in apo (328, 40) and the other three complexes.	baricitinib	92-103	Janus kinase 1	Homo sapiens	87-91
35224383-12	2022	The JAK1/baricitinib complex shows the highest probability of the highest-ranked community, indicating a compact network of the JAK1/baricitinib complex, consistent with its higher stability than the rest of the four systems.	baricitinib	9-20	Janus kinase 1	Homo sapiens	4-8
35224383-12	2022	The JAK1/baricitinib complex shows the highest probability of the highest-ranked community, indicating a compact network of the JAK1/baricitinib complex, consistent with its higher stability than the rest of the four systems.	baricitinib	9-20	Janus kinase 1	Homo sapiens	128-132
35224383-12	2022	The JAK1/baricitinib complex shows the highest probability of the highest-ranked community, indicating a compact network of the JAK1/baricitinib complex, consistent with its higher stability than the rest of the four systems.	baricitinib	133-144	Janus kinase 1	Homo sapiens	4-8
35224383-12	2022	The JAK1/baricitinib complex shows the highest probability of the highest-ranked community, indicating a compact network of the JAK1/baricitinib complex, consistent with its higher stability than the rest of the four systems.	baricitinib	133-144	Janus kinase 1	Homo sapiens	128-132
35131254-1	2022	Ruxolitinib is a Janus kinase 1/2 inhibitor (JAK1/2) that blocks signal transduction of interferon-gamma, a critical cytokine involved in the pathogenesis of cutaneous lichen planus (LP).	ruxolitinib	0-11	Janus kinase 1	Homo sapiens	45-51
35014922-4	2022	AREAS COVERED: This paper explores the use of upadacitinib (a selective JAK1 inhibitor) for the treatment of psoriatic arthritis.	upadacitinib	46-58	Janus kinase 1	Homo sapiens	72-76
35159191-4	2022	MB cells subjected to co-culture with microglia exhibited increased expression of phosphorylated JAK1 and STAT3, which was correlated with enhanced resistance to vincristine.	Vincristine	162-173	Janus kinase 1	Homo sapiens	97-101
35260349-0	2022	A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies.	incb052793	56-66	Janus kinase 1	Homo sapiens	30-44
35260349-0	2022	A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies.	INCB039110	71-81	Janus kinase 1	Homo sapiens	30-44
35260349-3	2022	PATIENTS AND METHODS: This phase 1/2 study evaluated 2 oral, novel JAK1 inhibitors (INCB052793 and itacitinib) in advanced hematologic malignancies.	incb052793	84-94	Janus kinase 1	Homo sapiens	67-71
35260349-3	2022	PATIENTS AND METHODS: This phase 1/2 study evaluated 2 oral, novel JAK1 inhibitors (INCB052793 and itacitinib) in advanced hematologic malignancies.	INCB039110	99-109	Janus kinase 1	Homo sapiens	67-71
34738874-7	2022	Mechanistically, the receptor tyrosine kinase signaling antibody array revealed that Janus kinase-1 (JAK1) was specifically inhibited by AZD3759, but not by osimertinib.	AZD3759	137-144	Janus kinase 1	Homo sapiens	85-99
34738874-8	2022	The effects of AZD3759 on RA efficacy in PC-9 cells and in a brain metastasis animal model were significantly abolished by the overexpression of JAK1.	AZD3759	15-22	Janus kinase 1	Homo sapiens	145-149
34738874-9	2022	Collectively, our results suggested that AZD3759 promoted RA antitumor effects in NSCLC by synergistic blockade of EGFR and JAK1.	AZD3759	41-48	Janus kinase 1	Homo sapiens	124-128
35505771-3	2022	Tofacitinib was the first pan-Janus kinase (Jak) inhibitor approved for the treatment of IBD, targeting the 4 isoforms of cytokine-associated Jaks (Jak1, Jak2, Jak3, and tyrosine-protein kinase 2).	tofacitinib	0-11	Janus kinase 1	Homo sapiens	148-152